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PSD-95 is an abundant scaffolding protein found in the postsynaptic densities (PSDs) 
of excitatory synapses throughout the mammalian brain, and plays a critical role in 
innate and learned behaviours. PSD-95 assembles with numerous other proteins, 
including glutamate receptors, adhesion molecules and signalling proteins, into 
postsynaptic supercomplexes that are then organised into nanoclusters that comprise 
the postsynaptic density of excitatory synapses. While the subcellular localisation of 
PSD-95 has been widely studied, much less is known about its turnover. In this thesis, 
I present novel insights into PSD-95 synthesis and degradation at synapses of cultured 
primary neurons gained using the HaloTag technology.  
 
The HaloTag consists of an engineered bacterial protein domain that covalently binds 
synthetic ligands labelled with fluorescent and affinity moieties. Hence, cells 
expressing proteins fused to the HaloTag can be used to study protein levels, 
complexes and turnover using these different ligands. This project was based upon a 
knock-in mouse line expressing the HaloTag fused to endogenous PSD-95 using gene 
targeting. After demonstrating that these mice were phenotypically normal and that 
PSD95-HaloTag fusion proteins normally assembled into supercomplexes in the PSD, 
hippocampal primary cultures were grown from this mouse line. Fluorescent HaloTag 
ligands were then used to label live neurons, allowing for the visualisation of PSD-95 
at synapses by confocal microscopy.  
 
Next, I established a pulse-chase labelling method, where one ligand is used to label 
all existing PSD-95 first, before a second ligand can then be used to label any newly 
synthesised PSD-95. This allows for the identification and characterisation of 
subpopulations of PSD-95, which can be separately analysed. I find that PSD-95 has 
a half-life of 36 hours at synapses, consistent with previous literature. I was also able 
to observe synaptic heterogeneity in PSD-95 turnover, and classify synapses into 
types according to their PSD-95 expression profile.  
 
Finally, a range of chemical compounds known to modulate protein turnover and 
neuronal activity was applied over a 24-hour period, and their effects on PSD-95 
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turnover analysed.  It was found that inhibiting either the proteasome or protein 
synthesis led to significant reductions in PSD-95 degradation as well as inhibiting 
PSD-95 synthesis. Thus, this project established a method offering a unique way of 
investigating the turnover of a specific, tagged protein, as well as gaining novel insights 

























Nerve cells (neurons) communicate with each other through connections called 
synapses. It is thought that changes in the strength of these synaptic connections are 
the basis of learning and memory formation. Messages can only be passed in one 
direction across these synapses, and on the receiving side of each synapse there is 
an area densely populated by a huge variety of proteins. This area is called the 
postsynaptic density (PSD). It is the proteins in this area that are thought to mediate 
the changes in synaptic strength that underlie learning and memory formation.  
The protein PSD-95 is one of the most abundant components of the PSD, and it 
functions as a scaffold that binds other proteins together, allowing them to interact with 
each other. Abnormal levels of PSD-95 have been linked to various psychiatric 
diseases including schizophrenia, and mice lacking this protein have severe deficits 
in learning certain tasks. While the localisation of PSD-95 in the brain and within 
neurons has been widely studied, little is known about how it is produced and how it 
is degraded (this cycle is termed ‘turnover’). However, we know that the turnover of 
proteins in the PSD plays an important role in synaptic function and learning.  
In this PhD project, I used a mouse in which the PSD-95 protein had been genetically 
fused to a protein that acts as a reporter, called HaloTag. This HaloTag reporter 
protein can be visualised with fluorescent labels. Only a single label can bind to a 
single protein, irreversibly. I grew neurons taken from the brains of embryos of these 
mice on glass coverslips for 2 weeks. This allowed me to take images of the neurons 
and their synapses using a high-magnification microscope. In these neuronal cultures, 
I visualised the PSD-95-HaloTag fusion proteins with fluorescent labels. I added 
differently-coloured labels 24 hours apart, and studied old and new PSD-95 proteins 
separately. Thus, I could analyse the turnover of PSD-95, as well as categorise 
synapses into different types based on their PSD-95 turnover. I also treated neurons 
with various chemicals over the 24-hour period, and analysed their effects on PSD-95 
turnover. The main findings of this project were: a) that different synapses have 
different rates of PSD-95 turnover; and b) that chemicals known to block either protein 
synthesis or degradation appear to simultaneously block both synthesis and 
degradation of PSD-95, indicating the presence of a mechanism that aims to keep 
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Chapter 1.1 Neurons and memories 
 
1.1.1 The discovery of the synapse 
 
Humanity’s quest to understand the brain has been complex and full of paradigm 
shifts. Early on, it was believed that brains were made up of a continuous, rather than 
contiguous, network of cells that were seamlessly attached to each other. It was 
Ramon y Cajal’s work, utilising Camillo Golgi’s staining technique, which first allowed 
for the visualisation of individual nerve fibres in the late 19th century. Ultimately, it was 
the advent of electron microscopy which completely settled this issue. This discovery 
naturally led to a new controversy over the nature of the communication between these 
cells- was it electrical, like the propagation of activity through a single neuron, or were 
there chemicals involved in passing the messages across these minute gaps? It took 
many decades to settle this question, and only in the early 1960s did it become widely 
accepted that communication between neurons in the brain is predominantly chemical. 
This realisation kicked off a prodigious amount of research into understanding the 
mechanisms governing synaptic transmission; from identifying the neurotransmitters 
involved and their receptors, to their mechanisms of release and cessation of activity. 
While many of these riddles have been solved, many more have appeared. One of the 
most fascinating areas of synaptic research has aimed at understanding their role in 
learning and memory. 
 
1.1.2 Neuronal communication 
 
While ‘messages’, or action potentials, in the form of neuronal activity propagate 
through the neuron in waves of depolarisation caused by the influx of Na+ following 
the opening of voltage-gated sodium channels, these messages need to be 
transmitted across the synaptic cleft that separates two neurons by chemicals called 
neurotransmitters. In many cases, the message will be strong enough to elicit the 
activation of an action potential in the receiving, postsynaptic nerve cell. 
However, not every action potential that arrives at a presynaptic terminal and causes 
the release of neurotransmitter also causes an action potential to be evoked in the 
postsynaptic terminal. This is because a certain firing threshold needs to be reached 
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in the receiving neuron, and if this is not the case, the message fails to be transmitted. 
Crucially, the ‘strength’ of a synapse is plastic, and a ‘stronger’ synapse will be more 
likely to reach this threshold and transmit a message. This is not done by lowering the 
threshold, but rather by increasing the ability of the postsynaptic terminal to reach this 
threshold via an increased ion influx. The mechanism underlying this long-term 
change is referred to as long term potentiation (LTP), but the opposite effect can also 
occur, and this weakening of synaptic strength is called long term depression (LTD). 
It has been proposed that this strengthening, or potentiating, of synapses, underlies 
learning and memory (Nabavi et al., 2014). Both LTP and LTD are thought to be 
equally important, and in both cases, long term structural changes occur at the 
synapse, primarily on the postsynaptic, receiving side (Nicoll, 2017).  
 
1.1.3 Long term potentiation and long term depression 
 
As one of the first steps of activating LTP, α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptors (AMPARs) are activated by the excitatory 
neurotransmitter glutamate, and their activation causes an influx of Na+ and (weaker) 
outflow of K+ ions resulting in depolarisation. While this may be enough to trigger an 
action potential in the postsynaptic neuron, this depolarisation needs to crucially be 
large enough to also allow N-Methyl-D-Aspartate receptors (NMDARs) to become 
activated, which occurs when Mg2+ ions, that block NMDARs, are expelled by the 
strong depolarisation. A depolarisation large enough to cause this effect is usually only 
achieved by coincident firing of several nearby synapses, or by a back-propagating 
action potential (Kennedy, 2000). These NMDARs, once unblocked and activated by 
glutamate, allow not only Na+ but importantly also Ca2+ ions to enter the postsynaptic 
terminal. This is vital because Ca2+ influx triggers various protein signalling cascades, 
but chiefly activates Ca2+-calmodulin-dependent protein kinase IIα (CaMKIIα). 
CaMKIIα is thought to be critical to LTP induction (Lisman et al., 2012; Nicoll, 2012), 
and due to its numerous interactions with other proteins, such as Kalirin-7 (Xie et al., 
2007), it acts as a signalling hub. CaMKIIα has also been shown to interact with the 
actin cytoskeleton, causing spine enlargement (Herring and Nicoll, 2016). Linked to 
this activation of CaMKIIα is a concomitant increase in AMPA receptors at the 
postsynaptic density (PSD), an electron-dense, protein-rich area within the synapses 
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of postsynaptic neurons, opposite the active zone. While CaMKIIα activation has been 
linked to AMPA receptor enrichment at the PSD, the exact mechanism that governs 
this relationship has not been definitively elucidated. While the paradigm within the 
field for 20 years was that CaMKIIα directly modifies AMPARs and/or associated 
transmembrane AMPAR-regulatory proteins (TARPs), thereby causing their increased 
trafficking into the PSD, more recent data has begun to disprove this hypothesis 
(Herring & Nicoll, 2016). Two emerging theories are replacing this old paradigm. The 
first is the PSD-centric model, while the second is the vesicle-centric model.  
In the PSD-centric model, CaMKIIα is proposed to rearrange synaptic scaffolding 
proteins via cytoskeletal actin polymerisation, allowing these scaffolding proteins to 
more effectively ‘capture’ AMPARs diffusion throughout the membrane and into the 
synapse. This increases the total number of AMPARs at the PSD (Herring & Nicoll, 
2016). According to the vesicle-centric model, however, CaMKIIα promotes the fusion 
of AMPAR-containing vesicles within the synapse via actin polymerisation. While 
neither of these theories has, as of yet, come to dominate the field, it is clear overall 
that LTP involves a complex interplay between multiple protein actors: from glutamate 
receptors to signalling and scaffolding molecules. The ultimate outcome, then, is an 
increased number of AMPARs in the postsynaptic membrane for the neurotransmitter 
to bind to, ‘potentiating’ that synapse and making it easier for subsequent action 
potentials to depolarise and activate the postsynaptic cell.  
Critically, neurons that are activated at the same time will potentiate their synapses in 
ways that will mean that the next time, when one of them is activated, the other 
neurons will be more easily activated as well- a process thought to be important in 
information recall (Kennedy, 2000). The synthesis of new proteins as a result of LTP, 
as well as their degradation, is also crucial. Not only can it affect the entire cell, it also 








1.1.4 The role of protein synthesis and degradation in LTP and LTD 
 
It was discovered quite early on, in the 1960’s, that memory formation required the 
synthesis of proteins (Tai and Schuman, 2008). To date, numerous studies have 
shown that LTP also requires protein synthesis, and blocking protein synthesis 
prevents synaptic plasticity (Kang and Schuman, 1996; Krug et al., 1984). As 
mentioned above, the protein CaMKIIα has been identified as one of the key proteins 
involved in synaptic plasticity and is rapidly synthesised in response to synaptic activity 
(Muddashetty et al., 2007). Furthermore, it is believed that most of this activity-induced 
protein synthesis occurs locally, within dendritic spines, as polyribosomes and smooth 
endoplasmic reticulum have been documented in spines (Spacek and Harris, 1997) 
and it has been found that LTP induction enhances the proportion of spines containing 
polyribosomes (Ostroff et al., 2002). mRNAs of synaptic proteins are also found 
distributed along dendrites (Cajigas et al., 2010; Muddashetty et al., 2007), and in fact, 
local protein synthesis of CaMKIIα and other synaptic proteins such as PSD-95 has 
been observed occurring throughout dendrites (Dieck et al., 2015; Ifrim et al., 2015).  
 
More recently, however, studies have shown that the degradation of proteins is just as 
important for synaptic plasticity as synthesis (Lopez-Salon et al., 2001; Fonseca et al., 
2006; Karpova et al., 2006; Patrick et al., 2003, Lee et al., 2008). These studies have 
also found that the ubiquitin-proteasome system (UPS) is the main driving force behind 
this plasticity-driven protein degradation. Indeed, Bingol and Schuman (2006) have 
shown that in response to NMDAR-driven synaptic activity, the proteasome is enriched 
at the synapse. Both protein synthesis inhibitors and proteasome inhibitors have been 
demonstrated to be potent inhibitors of LTP (Karpova et al., 2006; Krug et al., 1984), 
unless they are applied together, in which case they alleviate each other’s effects (Lee 
et al., 2008; Fonseca et al., 2006). Taken together, this data implies that there is a 
strong interplay between protein synthesis and degradation at synapses that drives 
synaptic plasticity. Based on the evidence, Alvarez-Castelao and Schuman (2015) 
have put forward a model of a highly coordinated protein synthesis and degradation 
system, whereby continuous crosstalk between the two ensures that protein 
concentrations at individual synapses are maintained within optimal ranges and 
adapted to the needs of each synapse.   
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1.1.5 The role of protein synthesis and degradation in disease 
 
A further line of evidence for the critical role of protein turnover, the continuous process 
of protein synthesis and degradation (Alvarez-Castelao and Schuman, 2015), is its 
role in disease states. There are now many neurodegenerative diseases that are 
recognised to contain an element of protein degradative dysfunction. Alzheimer’s 
(AD), Parkinson’s (PD) and Huntington’s (HD) diseases, as well as prion diseases, are 
all associated with the abnormal aggregation of proteins (Ross and Poirier, 2004; 
Rubinsztein, 2006). These diseases are characterised by aggregations of misfolded 
proteins that are resistant to degradation, such as plaques, tangles and Lewy bodies 
(AD, PD). The fact that many of the proteins making up these aggregates are 
ubiquitylated and thus tagged for degradation (Ross and Poirier, 2004), and that 
proteasome activity in the brain is reduced in AD, PD and normal aging (Dahlmann, 
2007), implies a dysfunction of the protein degradation system in these conditions.  
 
Fragile X syndrome, one of the most common causes of autism spectrum disorder 
(ASD) and inherited intellectual disability (Kazdoba et al., 2014), is a condition very 
strongly linked to a dysregulation of protein translation. It is characterised by the loss 
of the fragile X mental retardation protein (FMRP, encoded by the Fmr1 gene), a 
protein that binds various mRNAs, frequently repressing their translation (Ifrim et al., 
2015). One of its most prominent targets is the scaffolding protein PSD-95, the most 
abundant protein within the PSD, thought to be a chief organizer at the synapse (Gray 
et al., 2006). Local PSD-95 synthesis is triggered by the activation of Group 1 
metabotropic glutamate receptors (mGluRs), however, in Fmr1 knock-out mice basal 
translation of PSD-95 mRNA is increased while mGluR activation does not activate 
PSD-95 translation further (Ifrim et al., 2015). Additionally, PSD-95 degradation is 
reduced in Fmr1 KO mice (Muddashetty et al., 2007, 2011). The dysfunction of FMRP, 
which normally acts to repress PSD-95 translation, thus has profound effects on the 
turnover of a key synaptic protein (Muddashetty et al., 2011). Other well-known 
diseases whose profile is defined by aberrant protein synthesis are vanishing white 
matter disease (VWMD), Charcot-Marie-Tooth disease and cancer, whose 
oncogenesis is driven by dysregulated protein synthesis (Le Quesne et al., 2010).  
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Chapter 1.2 The postsynaptic density protein PSD-95 
 
1.2.1 Introducing PSD-95 
 
We currently believe there to be less than 20,000 protein-coding genes in humans 
(Ezkurdia et al., 2014), and this number is continuously being revised downwards. At 
the same time, ever more proteins are being identified within the postsynaptic density 
(PSD), the key site of synaptic plasticity. A recent study identified nearly 1500 different 
proteins in the PSD of the human neocortex (Bayés et al., 2011), implying that around 
7.5% of the proteins encoded by the human genome are represented in the PSD. It 
was also found that many of the proteins that make up this PSD are absolutely crucial 
to the brain’s normal function, as they are implicated in a variety of psychiatric 
disorders when dysfunctional. Indeed, Bayés et al. (2011) found that mutations in 199 
human PSD genes resulted in 269 diseases, ranging from common 
neurodegenerative diseases such as AD, PD and HD to cognitive disorders, epilepsies 
and many rare diseases.  
 
Not only is it known that the proteins making up the PSD are vital to the synapse’s 
function and health, but it is also thought that these proteins are not simply diffusely 
arranged within the PSD, but rather assembled in a modular fashion into molecular 
machines, or complexes (Husi et al., 2000; Collins et al., 2006; Frank and Grant, 
2017). A number of proteins in the PSD are known to fulfil particularly crucial roles, 
since they function as hubs that link receptors to their signalling cascades and facilitate 
the interactions of numerous other proteins in the PSD. One group of proteins has 
received particular attention. This is the Discs Large homolog (DLG) family. These 
proteins are scaffolding proteins expressed abundantly at the PSD of excitatory 
glutamatergic synapses, and they are part of the Membrane-Associated Guanylate 
Kinase (MAGUK) super-family. In humans and mice, there are four known members 
of the DLG family: DLG4 (also known as PSD-95), DLG3 (SAP102), DLG2 (PSD-93) 
and DLG1 (SAP97). Invertebrates only express a single Dlg gene. Indeed, the 
evolution of the Dlg-gene family can be traced back to a shared common ancestor 
about 550 million years ago, and the four members (paralogs) of this gene family in 
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vertebrates arose from two whole genome duplication events early during chordate 
evolution (Nithianantharajah et al., 2013).  
 
These four paralogs all have very similar structures that contain multiple domains 
required for protein-protein interactions, thereby facilitating the formation of large 
protein networks. The conserved domains are three PSD-95/Discs large/Zona 
occludens-1 (PDZ) domains, a Src-homology-3 (SH3) domain and a guanylate kinase 
(GK) domain (Fernández et al., 2009). The members of this family do, however, have 
distinct N-termini (Won et al., 2017). These proteins are known to form large 
complexes, some of which integrate the NMDA receptor with a host of other proteins. 
DLG4, also known as PSD-95, is the most prominent member of this family as a major 
component of the PSD (Cho et al., 1992), and has been recognised as the 
predominant antigen in rabbit antiserum produced after immunization with isolated 
bovine PSD fractions (Sampedro et al., 1981). Thus, PSD-95 is now widely used as a 
marker for glutamatergic postsynaptic terminals. It is known to interact with the NMDA 
receptor, with which it forms large, 1.5MDa complexes containing not only the NMDAR 
tetramer but a variety of other proteins as well, such as kinases, activity-regulated 
proteins, and potassium channels, among others (Frank et al., 2016).  
 
1.2.2 PSD-95 interaction with AMPA receptors and synaptic maturation 
 
It is clear that the role of PSD-95 is central to healthy synaptic plasticity. While PSD-
95 is known to directly interact with the NMDA receptor, it is also known to interact 
with AMPA receptors, albeit indirectly. It does this through TARPs (Transmembrane 
AMPA receptor Regulatory Proteins) such as Stargazin (Chen et al, 2000), thereby 
influencing the concentration of AMPARs at the postsynaptic membrane (Beique et 
al., 2006). Thus, PSD-95 also exerts a direct control over synaptic strength, and 
indeed PSD-95 overexpression has been shown to result in increased levels of 
AMPARs in the postsynaptic membrane (El-Husseini et al., 2000). Furthermore, Levy 
et al. (2015) have reported that the knockdown of PSD-95 reduces AMPAR endplate 
synaptic currents (EPSCs) as well as the number of synapses containing AMPARs. 
However, a synaptic program of homeostasis appears to become activated, ensuring 
that those synapses that retain AMPARs do so at full strength, i.e. with their full 
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complement of AMPARs (Levy et al., 2015). Quite recently, PSD-95 nanoclusters 
have been described by various groups, made up of PSD-95 sub-domains within the 
PSD that are between 50 and 250 nm in diameter and can thus only be resolved by 
super-resolution imaging (Broadhead et al., 2016; MacGillavry et al., 2013; Nair et al., 
2013; Fukata et al., 2013).  
These PSD-95 nanodomains have also been shown to cluster AMPARs (MacGillavry 
et al., 2013; Nair et al., 2013), and indeed PSD-95 and the AMPAR subunit GluA2 
appear to colocalise to a far greater degree than PSD-95 and NMDARs. This 
clustering effect is an important determinant of synaptic strength (Nair et al., 2013), as 
the local AMPAR density opposite the glutamate release site on the presynaptic 
bouton determines the strength of the synaptic response (Lisman et al., 2007). It is 
through the incorporation of AMPARs into the postsynaptic membrane along with this 
AMPAR clustering that PSD-95 most directly and immediately enhances synaptic 
strength during LTP (Ehrlich and Malinow, 2004; Beique et al., 2006; Schnell et al., 
2002).  
 
The link between PSD-95 and AMPARs is also intriguing as it links PSD-95 to the 
process of synaptic maturation. During the first two postnatal weeks, very little PSD-
95 is expressed at synapses in vivo, whereas PSD-95’s paralog SAP102 is highly 
expressed at this time (Sans et al., 2000). Over this time period, SAP102 is 
responsible for the trafficking of AMPA and NMDA receptors to synapses, but PSD-
95 is not (Elias et al., 2006; Elias et al., 2008). However, at a later developmental 
stage, around postnatal day 15 (P15), PSD-95 expression has increased dramatically 
and synapses have become functionally mature. Overexpressing PSD-95 at an earlier 
time point, around P5-P8, prematurely leads to synaptic maturation, indicating that 
PSD-95 is responsible for the functional maturation of synapses (Elias et al., 2008). 
Furthermore, the knockout of PSD-95 retained synapses in an immature state, and 
this effect could be rescued by restoring PSD-95 expression (Elias et al., 2008).  
What are the hallmarks of functional maturation of synapses? According to Elias et al. 
(2008), it is the enhanced expression of AMPARs and the replacement of NR2B-
NMDARs with NR2A-NMDARs. Functionally immature synapses are also called 
‘silent’ synapses, and do not contain any AMPARs, but do still contain NMDARs (Isaac 
et al., 1995; Takumi et al., 1999). PSD-95 is absolutely required for the experience-
dependent maturation of silent synapses, inserting AMPARs into such synapses 
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(Huang et al., 2015; Ashby et al., 2011). The loss of PSD-95, on the other hand, 
reinstates or induces a silent state (Huang et al., 2015; Elias et al., 2006). Studies by 
Béique et al. (2006) and Chen et al. (2015) also established that PSD-95 KO mice 
express a greater proportion of silent synapses; however, they were also able to find 
silent synapses within morphologically mature spines. This indicates that functional 
and morphological maturation are not one and the same. Interestingly, El-Husseini et 
al. (2000) also found that overexpressing PSD-95 in hippocampal primary cultures 
around day in vitro 10-12 (DIV10-12) not only vastly increased synaptic AMPAR 
labelling and mEPSC amplitude, but also enhanced the staining for presynaptic 
marker proteins and the presynaptic vesicle pool, indicating that PSD-95 can drive not 
only the maturation of postsynaptic components, but also that of the presynaptic 
terminal.  
 
Taken together, then, PSD-95 is a critically important protein for the modulation of 
synaptic strength, and is significantly involved in the functional maturation of synapses 
as well as playing a role in LTP. Many of these effects appear to be mediated through 
PSD-95’s indirect interaction with AMPARs, which allows it to regulate synaptic 
AMPAR number.  
 
1.2.3 Post-translational modifications of PSD-95 
 
While the role of PSD-95 as a synaptic scaffolding protein has been studied 
extensively, it is also interesting to evaluate the role that various post-translational 
modifications can have on a protein. Li et al (2004) used 2D-gel electrophoresis and 
Mass Spectrometry (MS) to discover 6 different forms of PSD-95, some of which are 
different isoforms and others due to post-translational modifications. While all 
modifications and different splice forms of PSD-95 have not been conclusively defined, 
it has been established that PSD-95 is subject to phosphorylation, palmitoylation and 
ubiquitination, all of which are critical to its function.  
 
There is evidence that activity modulates the interaction of PSD-95 with NMDA 
receptors. PSD-95 directly binds to the PDZ ligand of GluN2B and stabilizes its surface 
expression at synapses (Lau et al., 2007). Synaptic activity activates CaMKII, which 
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phosphorylates the C-terminal of the NR2B subunit of NMDA receptors, disrupting 
their interaction with PSD-95. This results in a dramatically reduced synaptic surface 
expression of NMDARs, indicating that an activity-dependent phosphorylation of 
NMDARs may regulate NMDAR function and synaptic plasticity (Chung et al, 2004; 
Lau et al., 2007). Similarly, CaMKII phosphorylates stargazin, facilitating the 
interaction of stargazin with PSD-95 and thereby mediating AMPAR stabilisation in the 
PSD (Constals et al., 2015). PSD-95 has also been shown to interact in a 
palmitoylation-dependent manner with the tyrosine phosphatase PTPN5, a protein 
known to regulate surface expression of NMDARs by dephosphorylating GluN2B and 
causing their internalization (Won et al., 2016). Through this interaction PSD-95 
causes PTPN5 degradation, preventing GluN2B internalisation. It has also been 
demonstrated that the binding of the inward rectifying K+ channel Kir2.3 to PSD-95 is 
disrupted by phosphorylation of Kir2.3 (Cohen et al., 1996). Further, PSD-95 is itself 
phosphorylated at serine 73 by CaMKII in an activity-dependent manner, and this 
phosphorylation disrupts PSD-95’s interaction with the NR2A subunit of NMDARs 
(Gardoni et al., 2006). This phosphorylation event also triggers the trafficking of PSD-
95 out of the spine, terminates spine growth, and ultimately results in the inhibition of 
LTP (Steiner et al., 2008). A further phosphorylation site on PSD-95 has recently been 
described, causing a similar destabilisation of PSD-95 at the PSD (Nelson et al., 
2013).  
 
Palmitoylation, in fact, is a critical modulator of PSD-95 localisation. Palmitoylation of 
the N-terminal cysteine residues is crucial for the membrane localisation of PSD-95 in 
the PSD, and palmitoylation-deficient PSD-95 mutant mice display PSD-95 diffusely 
distributed in dendrites and the cell body (Topinka and Bredt, 1998). El-Husseini et al. 
(2000b) found that this synaptic localisation of PSD-95 is mediated by dual 
palmitoylation of PSD-95 on N-terminal cysteines 3 and 5, which has the effect of 
associating PSD-95 with perinuclear membranous compartments that traffic with 
vesiculotubular structures in a microtubule-dependent manner. If this dual 
palmitoylation is inhibited, PSD-95 does not localise to synapses nor cluster ion 
channels such as the AMPAR. Indeed, the depalmitoylation of PSD-95 by activity-
induced glutamate causes PSD-95 clusters to disperse, which in turns triggers 
AMPAR internalisation (El-Husseini et al., 2002). Inversely, blocking synaptic activity 
leads to the rapid induction of PSD-95 palmitoylation, and concurrent PSD-95 and 
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AMPAR clustering (Noritake et al., 2009). At a super-resolution level, it was found that 
when the palmitoylating enzyme DHHC2 was targeted to the postsynaptic plasma 
membrane, this resulted in the palmitoylation and hence recruitment of PSD-95 to the 
plasma membrane as well (Fukata et al., 2013). Enhanced synaptic activity caused 
the depalmitoylation of PSD-95, and the dissociation of both these proteins from the 
plasma membrane. Furthermore, Fukata et al. (2013) also found that this is the 
mechanism by which palmitoylated PSD-95 forms postsynaptic nanodomains, and 
these nanodomains cluster AMPAR, thereby controlling their activity-dependent 
surface expression. Thus, palmitoylation is essential to PSD-95’s role in the synapse, 
controlling synaptic localisation, nanodomain formation and AMPAR clustering.  
 
PSD-95 also interacts with proteins that are involved in dendritic spine morphology, 
and thus indirectly plays a role in the structural modelling of spines, as well as their 
morphogenesis. At synapses, PSD-95 binds directly to Kalirin-7, a GDP/GTP 
exchange factor for Rac1 that interacts with the cytoskeleton to control actin dynamics 
and thereby regulate spine morphogenesis (Penzes et al., 2001). SPAR, a Rap-
specific GTPase-activating protein (RapGAP), has been found to form a complex with 
PSD-95 and NMDARs at synapses and also interacts with the actin cytoskeleton to 
effect changes in spine morphology, causing spine heads to enlarge, and enhancing 
PSD-95 expression at such synapses (Pak et al., 2001). Finally, PSD-95 has been 
found to indirectly interact with SNAP-25, a component of the SNARE complex that is 
involved in synaptic vesicle exocytosis, in protein complexes at the PSD (Fossati et 
al., 2015). A reduction in SNAP-25 levels was found to reduce dendritic spine density, 
impair synaptic potentiation, and reduce PSD-95 clustering at synapses. A reduction 
in SNAP-25 levels is associated with attention deficit hyperactivity disorder (ADHD) 
and schizophrenia, and may thus cause synaptic defects through its interaction with 
PSD-95 (Fossati et al., 2015). Overall, then, PSD-95 appears to be linked to dendritic 
spine morphology in an indirect fashion, interacting with proteins that directly control 
cytoskeletal dynamics and spine morphogenesis. The presence of PSD-95 at spines 
is also strongly correlated with spine stability in vivo (Cane et al., 2014). Newly formed 
dendritic spines that fail to recruit PSD-95 are quickly pruned, whereas PSD-95 
accumulation at spines is positively correlated with an increased spine lifetime. Cane 
et al. (2014) also found that mature spines that were destined to be pruned reduced 
their PSD-95 content well in advance of the pruning event. Thus, PSD-95 not only 
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plays an important role in recruiting other synaptic proteins to the PSD, but its 
presence at synapses is also a strong indicator of spine stability. Note, however, that 
PSD-95 itself is not directly involved in synaptogenesis or spine maintenance, as PSD-
95 knock-down does not appear to affect dendritic spine density (Levy et al., 2015).  
 
Another posttranslational modification of PSD-95 that plays an important role is its 
ubiquitination, insofar as it mediates its degradation. Colledge et al. (2003) found that 
NMDAR activation leads to the ubiquitination of PSD-95 by the E3 ligase Mdm2, which 
in turn causes PSD-95 to be degraded by the 26S proteasome. Blocking this 
ubiquitination prevents PSD95 degradation as well as NMDA-induced endocytosis of 
AMPA receptors. Taken together, then, PSD-95’s function is heavily dependent upon 
post-translational modifications. Palmitoylation is critical for the localisation of PSD-95 
to the PSD, which in turn is essential for PSD-95 to be able to fulfil its function. 
Phosphorylation is another key modification, and one particular phosphorylation event 
by CaMKII appears to be critically involved in PSD-95’s synaptic localisation and role 
in dendritic spine growth and LTP. Other phosphorylation events target interactors of 
PSD-95 and thus modulate its function. Other post-translational modifications of PSD-
95 have also been described, such as nitrosylation, and neddylation (Vallejo et al., 
2016), and while ubiquitination is thought to cause its degradation by the proteasome, 
one study has shown that this is not always the case (Bianchetta et al., 2011).  
 
1.2.4 PSD-95 as a molecular organizer of supercomplexes 
 
While PSD-95 has long been known to play important roles in AMPAR clustering, LTP, 
synaptic maturation and synaptic stability, its perhaps most critical role has only 
recently begun to be understood more fully.  As mentioned above, PSD-95 localises 
with NMDA receptors into large multiprotein complexes, and this interaction has been 
known for some time (Husi et al., 2000). However, newer research has revealed that 
PSD-95 is in fact one of the key components of these supercomplexes, acting as one 
of their central organisers. Two recent studies, Frank et al. (2016) and Frank et al. 
(2017), have together shown that PSD-95 is not merely a component of 1.5MDa 
NMDAR supercomplexes, but rather acts as a critical organizer of these 
supercomplexes. In fact, they found that almost all PSD-95 of the forebrain is retained 
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within these supercomplexes. Furthermore, PSD-95 assembles a large variety of 
these 1.5MDa complexes, and only a minority of these contain NMDARs at all. In 
Frank et al. (2016), it was demonstrated that there are two discrete populations of 
NMDAR complexes: 0.8MDa complexes and 1.5MDa complexes. The complex at 
0.8MDa is largely made up of the tetrameric NMDAR ion channel, and does not 
contain PSD-95. Within the 1.5MDa NMDAR supercomplex, however, 50 different 
proteins were identified, ranging from other ion channels over receptors and adhesion 
proteins to signalling enzymes. PSD-95 is essential for the formation of these 1.5MDa 
NMDAR complexes, and Frank et al. (2016) were able to establish a ‘tripartite rule’, 
stipulating that three proteins were absolutely mandatory for the assembly of these 
complexes. These three proteins are PSD-95, PSD-93 (DLG2, one of PSD-95’s 
paralogs), and the GluN2B subunit of the NMDAR. Without the presence of these three 
fully functional proteins, 1.5MDa NMDAR supercomplexes are unable to form. In 
accordance with these rules and PSD-95’s developmental expression profile, the 
study also showed that 0.8MDa NMDAR complexes are present at all postnatal ages, 
whereas 1.5MDa NMDAR supercomplexes are only found from P16 onwards, when 
PSD-95 expression increases. The second study (Frank et al., 2017) demonstrated 
that only 3% of the 1.5MDa complexes containing PSD-95 also contain NMDARs. This 
means that NMDAR supercomplexes are merely a subset of a much greater family of 
PSD-95 supercomplexes. They were further able to subdivide these PSD-95 
supercomplexes, identifying complexes that were characterised by the presence of 
the proteins Arc/Arg3.1, Kir2.3, IQsec2/BRAG1 and Adam22. Thus, these studies 
concluded, there appears to be a hierarchy of PSD-95 supercomplexes, each 
comprising functionally distinct proteins and assembled with unique genetic 
prerequisites. PSD-95, however, is the key organizer of most of these 1.5MDa 
supercomplexes, and is on average present as a dimer in each (Frank et al., 2017). 
Note, however, that not all 1.5MDa supercomplexes require PSD-95 to assemble: in 
PSD-95 knock-out mice, PSD-93 is still able to assemble some 1.5MDa 
supercomplexes. However, these do not contain NMDARs, and are differ from PSD-
95 1.5MDa complexes, which disappear together with PSD-95. These findings are in 
line with previous studies, which have shown that the loss of PSD-95 leads to a 
structural fragmentation of the PSD, while the simultaneous loss of the three MAGUKs 
PSD-95, PSD-93 and SAP102 causes the PSD to profoundly disintegrate and shrink 
in size (Chen et al., 2011; Chen et al., 2015).  
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Functionally, it is thought that these diverse supercomplexes are central to synaptic 
function and ultimately higher cognition and the ability to effectively process and store 
information. Thus, PSD-95 and the complexes it forms are thought to be key elements 
in the processes of learning and memory formation, as well as the normal functioning 
of the brain. While the NMDA receptors have been shown to function normally as an 
ion channel in mice lacking PSD-95 (since 0.8MDa NMDAR complexes do not contain 
PSD-95), these animals have impaired learning, indicating that the proteins associated 
with the receptors are what is crucial to the formation of memory traces. Intriguingly, 
Migaud et al (1998) found that when PSD-95 is knocked out, such mice display 
strikingly enhanced LTP, but LTD is eliminated and spatial learning severely impaired. 
Thus PSD-95’s role in relation to NMDARs seems to be to couple these receptors to 
pathways that modify synaptic strength in a bidirectional manner, potentiating and 
depressing synaptic strength as appropriate. The lack of PSD-95 may thus result in 
an inappropriate strengthening of too many synapses and hence yield a degradation 
of information storage, manifested as a learning impairment (Migaud et al., 1998). It 
may be unsurprising, then, that there are a variety of diseases in which a reduction in 
functional PSD-95 has been observed, such as Fragile X syndrome (Ropers, 2008), 
bipolar disorder and schizophrenia (Toro and Deakin, 2005; Cheng et al., 2010), major 
depression (Feyissa et al, 2009), and autism spectrum disorder (Feyder et al, 2010; 


















Figure 1.1. Structure and function of PSD-95.  
a. Family tree and structure of the four Dlg paralog members of the MAGUK superfamily: Dlg4 
(PSD-95), Dlg3 (SAP102), Dlg2 (PSD-93) and Dlg1 (SAP97). Comparison with the invertebrate 
Dlg protein. Adapted from Nithianantharajah et al. (2013). b. The scaffolding protein PSD-95 
forms a core component of multiprotein supercomplexes found in the postsynaptic density 
(PSD) of excitatory synapses. In this way, many different synaptic proteins are brought 
together and assembled into a complex molecular machine. Adapted from Emes and Grant 
(2013). c. Conceptual diagram of an excitatory synapse. Diverse 1.5MDa supercomplexes are 
assembled to form integral components of the PSD. These complexes participate in synaptic 
plasticity and are thought to be important for learning and memory, and are implicated in 







1.2.5 PSD-95, the dynamic protein 
 
We can gather from the recently reviewed literature that PSD-95 is central to the 
formation and integrity of the PSD, and acts as a hub that brings together a multitude 
of other proteins in large complexes that are organized into nanodomains, including 
NMDA and AMPA receptors. In this way, PSD-95 can help shape spine morphology, 
determine synaptic strength, and affect LTP and LTD. While I have discussed the 
importance of various factors such as palmitoylation in the synaptic localisation of 
PSD-95, it is important to give an insight into the dynamic properties of PSD-95 at 
healthy synapses, and the role that these dynamics play in PSD-95’s function.  
 
Early studies found evidence for a two-tiered population of PSD-95 within synapses 
and dendrites. These studies used Fluorescence-recovery after photobleaching 
(FRAP) to analyse the stability of PSD-95, and found that there was a small pool of 
‘mobile’ PSD-95 molecules that rapidly moved between synapses, while the majority 
of PSD-95 was ‘stable’ and did not readily move out of synapses (e.g. Todd et al., 
2003). However, these studies monitored PSD-95 mobility over short time frames 
(seconds to minutes), and more recent studies conducted over long time periods 
(hours) have found that the entire population of PSD-95 is in fact dynamic rather than 
immobile (Ziv and Fisher-Lavie, 2014). These newer studies indicate that the 
previously-observed ‘mobile’ PSD-95 is in fact not fully incorporated into the PSD, but 
only weakly associated with it and more closely connected with dynamic cytoskeletal 
components such as actin filaments (Zheng et al., 2010). Furthermore, these more 
recent studies concluded that the ‘stable’ fraction of PSD-95, which is fully 
incorporated into the PSD and associated with NMDAR and AMPAR complexes, in 
fact does move between PSDs. The study by Gray et al. (2006) is particularly notable, 
as it was conducted in vivo, within the intact cortex of mice. This study demonstrated 
that PSD-95 molecules do indeed move between synapses (remaining within a given 
synapse for less than an hour, on average), that PSD-95 mobility is greater in smaller 
synapses compared to larger ones, and that the mobility of PSD-95 goes down as 
mice mature.  Finally, the study showed that the total PSD-95 content of a given 
synapse changes over the course of days, and this finding was more recently 
corroborated by Cane et al. (2014). The study by Butko et al. (2012) also demonstrated 
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that newly synthesised PSD-95 travels to synapses and is incorporated into PSDs 
within 6 hours of synthesis, rather than replenishing ‘dendritic stores’. Moreover, the 
PSD-95 nanodomains within the PSD have also been shown to morph and appear to 
have lifespans shorter than one hour (MacGillavry et al., 2013; Nair et al., 2013), 
implying that clusters of PSD-95 within the PSD and their associated multiprotein 
complexes are themselves mobile. This paints a picture of a much more fluid PSD 
than the rigid structure initially conceptualised (Ziv and Fisher-Lavie, 2014). Within this 
PSD, multiprotein complexes are likely assembled and disassembled frequently, and 
this restructuring is mediated by the post-translational modifications of scaffolding 
proteins such as PSD-95 that are induced by various states of synaptic activity. One 
thing that is worth noting, however, is that while PSD-95 has been shown to be mobile 
and move between spines, it is nonetheless a lot more stable than many other synaptic 
proteins, such as CaMKII, Stargazin, and GluR2, which all move more rapidly between 
spines (Sturgill et al., 2009). As mentioned above, factors such as NMDAR activation, 
PSD-95 palmitoylation and PSD-95 phosphorylation all regulate the stability of PSD-
95 within the synapse, and enhance or reduce its rate of removal from the PSD 
(Sturgill et al., 2009). One good example is the trans-synaptic organizing protein 
ephrin-B3, which directly interacts with PSD-95 and appears to be crucial for PSD-
95’s synaptic localisation and stability at the PSD (Hruska et al., 2015).  
 
1.2.6 PSD-95 synthesis and degradation 
 
While multiple recent studies have demonstrated that PSD-95 is a protein that is 
mobile and moves between synapses, there is another aspect of PSD-95’s presence 
at the synapse, and that is its turnover rate, made up of both synthesis and 
degradation. As reviewed above, protein turnover has been established as being 
crucial to synaptic function and the induction of both LTP and LTD. The role of PSD-
95 turnover, however, is much less clear. It appears that PSD-95 is synthesized in the 
cytosol and trafficked to synapses in vesicles (Yoshii and Constantine-Paton, 2007), 
however, local translation also plays a big part in PSD-95 synthesis. Thus, PSD-95 
mRNA is found distributed throughout dendrites (Muddashetty et al., 2007), and local 
synthesis has been directly observed in dendrites and spines using single-molecule 
imaging of reporter-tagged PSD-95 (Ifrim et al., 2015). One explanation for these 
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different sites of PSD-95 synthesis may be that there is a certain amount of constitutive 
PSD-95 turnover, which functions to replace old proteins and hence is not urgent. It 
takes place in the cytosol, therefore requiring more time to deliver the synthesised 
proteins to their destinations. On the other hand, local synthesis of PSD-95 in 
dendrites and spines is induced by acute factors, necessitating a rapid increase in 
local PSD-95 levels. The activation of mGluRs by substances such as S-3,5-
dihydrophenylglycine (DHPG) has been demonstrated to cause such a rapid, local 
increase in PSD-95 synthesis (Ifrim et al., 2015; Todd et al., 2003). A study by Butko 
et al. (2012) also demonstrated that treating neurons with chemicals enhancing or 
mimicking synaptic activation (bicuculline, DHPG and BDNF) increases the 
concentration of newly-synthesised PSD-95 both at the level of stimulated synapses 
and the whole neuron, although the source of this new PSD-95 was not determined. 
Interestingly, this study also found that immature synapses with incompletely 
developed PSDs tended to contain newly-synthesised PSD-95 while mature synapses 
are enriched in older PSD-95 molecules that are incorporated fully into the PSD.  
The other determinant of PSD-95 turnover is its degradation, mediated primarily by 
the ubiquitin-proteasome system (Colledge et al., 2003; Tsai et al., 2012). The main 
measure of a protein’s degradation rate is the half-life, which represents the amount 
of time it takes for half of a given starting amount of PSD-95 to degrade (Ziv and 
Fisher-Lavie, 2014). In fact, the half-life of PSD-95 has been widely studied, and has 
yielded a bewildering range of results. The main determinant of this diversity in results 
appears to be the methods utilised to obtain them. First, a study by Ehlers (2003) 
obtained a half-life of 8 hours, using 35S-methionine metabolic labelling of isolated 
PSDs (12 hour pulse). Second, El-Husseini et al. (2002) derived a half-life of 
approximately 36 hours, also using 35S-methionine metabolic labelling but in intact 
cultures, with a 1-hour pulse. Next, Cohen et al. (2013) found PSD-95’s half-life to be 
about 88 hours using stable isotope labelling by amino acids in cell culture (SILAC), 
with a long pulse time (7 days pulse labelling). Indeed, the pulse labelling time period 
is critical in these metabolic labelling experiments, as its length determines what 
proportion of a protein’s population is labelled and thus monitored. Finally, a study by 
Price and colleagues (2010) was conducted in which live mice were fed on a diet 
leading to organism-wide isotopic labelling, which could then be monitored by mass 
spectrometry. The results indicated a half-life of 367 hours (15.3 days) for PSD-95. 
The pulse period here was 32 days, but it is likely that proteins within live adult mice 
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simply experience greater half-lives than those within young, cultured neurons. Taken 
together, the results indicate that longer pulse labelling times are linked to longer half-
lives, that is to say that the more accurate results indicate a longer half-life.  
Intriguingly, the regulation of PSD-95 degradation appears to play an important role in 
synaptic plasticity. Colledge et al. (2003) found that brief NMDAR activation, inducing 
LTD, causes PSD-95 to be ubiquitinated and degraded by the proteasome as a result. 
This in turn leads to AMPAR internalisation and weakening of these synapses, and 
inhibition of the proteasome prevents PSD-95 degradation, AMPAR internalisation 
and LTD. Numerous studies have shown that blocking protein degradation by 
inhibiting the proteasome blocks LTP and LTD (Fonseca et al., 2006; Lopez-Salon et 
al., 2001; Karpova et al., 2006), and while PSD-95 is far from the only protein affected 
by this blockade, it may contribute significantly to the resulting effects.  
 
1.3 The HaloTag technology 
 
1.3.1 Introduction to the HaloTag technology 
 
Over the past decades, many different reporter proteins have been engineered on the 
basis of naturally occurring proteins. The most famous example of this is the green 
fluorescent protein, GFP, which was derived from a jellyfish protein and is today used 
in a huge variety of different settings to visualise a protein of interest (Chalfie et al., 
1994). The tandem affinity purification (TAP) tag is another example of a protein 
frequently used to affinity-purify proteins of interest and their interacting partners 
(Rigaut et al., 1999). There is a huge variety of such proteins nowadays, but what they 
have in common is that they tend to be relatively small, allowing them to be fused to a 
protein of interest (POI), thereby allowing us to study this POI in its natural state by a 
variety of methods. More recently, Promega developed another such reporter protein, 
called HaloTag. The HaloTag protein is a monomeric protein that has a molecular 
mass of 33 kDa. Like other reporters, it can be genetically fused to a POI. The original 
protein was derived from a haloalkane dehalogenase enzyme found in the bacterium 
Rhodococcus rhodochrous, and is thus not found in mammals, insects, yeast and even 
E. coli (Urh and Rosenberg, 2012). This has the great advantage of avoiding 
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interference by endogenous proteins or ligands if used in these systems. In its natural 
state, this haloalkane dehalogenase enzyme reacts with an aliphatic hydrocarbon 
substrate by a nucleophilic displacement reaction, forming a covalent ester bond. This 
intermediate is then released again by a base-catalysed hydrolysis reaction, allowing 
for further rounds of catalysis (Los et al., 2008). However, this Rhodococcus enzyme 
was modified, and a mutation now prevents the release of the hydrocarbon substrate. 
Instead, the chloroalkane substrate molecule remains tightly and covalently bound to 
the haloalkane dehalogenase enzyme (now called HaloTag). The chloroalkane 
substrate was further engineered to bear a variety of useful molecules that allow, 
among other things, the detection and purification of the HaloTag protein and any POI 
it may be fused to. These substrates are termed ‘ligands’.  
Los et al. (2008) then further engineered the HaloTag protein to enhance the binding 
rate and efficiency of these ligands to the HaloTag protein. The final binding kinetics 
of the HaloTag protein to its ligands display a rate similarly rapid to those of the biotin-
streptavidin interactions. For instance, the HaloTag protein binding rates to a ligand 
bearing a fluorescent carboxytetramethylrhodamine (TMR) ligand have a second-
order rate constant of 2.7 x 106 M-1 s-1, which is comparable to the binding rate of 
streptavidin to TMR-biotin (Los et al., 2008).  
 
The key aspect of this Halotag technology is the fact that the HaloTag ligands are 
incredibly versatile, and can be bestowed with a wide variety of functionalities, while 
retaining their binding affinity for the HaloTag protein. This is achieved because the 
ligands are designed to consist of two elements- a constant reactive group and a 
variable functional group. The constant group is based upon the original HaloTag 
enzyme’s substrate and consists of a chloroalkane. This chloroalkane binds covalently 
to the HaloTag protein, and this covalent binding is irreversible: incubating the 
HaloTag protein bound by TMR ligand with GST-HaloTag protein bound by FAM 
ligand does not lead to cross-labelling (Los et al, 2008). This bond, which consists of 
an ester bond buried deep in a hydrophobic pocket (Newman et al, 1999), is stable 
even under conditions expected to disrupt protein structure, such as boiling in SDS for 
20 minutes at 95°C. (Los et al, 2008). It is also important to note that only a single 
ligand binds to a single HaloTag protein in this permanent, irreversible manner.   
The second element, the variable functional group, can be selected according to the 
desired properties. Promega supplies a number of ready-made ligands with functional 
 22 
groups that are fluorescent molecules, affinity handles such as biotin, and solid 
support such as sepharose. Many of these are cell permeable, while some are not. All 
are designed to be non-toxic and to not alter cellular morphology. Cell permeable 
ligands have a very low molecular weight, between 439 and 702 g/Mol. Broadly, these 
commercially available ligands can be placed into two categories: fluorescent ligands 
for the visualisation of the POI, and affinity handles, for the purification of the POI and 
possibly interactors.  
 
Figure 1.2. Structure of the PSD-95-HaloTag fusion protein.  
a. This figure demonstrates the structural relationship between the protein of interest, in this 
case PSD-95, and the HaloTag protein it is fused to. A HaloTag ligand binding to the PSD-95-
HaloTag fusion protein is also depicted. b. Model of HaloTag protein with HaloTag ligand 
inserted into binding pocket. HaloTag ligands bind to HaloTag proteins specifically, covalently 
and irreversibly. c. HaloTag ligands are characterised by their invariable binding domain and 
variable functional domain. Functional domains can be bestowed with a variety of properties, 
ranging from fluorescent groups and affinity surfaces such as biotin to custom-made reactive 
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groups, such as the degradation-inducing ligand presented in Neklesa et al. (2011). Entire 
figure adapted from Urh and Rosenberg (2012).  
 
1.3.2 Imaging with HaloTag 
 
Commercially available fluorescent ligands cover a wide range of wavelengths, from 
blue (Coumarin ligand, emission: 450nm) to far-red (AlexaFluor660, emission: 690nm) 
and everything in between. Apart from the AlexaFluor660, all of these ligands are 
membrane-permeating, meaning that they can penetrate live cell membranes without 
the need for these to be perforated beforehand. This facilitates live-cell labelling of 
cultured cells, allowing one to simply add the ligand to the culture media and resulting 
in HaloTag labelling within a short space of time (labelling protocols typically require a 
mere 15 minutes of incubation- see Promega’s Focus on Imaging handbook). These 
characteristics result in the HaloTag technology being ideally suited for Pulse-Chase 
based experiments for the analysis of protein synthesis and degradation. In a cell 
culture environment, this involves labelling the entire pool of existing proteins in the 
cell culture with ligand A (the ‘Pulse’ ligand), and subsequently washing the excess 
unbound ligand A off. Following a stimulus or a period of time which will result in a new 
population of fusion proteins being synthesised, this is then followed up with a second 
labelling regime, this time with a different ligand, ligand B (the ‘Chase’ ligand). In this 
manner, one has labelled two discreet populations of the same fusion protein, but at 
different time points and with different, distinguishable ligands (Uhr & Rosenberg, 
2012). This allows, for example, differences in the localisation of old and new proteins 
to be identified, and their half-life to be calculated (Huybrechts et al, 2009). He et al. 
(2011) and Okada et al. (2010) have similarly used a pulse-chase protocol with 
fluorescent HaloTag ligands to visualise the degradation rate of a POI, and hence 
calculate its half-life.  
 
1.3.3 Purification with HaloTag 
 
While this approach is interesting from an imaging perspective, it also creates a 
powerful tool for the proteomic isolation of newly synthesised proteins. If this is coupled 
with a stimulus protocol, it allows for the precipitation of proteins interacting with fusion 
proteins that were synthesised specifically in response to stimulation. Once isolated, 
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such multiprotein complexes could then simply be compared with complexes purified 
prior to stimulation, and thereby allow for a detailed analysis of different complex 
populations. This approach to identify protein complex members has, for instance, 
been used by Daniels et al. (2012). The HaloLink resin also allows newly synthesized 
proteins to be isolated directly, as they are captured by the chloroalkane linker 
attached to a resin surface. In this way, one only captures newly synthesised fusion 
proteins (and associated complexes) that have no ligand A bound to them, as older 
proteins have their binding site blocked by ligand A. Due to the very rapid and highly 
specific binding of this resin to the HaloTag fusion protein, this technique allows for 
the isolation of even a relatively small number of newly synthesised proteins. As 
Daniels et al. (2012) point out, this minimises the background caused by non-specific 
interactors when immunoprecipitating, greatly aiding Mass Spectrometry studies. 
The drawback of using HaloLink resin directly is the fact that the fusion protein cannot 
be eluted or boiled off the resin; however, this can be circumvented by use of a TEV 
protease, which cleaves the HaloTag protein off the fusion partner (POI) at a specific 
site (Urh & Rosenberg, 2012). Since this TEV treatment will cleave the POI off the 
HaloLink resin, it retains all interacting proteins attached to the POI, allowing for the 
analysis of protein complexes.  
 
1.3.4 Homemade tags 
 
A further important aspect to note is that the HaloTag ligands can also be purchased 
from Promega in a basic form, consisting only of the chloroalkane linker region that 
binds to the HaloTag protein, but lacking the functional group. Instead, these ‘bare’ 
ligands can be bestowed with a functional group of one’s choice, and thus many 
groups have used this option to produce a variety of unique ligands with exceptional 
properties. Thus, a number of groups has created infrared and near-infrared ligands 
(Tseng et al., 2012; Fujita et al., 2012). Other groups have created ligands that have 
allowed them to target a HaloTag fusion protein with a contrast reagent for MRI 
(Strauch et al., 2011) as well as a reporter for positron emission tomography (PET) 
(Hong et al., 2011). One of the most intriguing advances in this area, however, was 
the discovery that a small hydrophobic tag could induce the acute degradation of a 
HaloTag fusion protein upon binding. In 2011, Neklesa at al. reported that a small 
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hydrophobic membrane permeable HaloTag ligand bearing adamantyl groups leads 
to the delivery of the fusion protein to the proteasome for degradation. The underlying 
mechanism appears to be that the hydrophobic tag mimics a partially denatured 
protein state. Neklesa et al. (2011) were able to degrade tumours expressing the 
HaloTag fusion protein in live mice by over 80% over 13 days through the 
intraperitoneal injection of this ligand. A truly exciting application of this ligand is that 
it allows the acute knock-down of a single specific POI only. Furthermore, 
subpopulations of this protein can be degraded if a pulse-chase protocol is used to 
label previously-present proteins with a non-degrading ligand (thereby keeping them 
safe from degradation), and labelling only newer proteins with the degradation-
inducing ligand. This way, one could effectively prevent the synthesis of a specific 
target POI while retaining older proteins, with no off-target effects on other proteins.  
This allows for novel insights to be gained into protein functions and seems to be the 
first method to allow for such deft manipulation.  
 
Finally, the HaloTag technology has been utilised in live animal models as well. 
Various studies have xenografted tumours expressing the HaloTag protein fused to a 
POI into live mice, and subsequently labelled these tumours using various HaloTag 
ligands (Tseng et al., 2012; Kosaka et al., 2009), including PET imaging of tumours 
(Hong et al., 2011). The study by Neklesa et al. (2011) was conducted in live mice and 
zebrafish, as well as cell cultures. Finally, Fujita et al. (2012) managed to label a 
tagged POI within the brain of a live mouse using a ligand bearing a near-infrared 
fluorescent dye, allowing them to visualise brain ischemia in a mouse model of stroke.  
 
1.3.4 HaloTag conclusions 
 
The key advantage of the HaloTag technology over most other reporter proteins, then, 
is its incredible versatility. This technology allows for a POI to be analysed in a huge 
variety of different ways, ranging from biochemistry to super-resolution microscopy 
(Chen et al., 2013). It even allows for the manipulation of the expression of the POI, 
and can be used in vivo as well as in vitro. Importantly, it also allows different 
subpopulations of the same target protein to be labelled with different tags. While other 
reporters may permit aspects of this sort of analysis as well, none are able to unite all 
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of these techniques within a single tag: creating a single genetically engineered mouse 
expressing a POI fused to the HaloTag protein allows one to utilise this entire 
complement of analytical techniques.  
 
1.4 Conclusion, aims and hypotheses 
 
Over the past decades, a lot of progress has been made in our understanding of how 
memories and behaviours are induced, neurons and synapses function, and 
molecules such as PSD-95 tie these mechanisms together. We have discovered a 
wide range of molecules that play important roles in the PSD, and begun to understand 
how they are organized within this structure in order to mediate their effects. However, 
there is much left for us to learn. We have also made massive strides forward in terms 
of scientific techniques, developing game-changing technologies such as super-
resolution imaging and the CRISP-Cas9 system that constantly allow us to push the 
boundaries of the possible within various scientific fields.  
 
More recently, the postsynaptic scaffolding protein PSD-95 was established as one of 
the major actors in structuring the PSD within excitatory neurons and mediating protein 
interactions and synaptic plasticity. PSD-95 has been found to undergo various 
modifications, such as palmitoylation and phosphorylation, and these modifications 
strongly affect its localisation and function. Palmitoylation appears to be critical for 
PSD-95’s recruitment to synapses and incorporation into the PSD, and the 
phosphorylation of certain PSD-95 residues appears to affect its interaction with 
NMDA receptors as well as its removal from synapses. Its localisation and stability at 
the PSD are also influenced by its interactions with a variety of proteins, which can 
cause it to be stabilized at PSDs or removed from them. While PSD-95 is affected by 
a multitude of factors, it plays a role itself in recruiting and clustering AMPA receptors 
at the PSD, LTD, LTP, spine growth and stability, and more. It has also been found to 
be activity regulated, being synthesised locally in dendrites in response to mGluR 
activation and cycled out of synapses or degraded in response to NMDAR activation. 
As such, it is a dynamic protein that has been demonstrated to regularly move between 
synapses, while simultaneously playing an important structural role in the PSD. There, 
it has recently been found to be a core component of a wide variety of large, 
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multiprotein supercomplexes that form nanodomains and are thought to be the 
modular cornerstones of the PSD.  
 
In this project, I will be utilising the novel HaloTag technology to investigate the 
turnover of PSD-95 at the synapses of excitatory neurons. My project is based upon 
a strain of genetically engineered mice expressing the HaloTag protein fused to 
endogenous PSD-95, allowing me to visualise the localisation of this PSD-95-HaloTag 
fusion protein using fluorescent HaloTag ligands. My project is principally based upon 
primary neuronal cultures, and in this system, I have developed a novel pulse-chase 
method for the differential labelling of old and new PSD-95 molecules, allowing me to 
localise and analyse these two subpopulations separately.  
 
To provide a very brief overview of the structure of this thesis, I would like to highlight 
that there is a clear division of the results into two parts. The first part is chapter 3, 
which lays a foundation upon which the results of chapter 4 are built. Chapter 3 
essentially characterises the PSD-95-HaloTag knock-in mouse line, probing the 
expression of PSD-95 using a variety of methods, from biochemistry to 
immunohistochemistry and more. In chapter 3, I also present my pulse-chase labelling 
method using the HaloTag technology, and apply it to a simple PSD-95 turnover study. 
In chapter 4, I use these findings to probe PSD-95 turnover at synapses in depth, 
categorising synapses based upon their turnover profiles and ultimately investigating 
















• It is hypothesised that using two different HaloTag fluorescent ligands 
consecutively, in a Pulse-Chase labelling manner, will permit the labelling of 
old and new PSD-95 proteins separately and thereby allow for the calculation 
of PSD-95 turnover.  
 
• It is hypothesised that using fluorescent HaloTag ligands in primary cultures 
and in conjunction with confocal microscopy will enable the quantitative 
visualisation of PSD-95 synthesis and degradation at single synapses.  
 
• It is hypothesised that chemical modulatory drugs that affect neuronal 
signalling will increase or decrease synaptic PSD-95 synthesis and 
degradation.  
 
• It is hypothesised that drugs that prevent protein synthesis will reduce PSD-95 
turnover.  
 
• It is hypothesised that drugs that prevent protein degradation will also reduce 




Main aims:  
 
• Establish a protocol, using the HaloTag technology, that allows me to 
measure PSD-95 turnover at the synapse in neuronal primary cultures.  
 
• Use this protocol to analyse PSD-95 turnover at single synapses.  
 
• Analyse the effects of a range of chemical modulators on PSD-95 turnover.  
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2.1 Biochemistry and mouse genetics 
 
2.1.1. Genetic engineering of PSD-95-HaloTag knock-in mice 
 
All mouse procedures were performed in accordance with Home Office regulations. 
The method and targeting strategy that was used to create the PSD-95-HaloTag mice 
is identical to the one described by Fernandez et al., (2009). The genetic experiments 
were performed by Dr Fei Zhu, Dr Noboru Komiyama and David Fricker. A PSD-95 
intermediate targeting vector that had been previously constructed for use in the 
generation of PSD-95 TAP-tag mice (Fernandez et al., 2009) was used. The HaloTag 
protein was fused to the C-terminal domain of PSD-95 and designed so as to not 
interfere with splicing, as three murine PSD-95 isoforms have been identified as 
containing conserved C-terminal sequences (Bence et al., 2005). The HaloTag coding 
sequence was obtained from Promega. The HaloTag coding sequence was inserted 
into the open reading frame of the PSD-95 gene on the 3’ end, immediately before its 
stop codon (Figure 2.1), using recombination in Escherichia coli as described in 
previously published methods (Liu et al., 2004). Extraction of targeting plasmid DNAs 
was performed using XhoI and BglII endonuclease restriction sites, and the targeting 
vector was linearized with the PvuI enzyme before being electroporated into mouse 
embryonic stem cells. The identification of positive targeting clones was achieved by 
PCR, following which they were cloned, expanded and frozen down, before being 
injected into blastocysts from C57BL/6J mice. Chimeric male mice were then 
backcrossed to wildtype females, generating heterozygous mice. These animals were 
then crossed with transgenic CAG Cre-recombinase-expressing mice, in order to 
excise the neomycin cassette. Once the neomycin cassette was removed, 
heterozygous mice were then crossbred to produce homozygous animals.  
 
2.1.2 Crude synaptosome preparation from mouse brains 
 
This protocol was used on mouse brain tissue to lyse cells and enrich for the PSD 
protein fraction. The brain was taken out of -80 storage, placed into a tight-fitting glass 
homogeniser, 5ml Homogenisation buffer (320mM sucrose, 1mM HEPES (pH7.4)) 
was added, and the brain was homogenised with 12 strokes on ice. This was divided 
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up into 3 2ml Eppendorf tubes and centrifuged at 1000 xg and 2°C for 10 minutes to 
remove debris and vascular tissue. The supernatant (S1) was collected and saved on 
ice. The pellets were resuspended in a total volume of 2ml Homogenisation buffer, 
transferred to the glass homogeniser, and 6 strokes performed. This was transferred 
to Eppendorf tubes and centrifuged again at 1000 xg and 2°C for 10 minutes to remove 
further debris. The supernatant was collected again and pooled with the S1 
supernatant in large centrifuge tubes. This was centrifuged at 18,600 xg and 2°C for 
15 minutes. The supernatant was discarded, and the pellet retained. This pellet was 
resuspended in 2.5ml Homogenisation buffer and 2.5ml 2x Extraction buffer (0.05M 
Tris.HCl (pH8.0), 0.1M NaCl, 2% Na Deoxycholate (DOC)), and left on ice for 1 hour 
to allow for protein extraction. Following this incubation, the lysate was centrifuged at 
10,000 xg for 20 minutes. The supernatant was saved and filtered with a 0.22µm filter 
before being aliquoted, frozen on dry ice and stored at -20°C. Note that all buffers 




Figure 2.1. Generation of HaloTag-PSD-95 knock-in mice.  
a. Domain structure of HaloTag modified PSD-95. PSD-95 domains, including three PDZ, an 
SH3, a GK and C-terminal HaloTag domain. b. Schematic diagram of the targeting strategy 
used for the genomic PSD-95/Dlg4 locus. The Dlg4 allele was targeted with the HaloTag 
sequence inserted before the stop codon (asterisk). The neomycin resistance cassette (neo) 
was deleted between loxP sites (triangle) by crossing the HaloTag-PSD-95 mouse line with 
transgenic Cre-recombinase-expressing mice (bottom diagram). Figure adapted from 
Fernandez et al. (2009).  
 
2.1.3 Crude synaptosome preparation from primary cultures 
 
This protocol used the same principles as those used for the mouse brain PSD 
enrichment, above. The culture dish was taken out of the incubator, the media was 
removed, and the dish placed on ice. The cells were gently washed in ice cold PBS, 
and 500µL ice cold homogenisation buffer (320mM sucrose, 1mM HEPES (pH7.4)) 
containing protease and phosphatase inhibitors was added to each well. Cells were 
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scraped free using a cell scraper or bent pipette tip, before being transferred to a tight-
fitting glass homogeniser on ice. After homogenising with 12 strokes, the lysate was 
transferred to Eppendorf tubes and centrifuged at 18,500 xg for 15 minutes at 2°C. 
The supernatant was aspirated and the pellet retained. The pellet was resuspended 
in 0.5ml Homogenisation buffer and 0.5ml 2x Extraction buffer (0.05M Tris.HCl 
(pH8.0), 0.1M NaCl, 2% Na Deoxycholate (DOC)) containing inhibitors, and left on ice 
for 1 hour to allow for protein extraction. Following this incubation, the lysate was 
centrifuged at 10,000 xg for 20 minutes. The supernatant was saved and filtered with 
a 0.22µm filter before being aliquoted, frozen on dry ice and stored at -20°C.  
 
2.1.4 Bradford assay for protein concentration 
 
This assay was used to detect the total protein concentration in a given sample. The 
exact buffer that the sample was stored in was made up fresh, including inhibitors, and 
diluted down to a DOC concentration of 0.2%. This buffer was used to prepare a serial 
dilution using BSA to obtain the following BSA protein concentrations: 2, 1.5, 1, 0.75, 
0.5, 0.25, 0.125 and 0 mg/ml.  10µL of each sample were mixed with 250µL Bradford 
solution. This was left to sit for 10 minutes at room temperature.  Using the nanodrop, 
a standard curve of the absorbance at the various BSA protein concentrations was 
made, and the R2 value as well as the equation of the line calculated. The R2 value 
was required to be above 0.9 before being accepted. Next, a small quantity of the 
protein samples was diluted down to a Doc concentration of 0.2%. Then 5µL of diluted 
sample were taken, mixed with 125µL Bradford solution, and left to rest for 10 minutes. 
Then the absorbance was measured on the nanodrop, using the same blank (i.e. 0 
mg/ml BSA in the same buffer) as before, with fresh Bradford solution. Using the 
absorbance of the samples and the equation from the standard curve, where y= 
absorbance and x= protein concentration, the protein concentration of each of the 
samples was calculated.  
 
2.1.5 SDS polyacrylamide gel electrophoresis (SDS PAGE) 
 
Samples were thawed on ice. Depending on the number of samples, a 10-well, 12-
well or 15-well gel was used. 12- and 15-well gels could be loaded with up to 15µL 
 34 
and 10-well gels with up to 30µL of sample per well. Samples were prepared in 25% 
LDS sample loading buffer and 10% Dithiothreitol (DTT), with the remaining 65% being 
made up by the sample. When loading equal protein amounts, an amount of each 
sample that corresponded to the same amount of total protein as could be loaded into 
the limiting sample was loaded. The rest of the volume was made up with sterile Mili-
Q water (MQW) in the non-limiting samples. When loading equal volumes, instead the 
same volume of each sample was added to the LDS and DTT. The samples were then 
boiled at 100°C for 5 minutes.   
The gels used were NuPAGE® Bis-Tris pre-cast 4-12% gradient gels. 1x NuPAGE 
MOPS SDS running buffer (Invitrogen), and the XCell SureLock™ Mini-Cell set-up 
were used. Samples were carefully loaded and a pre-stained molecular weight protein 
ladder using a P1000 gel-loading tip. The gel was then run at 200 volts for 50-60 
minutes, or until the first protein bands reached the bottom of the gel.  
Once the run was complete, the gel was removed and transferred to a membrane 
using a semi-dry transfer protocol. This was done by placing the gel onto a membrane, 
between two layers of filter paper. Both filter paper and membrane were incubated in 
NuPAGE transfer buffer (Invitrogen) for about 10 minutes prior. Either a nitrocellulose 
or PVDF membrane were used. Once the set-up for the semi-dry transfer was 
prepared (filter paper, membrane, gel, filter paper), bubbles were removed. The 
current was set to 15 volts and run for 45-90 minutes. After transferring was complete, 
the membrane was removed and stored in 1x PBS, and western blotting performed.  
 
2.1.6 Blue-Native PAGE (BN-PAGE) 
 
This is a form of polyacrylamide gel electrophoresis in which the proteins are not 
denatured or reduced but kept in their native conformation as well as being retained 
within their native complexes. This is done by a) using a Native PAGE sample loading 
buffer rather than LDS or SDS, and no DTT, and b) by not boiling the samples but 
keeping them on ice while preparing the samples.  
 
Samples were prepared on ice as for an SDS PAGE, but in 25% Native PAGE sample 
loading buffer and ~3% coomassie G-250 dye. The remainder was made up with 
sample, and MQW when loading equal protein content. All work was performed on 
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ice. The XCell SureLock™ Mini-Cell set-up was used and samples loaded into the 
well. A Native Mark pre-stained protein standard ladder was used. Native PAGE dark 
blue cathode buffer was added to the centre of the set-up, and Native PAGE anode 
buffer to the sides. The gel was run at 150 volts. The overall running time was 90+ 
minutes. After 20-30 minutes, most (3/4) of the Native PAGE dark blue cathode buffer 
was removed from the centre, and replaced with Native PAGE light blue cathode 
buffer, after which the run was continued. The gels were run until the samples had 
migrated to the very bottom of the gels. This took a total of 90-120 minutes. When the 
progress was very slow, the voltage was increased to 175-200 Volts. After running 
was complete, the gels were transferred gels to 1x NuPAGE transfer buffer for 10 
minutes so as to allow excess coomassie stain to wash off. The semi-dry transfer 
apparatus was set up as in chapter 2.1.5 (SDS PAGE), above. A nitrocellulose 
membrane was used, and once transferring was complete, the protein complexes 
were anchored in the membrane by incubating it for 5 minutes in acetic acid. 
Thereafter, wash the membrane was washed and stored in 1x PBS. Western blotting 
was then performed.  
 
2.1.7 Western blotting and membrane stripping 
 
This is a form of protein immunoblotting which utilises primary and secondary 
antibodies to recognise and visualise a specific epitope.   
The membrane that contained the proteins and/or complexes following SDS or BN 
PAGE was first blocked for 1 hour in 3% milk. After blocking was complete, the 
membrane was washed in 1x PBS containing 1% Tween 20 detergent (PBS-T) to 
wash away excess milk. 3 washes of 5 minutes were performed.  
Primary antibodies were then added overnight. The typical dilution used was 1:1000 
for primary antibodies, and 1% milk was added to continuously coat the membrane 
with milk proteins and hence reduce background noise. About 3ml were required.  
The next morning, the primary antibody was removed. The membrane was again 
washed in PBS-T three times to ensure removal of excess unbound primary antibody. 
Subsequently the secondary antibody was added (often conjugated to HRP for 
visualisation). It was usually diluted to about 1:40,000 or 1:80,000, and contained 1% 
milk. Incubation occured at room temperature, for 1 hour. Following this, the 
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membrane was stringently washed three times in PBS-T for 10-15 minutes per wash. 
A final wash of pure 1x PBS for 5 minutes was performed and the membrane imaged.  
 
Blot membranes were also stripped and re-probed for a different protein in some 
instances. To this end, a stripping buffer such as the Restore western blot stripping 
buffer from Thermo Fisher was used. The membrane was incubated for 5-10 minutes 
(depending on the strength of the bands that needed to be stripped) in the buffer at 
constant rotation and RT. Thereafter, the membrane was washed 3x with PBS-T, 
before beginning the blocking and labelling process anew.  
 
2.1.8 Image acquisition using LI-COR Odyssey system 
 
Once the sample was prepared with primary and secondary antibodies, it was 
proceeded to the image acquisition step. If the secondary antibodies were conjugated 
with HRP, these steps were followed:  
First, the substrate solution was prepared. A 1:1 mix of SuperSignal West Femto 
Stable Peroxide Buffer and Super Signal West Femto Luminol Enhancer Solution 
(stored at 4°C) were added to a falcon tube and vortexed. Carefully the membrane 
was moved out of the 1x PBS it was stored in and placed it into a plastic container that 
allowed the membrane to lie flat. The mixed substrate solution was added onto the 
membrane. Over the course of a minute, the container was tilted repeatedly and a 
pipette used to ensure that the entire membrane was coated.  
Using forceps, the membrane was lifted up and dripped onto some tissue paper. Then 
the membrane was carefully placed onto plastic foil and covered while making sure 
that no air bubbles were trapped inside. The membrane was then placed onto a LI-
COR plastic tray and insert into machine. The relevant channels and capturing time 
were selected. For example, 30 seconds at 700 to capture the pre-stained molecular 
weight ladder and 2 minutes for each other channel. Wavelengths between 500nm 
and 800nm can be captured. Once the correct settings were chosen, imaging was 
completed. After imaging was done, the membrane was carefully removed from the 
plastic pouch and returned to 1x PBS for storage at 4°C. When fluorescent secondary 
antibodies were used, the substrate labelling step was skipped, and the membrane 
imaged immediately, as described above.  
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2.2 HEK cell experiments 
 
2.2.1 Human Embryonic Kidney cell maintenance 
 
In order to gain insights into the HaloTag system, three lines of Human Embryonic 
Kidney (HEK) cells were obtained. One of these lines expressed the HaloTag protein 
fused to another protein, Ahrgap11a. The second line expresses only the HaloTag 
protein on its own, while the third line consisted of plain 293T HEK cells expressing 
no HaloTag protein, as controls.  
All three lines were grown in the same manner. As growth media, Dulbecco’s Modified 
Eagle Medium (DMEM) was used, containing the following supplements: 4.5g/L D-
Glucose, L-glutamine and 25mM HEPES. Stock cells were grown in T75 flasks. Cells 
were grown to 60-90% confluence before being passaged and reseeded, at about 1-
2x106 cells per T75 flask. Cells were passaged roughly every 3-4 days.  
For proteomic analysis, cells were grown in 6-well plates until reaching 80-90% 
confluence before being harvested and subjected to a cell lysis protocol.  
For imaging analysis, cells were grown in 24-well plates on 1.5 thickness glass 
coverslips that had been pre-treated with PDL for 1 hour prior to plating.  
 
2.2.2 Labelling live HEK cells with HaloTag ligands 
 
To test various HaloTag ligands, the HEK cells were subjected to various protocols as 
provided by the Promega manual. Rapid labelling:  
Once cells were grown to 80-90% confluence, the medium was replaced with pre-
warmed medium containing the HaloTag ligand at the desired dilution (typically at 
1:1000). The cells were incubated with the ligand for a given amount of time (typically 
15 minutes). Following ligand incubation, the entire medium was removed, and cells 
were rinsed three times with warm fresh medium. Cells were then incubated in warm 
fresh medium for 30 minutes to wash out unbound ligand from within the cells. 
Following this, cells were harvested for proteomic analysis, or coverslips were fixed 




2.2.3 HEK cell collection for proteomic analysis 
 
Following the ligand addition protocol, above, the 6-well plates were taken out of the 
incubator and the growth medium removed. The plates were placed on ice. Each well 
was gently rinsed with 1ml/well (for a 6-well plate) ice cold PBS two times. 0.3ml ice 
cold Mammalian lysis buffer (0.05M Tris-HCl (pH8.0), 0.15M NaCl, 1% Triton X-100 
and 0.1% Na deoxycholate (DOC)) containing protease and phosphatase inhibitors 
were added to each well. The cells were then scraped free using a cell scraper or bent 
pipette tip  before being collected in a 2ml Eppendorf tube. Cells were then pipetted 
up and down repeatedly (25-30 times) to shear the cells, using a P1000. The cells 
were then incubated in lysis buffer on ice for 30 minutes. They were sheared 
occasionally. After 30 minutes and a final shearing bout, the cells werte spun down at 
14,000 xg and 2-4°C for 5 minutes. The supernatant, being the cell extract, was 




2.3 Neuronal primary cultures 
 
2.3.1 Reagents used during primary culturing 
 
These are the essential stock solutions that were used for primary culturing of neurons:  
 
500 ml working solution of Neurobasal medium (NB; Gibco, Life Technologies, UK): 
484ml Neurobasal, 10 ml B27 Serum Free Supplement (Gibco, Life Technologies, 
UK), 5ml Penicillin / Streptomycin (Gibco, Life Technologies, UK) and 1.25 ml L-
Glutamine (Gibco, Life Technologies, UK). Once ingredients were mixed, the solution 
was filtered using a 0.2μm diameter pore filter and stored for up to 2 weeks at 4°C.  
 
500ml working solution of Dulbecco’s Minimum Essential Medium (DMEM; Gibco, Life 
Technologies, UK): 445 ml of DMEM, 50ml Fetal Bovine Serum Heat-Inactivated and 
5ml Penicillin / Streptomycin. Once prepared, the DMEM solution was filtered using a 
0.2μm diameter pore filter and stored for up to 2 weeks at 4°C.  
 
500 ml working solution of Hank’s Buffered Salt Solution (HBSS; Gibco, Life 
Technologies, UK): 5ml penicillin / streptomycin was added to the solution and it was 
sterilised using a 0.2μm diameter pore filter. This was stored for up to 2 weeks at 4°C.  
 
Papain solution prepared from lyophilised Papain (LS003119, Worthington 
Biochemical Company, Lakewood, NJ, USA): made to 10mg/ml in 1x Dulbecco’s PBS 
(D-PBS; Gibco, Life Technologies, UK) and stored at 4°C for up to 6 months. Papain 
solution was sterilised using a 0.2μm diameter pore filter.  
 
100μg/ml poly-D-lysine hydrobromide (PDL; Sigma Aldrich, P7280) stock solutions 
were prepared in D-PBS and stored at -20°C. Working solutions were diluted to 






2.3.2 Preparation of coverslips and plates 
 
The preparation of coverslips and plates for the plating down of primary neurons was 
performed with care and precision in a sterile environment. The following steps were 
performed:  
 
1.5 thickness coverslips were prepared by first sterilising them via an autoclave and 
then storing them in 70% ethanol. Sterile 24-well plates were prepared by adding 
filtered 1ml 1xPBS to the outer 16 wells. The sterilised coverslips were prepared in 1x 
PBS, and after a final wash in sterilised Mili-Q water each copverslip was placed into 
one of the eight free central wells in the 24-well plate. This set-up ensured that cells 
were grown in conditions of maximum humidity, protected from evaporation and 
temperature fluctuations as much as possible.  
 
Aliquoted laminin mouse tail was slowly thawed out at 4°C, to prevent aggregation 
from rapid thawing. Once thawed, a 10µg/ml working solution was prepared in sterile 
1x PBS. Poly-D-Lysine (PDL) was also thawed. 100µg/ml PDL was diluted in sterile 
(0.2µm pore-filtered) 1x PBS, for a final concentration of 50µg/ml. 1ml filtered PDL 
solution was aqdded to each well containing a coverslip. Coverslips were incubated 
with PDL for 1 hour in an incubator at 37°C and 5% CO2. After PDL-incubation was 
complete, PDL was aspirated and washed in 1x in PBS. Thereafter, 400µL laminin 
working solution was added to each well. Incubation in laminin was for a minimum of 
4 hours at 37°C and 5% CO2, ideally overnight. After incubation was complete, 
coverslips were washed in 1x PBS, followed by the addition of fresh NB media. Plates 
were placed in an incubator for at least 30 minutes to allow NB media to enrich in CO2 
and warm up to 37°C.  
 
2.3.3 Setting up primary cultures of mouse hippocampal neurons 
 
This involved harvesting the hippocampi of mouse embryos at the age of 
approximately E17.5, and growing the neurons in incubators before harvesting them 
and analysing them either proteomically, following PSD protein enrichment, or by 
confocal microscopy if grown on coverslips.  
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Setting up primary cultures involved sacrificing pregnant female mice when the 
embryos had reached an age of about E17.5, removing the heads from the embryos, 
and, in Hank’s Buffered Saline Solution (HBSS) containing 1% Penicillin-
Streptomycin, dissecting out the hippocampus. The hippocampi from embryos were 
pooled and incubated for 20 minutes in papain, a digestive enzyme that breaks up the 
brain tissue into individual cells. The cells were then washed in Dulbecco’s Modified 
Eagle Medium (DMEM) containing 1% Pen-Strep and 10% Fetal Calf Serum (FCS). 
After 2 washes, the cells were re-suspended in 6ml Neurobasal media (NB), 
containing 1% Pen-Strep, 0.25% L-Glutamine, and 2% B27 supplement. The number 
of cells was estimated using a Haemocytometer, and cells were plated at the desired 
density. Cells in a single-cell suspension were diluted 1:1 in 0.4% Trypan Blue (Sigma 
Aldrich) to identify non-viable cells for count exclusion. Cells were then ready to be 
plated down. Wells and coverslips were prepared before plating. For details, see the 
protocol on preparing plates for primary neurons (chapter 2.3.2). For biochemical 
analysis, cells were plated at high density in 6-well plates in order to maximise protein 
yield (1x106 cells per well). For imaging purposes cells were grown in 24-well plates 
on 1.5 thickness glass coverslips at low density (100,000 cells per well). Incubation 
occurred at 37°C and 5% CO2.  
 
2.3.4 Primary culture care and maintenance 
 
Primary cultures were grown in sterile, copper-lined and humidified cell culture 
incubators kept at a constant 37°C and 5% CO2. Primary cultures intended for 
biochemical analysis were grown in 6-well plates in 3ml NB media per well. Following 
plating, after about 3 days in vitro (DIV), 1ml of media was removed, and replaced with 
2ml fresh media that had been pre-warmed to 37°C and incubated in 5% CO2.  
 
For imaging purposes, neurons were plated in 24-well plates. Neurons were not 
cultured in the outer wells (due to evaporation), and these were filled with ~1ml 1x 
PBS to increase the humidity within each plate. On these 24-well plates, initially 
neurons were plated down in 500µL of NB media. After 3 days, a further 300µL of 
fresh NB media was added that had been pre-warmed to 37°C in 5% CO2 for a final 
volume of 800µL per well.  
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From then on, media changes were performed roughly once per week, or when the 
media changed colour to orange (pH indication of a depletion of 
nutrients/accumulation of waste products). No more than half the media present was 
removed, as the neurons secrete chemicals into the media to create an ideal habitat. 
Furthermore, media changes were minimised (1x per week), as greater handling 
increases the stress on the cells. Cohen et al. (2013) remark that: ‘aggressive washes 
and complete media exchanges are severely detrimental to neuronal viability’.  
 
2.3.5 Fixation of cells for imaging 
 
This work was performed protected from light to prevent bleaching of fluorescence.  
Following the ligand addition protocol, the 24-well plates were taken out of the 
incubator and placed on ice. A second plate was prepared beforehand on ice by 
adding chilled 1x PBS. Using a needle with a bent tip for ease of use and clean forceps, 
each coverslip was removed and transferred to the designated well containing PBS. 
The PBS was removed and the coverslips carefully rinsed 2-3 times to remove media. 
0.5ml chilled 4% PFA was added to each well. The plates were then placed on a 
shaker at room temperature, under tin foil, and incubated for 15 minutes. After PFA 
incubation, they were rinsed 3x with PBS and washed in PBS for 5 minutes on shaker. 
They were then rinsed in autoclaved MQ water 1x to remove salt. The cells were then 
either stained with antibodies by following an immunocytochemistry protocol, or simply 




Once cells had been fixed in 4% PFA and washed thereafter, they were ready to be 
stained with antibodies if required. First, a blocking solution to reduce the background 
signal by diminishing the non-specific binding of antibodies to non-target proteins 
(BSA) and to rupture cell membranes and allow antibodies to enter the cellular 
compartments (detergent, e.g. Triton X-100) was prepared. The blocking solution was 
made up of 5% BSA + 0.1% Triton X-100 in 1x PBS. For blocking, the 1x PBS storage 
solution the cells are in was removed and replaced with 0.5ml blocking solution. The 
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plate containing the coverslips was placed onto a shaker, and incubated for 1 hour at 
RT, protected from light. While blocking, the primary antibody solution was prepared. 
This solution contained 1% BSA + 0.1% Triton X-100 and the primary antibody at the 
relevant concentration (usually diluted 1:1000 or 1:500). Once blocking was complete, 
coverslips were rinsed in 1x PBS one time before being carefully lifted out of PBS, 
their edge dabbed on a piece of tissue, and placed cell-side up into a wet-chamber 
(light-sealed petri dish containing a base of moist tissue atop which parafilm is placed 
as a surface). 60µL primary antibody solution was added to each coverslip, the wet-
chamber closed, incubate allowed at 4°C overnight (16 hours). After primary antibody 
incubation was complete, antibody solution was dabbed off and coverslips immersed 
into 1x PBS in prepared wells in a 12-well cell culture plate. They were then washed 
3x using 1x PBS. Secondary antibody solution was then prepared- this was the 
secondary antibody diluted to specifications in 1x PBS. Then the coverslips, after 
dabbing off excess liquid, were placed back into the wet-chamber. 60µL secondary 
antibody solution was added to each coverslip and they were incubated for 1 hour at 
RT. After incubation was complete, coverslips were returned to PBS-filled wells, and 
washed 3x 10 minutes on a shaker at RT. After a final wash in Milli-Q water to remove 
the salt from the PBS, coverslips were ready to be mounted or stored in 1x PBS at 
4°C for a few days.  
 
2.3.7 Mounting coverslips on slides 
 
Once cells were ready to be mounted in preparation for imaging, about 5µL Mowiol 
mounting media (stored in freezer at -20) was added to a glass slide, avoiding bubbles. 
A needle and forceps was used to gently lift the coverslips, dab off excess water, and 
place the coverslip, cells down, onto the mounting media on the slide. The slide was 
then placed horizontally into box, and the box left outside at room temperature 
overnight to allow the mounting media to dry. The boxes were then moved to a freezer 




2.4 Imaging and quantification 
 
2.4.1 High magnification confocal imaging 
 
The confocal Zeiss Laser Scanning Microscope 510 (LSM510) in our lab was 
equipped with multiple lenses, but during project the 63x oil immersion lens was 
exclusively used. The microscope was fitted with an Argon laser (458, 488, 514 nm, 
25 mW), HeNe laser 543 nm, (1mW) and HeNe laser (633 nm, 5mW) for illumination. 
The software used was the Zeiss LSM510 META software.  
In order to satisfy Nyquist sampling criteria, the optical zoom was set to provide pixel 
dimensions of 46 x 46 nm, and the pixel frame set to 1024 x 1024. Images were 
captured with a scan speed of 7 and line averaging of 4. The pinhole was set to one 
Airy disk unit. For each channel and data set, amplifier offset and detector gain were 
set manually in order to maximise capture while minimising saturation and therefore 
loss of information. These settings were then kept constant throughout experiments.  
Settings used throughout for the fluorophores were:  
 
TMR HaloTag ligand:  
The TMR HaloTag ligand has an excitation maximum at 552nm and emission 
maximum of 578nm. The following settings were used:  
HeNe laser (543 nm, 1mW) 
Excitation: 543nm 
Laser power: 50% 
Gain: 700 
Digital offset: -0.20 
Digital gain: 1.00 
Filter: Bandpass 560-615 
  
R110Direct HaloTag ligand:   
The R110Direct ligand has an excitation maximum at 498nm and emission maximum 
of 528nm.  
The following settings were used:  
Argon laser (458, 488, 514 nm, 25mW) 
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Output: 65% (3.3A) 
Excitation: 488 
Laser power: 50% 
Gain: 780 
Digital offset: -0.20 
Digital gain: 1.00 
Filter: Bandpass 505-530 
 
Anti-PSD-95 primary antibody staining with far-red (633) secondary antibody staining 
in neuronal primary cultures:  
HeNe laser (633 nm, 5mW) 
Excitation: 633nm 
Laser power: 30% 
Gain: 640 
Digital offset: -0.60 
Digital gain: 1.00 
Filter: Longpass 650 
 
2.4.2 Detection and quantification of puncta using Imaris 
 
The commercially available Imaris software was used to detect puncta in the high-
resolution images taken using the confocal LSM510 microscope. While the Imaris 
software was able to detect a variety of objects and shapes, such as surfaces, 
volumes, cells and nuclei, the ‘spots’ detection module was selected as this was best 
able to detect puncta within the synaptic size range of 200nm to 800nm (Carlin et al., 
1980; Südhof, 2012). This spots module used a Mexican hat algorithm to identify 
structures. There are certain parameters that needed to be set by the user in the Imaris 
software when detecting spots. These are the seed point estimation diameter, 
background subtraction and spot region threshold, as well as choosing between 
volume or diameter from border. It was opteded for an estimated detection diameter 
of 300nm, as this falls within the synaptic size range and also provided the optimal 
detection spread. Ultimately, it was necessary to adapt the settings to each channel 
individually. Different fluorophores yielded different puncta intensities and antibody-
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labelled puncta could differ in their staining pattern from HaloTag ligand-labelled 
puncta. The final settings used throughout my experiments were as follows:  
 
R110Direct:  
Estimated diameter: 0.3um 
Background subtraction: Quality above 6.00 
Spot region threshold: Automatic 
Diameter from border.  
 
TMR:  
Estimated diameter: 0.3um 
Background subtraction: Quality above 3.67 
Spot region threshold: Manual: 15.32 
Diameter from border.  
 
AntiPSD95:  
Estimated diameter: 0.3um 
Background subtraction: Quality above 5.80 
Spot region threshold: Automatic 
Diameter from border.  
 
When determining optimal settings, it was necessary to balance false positive results 
with false negative results, thus deriving settings that were deemed to minimise both. 
After synaptic puncta were detected, each image was manually inspected and any 
puncta that were clearly non-specific ‘blobs’ of aggregated ligand were deleted. This 
was only done in cases where there was no ambiguity over the identity of the puncta.  
 
Once puncta detection was complete, puncta colocalisation was performed in images 
where appropriate. This colocalisation tool of the Imaris software detected which spots 
from different channels were within a certain distance of each other, centre to centre. 
Since the spot detection parameters were set to an estimated diameter of 300 nm, the 
spot colocalisation parameters were set to a distance of 300 nm as well. For puncta 
juxtaposition, the same colocalisation tool was used, but set to a distance of 600 nm.  
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2.4.3 Statistical analysis 
 
Unless stated otherwise, statistical analysis was performed in Microsoft Excel for Mac, 
version 15.37 (2017 edition) and data was compared using Welch’s t-test. Welch’s t-
test was selected as the default test for statistical difference as studies have indicated 
that this test is superior to the commonly used Student’s t-test. Welch’s t-test reduces 
Type 1 error rates when the assumption of homogeneity of variance is not met, while 
losing little robustness compared to Student’s t-test when the assumptions are met 
(Delacre et al., 2017). Since many of the data sets in this project display unequal 
variance and unequal sample sizes, Welch’s t-test is the superior choice in most 
instances (Ruxton, 2006). In most cases data are written as mean averages ± 
standard error of the mean (SEM). Single-factor analysis of variance (ANOVA) was 
performed using Microsoft Excel. Graphs were also made using Microsoft Excel.  
 
2.5 HaloTag methods 
 
2.5.1 In vitro labelling of crude synaptosome preparation with HaloTag 
TMR ligand 
 
This protocol describes how PSD95-HaloTag fusion proteins were labelled with 
HaloTag ligands in brain lysate prepared from PSD95-HaloTag mice. For my 
experiments, brain lysate from heterozygous PSD95HaloTag/+ mice was used that had 
been enriched for synaptosomes (see crude synaptosome preparation protocol).  
 
The lysate was first thawed slowly on ice. HaloTag TMR ligand was then added to the 
brain lysate at a dilution of 1:500, for a final concentration of 5µM. This lysate was then 
incubated at 4°C on a rotator for 1 hour, and thereafter the SDS-PAGE protocol was 
performed. However, once gel electrophoresis was complete and proteins had been 
transferred to a membrane, no further treatment (such as blocking or western blotting) 
was required. Indeed, following transfer to a membrane, ligand-tagged proteins could 
immediately be visualised using the LiCOR Odyssey system. It was then simply 
proceeded with the Odyssey imaging protocol with the acquisition settings set to to 
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correspond to the HaloTag fluorophore. In this project, the HaloTag TMR ligand was 
used, yet this protocol should be applicable to other HaloTag ligands as well.  
 
2.5.2 Post-fixation labelling of cells and brain slices using TMR ligand 
 
Post-fixation labelling of specimens using HaloTag ligands was very simple and 
straight-forward when using a HaloTag ligand that is cell-membrane permeating. For 
both primary cultures and brain slices the labelling protocol was very similar, and only 
differed in the incubation time. After fixation in 4% PFA was completed, and the 
specimen had been washed, the coverslips or brain slices were moved to a wet-
chamber and an appropriate volume of HaloTag ligand was added to each specimen 
(e.g. about 60µL per 24-well coverslip). The HaloTag ligand was diluted in 1x PBS to 
a concentration of 1µM. The primary cultured neurons were incubated on coverslips 
for 30 minutes at room temperature (RT) and brain slices for 1 hour at RT, protected 
from light. After incubation was complete, the specimen were rinsed in 1x PBS three 
times, before continuing with any other procedures.  
 
2.5.3 Basic single-ligand labelling in live primary cultures 
 
This protocol was used to label all HaloTag fusion proteins in living primary cultures 
with a single membrane-permeating fluorescent ligand, allowing for a quantitative 
visualisation of target proteins within the cell at a given time point. This gave an 
indication of total PSD-95 in synapses and allowed for comparisons of total PSD-95 
levels per synapse with measurements at other time points.  
While the Promega ‘Focus on Imaging’ manual provided a set of concentrations to use 
the HaloTag ligands at, it was found that some of these concentrations were 
needlessly high. While Promega suggest using the TMR ligand at a concentration of 
1µM for 15 minutes and the R110Direct ligand at 0.1µM overnight, it was found that 
concentrations of 100nM for both these ligands were more than sufficient to guarantee 
complete labelling. For single-ligand labelling a concentration of 100nM for both the 
TMR ligand and the R110Direct ligand were suitable.  
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Neuronal primary cultures were grown in 24-well plates on 1.5 thickness glass 
coverslips, in a total volume of 800µL NB media. Fresh NB media that had been 
brought to 37°C and 5% CO2 by pre-incubation in a cell-culture incubator was used to 
prepare a working solution of NB media containing the HaloTag ligand. Per well, 
200µL of fresh NB media containing the HaloTag ligand at a concentration of 200nM 
was prepared. In single-ligand labelling experiments, 600µL of media were then 
removed from the well, leaving the cells in 200µL of remaining media. 200µL of ligand 
in working solution were then added, for a final volume of 400µL media per well and 
final concentration of 100nM HaloTag ligand. For most experiments in this project 
utilising the TMR ligand, a 30-minute incubation time was used. When using the 
R110Direct ligand, cells were incubated with the ligand overnight for about 16 hours. 
After labelling was complete, and since this protocol was a single ligand and single 
time point protocol, cells could immediately be further processed. For imaging, 
coverslips needed to be fixed as per the fixation protocol (chapter 2.3.5).  
 
When labelling primary cultures for biochemical analysis (for instance when using the 
HaloTag biotin-conjugated ligand), the protocol remained essentially the same, with 
the only difference being the volumes used. In that case, cells were grown in 6-well 
plates and a final volume of 3ml. Hence, 2ml of NB media was removed and replaced 
with 1ml fresh NB media containing the ligand at 200nM, for a final 2ml at 100nM. After 
labelling was complete, cells were washed and harvested for further biochemical 
analysis as per the protocol outlining PSD protein extraction from primary cultures 
(chapter 2.1.3).  
 
2.5.4 Titration of HaloTag ligands to establish saturation concentrations 
 
This experiment aimed to work out what concentration of the pulse ligand was required 
to saturate all the available HaloTag binding sites and thereby prevent labelling by a 
chase ligand added subsequently. It was also designed to demonstrate that there is a 
direct positive correlation between pulse ligand concentration and fluorescence 
intensity at concentrations below the saturation point, inversely linked to the chase 
ligand concentration (i.e. a negative correlation between pulse ligand intensity and 
chase ligand intensity).  
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Primary neurons were grown on glass coverslips until developmental stage DIV14. On 
DIV14, they were labelled with the TMR ligand as a pulse ligand. This was done by 
following the single-ligand labelling protocol (see chapter 2.5.3), but with varying TMR 
ligand concentrations. The TMR ligand was titrated from a concentration of 500nM to 
5x10-12nM in steps of a factor of 10, and a blank (no pulse ligand) was included. Cells 
were incubated with TMR pulse ligand for 30 minutes, before being washed and fixed 
in 4% PFA (see chapter 2.3.5). Following fixation, coverslips were then moved into a 
light-proof wet-chamber and incubated with diAcFAM ligand at a concentration of 1µM 
in PBS for 1 hour at RT. After incubation was completed, the coverslips were washed 
in 1x PBS three times, followed by antibody staining for PSD-95 using the 
immunocytochemistry protocol (chapter 2.3.6). Coverslips were then imaged using the 
LSM510 confocal microscope, and synaptic puncta detected using the Imaris 
software. The average puncta fluorescence intensity (APFI) per image for both pulse 
and chase ligand puncta was established. It was then possible to plot the APFI values 
of both pulse and chase ligand puncta over the titration steps in the pulse ligand 
concentration.  
 
2.5.5 Analysis of fluorophore stability using a plate reader 
 
This set of experiments was performed to evaluate the stability of HaloTag ligand 
fluorophores over longer time periods in neurobasal media in a cell culture incubator. 
Ligand working solution was prepared in five Eppendorf tubes by adding HaloTag 
ligand to PBS for a final concentration of 200nM. In a 96-well cell culture plate, 5 wells 
were filled from each Eppendorf, for a total of 25 wells. This gave a total of 5 technical 
replicates for each biological replicate (N=5). PBS and NB alone were used as controls 
and could be used to normalise to. This plate was then imaged using a plate reader, 
hence giving a fluorescence intensity read-out for each well. The 96-well plate along 
with the remaining working solution were then transferred into a cell culture incubator 
at 37°C and 5% CO2 and stored there for 24 hours. After 24 hours, 5 new wells in the 
same 96-well plate were filled from the same five Eppendorf tubes containing the 
ligand working solution. The well was then imaged again using the plate reader. This 
allowed for the monitoring of the change in fluorescence intensity for the samples that 
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had already been imaged on the first day of the experiment (i.e. the solution remaining 
in the wells), as well as measuring the fluorescence intensity of the working solution 
that was only imaged once, after 24 hours in the incubator. The samples that were 
imaged twice (on day 1 and day 2 of the experiment) gave a slightly reduced 
fluorescence reading after 24 hours (but not significantly so), most likely due to the 
photo-bleaching effect of the first imaging session. The samples that were retained in 
the Eppendorf tubes over the 24 hours and only imaged once, on day 2, displayed the 
same fluorescence intensity as the samples imaged on day 1 (see chapter 3.3.6).  
 
 
2.5.6 Pulse-Chase method for the study of protein turnover 
 
Introduction 
In this section, the pulse-chase method developed during this project that uses the 
HaloTag system to visualise the synthesis and degradation of PSD-95 will be outlined 
in detail. The underpinning principle is this: The pulse ligand labels all PSD95-HaloTag 
fusion proteins present, and thus saturates all HaloTag binding sites. After pulse 
labelling is complete, the pulse ligand is removed and replaced by the chase ligand. 
This ligand will initially be unable to bind to anything, as all existing fusion proteins will 
have their binding sites taken by the pulse ligand. However, over the 24 hours of chase 
incubation new fusion proteins will be formed, and as they are synthesised their 
HaloTag binding sites will be tagged by the chase ligand. Once the cells have been 
incubated with the chase ligand for 24 hours (or 48 hours, depending on the time-
window to be studied) and have been fixed, two different subpopulations of the fusion 
protein will exist: proteins labelled by the pulse ligand (in essence ‘old’ proteins that 
were present during the pulse-labelling phase) and proteins labelled by the chase 
ligand (these must have been synthesised within the chase labelling period, e.g. over 
the last 24 hours of the experiment). After 24 hours of chase incubation it is now 
possible to separately analyse synaptic puncta made up of old or new fusion proteins.    
 
Protocol 
A time frame was decided over which to perform the experiment- in this project, a 24-
hour time-frame of PSD-95-HaloTag turnover analysis (between DIV15 and DIV16) 
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was used. The R110Direct pulse ligand was prepared by making up a working 
solution. This working solution consisted of fresh, fully prepared NB media, to which 
the R110 ligand was added for a working concentration of 200nM. 100µL per well were 
needed. This working solution was incubated in the cell culture incubator for at least 
30 minutes to raise its temperature and CO2 levels to 37°C and 5%, respectively. On 
DIV 14 the cells in their plates were taken out of the incubator and into the sterile fume 
hood. To minimise photo-bleaching, the light inside the fume hood was turned off. 
500µL of the media the cells were being cultured in was removed (leaving the 
remaining 300µL in the well) and this media saved in a falcon tube (all the collected 
media was pooled together). This solution was stored in the cell culture incubator with 
the lid slightly opened. Gently, 100µL of the 200nM pulse ligand working solution was 
added to each well, giving a final pulse ligand concentration of 50nM in 400µL in each 
well. Carefully, the cells were returned to their incubators, and left undisturbed 
overnight, for about 16 hours. The next day, on DIV15, a chase ligand working solution 
was first prepared. However, the preconditioned media that was saved from the day 
before was used as the base. 300µL of working solution was needed per well. Enough 
TMR HaloTag ligand was added to this media to give a TMR concentration of 666nM 
in this working solution. The cells were moved out of the incubator and into the fume 
hood. 300µL of the 400µL were removed. Quickly and gently this exact volume was 
replaced with 300µL of chase ligand solution. This resulted in a final volume of 400µL 
in each well, at a final concentration of 500nM for the chase ligand and 12.5nM for the 
pulse ligand. At these concentrations, the chase ligand was able to outcompete the 
pulse ligand for all available HaloTag binding sites (see chapter 3.4.3). The plates 
were returned to the incubator and incubated for as long as designed in the 
experimental timeframe. After incubation was complete, the coverslips were carefully 
removed from the wells and moved to wells in a separate plate filled with ice cold 1x 
PBS. Then washing and fixing of the cells according to the ‘fixation’ protocol in chapter 
2.3.5 was performed. A ‘0’ time point was included, i.e. a measurement at the start of 
the experiment to which later time points could be compared. This time point also 
served as an internal control, as it permitted checking that pulse ligand labelling was 
saturating all HaloTag binding sites. In this protocol, a 1 hour incubation with the chase 
ligand was included. Since PSD-95 has a relatively long half-life (see chapter 3.4.5), 
this 1-hour incubation served as a ‘0’ time point, as minimal new PSD-P5 would have 
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formed or old PSD-95 have been degraded at this point. Thus, rates of synthesis or 
degradation could be calculated based upon this starting measurement.  
 
One thing that is important to note is that whole-media changes, as advocated by 
Promega’s ‘Focus on Imaging’ manual, are incompatible with primary neurons. While 
such protocols may be suitable for hardy cell lines such as HEK cells, primary neurons 
are unable to survive washing and complete media changes (Cohen et al., 2013). It is 
for this reason that the pulse ligand was merely diluted down from 50nM to 12.5nM 
during the chase ligand incubation, rather than entirely removed. However, it was 
demonstrated that at these experimental concentrations the TMR chase ligand is able 
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3.1 Chapter overview 
 
The primary aim of this chapter is to provide a thorough narrative of the experimental 
approach I took to develop a set of methods with which to quantify the synthesis and 
degradation of endogenous PSD-95 at individual synapses. In developing these 
methods, I am able to provide insights into the biological functioning of PSD-95, and 
thus this chapter will also provide an insight into the turnover rates of this protein. Most 
of the work presented in this chapter was conducted so as to establish an experimental 
toolkit that could be used to pursue more complex and probing questions into the 
dynamics of PSD-95 in future experiments- these results will be presented in chapter 
4. I will first outline my characterisation of the transgenic mouse model (PSD-95HaloTag) 
that is the basis of my project, and from there move on to exploring the applications of 
the HaloTag system with regards to studying PSD-95 turnover.  
 
In chapter 3.2 I will characterise different aspects of the PSD-95HaloTag mouse model, 
including a biochemical analysis of the protein’s expression level and 
electrophysiological analysis. In chapter 3.3 I explore different in vitro HaloTag ligand 
labelling techniques in the model, such as labelling live cells in primary cultures, and I 
investigate some of the limitations of the methods. In chapter 3.4 I focus on 
establishing a Pulse-Chase method with which I can quantify PSD-95 turnover, and 
which will form the basis of the experiments outlined in chapter 4. Chapter 3.5 will 
discuss my in vivo experimental efforts, and finally chapter 3.6 will summarise and 
discuss the overall findings of chapter 3.  
 
3.2 Characterisation of the PSD-95-HaloTag mouse model 
 
3.2.1 Biochemical analysis of PSD-95-HaloTag expression levels in the 
Knock-in mouse line 
 
The primary objective of my project was to utilise the PSD-95HaloTag mouse line to 
quantify the rate of turnover of PSD-95. Most previous knock-in (KI) mouse lines 
created in our lab using the same gene targeting technique were found to be 
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physiologically normal: the mice expressed the targeted protein at normal levels, they 
did not exhibit any aberrant behaviour and had a ‘normal’ electrophysiological profile 
(Frank et al., 2016; Fernandez et al., 2009; PhD thesis Dr. Fei Zhu); however, one KI 
mouse line did exhibit an abnormal profile (PSD-95-mEos2, Broadhead et al., 2016). 
PSD-95 deficiency is known to have a significant impact on synaptic activity and 
behaviour in mice (Migaud et al., 1998), and thus it is possible that a PSD-95 
deficiency could also affect PSD-95 turnover. It was therefore important to confirm that 
PSD-95-HaloTag expression levels in the KI mouse line were similar to those in WTs.  
 
To biochemically test the PSD-95HaloTag KI mouse line for phenotypic abnormalities, 
whole mouse brains from wild-type (WT), heterozygous (Het, PSD-95HaloTag/+) and 
homozygous (Hom, PSD-95HaloTag/HaloTag) mice were homogenised and crude 
synaptosome preparations performed, as per methods chapter 2.1.2. Three 
preparations for each genotype were loaded into 4-12% gradient Bis-Tris gels, with 
equal volumes loaded into each well (20µL). The gels were then subjected to SDS 
PAGE and western blotting. The membrane was probed with antibodies for three 
different proteins, sequentially. First, western blotting for PSD-95 was performed. The 
membrane was then stripped using western blot stripping buffer, and this was followed 
up with a western blot for α-Tubulin (as a loading control). The membrane was then 
stripped once more, and further western blotting performed for the HaloTag protein. 
Bands corresponding to PSD-95, PSD-95-HaloTag and α-Tubulin were then detected 
using the LI-COR Odyssey imaging system.  
 
WT PSD-95 has a molecular weight of 80kDa (Husi et al., 2000; Cai et al., 2006), while 
the HaloTag protein has a molecular weight of 33kDa (Los et al., 2008; Lang et al., 
2006). Thus, the PSD-95-HaloTag fusion protein can be expected to have a molecular 
weight of about 113kDa. The resulting bands from the western blotting revealed bands 
corresponding to precisely these molecular weights (Figure 3.1.a). Note that faint 
banding can be detected just below all of the PSD-95 and PSD-95-HaloTag bands. 
These bands were consistently detected, and as such are unlikely to be the result of 
protein degradation. Furthermore, they are not the result of the antibody labelling an 
off-target protein, as Figure 3.4 (below) also contains this band when only the HaloTag 
ligand is used for labelling. While it was impossible to determine the identify of this 
faint band, one explanation is that a truncation event may occur as part of a post-
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translational modification in a small subset of PSD-95 proteins, thereby lowering their 
molecular weight.  
 
Next, the total amount of PSD-95 protein present in each sample was quantified using 
the LI-COR Image Studio software. In the samples from heterozygous mice, both 
alleles (mutant and WT) were added together to obtain the total amount of PSD-95. 
Variations between samples could be detected using the tubulin loading control 
(Figure 3.1.b). The quantity of PSD-95 was thus normalised to the tubulin loading 
control. Average PSD-95 expression levels were calculated for each genotype (Figure 
3.1.c) (WT: 1785 ± 232; Het: 3004 ± 1299; Hom: 2407 ± 188 (Arbitrary Units, AU)), 
and a single-factor analysis of variance (ANOVA) performed. It was found that there 
is no significant difference in total PSD-95 expression at the p<0.05 confidence level 
between WT, Het and Hom samples [F(2, 6)=0.63, p=0.57]. However, it was observed 
that WT mice appear to express slightly less PSD-95 overall than either Het or Hom 
mice. Next, within heterozygous samples the amount of PSD-95 in WT and mutant 
alleles was compared. Again, the difference between the two was not found to be 
significant (Het: 492 ± 126; WT: 271 ± 64 AU), (Welch’s T-Test, p=0.22) (Figure 3.1.d), 
yet heterozygous mice do appear to express slightly more of the mutant than of the 
WT allele.  
 
The blot membrane was finally probed with a primary antibody against the HaloTag 
protein. This blot was performed by my lab colleague and fellow PhD student, Sarah 
Lempriere. The result reveals very strong and clear PSD-95-HaloTag bands at about 
113kDa, as expected, in both Hom and Het mice, with no bands present in WT mice 
(Figure 3.1.e). Bands from each genotype were quantified as before, averaged, and 
compared. This comparison revealed that Het mice express half as much PSD-95-
HaloTag as Hom mice (66.7 ± 8.1 vs 134.3 ± 6.7 AU, or 49.7%). This difference is 




































































































Figure 3.1. PSD-95 expression is normal in PSD-95-HaloTag knock-in mice.  
a. Western blot following SDS PAGE, stained with anti-PSD-95 antibody (Mouse, BD 
Bioscience, 1:5000). Samples loaded were crude synaptosome preparations taken from three 
WT, three Het (PSD-95HaloTag/+) and three Hom (PSD-95HaloTag/HaloTag) mice. WT PSD-95 was 
found to migrate as an 80kDa band, while the PSD-95-HaloTag fusion protein migrated as a 
113kDa band due to the addition of the 33kDa HaloTag protein. b. The membrane shown in 
(a.) was stripped and re-probed with an anti-α-Tubulin antibody (Rat, Serotec, 1:5000 
dilution) as a loading control. c. Graph showing the quantification of total PSD-95 levels in the 
blot shown in (a.) following a normalisation to the tubulin loading control shown in (b.). The 
graph depicts the total amount of PSD-95 as a mean of the three samples in each group. No 
significant difference was found in PSD-95 levels between WT, Het and Hom mice (single-
factor ANOVA, [F(2, 6)= 0.63, p=0.57]). d. Graph comparing mean PSD-95 expression levels of 
WT and mutant alleles of PSD-95 in Het mice. The difference was not found to be significant 
(Welch’s t-test, p=0.22). e. The membrane shown in (a. and b.) was stripped and re-probed 
with an anti-HaloTag antibody (Mouse, Promega, 1:1000 dilution) by fellow PhD student 
Sarah Lempriere. Hom and Het samples display a strong HaloTag signal, which is absent in WT 
samples. f. Quantification of the anti-HaloTag signal in Hom and Het mice found in (e.). Het 
mice express half as much (49.7%) PSD-95-HaloTag protein as Hom mice. This difference is 
statistically significant (Welch’s t-test, p=0.003). Note: in all graphs, error bars denote the 
standard error of the mean (SEM).  
 
 
The results indicate that the expression level of the mutant allele and the WT allele of 
PSD-95 are not significantly different in PSD-95HaloTag KI mice (N=3 mice for each of 
the three genotypes). However, a slightly enhanced expression level of the mutant 
allele was observed in both Hom and Het mice. This observation may warrant a closer 
examination in the future, as it could indicate an overexpression phenotype, 
particularly in the light of the fact that the sample size in this study was relatively small 
(N=3 mice for each of the three genotypes). A larger sample size may provide greater 
confidence in the result that the differences are not statistically significant. This study 
concludes that the HaloTag KI mutation does not impact upon overall PSD-95 
expression levels in the brains of adult mice. The study also finds that total PSD-95-
HaloTag protein expression levels are exactly proportional to the number of mutant 






3.2.2 Biochemical analysis of PSD-95-HaloTag fusion protein 
localisation to signalling complexes 
 
Having established that the overall expression level of the PSD-95-HaloTag fusion 
protein is not significantly different from PSD-95 expression in WT mice, I next wanted 
to demonstrate that the PSD-95-HaloTag fusion protein is still incorporated into the 
same multiprotein signalling complexes that WT PSD-95 is a part of. PSD-95, as one 
of the predominant scaffolding proteins in the postsynaptic densities of glutamatergic 
neurons in the CNS (Fernandez et al., 2009; Husi et al., 2000; Husi and Grant, 2001; 
Chen at al., 2005; Cho et al., 1992), is part of large, multiprotein signalling complexes 
found to be approximately 1.5MDa in size (Frank et al., 2016; Frank et al., 2017). In 
PSD-95 KO mice, these complexes fail to form, leading to deficits in learning and 
behaviour (Migaud et al., 1998). Hence, I wanted to test whether PSD-95-HaloTag 
proteins are able to be incorporated into 1.5MDa supercomplexes in our mouse line, 
and thus discover whether fusing the HaloTag protein to PSD-95 impacts upon the 
protein’s ability to assemble these complexes.  
 
Synaptosome preparations were prepared as in chapter 3.1.2 from mice of three 
different genotypes: Het (PSD-95HaloTag/+), WT (PSD-95+/+), and complete PSD-95 
Knock-out (PSD-95-/-). I then subjected these samples to a Blue-Native (BN) PAGE, a 
technique that neither denatures proteins, nor breaks apart protein complexes, 
thereby retaining them in their natural state (Schägger, 2001). I then proceeded with 
a western blot for the HaloTag protein, which I identified at the expected 1.5MDa size 
solely in the samples from the Het mice (Figure 3.2.a). The membrane was then 
treated with stripping buffer as per chapter 2.1.7, and re-probed with an antibody 
against PSD-95. This second blot revealed a complete overlap in PSD-95 signal with 
the previous HaloTag signal (Figure 3.2.b). As the samples were from heterozygous 
mice, the results strongly indicate that both mutant and WT alleles indeed form part of 
the large multiprotein complexes that PSD-95 is known to assemble. However, an 
alternative explanation for this result is that, since these extracts were made from 
heterozygous mice and synaptic PSD-95 is known to frequently form dimers while part 
of 1.5MDa complexes (Frank et al., 2017), the anti-HaloTag signal found at 1.5MDa is 
due to PSD-95-HaloTag proteins that have dimerised with wild-type PSD-95, which 
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has in turn tethered this dimer to the 1.5MDa signalling complex. In this scenario, it is 
possible that mutant PSD-95-HaloTag proteins are unable to incorporate into these 
signalling complexes without the aid of a WT PSD-95 molecule. This question is easy 
to resolve, however, by repeating this experiment with brain extracts from 
homozygous PSD-95HaloTag/HaloTag mice.  
 
An interesting study to follow up with could be to more deeply probe the composition 
of these 1.5MDa complexes, as was done by Husi et al. (2000) using mass 
spectrometry and immunoblotting. Thus one could investigate whether the mutation to 
the PSD-95 protein has any effect on the molecular composition of these 1.5MDa 
signalling complexes. Indeed, such a study would be facilitated by the HaloTag’s ability 
to function as an affinity pull-down tag. This is possible as there exist commercially 
available biotin-ligands, permitting the isolation of HaloTag fusion proteins and their 
interactors through the biotin-streptavidin interaction. Furthermore, Promega also 
offers resin beads with HaloTag ligand binding groups attached, meaning that these 
can also be used to purify PSD-95-HaloTag fusion proteins and their associated 
binding partners and complexes.  
 
In summary, the results from the BN PAGE analysis indicate that the PSD-95-HaloTag 
fusion protein is still capable of assembling the 1.5MDa super-complexes that are 
thought to play such an important role in synaptic signalling. This gives credence to 

















Figure 3.2. PSD-95-HaloTag fusion proteins continue to incorporate into multiprotein 
signalling complexes.  
a. Synaptosome preparations from a PSD-95HaloTag/+ (Het) mouse, a WT mouse and a PSD-95-
/- KO mouse where subjected to Blue-Native PAGE, and western blotting was performed using 
an antibody against the HaloTag protein (Mouse, Promega, 1:1000). Clear bands are visible at 
~1.5MDa in each of the two Het lanes, but not in any other lane.  
b. The membrane in (a.) was stripped and probed with an anti-PSD-95 antibody (Rb, BD 
Bioscience, 1:1000). Clear bands are visible at ~1.5MDa in the WT and both Het lanes, but not 
the PSD-95 KO lane. PSD-95-HaloTag appears to be normally incorporated into 1.5MDa 






3.2.3 Electrophysiological analysis of the PSD-95-HaloTag Knock-in 
mouse line 
 
It has previously been found that knocking out PSD-95 results in a distinct 
electrophysiological and behavioural phenotype (Migaud et al., 1998). Thus, we 
wanted to assess whether the PSD-95HaloTag mouse line displays significantly altered 
electrophysiological characteristics that might indicate altered synaptic function. This 
electrophysiological analysis was performed by Thomas O’Dell, and the results are 
displayed in Figure 3.3. It was found that for both heterozygous and homozygous PSD-
95HaloTag mice, none of the results differed significantly from wild-types (p>0.05; N= 5 
(WT); 5 (het); 4 (hom)). Properties analysed were: Fiber volley/fEPSP input/output 
curves generated by eliciting fEPSPs (Figure 3.3.a); Paired-pulse facilitation (Figure 
3.3.b); Excitatory postsynaptic currents (EPSCs) (Figure 3.3.c); Ratio of NMDAR to 
AMPAR-mediated currents (Figure 3.3.d); Weighted decay time constants for currents 
(Figure 3.3.e); Examples of sEPSCs (Figure 3.3.f); Cumulative probability plots of 
sEPSC amplitudes (Figure 3.3.g) and of inter-event intervals (Figure 3.3.h); analysis 
of fEPSP profiles in brain slices after LTP induction (Figure 3.3.i). It can thus be 
concluded that PSD-95HaloTag KI mice are electrophysiologically normal.  
 
It is important to note that no behavioural experiments were performed alongside the 
electrophysiological expoeriments. In 1998, Migaud et al. found that mice lacking 
PSD-95 also had an abnormal electrophysiological profile, as they displayed a 
dramatic propensity for LTP induction at very low frequency stimulation (1Hz). This 
included paired-pulse facilitation, which was significantly greater in mutant than WT 
mice. PSD-95-KO mice also displayed aberrant behaviour, as they failed to reveal 
spatial learning capabilities in the open-field watermaze.   
Our mouse line did not display aberrant paired-pulse facilitation. However, no 
behaviour experiments were conducted, and it is possible that the knocking-in of the 
HaloTag protein into the PSD-95 sequence could have had different effects than those 
found when PSD-95 was knocked out. As such, while behavioural deficits may be 
accompanied by electrophysiological phenotypes in some instances, the link between 
the two has been insufficiently explored to be able to rule out a behavioural phenotype 





Figure 3.3. PSD-95-HaloTag knock-in mice are electrophysiologically normal.  
a. Fiber volley/fEPSP input/output curves generated by eliciting fEPSPs with intensities of 
presynaptic stimulation corresponding to 100, 75, 50, and 25% of max. Results are from 5 wild 
type mice, 5 hets, and 4 homozygous mutants. b. Paired-pulse facilitation is normal in PSD-95 
halo mutants. Results are from 5 wild type mice (20 slices), 5 hets (21 slices), and 4 
homozygous mutants (18 slices). c. Example excitatory postsynaptic currents (EPSCs) 
recorded at membrane potential of -80 and +40 mV in wild type and homozygous mutants. 
d. Ratio of NMDAR to AMPAR-mediated currents recorded at Vm = +40 mV. No difference with 
one-way ANOVA, F(2,11) = 0.345, P = 0.717. e. Weighted decay time constants for currents 
elicited at Vm = +40 mV. No difference in decay times F(2,11) = 3.602, P = 0.071. Results in B and 
C are from 5 wild type mice (19 cells), 3 heterozygous mutants (12 cells), and 4 homozygous 
mutants (16 cells). f. Examples of sEPSCs (5 superimposed, 1 second-long recordings for each). 
g.-h. Cumulative probability plots of sEPSC amplitudes (g.) and inter-event intervals (h.). 
Results are from 4 wild type mice (11 cells), 3 hets (11 cells) and 4 homozygous mutants (15 
cells). Histograms show mean (± SEM) values. One-way ANOVAs for the results shown in the 
histograms: F(2,8) = 0.049, P = 0.952 for sEPSC amplitude and F(2,8) = 0.836, P = 0.921 for sEPSC 
frequency.  i. LTP induced by two, 1-second-long, trains of 100 Hz stimulation (delivered at 
time = 0, inter-train interval = 10 sec). Sixty minutes post-100 Hz stimulation fEPSPs were 
potentiated to 191 ± 4.5% of baseline in wild type slices (n = 10 slices from 5 mice), 179 ± 1.3% 
of baseline in het slices (n = 10 slices from 5 mice), and 186 ± 8.2% of baseline in slices from 
homozygous mutants (n = 9 slices from 4 mice). One-way ANOVA gives F(2,11) = 1.706, P = 
0.226. 
 
3.3 Using the HaloTag system to label PSD-95-HaloTag fusion 
proteins with ligands 
 
3.3.1 In vitro labelling of crude synaptosomes with HaloTag ligands 
 
One of the key aims early on in the project was to demonstrate that it is possible to 
label the PSD-95-HaloTag fusion protein with HaloTag ligands in a variety of 
experimental scenarios, thereby laying a foundation upon which to design future 
experiments. One early pilot study in this area involved adding a commercially 
available HaloTag ligand (carboxytetramethyrhodamine (TMR) ligand) to a crude 
mouse brain synaptosome preparation (brain lysate enriched for synaptic proteins), 
subjecting this to SDS PAGE and then imaging the membrane using the LI-COR 
imaging system. This technique functions similarly to a western blot in that it allows 





Figure 3.4. In crude synaptosome preparations the PSD-95-HaloTag fusion protein can be 
labelled with the HaloTag TMR ligand and be visualised by SDS PAGE  
Crude synaptosome preparations from a heterozygous PSD-95HaloTag/+ mouse (Het + TMR) and 
a wild-type mouse (WT + TMR) were incubated with carboxytetramethylrhodamine (TMR) 
ligand (1µM) for 1h at 4°C (negative control: Het, NO TMR). As further controls, HEK293 cells 
expressing the HaloTag protein, alongside WT HEK293 control cells, were lysed and also 
incubated with the HaloTag TMR ligand for 1h at 4°C (negative control: Halo-HEK cells not 
incubated with TMR). The gel was then subjected to SDS PAGE, and imaged using the LiCOR 
imaging system. A strong, distinct band is visible at 113kDa in the Het + TMR lane for the 
mouse synaptosome preparations, corresponding to the expected molecular weight of the 
fusion protein combining PSD-95 (80kDa) with the HaloTag protein (33kDa). There is an even 
stronger band at 33kDa in the Halo-HEK cell lane treated with TMR. Thus, both samples 
expressing the HaloTag protein and exposed to TMR ligand display very strong and specific 
labelling that is absent in all of the negative control lanes. This demonstrates the viability of 
using the HaloTag system to visualise proteins of interest using SDS PAGE without the 
requirement for antibodies. Note the lack of non-specific banding that is often associated 
with western blotting, and lack of signal in the negative control lanes.  
 
Crude synaptosomes were prepared from the brains of a heterozygous PSD-95HaloTag/+ 
mouse and a WT mouse, as per methods chapter 2.1.2. TMR ligand was then added 
to 100 µL of lysate at a final concentration of 5 µM, and incubated at 4°C with constant 
rotation for 1 hour.  
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Human Embryonic Kidney (HEK293) cells expressing the HaloTag protein on its own 
(not fused to a second protein) were kindly provided by Dr. Masaru Ishii’s lab in Japan 
and used as positive controls in this experiment. These Halo-HEK cells were lysed in 
mammalian lysis buffer (see chapter 2.2.3) and incubated with TMR ligand in the same 
manner as the mouse synaptosome preparations had been treated, i.e. incubated at 
4°C with constant rotation for 1 hour. For both HEK cells and synaptosome 
preparations, negative controls were either HaloTag-containing samples that did not 
receive any TMR ligand treatment (untreated controls), or WT samples 
(synaptosomes and HEK cells) not expressing the HaloTag protein that were treated 
with the TMR ligand (WT controls).  
 
These samples were subjected to SDS PAGE and transferred to a nitrocellulose 
membrane as per the protocol in chapter 2.1.5. The membrane was then imaged using 
the LI-COR Odyssey imaging system, without requiring the addition of antibodies.  
 
The results showed a distinct and highly specific band corresponding to PSD-95-
HaloTag at the expected molecular weight of 113kDa (Figure 3.4), with an emission 
range of 500-600nm (The TMR ligand emits maximally at 578 nM). Note that this 
experiment was performed on a synaptosome preparation from the brain of a 
heterozygous knock-in mouse, and thus in a homozygous sample an even stronger 
signal would be expected. The positive control lane, containing TMR-treated Halo-
HEK cell lysate, also displayed a very strong band at about 33kDa, thus corresponding 
to the molecular weight of the HaloTag protein. This band is markedly more intense 
than the band in the synaptosome sample, presumably because the HEK cell line is 
expressing the HaloTag protein at a very high level, driven by the human 
cytomegalovirus (CMV) intermediate early enhancer/promoter (see Promega website 
for product details). Furthermore, equal volumes were loaded into the gel wells, and 
the HEK cell culture had been grown to a very high density (About 90% confluence at 
the time of harvesting). Wild-type lanes and untreated control lanes did not exhibit any 
signal (not even non-specific background bands).  
 
This result reveals that in vitro labelling of homogenised brain tissue from PSD-95-
HaloTag mice is feasible and can be used in place of western blotting. This has great 
implications, as western blotting can frequently yield ambiguous results, arising due to 
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the experimental process producing ‘dirty’ blots from the blocking solution or 
nonspecific adherence of the antibody to the membrane, non-specific labelling of non-
target proteins, epitope similarities leading to other proteins being labelled, and 
potentially species cross-reactivity of the antibodies. Using a HaloTag ligand instead 
not only provides a much cleaner result, but also gives much greater confidence in the 
result since specificity is so high, and the potential cross-reactivity with native proteins 
in most systems is greatly reduced due to the HaloTag’s bacterial source (Los et al., 
2008).  
This experiment’s results also serves to underline the strength of the covalent ester 
bond formed between the chloroalkane linker of the HaloTag ligand and the deep 
hydrophobic pocket of the HaloTag protein. This bond was not broken by the boiling 
of the sample at 100°C for 5 minutes, nor by the subjection to the denaturing SDS 
detergent during SDS PAGE, in agreement with results by Los et al. (2008).  
 
3.3.2 Labelling of fixed mouse brain slices with HaloTag ligands 
 
A further important experiment that was performed was the attempt to stain fixed brain 
slices from PSD-95HaloTag KI mice using HaloTag ligands. According to Los et al. 
(2008), HaloTag ligands can be used to label HaloTag proteins in fixed tissue. 
Nevertheless, it was important to demonstrate that HaloTag ligands are capable of 
penetrating the protein-rich postsynaptic density after cross-linking by PFA fixation has 
taken place. Furthermore, this would reveal whether the expression pattern of the 
PSD-95-HaloTag fusion protein in the KI mouse line matches that of PSD-95 in control 
samples.  
 
Coronal brain sections were prepared from adult heterozygous PSD-95HaloTag/+ mouse 
brains that had been prepared by cardiac perfusion. Sections were cut to a thickness 
of 18µm using a cryostat. Perfusions and sectioning were kindly performed by 
technician Jamie Rose. TMR ligand was diluted in PBS to a 1µM concentration 
(1:1000), and brain sections incubated for 1 hour at room temperature. 
Immunohistochemistry was performed using a mouse anti-PSD-95 antibody 
(Neuromab, 1:1000). Sections were then imaged, first using the Zeiss Axio Scan.Z1 






c.      d.  
  
e.      f.  
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Figure 3.5. Imaging of coronal brain sections of PSD-95-HaloTag mice treated with TMR 
ligand post fixation.  
a.-b. Fixed brain sections were imaged at low-magnification (20x) using the Axio Scan slide 
scanner. Hippocampal areas are displayed. a. Section taken from het PSD-95HaloTag/+ mouse 
and treated with TMR ligand (1µM, 1h at RT). b. Section taken from hom PSD-95-eGFP mouse, 
untreated. The PSD-95 expression profile for both mouse lines appears to be very similar. c-
e. Fixed brain section of het PSD-95HaloTag/+ mouse treated with TMR ligand (1µM, 1h at RT) 
and stained with anti-PSD-95 antibody (Neuromab, 1:250). TMR ligand channel displayed in 
(c.) and antibody staining displayed in (d.), with overlay in (e.). Images taken in the CA1 region 
of the hippocampus. f. Brain slice of PSD-95-eGFP KI homozygous mouse line, imaged in the 
CA1 region of the hippocampus. Images in (c.-f.) acquired at high magnification (63x) using a 
Zeiss LSM510 confocal microscope. The synaptic expression pattern again looks very similar 
in the two genotypes (c. and f.), while the ligand signal overlaps strongly with the antibody 
staining (e.). Note that the scale bar in (f.) is 2µm in length. Both PSD-95-eGFP images (b. and 
f.) were taken and kindly provided by Dr. Matthew Broadhead.  
 
the confocal LSM 510 at 63x magnification. Imaging using the Axio Scan slide scanner 
was again kindly performed by Jamie Rose.  
 
Low magnification (20x) imaging of brain slices using the slide scanner and qualitative 
analysis revealed an expression profile very similar to that of eGFP-tagged PSD-95 
(Figure 3.5.a and 3.5.b). Based upon qualitative fluorescence intensity, PSD-95 
expression levels appear to be high in the CA1 area of the hippocampus in both mouse 
lines. More specifically, it appears that PSD-95 expression is particularly high in the 
CA1 Stratum Oriens (CA1 S.O.) and CA1 Stratum Radiatum (CA1 S.R.), whereas cell 
body layers such as the granule cell layer of the dentate gyrus and the pyramidal cell 
body layers of the CA1 – CA3 layers do not appear to express PSD-95 at all, as is to 
be expected (Yan et al., 2013).  
 
At higher magnification (63x), images taken in the CA1 region of the hippocampus 
reveal a dense pattern of bright PSD-95 puncta in the PSD-95HaloTag mouse brain slices 
treated with TMR ligand (Figure 3.5.c). The anti-PSD-95 staining with an antibody 
(Neuromab Mu anti-PSD-95, 1:1000) reveals a similar staining pattern (figure 3.5.d), 
with a high degree of colocalisation between the ligand and the antibody (figure 3.5.e). 
Note that the antibody staining appears to be less specific than the TMR ligand 
labelling, with the ligand displaying less background signal. Finally, this punctate 
staining pattern is very similar to that found in the PSD-95-eGFP mouse brain section 
(Figure 3.5.f).  
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Note that all images of the PSD-95-eGFP mouse line were kindly provided by Dr. 
Matthew Broadhead.  
 
There are two conclusions that can be drawn from the high and low magnification 
analysis of PSD-95HaloTag mouse brain sections treated with a HaloTag ligand (TMR). 
Firstly, it is possible to effectively label PSD-95-HaloTag fusion proteins within fixed 
brain tissue simply by using ligands briefly applied to mounted sections. Secondly, the 
staining pattern revealed by ligand-labelling of PSD-95-HaloTag fusion proteins in the 
hippocampus follows the expected expression pattern of PSD-95, and is similar to the 
PSD-95-eGFP expression pattern in another line of KI mice. Together, the biochemical 
and microscopic analysis indicates that the overall expression levels and expression 
pattern of PSD-95 in the adult mouse brain are unperturbed by the HaloTag protein 
fused to PSD-95. It therefore stands to reason that this mouse model is not only 
technically suitable for the study of PSD-95 using the HaloTag technology, but is also 
phenotypically normal in all measured criteria, and thus the legitimate claim can be 
made that results from experiments performed on this mouse line can be expected to 
be biologically representative of PSD-95 in all mice.  
 
3.3.3 Labelling living neurons grown in primary culture with HaloTag 
ligands 
 
The next step was to grow neuronal primary cultures to demonstrate that the HaloTag 
system could be used to reliably label PSD-95-HaloTag fusion proteins in the 
synapses of living neurons. To this end, primary cultures were grown as per the 
methodology detailed in chapter 2.3. Briefly, the brains of embryos at developmental 
stage E17.5 were dissected such that the forebrain portion was retained, and pooled 
together from the entire litter. These brain dissections were then turned into a single-
cell suspension, and plated onto PDL- and laminin-coated glass coverslips. These 
neuronal primary cultures were then grown for two weeks, and at developmental stage 
DIV14 (Day In Vitro 14) experiments were performed. This age was decided upon as 
this is the time when cultured mouse primary neurons are not yet fully mature, and 
undergoing high levels of synaptogenesis (Lesuisse and Martin, 2002; Cohen et al., 
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2013). At this stage, glutamate receptors are already being expressed strongly (Li et 
al., 1998), and PSD-95 levels are also high, making this a commonly used time point 
when studying this protein (Fernandez et al., 2009; El-Husseini et al., 2002).  
 
First experiments involved simply adding HaloTag ligands to the live PSD-95-HaloTag 
and WT control neurons, fixing them, and performing immunocytochemistry to stain 
for PSD-95. In early experiments, HaloTag ligands were diluted in the media 1:1000, 
as per instructions, for a final concentration of 1 µM. Cells were incubated for 15 
minutes, before being fixed in 4% paraformaldehyde (PFA), and immunocytochemistry 
being performed, as per protocols in chapter 2.3. Imaging of coverslips was performed 
using the laser scanning confocal as per chapter 2.4.1, and synapses detected using 
the IMARIS software as per chapter 2.4.2.  
 
A qualitative inspection of the images revealed a very strong and specific labelling of 
synapses when the R110Direct ligand was applied at 0.1 µM overnight (16h) (Figure 
3.6.a-c), but no labelling at all in WT neurons (Figure 3.6.d-f). The same effect was 
observed when using the TMR ligand, applied at a concentration of 1 µM for 30 
minutes (Figure 3.6.g-l). See Figure 3.7.a (page 76) for a lower-magnification view of 
the labelling of synaptic puncta along dendrites in neuronal primary cultures. 
Background labelling in both cultures was similarly low, with the exception being 
occasional large ‘blobs’ of very high intensity. These are much greater in diameter 
than synaptic puncta that are expected to range in size from 200 nm to 800 nm (Carlin 
et al., 1980; Südhof, 2012). These non-specific ‘blobs’, often many microns in size, 
were easily identified, and where not excluded automatically by the Imaris detection 
thresholds they were manually removed from any further analysis.  
 
I then calculated the percentage colocalisation of synaptic puncta with the PSD-95 
antibody label separately for each channel. Briefly, synaptic puncta were detected 
using a seed point estimation diameter of 300 nm, and puncta were considered as 
colocalised if within 300 nm of each other (centre to centre). The results indicated an 
average of 67.75 ± 2.0 % colocalisation of R110 ligand with the antibody staining, and 
a 73.88 ± 2.7 % colocalisation of the antibody staining with the R110 ligand (Figure 
3.6.m). For the TMR ligand, colocalisation of the ligand with the antibody staining was 
67.25 ± 3.4 %, while colocalisation of the antibody staining  
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Figure 3.6. The fluorescent HaloTag ligands R110Direct and TMR can be used to label PSD-
95-HaloTag fusion proteins in the postsynaptic densities of primary neuronal cultures  
a.-f. Heterozygous PSD-95HaloTag/+ (Het) primary cultures alongside WT control cultures were 
labelled with R110Direct ligand (100nM, 16h) at DIV14, fixed on DIV15, and stained with anti-
PSD-95 antibody (Mouse, Neuromab 1:1000). Images taken with confocal LSM510 at 63x 
zoom3.1. a. Anti-PSD-95 antibody labelling in Het neurons. b. R110 ligand labelling in Het 
neurons. c. Overlay of anti-PSD-95 channel and R110 ligand channel in Het neurons (a. and 
b.). d. Anti-PSD-95 antibody labelling in WT neurons. e. R110 ligand labelling in WT neurons. 
f. Overlay of anti-PSD-95 channel and R110 ligand channel in WT neurons (d. and e.). A high 
degree of overlap of R110 signal with antibody staining is visible in Het cultures (a-c). In WT 
cultures (d-f), no ligand signal is detectable at all. (g.-l.) As in (a.-f.), primary neurons were 
cultured from WT or Het KI mice, and labelled with carboxytetramethylrhodamine (TMR) 
HaloTag ligand (1µM, 15 mins) on DIV14. g. Anti-PSD-95 antibody labelling in Het neurons. h. 
TMR ligand labelling in Het neurons. i. Overlay of anti-PSD-95 channel and TMR ligand channel 
in Het neurons (g. and h.). j. Anti-PSD-95 antibody labelling in WT neurons. k. TMR ligand 
labelling in WT neurons. l. Overlay of anti-PSD-95 channel and TMR ligand channel in WT 
neurons (j. and k.). As before, a high degree of overlap is visible between the TMR ligand signal 
and the anti-PSD-95 signal in Het cultures, whereas no ligand signal at all is visible in WT 
cultures. Note that for the whole panel, white arrows denote synaptic puncta. m. Graph 
showing analysis of colocalisation between anti-PSD-95 antibody labelling and PSD-95-
HaloTag labelled with R110 ligand (100nM, 16h) or TMR ligand (1µM, 15 mins) in Het PSD-
95HaloTag/+ cultures. Puncta were deemed colocalised if their centre points were within 0.3um. 
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with the TMR ligand was 70.25 ± 3.0 % (Figure 3.6.m). WT cultures did not exhibit any 
detectable synaptic puncta in the TMR or R110 ligand channels.  
 
As a control, one of the image channels was rotated 90° in order to evaluate the 
probability of puncta overlapping by chance (Figure 3.7.a-b). The actual observed 
colocalisation rate (as opposed to after rotation) was found to be very significantly 
higher both when looking at the overlap of antibody with R110 ligand (non-rotated: 
73.88 ± 2.69; rotated: 6.43 ± 0.84; Paired T-test: p=6.71x10-8) and R110 ligand with 
antibody (non-rotated: 67.75 ± 2.01; rotated: 6.76 ± 1.11; Paired T-test: p=4.88x10-8) 
(Figure 3.7.c). In TMR ligand-labelled cultures the actual observed colocalisation rate 
was also found to be significantly higher in both instances: antibody with TMR ligand: 
non-rotated: 70.25 ± 2.99; rotated: 8.51 ± 2.34; Paired T-Test p=8.54x10-7; and TMR 
ligand with antibody: non-rotated: 67.25 ± 3.42; rotated: 6.94 ± 1.74; Paired T-test 
p=1.31x10-8; (Figure 3.7.d).  
 
It should be noted that these results were gained from cultures that were grown from 
heterozygous embryos, thereby expressing both mutant and WT alleles of PSD-95. It 
is unlikely that this would affect the results, since the presumption is that all synapses 
would incorporate a mixture of mutant and WT PSD-95 proteins. Therefore, all 
postsynaptic densities would be labelled by HaloTag ligands. Nevertheless, it would 
be of value to repeat these colocalisation experiments using Homozygous PSD-
95HaloTag/HaloTag mice.  
 
As a further control experiment, PSD-95-HaloTag mice were crossed with PSD-95-
eGFP mice, and embryos from these PSD-95HaloTag/eFP (Het/Het) mice used as the 
basis for another set of primary cultures. This stably PSD-95-eGFP expressing KI 
mouse line has previously been used for a lot of imaging work in our lab, and is known 
to display no aberrant phenotype, with PSD-95 localising to synapses normally 
(Broadhead et al., 2016).  
 
As above, DIV14 cultured primary forebrain neurons were treated with TMR ligand 
and stained with anti-PSD-95 antibodies (Figure 3.8.a-d). Colocalisation analysis 
between the TMR ligand puncta and the eGFP puncta revealed a colocalisation of 
71.20 ± 2.5 % between TMR ligand puncta and eGFP puncta, and a colocalisation of  
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Figure 3.7. The colocalisation of antibody staining with ligand signal is not due to chance.  
a. Image of Het PSD-95HaloTag/+ hippocampal primary neurons labelled with R110Direct ligand 
overnight (100nM, 16h), fixed DIV15 and stained with anti-PSD-95 antibody (Mouse, 
Neuromab 1:1000). Note the strong puncta overlap (white spots). b. The same image as in 
(a.), but the ligand channel of the image was rotated 90° using the ImageJ software. Note the 
lack of puncta overlap. c. Graph showing the percentage colocalisation between antibody and 
R110 ligand signal, before and after 90° rotation. d. Graph showing the percentage 
colocalisation between antibody and TMR ligand signal, before and after 90° rotation.  
 
63.31 ± 1.8 % between eGFP puncta and TMR ligand puncta (Figure 3.8.e). In this 
experiment, too, 90° rotations of the images were performed, to evaluate the 

























































cases is very significantly higher than would be expected by chance (Paired T-test: 
p=8.95x10-9 (eGFP with ligand) and p=3.47x10-9 (ligand with eGFP)).  
 
Finally, it was of interest to discover whether HaloTag ligands are able to label Halo-
PSD-95 in primary neurons after these have been fixed in 4% PFA for 15 minutes. As 
per the protocol given in chapter 2.3.5, primary neurons aged DIV14 were fixed and 
washed. Following the final washing step, the 24-well glass coverslips with the primary 
neurons attached were incubated for 30 minutes at room temperature with PBS 
containing TMR ligand at a concentration of 1µM. Coverslips were then stained with 
anti-PSD95 antibody, imaged using the LSM510 confocal and puncta detected with 
the Imaris software, as usual. When comparing antibody and ligand colocalisation in 
live-treated cells with post-fixation-treated cells, no statistically significant difference 
between the two groups was found (Welch’s t-test, antibody colocalisation with TMR 
ligand p= 0.07; TMR colocalisation with antibody p=0.81) (Figure 3.9.a).  
 
Overall, it was found that there is a high level of overlap between HaloTag ligand-
labelled synapses and both anti-PSD-95 antibodies as well as eGFP-tagged synaptic 
puncta. WT cultures, displayed no ligand-labelling whatsoever. It may be expected 
that both HaloTag ligands and anti-PSD-95 antibodies would label all existing PSD-
95-HaloTag proteins, and thus one should expect a 100% colocalisation between the 
two. The same holds true in PSD-95HaloTag/eGFP (Het/Het) cultures, where one might 
expect PSD-95 molecules of both alleles to be present in every postsynaptic density, 
and therefore likewise expect a 100% colocalisation rate. Nevertheless, colocalisation 
falls between 65% and 75% in both cases. One explanation for this discrepancy is 
incomplete labelling by the HaloTag ligands. However, this is highly unlikely, also 
because of numerous later results that imply complete saturation of all HaloTag 
binding sites by ligands (see chapters 3.4.3 and 3.4.4 as examples). It is more likely 
that the results are due to a combination of factors such as incomplete and irregular 
staining by the anti-PSD-95 antibody and imperfect detection and/or colocalisation 
measurements. This is because antibody staining can be varyingly effective 
(depending on the degree of cell membrane permeabilisation for example), and the 
settings used for the taking and analysing of images are optimised, but nonetheless 
never perfect. It was found that primary neurons grown on glass coverslips can indeed 
be successfully labelled with HaloTag ligands after fixation. This adds a useful 
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dimension to the HaloTag toolkit, as in some scenarios, it may be advantageous to fix 
cells and label them with ligands subsequently (see chapter 3.4.2).  
 
A further point of discussion is that the results in chapter 3.3.3 indicate that there are 
marked differences in synaptic puncta size (diaqmeter and area). While puncta size 
was not used during the analysis, this could indeed have been an interesting aspect 
to investigate. Thus, correlating puncta size with intensity could have provided an 
interesting perspective on understanding the link between the size of synapses with 
the concentration of PSD-95 molecules within. Indeed, the normalisation of puncta 
intensity to size could have been an important aspect of analysis. This would have 
allowed for puncta size to be factored into the calculation of PSD-95 expression levels 
at synapses. Further, normalising ligand puncta intensity to antibody puncta intensity 
could have allowed for more direct comparisons between different ligand labels. 
However, the slight variability in labelling efficiency between samples when antibody 
staining could have caused difficulties in such an approach.  
 
In the experiments conducted throughout this project, only single z-stacks were used 
when acquiring images. This means that the results represent information gathered at 
a single focal plane, with no information about planes above and below. This prevents 
conclusions from being drawn regarding the 3-dimensional structure of the puncta, as 
we do not know if individual puncta stretch across multiple focal planes, and thus what 
shape they take. Incorporating images taken across multiple z-stacks, while 
undoubtedly vastly more time consuming, would have allowed for interesting insights 
into PSD-95 expression levels at synapses of different shapes and sizes. Using 
multiple z-stacks would also have permitted a greater analysis of puncta 
colocalization, as it would facilitate our understanding of the spatial relationship 
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Figure 3.8. PSD-95-eGFP puncta overlap strongly with HaloTag ligand puncta in PSD-
95HaloTag/eGFP (Het/Het) mice.  
a.-d. Primary neuronal cultures from mice expressing PSD-95 tagged with eGFP and HaloTag 
(Het/Het, PSD-95HaloTag/eGFP). LSM510 images of PSD-95HaloTag/eGFP cultures at DIV14, treated 
with TMR ligand (1µM, 15 mins) and anti-PSD-95 antibody. a. LSM510 green channel 
(excitation: 488nm) revealing synaptic puncta labelled by eGFP-PSD-95. b. LSM510 red 
channel (excitation: 543nm) revealing synaptic PSD-95-HaloTag puncta labelled by TMR 
ligand. c. LSM510 far red channel (excitation: 633nm) revealing synaptic puncta labelled by 
anti-PSD-95 antibody. d. Composite image of (a.) and (b.) showing both eGFP-tagged PSD-95 
and PSD-95-HaloTag labelled with TMR ligand. A strong overlap between the eGFP signal and 
the TMR signal is evident. White arrows point out some overlapping puncta. e. Graph of 
colocalisation analysis between synaptic puncta labelled with TMR ligand and eGFP puncta. 
As controls, images were rotated 90° to be able to evaluate random puncta overlap. Error 






Figure 3.9. The TMR ligand is able to label Halo-PSD-95 fusion proteins in fixed primary 
cultures to the same extent as in live cells.  
Hippocampal primary neurons were fixed in 4% PFA for 15 minutes on DIV14, and 
immediately after fixation and subsequent washing was completed, cells were incubated with 
TMR ligand diluted in PBS at 1µM for 30 minutes at room temperature. Thereafter they were 
stained with anti-PSD-95 (Mouse, Neuromab, 1:1000). Subsequent colocalisation analysis 
revealed a high degree of puncta colocalisation between TMR ligand and antibody. This was 
indistinguishable from live-cell labelling results (Welch’s t-test, antibody colocalisation with 





























3.3.4 Analysis of postsynaptic density puncta juxtaposition with 
presynaptic markers 
 
As a further validation that observed puncta indeed represent the postsynaptic density 
of glutamatergic synapses, I decided to perform antibody staining for presynaptic 
markers, and quantify the juxtaposition of pre- and postsynaptic puncta. VGlut1 is the 
predominant vesicular glutamate transporter in the mammalian brain, accounting for 
the uptake of about 80% of glutamate (Fremeau et al, 2004). Synapsin1 is another 
presynaptic marker protein that is widely expressed in the mammalian forebrain 
(Schiebler et al, 1986). It is associated with the cytoplasmic surface of synaptic 
vesicles, and makes up about 6% of the total protein amount in synaptic vesicles 
(Huttner et el, 1983). As such, it stands to be expected that the majority of excitatory 
glutamatergic synapses would express VGlut1 and Synapsin1a at synaptic vesicles in 
the presynaptic bouton. However, the distance between these areas of presynaptic 
VGlut1 density and the PSD is great enough to be visible when viewing merged 
images of PSD-95 and VGult1 staining. Hence, unlike when quantifying colocalisation, 
the ‘colocalisation’ distance was extended to 600 nm (centre to centre) when 
quantifying pre- and postsynaptic puncta juxtaposition.  
 
Hippocampal primary cultures were grown as per my standard protocol (chapter 2.3), 
again using embryos from the PSD-95HaloTag/eGFP (Het/Het) cross, as detailed above in 
chapter 3.3.3. At DIV14, cells from these cultures were treated with the TMR ligand 
(500nM) for 1h, before being fixed and immunocytochemistry performed as per the 
standard protocol (chapter 2.3.6). Immunocytochemical staining was performed for 
either VGlut1, or Synapsin1a. Coverslips were then imaged using the Leica 510 laser 
scanning confocal microscope, and synaptic puncta identified and colocalisation 
determined as per protocols in chapter 2.4.2. As before, synaptic puncta were 
detected using a seed point estimation diameter of 300 nm.  
 
A qualitative analysis revealed that postsynaptic puncta labelled with the HaloTag 
TMR ligand appeared to be frequently juxtaposed with presynaptic marker puncta, in 
the case of both VGlut1 (Figure 3.10) and Synapsin1a (Figure 3.11) staining. 
Quantitative analysis revealed that 50.4 ± 6.4 % of Vglut1 puncta were juxtaposed with  
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Figure 3.10. Postsynaptic puncta labelled by HaloTag ligands are juxtaposed with VGlut1 
presynaptic marker puncta.    
Primary neuronal cultures from mice expressing PSD-95 tagged with eGFP and HaloTag 
(Het/Het, PSD-95HaloTag/eGFP) were treated with TMR ligands at DIV14 and stained for the 
presynaptic marker VGlut1. a. Red channel of LSM510 image showing postsynaptic puncta 
visualised by TMR ligand bound to PSD-95-HaloTag proteins. b. Green channel of image 
showing postsynaptic puncta visualised by eGFP-tagged PSD-95. c. Overlay of red and green 
channels, revealing colocalisation of PSD-95 tagged with HaloTag-TMR and eGFP. Note the 
very high degree of colocalisation. d. Far-red channel of image showing VGlut1 antibody 
staining of presynaptic puncta. e. Overlay of far-red and red channels, revealing juxtaposition 
of presynaptic puncta visualised by anti-VGlut1 staining with postsynaptic puncta labelled by 
TMR ligands bound to PSD-95-HaloTag proteins. f. Panel of close-up images of individual 
synapses displaying presynaptic VGlut1 staining and postsynaptic TMR labelling of PSD-95-
HaloTag. g. Graphs showing the average number of TMR-ligand labelled postsynaptic puncta 
juxtaposed with presynaptic VGlut1 puncta, and vice versa. h. Graph showing the percentage 
of TMR-ligand labelled postsynaptic puncta juxtaposed with presynaptic VGlut1 puncta and 
vice versa, alongside the colocalisation analysis of the same images when the TMR ligand 
channel is rotated by 90°.  
 
TMR ligand puncta, and 62.1 ± 7.2 % of TMR ligand puncta were juxtaposed with 
VGlut1 puncta (Figure 3.10.h). The average number of juxtaposed puncta in each of 
these groups was 276.2 ± 56.7 and 239.7 ± 43.0 puncta respectively, per image 
analysed (Figure 3.10.g). Images used were also rotated 90° as a control as before, 




























is significantly higher than would be expected by chance (Paired T-test: p=7.92x10-6 
(eGFP with ligand) and p=5.69x10-7 (ligand with eGFP)).  
 
Quantitative analysis of Synapsin1a juxtaposition revealed that 68.02 ± 3.1 % of 
Synapsin1a puncta were juxtaposed with TMR ligand puncta, while 74.21 ± 1.2 % of 
TMR ligand puncta were juxtaposed with Synapsin1a puncta (Figure 3.11.e). The 
average number of juxtaposed puncta in each of these groups was 389 ± 47.1 and 
379 ± 61.5 puncta respectively, per image analysed (Figure 3.11.d). 90° rotation once 
again revealed a very low level of juxtaposition by chance, which was significantly 
different from observed puncta juxtaposition (Synapsin1a with TMR: 7.50 ± 1.8 %, 
paired T-test: p= 4.67x10-8) (TMR with Synapsin1a: 8.36 ± 0.8 %, paired T-test: p= 
1.39x10-9).  
 
These results indicate that the majority of puncta analysed by my method are indeed 
excitatory synapses that are made up of pre- and postsynaptic components. As in 
chapter 3.3.3, it is possible that the observed colocalisation level is lower due to 
inaccuracies in the staining by the presynaptic antibody, detection and/or 
colocalisation measurements. However, there are alternative explanations for the 
reduced level of colocalisation, particularly in the case of VGlut1, which had an even 
lower level of colocalisation (between 50% and 62% (Figure 3.10.h)). There are in fact 
two different major subtypes of the vesicular glutamate transporter: VGlut1 and 
VGlut2. While in adult mice, VGlut1 is the dominant isoform, in neonatal mouse brains 
VGlut2 predominates (Herzog et al, 2006; Miyazaki et al, 2003). The transition from 
one isoform to the other occurs at around 2 weeks of age, which corresponds roughly 
to DIV14 in primary cultures, and this maturation process is indeed recapitulated in 
vitro (Wojcik et al, 2004). It is therefore very possible that the lower level of 
colocalisation between postsynaptic PSD-95 puncta and presynaptic VGlut1 puncta is 
partially due to a lower expression level of VGlut1 at this developmental stage.  
 
Synapsin1 similarly undergoes a shift in its expression level throughout postnatal 
development. While in mature neurons synapsin1 is localised to the majority of nerve 
terminals, synapsin1 expression correlates with synapse formation in the CNS and is 
implicated in their functional maturation (Di Liegro et al, 1995). Thus, synapsin1 levels 
have been shown to become detectable immunocytochemically around DIV14 in  
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Figure 3.11. Postsynaptic puncta labelled by HaloTag ligands are juxtaposed with 
Synapsin1a presynaptic marker puncta.  
Primary neuronal cultures from Homozygous PSD-95HaloTag/HaloTag mice were treated with TMR 
ligands at DIV14 and stained for the presynaptic marker Synapsin1a.  
a. Red channel of LSM510 image showing postsynaptic puncta visualised by TMR ligand bound 
to PSD-95-HaloTag proteins. b. Far-red channel of image showing VGlut1 antibody staining of 
presynaptic puncta. c. Overlay of far-red and red channels, revealing juxtaposition of 
postsynaptic puncta visualised by anti-Synapsin1a staining with postsynaptic puncta labelled 
by TMR ligands bound to PSD-95-HaloTag proteins. d. Graphs showing the average number 
of TMR-ligand labelled postsynaptic puncta juxtaposed with presynaptic Synapsin1a puncta, 
and vice versa. e. Graph showing the percentage of TMR-ligand labelled postsynaptic puncta 
juxtaposed with presynaptic Synapsin1a puncta and vice versa, alongside the colocalisation 
analysis of the same images when the TMR ligand channel is rotated by 90°.  
 
neuronal primary cultures, at which point they begin to rapidly increase (Salemi et al, 
1990). Since the age of my cultures again falls directly into this period of increasing 
level of expression, this may account for the colocalisation rate being lower than 
anticipated.  
 
3.3.5 MAP2 staining analysis 
 
As a further validation of the primary culture model I used as the basis of my study, I 
decided to visualise dendrites and thereby evaluate the localisation of PSD-95 puncta 
relative to the dendrites. To this end, I used an antibody against microtubule-
associated protein 2 (MAP2) as a dendritic marker. MAP2 is one of the major 
microtubule-associated proteins in the brain, critical for microtubule assembly and 
stability and, within neurons, confined to dendrites (Goedert et al, 1991).  
 
Primary cultures at DIV14 were treated with R110 ligand as before, fixed, and stained 
with MAP2 antibodies. A qualitative analysis revealed that synaptic puncta were 
indeed distributed along dendrites positive for MAP2 (Figure 3.12). One observation 
one makes when viewing these images is that there appears to be significant 
heterogeneity in the synaptic morphology along a single dendrite. PSD-95 puncta vary 
in shape, diameter and fluorescence intensity (e.g. Figure 3.10.b). While such 
heterogeneity of synapses along single dendrites is not surprising (Craig & Boudin, 
2001), it does raise the possibility of utilising the HaloTag technology to observe PSD-
95 turnover at individual synapses along the same dendritic branch. This would allow 
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for novel insights into the turnover of a postsynaptic protein. However, while certainly 
interesting, I was unable to address this particular aspect of PSD-95 turnover during 
my project due to time constraints.  
 




Figure 3.12. Postsynaptic puncta labelled by HaloTag ligands are located along dendrites.  
Hippocampal primary cultures were treated with R110Direct ligand (100nM 16h) before being 
fixed and stained with a MAP2 antibody (Chicken, Abcam, 1:1000). a. R110 ligand visualising 
PSD puncta. b. Anti-MAP2 antibody marking a dendritic branch. c. Overlay of (a.) and (b.) 
revealing that synaptic puncta tagged by the R110 HaloTag ligand lie along a dendritic branch 
stained with MAP2. White circles mark out synaptic puncta labelled by R110 HaloTag ligand.  
 




3.3.4 Using single-ligand labelling to compare puncta intensities on 
DIV15 with DIV16. 
 
Once I had established that the HaloTag ligands could be used to highly specifically 
label Halo-PSD-95 fusion proteins in the postsynaptic densities of excitatory primary 
neurons, I decided to apply this technique to explore the change in absolute PSD-95 
expression as well as synapse number over the time-frame I intended to investigate 
PSD-95 turnover over (i.e. DIV15-DIV16). As explained in chapter 3.3.3, this is a good 
time period for the investigation of PSD-95 turnover in primary cultures.  
 
To this end, I added the TMR ligand to hippocampal primary cultures at DIV15 or 
DIV16 for 30 minutes at a 1µM final concentration. After labelling was completed, cells 
were fixed, imaged and puncta detected and analysed with the standard protocol using 
the Imaris software (see chapter 2.4.2). This analysis was performed for five different 
cultures (N=5) and four images were used per culture (taken from a single coverslip).  
 
In each of the five distinct cultures analysed, the average puncta intensity was slightly 
greater at DIV16 than at DIV15 (figure 3.13.a). However, this difference was only 
statistically significant at the p<0.05 confidence level in a single case, culture 21 E2 
(using Welch’s t-test). I then calculated the mean puncta fluorescence intensity for all 
groups at DIV15 and DIV16 to give a more complete picture (figure 3.13.c). While the 
mean puncta intensity was overall greater at DIV16 (89.84 ± 3.79) than DIV15 (80.86 
± 2.03), this difference was not statistically significant (p=0.08, Welch’s t-test).  
 
Using the same images, the number of puncta per image at these two time points was 
explored. When analysing each culture separately, the picture that emerged was 
similar to the evaluation of puncta intensity: for three out of five cultures, more synaptic 
puncta were detected on DIV16 than DIV15 (figure 3.13.b). The difference between 
these results was only significant at the p<0.05 confidence level in two cases: culture 
21 E1 and culture 21 E2 (in both cases, there were more puncta at DIV16 than DIV15). 
When the mean puncta number for all groups was calculated, the result was the same 
as when evaluating puncta intensity: there was an overall greater number of synaptic 
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puncta per image at DIV16 (445.32 ± 86.64) than DIV15 (351.36 ± 67.17) (figure 
3.13.d). This difference was, again, not statistically significant (p=0.42, Welch’s t-test).  
 
Interestingly, no significant increase in puncta intensity or number was detected from 
DIV15 to DIV16, a time period that falls precisely into the developmental stage when 
primary neurons undergo high levels of synaptogenesis (Lesuisse and Martin, 2002).  
 
However, when analysing puncta numbers, there is a much greater range of puncta 
per image than when analysing puncta intensity. This is due to the variability of the 
images taken- while it was attempted to take images at similar locations (i.e. along 
dendrites and without including cell bodies), there is nevertheless a lot of 
heterogeneity in the way primary cultures grow and neurons connect with each other. 
This large variability may explain the lack of statistical significance of the difference in 
puncta number between DIV15 and DIV16.  
 
Puncta intensity, on the other hand, is directly proportional to the number of PSD-95 
molecules present in the postsynaptic density that makes up each punctum. The 
number of PSD-95 molecules in a synapse is thought to be approximately 300 (Chen 
et al., 2005; MacGillavry et el., 2013), restricting the possible variability of synaptic 
puncta intensity. Furthermore, the puncta detection parameters used when analysing 
images with the Imaris software have a lower intensity detection threshold to reduce 
the incidence of false positives. Thus, any synapses containing a very small number 
of PSD-95 molecules will likely fall under this threshold, and not be detected as puncta. 
This limits the variability in detected puncta intensity.  
 
It appears from these results that while the overall synaptic population at this stage 
may be undergoing both synaptogenesis and synaptic pruning (Tang et al., 2014), the 
mean puncta intensity across this large population did not significantly change within 
the 24-hour time window. However, it might be expected that if this synaptic population 
at DIV15 were compared with a synaptic population at a later developmental stage, 
say DIV28, the ratios of mature to immature synapses and thus PSD-95 content would 
be significantly different. At DIV28 more synapses might have matured, with fewer 
immature synapses present that express lower PSD-95 levels and reduce the mean 















































































































Figure 3.13. There is no difference in average puncta fluorescence intensity and number 
between DIV15 and DIV16.  
a. Graph depicting the average fluorescence intensities of PSD puncta labelled with the 
HaloTag TMR ligand in five different Het (PSD-95HaloTag/+) cultures (N=5), on DIV15 and DIV16. 
b. Graph depicting the average number of PSD puncta labelled with the HaloTag TMR ligand 
in five different Het (PSD-95HaloTag/+) cultures (N=5), on DIV15 and DIV16. c. The mean puncta 
intensity was calculated over the five cultures depicted in (a.). The graph thus depicts a ‘mean 
of means’ regarding TMR ligand puncta intensity at DIV15 and DIV16. d. As in (c.), the mean 
puncta number was calculated over the five cultures depicted in (b.). The resulting graph 
depicts a ‘mean of means’ regarding TMR ligand puncta number at DIV15 and DIV16.  
 
3.3.6 Evaluating HaloTag ligand fluorophore stability 
 
Having established that the HaloTag ligands can be used to reliably and specifically 
label the Halo-PSD-95 fusion protein in live primary cultures, and thereby accurately 
visualise glutamatergic synapses, I next wanted to investigate the stability of the R110 
and TMR HaloTag ligands’ fluorophores. This step is crucial to allow for the accurate 
quantification of PSD-95 turnover, as it is essential to take into consideration any loss 
of fluorescence intensity of fluorophores when monitoring the degradation of ligand-
labelled Halo-PSD-95 proteins. I decided upon two separate tests to probe fluorophore 
stability. The first involved using a plate reader to record fluorescence intensities of 
HaloTag ligands diluted in NB media at representative concentrations with or without 
incubation in a cell culture incubator for 24 hours (see chapter 2.5.5 for the full 
protocol). The labelled live primary neurons as per the standard protocol and 
measured puncta intensity with or without incubation in a cell culture incubator for 24 
hours following fixation (details below).  
 
Both sets of experiments should allow for the evaluation of the effect of incubating 
HaloTag ligands with fluorophores attached in in a cell culture incubator for 24 hours, 
thereby replicating the conditions the live cells experience over the duration of a Pulse-
Chase experiment.  
 
The advantage of analysing fluorescence intensities of entire wells of HaloTag ligands 
in a 96-well plate is that, apart from being fairly quick to perform, there is much less 
variability involved than is the case when comparing the average intensities of synaptic 
puncta. Nevertheless, there is the caveat that if wells that have already been imaged 
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are reimaged, photobleaching will have to be taken into consideration. Analysing the 
difference in R110 ligand fluorescence intensity between wells that were not incubated 
(16.99 ± 1.7 at the ‘0-hour’ time point) and wells that were incubated for 24 hours 
(18.76 ± 1.8 after 24-h incubation), I find there to be no difference in the average 
fluorescence intensity of the wells (Welch’s t-test, p=0.32) (Figure 3.14.a). However, 
when comparing the exact same wells that were imaged at the 0-hour time point with 
their fluorescence intensity reading after 24 hours of incubation, I find that 
photobleaching has indeed occurred, and the intensity has gone down from 16.99 ± 
1.7 to 14.38 ± 1.6 (Figure 3.14.b). Note that this difference is still statistically 
insignificant (Welch’s t-test, p=0.10).  
 
Finally, I placed all of the imaged wells in the incubator for a further 4 days, and 
reimaged them at the 120-hour time point. This time point consisted of well that had 
been imaged a variable amount of times, making it the least reliable comparison, but 
I decided to include it nevertheless, as it still provides some valuable information. The 
results indicate that while there is a slight loss in fluorescence intensity, most likely 
solely due to the photobleaching induced by multiple imaging sessions in the plate 
reader, the R110 HaloTag ligand fluorophore is remarkably stable and there is no 
significant change in its intensity, even over 120 hours in neurobasal media in a cell 
culture incubator (single-factor ANOVA, F(2,122)=0.62, p=0.54).  
Note that the R110 ligand was selected for this experiment over the TMR ligand, as 
the R110 ligand is used as the Pulse ligand in later Pulse-Chase experiments. This 
means that this fluorophore is exclusively used to provide information about the 
degradation of PSD-95, whereas the TMR ligand labels newly-formed PSD-95 and 
therefore does not provide information about PSD-95 degradation. Nevertheless, 
future studies may wish to repeat this experiment with the TMR ligand.  
 
Having established that the R110 ligand’s fluorophore is unaffected by incubation 
while diluted in neurobasal media, it was necessary to investigate whether the same 









Figure 3.14. The HaloTag R110Direct ligand fluorophore does not decay in intensity while 
kept in a cell culture incubator.  
a. For 5 separately prepared stock vials (N=5), R110Direct ligand was diluted to a 
concentration of 200nM in NB media. From each stock vial 5 different wells in a 96-well plate 
were filled (5 technical replicates), and fluorescence intensity measured using a plate reader 
in on day 1 (0 hours). Stock vials were then incubated for 24 hours in a cell culture incubator 
at 37°C and 5% CO2, and thereafter 5 new samples were taken from each vial and fluorescence 
intensity measured on day 2 (24 hours). Fluorescence intensity was not statistically 
significantly different (Welch’s t-test, p=0.32). b. For the experiment in (a.), the samples 
imaged at the 0-hour time point were incubated at 37°C and 5% CO2 for 24 hours, and then 
the same samples reimaged. Fluorescence intensity has gone down due to photobleaching, 
but not significantly (Welch’s t-test, p=0.1). c. For the same experiment, the samples were 
imaged after 0 hours, 24 hours and 120 hours of incubation at 37°C and 5% CO2. Note that at 
the 24-hour time point, half of the samples had been previously imaged at the start of the 
experiment, and at the 120-hour time point all of the samples had been imaged at least once, 
and in some cases twice before. Nevertheless, a single-factor ANOVA did not reveal a 
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neurons. This set of experiments involves treating live cells with both pulse and chase 
HaloTag ligands as per the single-ligand labelling standard protocol (see chapter 
2.5.3). The cells are fixed in 4% PFA immediately after labelling is complete (see 
chapter 2.3.5). Coverslips are then split into two groups: coverslips in one group are 
submerged in standard cell culture NB media, and returned to the cell culture 
incubators. There, they are incubated at 37°C and 5% CO2 for 24 hours. Coverslips in 
the second group are stored for 24 hours, protected from light, at 4°C in 1x PBS. After 
the 24 hours, coverslips in both groups are washed and mounted on glass slides, 
before being imaged and puncta detected and quantified with the Imaris software. It is 
then possible to compare average puncta intensities and numbers as usual between 
the two groups. This process was performed for both R110 and TMR ligands.  
 
Qualitatively, the images taken from the two treatment groups are indistinguishable for 
both ligands (Figures 3.15.a-b and Figures 3.16.a-b). Quantitative analysis revealed 
that there was no statistically significant difference between the two treatment groups 
in terms of average puncta intensity (R110 ligand: Welch’s t-test p=0.67 (Figure 
3.15.c); TMR ligand: Welch’s t-test p=0.58 (Figure 3.16.c)) and average puncta 
number (R110 ligand: Welch’s t-test p=0.68 (Figure 3.15.d); TMR ligand: Welch’s t-
test p=0.45 (Figure 3.16.d)), for both ligands. It was noted that the puncta number in 
these experiments displayed a very high degree of variance, ranging between 350-
650 (R110Rirect, Figure 3.15) and 130-330 (TMR, Figure 3.16) puncta per image. A 
possible explanation for this is that the images, which were taken along the dendrites 
of neurons grown on glass coverslips, varied in the number of dendrites that were 
captured (in some cases including larger numbers of dendrites, in others only few). 
Within these images, the Imaris software was then used to detect the synaptic puncta 
as outlined in chapter 2.4.2. Briefly, the ‘spots’ detection module was used to identify 
areas that displayed a signal above a certain intensity threshold (manually set) and at 
an estimated diameter from the seedpoint (set to 300nm). The software then utilises 
the Mexican Hat algorithm to identify structures based on these parameters.   
 
The results from this set of experiments clearly indicate that the fluorophores used in 
the R110 and TMR HaloTag ligands are highly stable in, and unaffected by, the 
incubation conditions they are exposed to during all of my experiments conducted on 
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neuronal primary cultures. This allows me to make the assumption that any loss of 
fluorescence intensity over time during an experiment is due to cellular processes such 
as the degradation of the Halo-PSD-95 proteins that have been tagged by these 
ligands. It allows me to rule out the possibility that reduced fluorescence intensity may 
be caused by fluorophore instability while being incubated in cell culture conditions, 
and as such provides a crucial baseline for subsequent Pulse-Chase experiments.  
a.        b.  
  
c.        d.  
  
Figure 3.15. Synaptic puncta labelled by the R110Direct ligand do not lose their fluorescence 
intensity after being kept in a cell culture incubator.  
a. Hippocampal primary neurons were labelled with R110 ligand at DIV14 (50nM, 16h), fixed 
on DIV15, and stored at 4°C in PBS for 24 hours before being mounted and imaged.  
b. As in (a.), hippocampal primary neurons were labelled with R110 ligand at DIV14 (50nM, 
16h), fixed on DIV15, but stored at 37°C and 5% CO2 in Neurobasal medium for 24 hours 
before being mounted and imaged. c. Graph of average puncta fluorescence intensity for 


























































R110 ligand after labelling R110 ligand after 24h in incubator 
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Neurobasal medium for 24 hours (24 hours in incubator). The difference is not significant 
(Welch’s t-test, p=0.67). d. Graph as in (c.), but analysing puncta number instead. The 
difference is not significant (Welch’s t-test, p=0.68). N=5 cultures.  
 
a.        b.  
  
c.        d.  
  
Figure 3.16. Synaptic puncta labelled by the TMR ligand do not lose their fluorescence 
intensity after being kept in a cell culture incubator.  
a. Hippocampal primary neurons were labelled with TMR ligand at DIV15 (500nM, 1h), fixed, 
and stored at 4°C in PBS for 24 hours before being mounted and imaged.  
b. As in (a.), hippocampal primary neurons were labelled with TMR ligand at DIV15 (500nM, 
1h), fixed, but stored at 37°C and 5% CO2 in Neurobasal medium for 24 hours before being 
mounted and imaged. c. Graph of average puncta fluorescence intensity for coverslips stored 
at 4°C in PBS for 24 hours (0 hours in incubator) or at 37°C and 5% CO2 in Neurobasal medium 
for 24 hours (24 hours in incubator). The difference is not significant (Welch’s t-test, p=0.58). 
d. Graph as in (c.), but analysing puncta number instead. The difference is not significant 
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3.4 Developing a Pulse-Chase method for the accurate 
measurement of PSD-95 synthesis and degradation 
 
3.4.1 Developing a Pulse-Chase method for the study of PSD-95 
turnover 
 
One of the main aims of this project was to develop a method of studying the turnover 
of PSD-95. The first steps were to perform the basic experiments of characterising our 
KI mouse model (chapter 3.2) and establishing the viability of the in vitro model of 
using neuronal primary cultures in conjunction with the HaloTag system (chapter 3.3). 
Once these hurdles had been cleared, the next step was to develop a methodology 
that would allow me to use the available tools to probe the turnover of PSD-95 and 
ask biologically pertinent questions. As outlined in the introduction (chapter 1), there 
is a wide variety of ways of probing a protein’s turnover rate, and indeed multiple 
interpretations of what constitutes ‘turnover’. As mentioned before, my project focuses 
upon protein turnover in the context of degradation and synthesis, rather than protein 
mobility. As such, turnover measurements such as FRAP were eschewed in favour of 
focussing on methods that permit the isolated analysis of protein degradation and 
synthesis. The HaloTag system allows for many different applications, as outlined in 
chapter 1, and it is this versatility that makes it such a unique technology. However, 
after performing the various experiments outlined thus far, utilising the fluorophore-
bearing HaloTag ligands in a Pulse-Chase approach was deemed the most promising 
avenue.  
 
In chapter 3.2, I established that labelling live primary neurons could be accomplished 
successfully while retaining the stability of the HaloTag ligand’s fluorophores, as well 
as ensuring that these ligands were indeed labelling PSD-95-HaloTag fusion proteins 
at glutamatergic postsynaptic densities. The next step was working out ideal 
concentrations for these ligands to be used at, as well as deriving a working protocol 
to investigate PSD-95 turnover. Chapter 3.4 is therefore dedicated to working out the 
concentrations at which the R110 and TMR ligands are able to successfully saturate 
HaloTag binding sites and outcompete each other, as well as exploring whether there 
is a significant change in overall PSD-95 levels over the time course of 
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experimentation (DIV15-DIV16). Finally, I apply all of the results from the previous 
experiments to design a Pulse-Chase experiment allowing me to work out the rate of 
degradation of PSD-95 (half-life).  
 
3.4.2 Titration of ligand concentrations to establish Pulse-Chase protocol 
 
This experiment was designed to work out what concentration of the pulse ligand is 
required to saturate all the available HaloTag binding sites and thereby prevent 
labelling by a chase ligand added subsequently. This concept was also used in one of 
the original HaloTag papers by Los et al. (2008) to prove saturation of binding sites by 
a HaloTag ligand.  
My experiment also aimed to act as a proof of concept and demonstrate a theoretical 
model in practice: that reducing the concentration of the pulse ligand from the point of 
saturation in a step-by-step titration series would increase labelling with the chase 
ligand (kept at a constant, high concentration) concomitantly.  
 
The exact protocol used is outlined in chapter 2.5.4. Briefly, the TMR ligand (pulse) is 
added to live primary neurons at DIV14 at concentrations titrated down by a factor of 
10, from 500nM to 5x10-12nM, for 30 minutes. Cells are then fixed in 4% PFA and 
thereafter labelled with a second ligand, the diAcFAM ligand, at a constant 
concentration of 1µM for 1 hour. Cells are then imaged, synaptic puncta detected as 
usual (see methods chapter 2.4), and average puncta fluorescence intensity recorded.  
 
There are some key aspects that differ in this experiment from later pulse-chase 
experiments: Firstly, later experiments use the R110Direct HaloTag ligand as the 
pulse and the TMR ligand as the chase. In this experiment, I used the TMR ligand as 
the pulse ligand, and then a different ligand, the diAcFAM ligand, as the chase. The 
reason for this disparity is that this experiment was performed early on during the 
study, when the final ligand combination had not yet been decided upon, and thus it 
was not clear which ligands were ideally suitable for certain roles.  
Furthermore, the chase ligand was applied post-fixation, i.e. once the cells had been 
fixed, whereas pulse-chase experiments have both ligands added to live cells. This 
difference is due to the experiments fundamentally having the opposite objectives. In 
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the later pulse-chase experiments aimed at studying PSD-95 turnover, it is crucial for 
the cells to continue their production and degradation of proteins after pulse ligand 
labelling. In this experiment, however, it is essential that there is no further protein 
turnover after labelling with the pulse ligand is complete, since the objective is to 
evaluate the ability of the pulse ligand to saturate all available binding sites. Had 
protein turnover been allowed to continue, new, unlabelled proteins would have been 
synthesised for the chase ligand to bind, confounding the results. Fixation of the cells 
after pulse labelling is therefore required. The efficacy of post-fixation labelling of cells 
with ligands had previously been tested, and found to be indistinguishable from live 
cell labelling (see chapter 3.3.3).  
 
The graphs in figure 3.17 reveal a number of things. The graph in figure 3.17.a, 
depicting average TMR ligand intensity of synaptic puncta over the range of titrated 
TMR concentrations, shows that TMR intensity starts off at a maximum intensity 
plateau between 75-80 arbitrary units (AU) of fluorescence intensity, at TMR 
concentrations of 500nM and 50nM. At a TMR concentration of 5nM, the fluorescence 
intensity begins to drop, and continues to do so until the TMR concentration is reduced 
to 5x10-8 nM. At this point, average fluorescence intensity appears to level off between 
15-30 AU, and does not dip below this range of signal strength. Finally, in the blank 
group, when no TMR ligand at all is added, no TMR puncta are detectable. Thus there 
is a direct (positive) correlation between TMR ligand concentration and TMR puncta 
intensity.  
 
The graph in figure 3.17.b shows the chase ligand (diAcFAM) average puncta 
fluorescence intensity over the range of titrated TMR concentrations. When TMR 
ligand concentration is at 500nM and 50nM, no diAcFAM signal could be detected. At 
a TMR concentration of 5nM, diAcFAM puncta start being detectable, at a low intensity 
around 30 AU. From this point onwards, average diAcFAM puncta intensity gradually 
increases, and appears to level off around 70-80 AU, when TMR concentration has 
been titrated to between 5x10-10 nM and 5x10-12 nM. When no TMR ligand is added at 
all (blank), diAcFAM signal is at its highest, at about 95 AU. It is noteworthy that the 
gradient of the curve (isignifiying the rise in average puncta fluorescence intensity) 
appears to be greatest between a TMR concentration of 50nM and 5x10-4 nM. At a 
TMR concentration of 5x10-4 nM, diAcFAM puncta intensity levels off around 60 AU, 
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and further increases in intensity are modest. Again, there appears to be a direct 
(negative) correlation between TMR ligand concentration and diAcFAM puncta 
intensity.  
 
From the graphs in figures 3.17.a and 3.17.b, it is evident that there is a direct 
correlation between pulse ligand concentration, and the degree to which pulse and 
chase ligands are able to bind the Halo-PSD-95 fusion protein binding sites. At high 
TMR (pulse) concentrations all the binding sites are saturated by it, and as the TMR 
concentration goes down, more and more binding sites remain unbound and thus 
available for the chase (diAcFAM) ligand to bind. This becomes particularly clear when 
looking at the graph in figure 3.17.c. Here, the overlay of the two previous graphs 
nicely demonstrates the inverse relationship between the two ligands. Indeed, the 
small periods over which both ligands experience some of the greatest amount of 
change overlap strongly (TMR ligand: 5nM to 5x10-3 nM, -31.8%; diAcFAM ligand: 
50nM to 5x10-4 nM, +66.4%).  
 
Based on these results, we can therefore conclude that it is possible for the pulse 
ligand (in this case the TMR ligand) to saturate all of the binding sites on the Halo-
PSD-95 fusion proteins, thereby preventing binding by the chase ligand. In this 
experiment, the saturating concentration of pulse ligand was found to be 50nM, 
incubated with the live cells for 30 minutes. At this pulse ligand concentration, no 
chase ligand (diAcFAM) labelling could be detected. We can also conclude that 
indeed, titrating down the pulse ligand concentration reduces the proportion of Halo-
PSD-95 proteins that are labelled by the pulse ligand, and increases the proportion 
labelled by the chase ligand. This early experiment was thus an important step in 
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Figure 3.17. Titrating a pulsed HaloTag ligand (TMR) followed by a chase HaloTag ligand 
(diAcFAM) demonstrates the ability of ligands to saturate and compete for binding 
sites.  
Neuronal primary cultures at DIV14 were treated for 30 minutes with a pulse ligand (TMR) at 
a titrated concentration, ranging from 500nM to 5x10-12nM. Cells were then fixed and treated 
with the diAcFAM ligand at a concentration of 1µM for 1 hour. They were then imaged using 
the LSM510 and puncta detected for each ligand channel separately using the Imaris 
software. a. Graph plotting the average intensity of TMR (pulse) ligand puncta at titrated TMR 
ligand concentrations. As TMR concentration goes down, so too does TMR ligand puncta 
intensity. b. Graph plotting the average intensity of diAcFAM (chase) ligand puncta at titrated 
TMR ligand concentrations. As TMR concentration goes down, diAcFAM puncta intensity goes 
up. c. Combination of the graphs in (a.) and (b.). This clearly illustrates that there is an inverse 
relationship between pulse and chase ligand puncta intensity. At high TMR (pulse) 
concentrations, HaloTag binding sites are saturated, preventing diAcFAM (chase) ligand 
binding. As TMR concentrations are titrated below the saturation point, an increasing amount 
of HaloTag binding sites remain unbound and available for the diAcFAM ligand.  
 
3.4.3 ‘Competition experiment’- applying Pulse and Chase ligand 
simultaneously 
 
Having established that it was possible to saturate HaloTag binding sites on Halo-
PSD-95 fusion proteins in live primary neurons with a first ligand (pulse), and thereby 
block any binding by a second ligand (chase) if added immediately afterwards, the 
next step was to develop an actual protocol that would allow for the measurement of 
PSD-95 turnover.  
The objective, then, was to determine what combination of ligands and ligand 
concentrations would allow not only for all existing HaloTag binding sites to be 
occupied by the pulse ligand, but also for newly synthesised Halo-PSD-95 proteins to 
exclusively be bound by the chase ligand. In this manner, previously-present (‘old’) 
and newly synthesised (‘new’) Halo-PSD-95 proteins would be labelled with different 
ligands. This differential labelling is the key to separating these two subpopulations of 
the same protein, and thus being able to monitor each of them independently. In 
addition to such exclusive labelling of old and new protein populations by pulse and 
chase ligands respectively, the protocol would have to ensure that neuronal health 
remained intact and protein turnover continued throughout the experiment.  
 
Initial experiments roughly followed Promega’s ‘Focus on imaging’ manual. Primary 
neurons were incubated with 500nM TMR ligand as the pulse for 30 minutes (as this 
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concentration had been shown to saturate HaloTag binding sites, see chapter 3.4.3). 
Following Promega’s manual, the culture media that the neurons were submerged in 
was then entirely removed, and the cells washed using warm complete medium in 
order to remove the pulse ligand. However, it was noted, as Cohen et al (2013) did as 
well, that: ‘aggressive washes and complete media exchanges are severely 
detrimental to neuronal viability.’ Indeed, very few of the neurons survived this 
treatment. This meant that incomplete media changes were the only viable option 
going forward, if the cells were to remain healthy and continue to turnover proteins. 
Incomplete media exchanges brought a different problem with them, however: the 
TMR ligand proved to be extremely effective at labelling Halo-PSD-95 proteins, so 
much so that even an extremely low concentration was enough to visibly label synaptic 
puncta. As can be seen in figure 3.17, even the lowest concentration of TMR ligand 
(5x10-12 nM or 5 zeptomolar) still yielded detectable puncta labelling.  
 
This labelling is also extremely rapid. At one point, it was attempted to titrate down the 
incubation time required for successful labelling of Halo-PSD-95 using the TMR ligand. 
The first time point used was 1 second- the ligand-containing media was added to the 
cells, and media immediately removed, followed by the rinsing of the cells in PBS and 
fixing them. Even at this time point, synaptic puncta were clearly labelled, prompting 
that experiment to be abandoned. Having gained experience with the diAcFAM ligand 
(see chapter 3.4.2), it was known that this ligand required a much higher concentration 
to be effective, and its labelling ability was in fact inconsistent. It was thus surmised 
that the TMR ligand had to be used as the chase ligand, as it was likely that it would 
be able to outcompete other ligands for the HaloTag binding pocket.  
 
This raised an interesting point of discussion: different ligands displayed seemingly 
different levels of affinity for the HaloTag binding site. However, since the binding 
domain of HaloTag ligands is identical, there are two alternative explanations for these 
differences in binding kinetics, both linked to the variable functional group: firstly, that 
the different functional groups interact varyingly with other molecules, particularly the 
area around the binding pocket; and secondly, that these different functional groups 
allow the ligand molecules to penetrate through cells, membranes, and protein-dense 
areas such as the PSD at varying rates. These differences in properties may explain 
why some ligands are able to bind to PSD-95-HaloTag fusion proteins more rapidly 
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than others. Further on from this point, it was noted that there are differences in relative 
brightness between the different fluorophores attached to the HaloTag ligands. This 
meant that acquisition settings when taking images using the LSM510 microscope 
differed substantially between ligands, including laser power and gain settings. Even 
with optimised settings, it was noted that some ligands yielded a stronger signal than 
others. Imaris analysis settings were optimised separately for each fluorophore and 
no direct comparisons were made in terms of absolute fluorescence intensity between 
different ligands, meaning that this should not directly affect the results in this study. 
Nevertheless, these are points worth bearing in mind, particularly when designing 
future projects that may aim to quantify absolute PSD-95 molecule numbers or 
compare the intensities of different fluorophores with each other.   
 
A variety of different ligands were tested for the pulse role, and ultimately the 
R110Direct ligand (R110) was selected. This ligand is sold as a ‘direct’ ligand by 
Promega, meaning that it needs to be applied to live cells over a much longer time 
period (overnight) at a lower concentration. The upside of this is that it is unnecessary 
to wash out the ligand, presumably because the lower concentration reduces the 
background. This R110Direct ligand proved to be highly effective at labelling Halo-
PSD-95 proteins, and capable of saturating all HaloTag binding sites when cells were 
incubated overnight. However, it is also slower to bind to HaloTag proteins than the 
TMR ligand, meaning that even if it is not entirely removed from the media, the TMR 
ligand should still be able to bind to the vast majority of HaloTag binding sites if added 
in excess. This did, however, mean that it was required to add the chase ligand (TMR) 
immediately after the pulse labelling was complete rather than at the end of the 
experiment, thereby labelling newly synthesised Halo-PSD-95 proteins as soon as 













Figure 3.18. The TMR ligand outcompetes the R110Direct ligand when simultaneously 
applied at experimentally representative concentrations.  
a. Heterozygous PSD-95HaloTag/+ hippocampal primary cultures at DIV15 had the R110Direct 
ligand (12.5nM) and the TMR ligand (500nM) added to them. After 24 hours of incubation, 
the cells were fixed, stained with anti-PSD-95, mounted and imaged using the LSM510. 
Qualitative analysis reveals very strong TMR labelling (white arrows). b. In the R110 ligand 
channel (green channel), so ligand-staining is visible at all. c. Strong anti-PSD-95 antibody 
staining is visible in the far-red channel. Antibody puncta overlap with TMR ligand puncta (see 
white arrows). White arrows denote some strong TMR ligand puncta for reference purposes. 
The results clearly demonstrate that at the experimentally representative conditions, the 
TMR ligand is able to outcompete the R110Direct ligand, binding to the vast majority of 
HaloTag binding sites.  
 
TMR ligand R110 ligand 
Anti-PSD95 
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Combining the experience gained with various ligands and primary neurons, a final 
protocol was derived that allowed for the successful labelling of Halo-PSD-95 fusion 
proteins at different time points with different ligands, thereby permitting the study of 
PSD-95 turnover. The full detailed protocol is given in chapter 2.5.6. In brief:  
 
1. R110Direct ligand is added to the primary neurons for a final ligand 
concentration of 50nM.  
2. The neurons are incubated with the R110 ligand overnight (16 hours), 
saturating all of the binding sites on Halo-PSD-95 proteins.  
3. After pulse incubation is complete, 75% of the media is removed from the 
cultures, and replaced with preconditioned media containing the TMR ligand, 
for a final TMR concentration of 500nM (final R110 concentration: 12.5nM).  
4. The cultures are then incubated for as long as the time period over which 
turnover is to be measured- 1 hour, 24 hours, or 48 hours.  
5. After this time period, cultures are washed in PBS, fixed in 4% PFA, stained 
with an antibody if appropriate, mounted, imaged and analysed.  
 
This protocol has an internal control in that the 1-hour incubation time point ensures 
that R110 (pulse) ligand labelling has indeed saturated all of the binding sites, as the 
1-hour time window was deemed insignificant in terms of PSD-95 turnover. This 
permitted confirmation that there is no TMR (chase) signal present after 1 hour of 
incubation. The remaining uncertainty in this protocol was, then, whether or not the 
TMR ligand was indeed capable of fully outcompeting the remaining R110 ligand.  
 
To test this, both R110 (12.5nM) and TMR (500nm) ligands were simultaneously 
added to primary neurons at these representative concentrations and incubated for 24 
hours. These are the final concentrations that neurons are exposed to once the chase 
ligand has been added in a pulse-chase experiment. Figure 3.18 reveals that no R110 
signal could be detected at all, while robust TMR labelling is present. This experiment 
was performed on 6 different coverslips, with identical results- strong TMR labelling 
with no detectable R110 signal. The Imaris software was used with the usual puncta 
detection parameters for the R110 ligand (seed point estimation diameter of 300 nm, 
Background subtraction quality above 6.00, automatic spot region threshold, diameter 
from border). None of the images contained any detectable puncta (Figure 3.18.b).  
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3.4.4 Performing a basic Pulse-Chase experiment 
 
Once a working pulse-chase protocol had been established, I wanted to utilise it to 
perform a full set of 48-hour experiments, and work out the half-life of PSD-95. Using 
the final pulse-chase protocol detailed in chapter 2.5.6, I incubated the cells with the 
chase ligand for 1 hour, 24 hours and 48 hours after pulse labelling was complete. 
This experiment was performed on hippocampal primary neurons taken from PSD-95-
Halo-/- (homozygous) mouse embryos at E17.5, starting at neuronal age DIV14 (time 
of pulse ligand addition). It was performed on a single culture, i.e. all the neurons were 
derived from the same embryonic litter. Each time point (1h, 24h, 48h) was made up 
of 3 coverslips, and three images from each coverslip were used (for a total of 9 
images per time point). Mean puncta intensity and number was derived for each image 
separately, and then these means per image were averaged together to give the final 
mean puncta intensity and number per group (i.e. time point).  
 
Figure 3.19 depicts the qualitative results of these experiments. Figures 3.19.a-d 
represent the 1-hour incubation time point. From these four images, it is clear that the 
R110 ligand has labelled all HaloTag binding sites on the fusion proteins, and the TMR 
ligand has been unable to bind to any Halo-PSD-95 proteins. The 24-hour incubation 
time point is shown in figures 3.19.e-h, revealing that, qualitatively, R110 ligand 
intensity has gone down, while synaptic puncta labelled with the TMR ligand have now 
clearly appeared. The overlay (Figure 3.19.h) reveals that most of the puncta labelled 
with either ligand overlap with those labelled by the other ligand, indicating that these 
are synapses in which PSD-95 is actively being turned over. It is also interesting to 
note that there appears to be a lot of heterogeneity in terms of the ratio of R110 to 
TMR signal intensity in these synaptic puncta. Some of the puncta appear to contain 
a lot more ‘old’ than ‘new’ PSD-95, whereas others are dominated by ‘new’ proteins.  







a.      e.     i.  
  
b.      f.     j.  
   
c.      g.     k.  
  
d.      h.     l.  
  
 
R110 ligand R110 ligand R110 ligand 
TMR ligand TMR ligand TMR ligand 








Figure 3.19. A 48-hour Pulse-Chase experiment.  
Hippocampal primary cultures derived from homozygous PSD-95HaloTag/Halotag mice were 
cultured to DIV14, when they were labelled with the R110Direct HaloTag ligand (50nM, 16h). 
On DIV15, the TMR ligand was added to the cultures at 500nM and the concentration of the 
R110 ligand reduced to 12.5nM. Cells were fixed after either 1 hour, 24 hours, or 48 hours of 
incubation thereafter. Coverslips were then stained for PSD-95 (Mouse, Neuromab 1:1000), 
imaged on the LSM510, and puncta detected using the Imaris software.  
a.-d. Images taken from the 1-hour incubation time point. a. R110 pulse ligand signal. b. TMR 
chase ligand signal. c. Anti-PSD-95 staining signal. d. Overlay of pulse and chase ligand signals 
in (a.) and (b.). Note that a strong pulse but no chase signal are visible.  
e.-h. Images taken from the 24-hour incubation time point. e. R110 pulse ligand signal. f. TMR 
chase ligand signal. g. Anti-PSD-95 staining signal. h. Overlay of pulse and chase ligand signals 
in (e.) and (f.). Note that both pulse and chase signals are clearly visible.  
i.-l. Images taken from the 24-hour incubation time point. i. R110 pulse ligand signal. j. TMR 
chase ligand signal. k. Anti-PSD-95 staining signal. l. Overlay of pulse and chase ligand signals 
in (i.) and (j.). Note that both pulse and chase signals are clearly visible, but the pulse signal 
has weakened and the chase signal become stronger.  
 
Finally, figures 3.19.i-l represent the 48-hour time point. Here it has become evident 
that those Halo-PSD-95 proteins labelled by the pulse ligand are slowly being 
degraded, with their signal intensity markedly reduced. On the other hand, many more 
PSD-95 proteins have been synthesised over this time period, leading to an enhanced 
TMR signal. Indeed, there appear to be some synaptic puncta entirely devoid of old 
proteins, containing only new PSD-95 (rings, figure 3.19.l). In fact, such chase-only 
synapses can also be observed at the 24-hour time point (rings, figure 3.19.h). It is 
possible that such synapses have only appeared in this 24- or 48-hour time window 
through the process of synaptogenesis, and thus don’t contain any older PSD-95. An 
alternative explanation would be that such synapses have a higher turnover rate of 
PSD-95 and may simply have degraded all of their older PSD-95 proteins.  
 
Note that for both the 24-hour and 48-hour time points, the white rings highlight 
synaptic puncta that are exclusively labelled by one or the other ligand. The white 
arrows point to synapses tagged by both ligands. Note further that all synapses tagged 
by either ligand display a strong overlap with the anti-PSD-95 antibody label.  
 
The quantitative analysis of these results reflects what is visualised in figure 3.19. 
Pulse ligand fluorescence intensity is highest at the first time point (1h, figure 3.20.a), 
right after pulse labelling is complete (67.11 ± 2.76 Arbitrary Units). At this time point, 
no chase label is detectable at all (figure 3.20.b), since all of the binding sites are 
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saturated with pulse ligand. As mentioned before, this result acts as an internal control 
by demonstrating that the pulse ligand does in fact saturate all of the HaloTag binding 
sites. After 24 hours of chase ligand incubation, some of the pulse labelled proteins 
have been degraded, leading to a loss of pulse fluorescence intensity, with average 
puncta intensity significantly reduced to 43.53 ± 1.9 AU (Welch’s t-test: p=9.99x10-7). 
Conversely, chase ligand intensity has massively increased over these 24 hours as 
new Halo-PSD-95 proteins are being synthesised, giving an average puncta intensity 
of 30.50 ± 1.59 AU (figure 3.20.b). This trend continues after 48 hours, with pulse 
ligand intensity falling significantly to 29.71 ± 1.99 AU (Welch’s t-test, p=2.4x10-4), and 
chase ligand intensity rising to 35.23 ± 2.63 AU (not statistically significant at p<0.05). 
This increase is a lot smaller than in the first 24 hours; however, one explanation for 
this is that a significant portion of the proteins synthesised within the first 24-hour 
incubation phase were degraded again during the subsequent 24 hours.  
 
Note that the absolute puncta fluorescence intensities cannot be directly compared 
between pulse (R110) and chase (TMR) ligands, as each is a different fluorophore 
with different properties. We can, however, directly compare the intensities within each 
ligand, as each HaloTag protein is only labelled by a single ligand molecule in a highly 
quantitative manner.  
 
The second aspect of the pulse-chase experiment that I wanted to evaluate is the 
change in synaptic puncta number. While not a direct measurement of PSD-95 
synthesis or degradation the way puncta intensity is, looking at puncta number can 
nevertheless provide valuable insights into PSD-95 turnover. An estimation of the 
number of pulse-labelled puncta that disappear over 24 hours can give an indication 
of the proportion of puncta that turn over all of their copies of PSD-95 in that time 
period (although synaptic pruning is an alternate explanation). I found that on average, 
each image contained 598.67 ± 69.1 synaptic puncta when labelled with the pulse 
ligand at the start of the experiment, and this number goes down to 329.55 ± 49.3 
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Figure 3.20. Quantification of a 48-hour pulse-chase experiment.  
Using the Imaris software, I detected synaptic puncta labelled by the R110 pulse ligand and 
the TMR chase ligand for cells fixed after 1 hour, 24 hours or 48 hours of chase ligand labelling. 
This allowed me to quantify the average fluorescence intensity of synaptic puncta per image 
at the experimental time points as well as the average puncta number per image. a. Graph of 
the average R110 pulse ligand puncta intensity. Note the gradual reduction in puncta intensity 
as pulse-labelled ‘old’ PSD-95 proteins are degraded over time. b. Graph of the average TMR 
chase ligand puncta intensity. Note the lack of signal after 1 hour of incubation due to the 
complete HaloTag binding-site saturation by the pulse ligand at this time point. c. Graph of 
the average R110 pulse ligand puncta number. The decrease in puncta number mirrors the 
decrease in fluorescence intensity seen in (a.). d. Graph of the average TMR chase ligand 
puncta number. As in (b.), no puncta are detected at the 1 hour incubation time point due to 
saturation by the pulse ligand.  
 
remain (figure 3.20.c). The difference in between each time point is statistically 
significant in each case: P= 0.005 and 0.0003 between the 1 and 24, and 24 and 48 
hour time points, respectively (Welch’s t-test). From these changes in puncta 
numbers, we can infer that roughly 45% of synapses that are labelled by the pulse 
ligand at the 1h time point no longer express pulse-labelled ‘old’ PSD-95 proteins after 
24 hours, and over 48 hours this number rises to 88%. One explanation for this is that 
these synapses have completely degraded all of their ‘old’ PSD-95 in order to replace 
it with ‘new’ PSD-95 that is labelled by the chase ligand. A second explanation is that 
these synapses have been pruned away and have thereby completely disappeared, 
potentially being replaced by new synapses through the process of synaptogenesis. 
Most likely, both of these factors combine to cause this drop in pulse ligand puncta 
number.  
 
Chase ligand puncta number, meanwhile, goes up dramatically within the first 24 hours 
of the experiment, from no puncta at all being detectable after 1 hour of labelling, to 
an average number of 386.09 ± 39.84 of puncta being detected after 24 hours. This 
amount also appears to be the maximum total number of puncta labelled with the 
chase ligand, as average puncta number actually decreases over the next 24 hours 
down to 325.17 ± 11.40 puncta, at the 48-hour time point. This difference is, however, 
not statistically significant at the p<0.05 confidence interval. The majority of these 
puncta are most likely made up of synapses that are stable and thus were present at 
the start of the experiment, thereby containing both ‘old’ and ‘new’ PSD-95. Over time, 
these synapses are likely to lose all of their ‘old’ PSD-95, and only contain PSD-95 
molecules that are labelled by the chase ligand. However, at this early developmental 
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stage that experiences a lot of synaptogenesis, many of these chase-labelled 
synapses may also have newly formed over the past 24 or 48 hours. This is a topic of 
considerable interest and complexity, and I will further address it in more depth in 
chapter 4.  
 
It does appear strange that the maximal number of puncta labelled with pulse ligand 
is nearly 600 at the 1h time point, yet only about 400 with the TMR ligand at the 24-
hour time point. It is possible that this discrepancy is linked to the lower intensity 
detection threshold in the Imaris software, which was set at 3.67 AU for the TMR 
ligand. 3.67 makes up 10.42% of the maximal average puncta intensity of 35.23 AU, 
whereas the intensity threshold of the R110 pulse ligand was set at 6.00, thereby only 
making up 8.94% of the average maximal intensity of 67.11 AU. It is further possible 
that, since the chase ligand labels ‘new’ PSD-95 proteins only, it may label many newly 
formed synapses that only express low levels of PSD-95 at this immature stage, 
thereby falling below the detection threshold.  
 
Overall, then, the results reveal a clear pattern that follows the trajectory one would 
predict for a protein being turned over continuously. Synapses lose their populations 
of ‘old’, pulse labelled PSD-95 molecules, and replace them with ‘new’, chase-labelled 
PSD-95 molecules. This, alongside synaptic pruning and synaptogenesis, contributes 
to the declining number of pulse-labelled synapses and the increasing number of 
chase-labelled synapses. It appears that the HaloTag system is well-suited to 
analysing the turnover of a fusion protein, Halo-PSD-95, by using two different 
fluorescent HaloTag ligands in a pulse-chase approach.  
 
3.4.5 Calculating the half-life of PSD-95 
 
Once I had established a working pulse-chase method for the study of PSD-95 
turnover, I wanted to use these results to work out the half-life of PSD-95. The half-life 
of a protein represents the amount of time it takes for a given protein quantity to 
degrade to half of its original value (Ziv and Fisher-Lavie, 2014), thereby quantifying 
the stability of that protein. This value can be calculated from the change in a protein’s 
concentration over a known time period.  
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In this case, I can calculate the half-life of PSD-95 using the change in fluorescence 
intensity of the pulse ligand over a known time period (representing the change in the 
concentration of pulse-labelled Halo-PSD-95 over that time period).  
 
Using the change in pulse ligand intensity over the space of 24 hours, I calculated that 







This calculation matches closely with the greater-than-36-hour half-life estimation 
published in El-Husseini et al. (2002). However, when using the change in pulse ligand 







While the difference between these two results above is not massive, if we calculate 
the half-life from the average intensity at the 24h and 48h time points, we get an even 
greater half-life measure of 43.55 hours. There is a possible biological explanation for 
this difference in results, apart from the conceivable experimental variability that may 
have had an effect. It is possible that synapses are heterogeneous in their rate of PSD-
95 turnover, with some synapses perhaps degrading and synthesizing PSD-95 more 
rapidly than other synapses. If this is the case, then we might expect a shorter half-life 
estimation (i.e. more rapid degradation rate) over the first 24 hours than over the 
following 24 hours. This is because synapses turning over PSD-95 more rapidly would 
contribute to the puncta intensity calculation over the first 24 hours (lowering the mean 
intensity), but might have completely degraded all of their pulse-labelled PSD-95 
proteins after 48 hours, thereby no longer contributing to the mean puncta intensity at 
that time point. It would therefore seem that overall PSD-95 degradation has slowed 
down over the second 24 hours, when in reality we are now restricted to measuring 
the turnover rate of PSD-95 in the subpopulation of synapses that are turning over 
PSD-95 more slowly, as we are no longer taking into account synapses that contain 
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no pulse ligand. If one wanted to correct for this, one could look at the number of 
synapses expressing pulse-labelled PSD-95 on all three days of measurement (i.e. 
DIV15/1h, DIV16/24h and DIV17/48h), and calculate the difference in each group from 
the starting number (DIV15/1h). This difference could be taken to represent synapses 
that degraded all of their PSD-95, and thus each of these would represent a pulse 
ligand intensity of ‘0’. If all of these ‘0’ puncta values were added to the calculation, 
the mean puncta intensity would drop for the 24 hour and 48 hour time points. An 
additional point to consider in this context is that we are not actually losing synapses 
from the calculation at an intensity of ‘0’, but rather at an intensity of 6.00 AU, as this 
is the detection threshold applied to the Imaris software for this pulse ligand channel. 
Finally, it is certainly possible that the half-life of PSD-95 increases with the age of the 
primary neurons, as in the case of some proteins, more mature neurons contain 
proteins with greater half-lives (Mammen et al., 1997). This is a question I will address 
further in chapter 4. Holistically, then, it would seem that the best method of analysing 
the results from this set of pulse-chase experiments is to calculate the half-life of PSD-
95 over the first 24 hours only, since we want to calculate the half-life of the average 
PSD-95 molecule in any synapse between DIV15 and DIV16, as well as mitigating the 
other factors as much as possible.  This experiment thus concludes with a half-life 
measurement of 38.43 hours for PSD-95 between DIV15 and DIV16.  
 
Regarding PSD-95 synthesis, it is not truly possible to calculate an absolute ‘rate’ of 
synthesis in terms of number of PSD-95 molecules synthesised per hour using my 
pulse-chase method, as we do not know what the specific number of PSD-95 proteins 
is that a certain ligand fluorescence intensity correlates with. We could attempt to 
calculate a rough synthesis rate for PSD-95 based on certain assumptions, but the 
primary presumption would have to be that all the synapses have a total average PSD-
95 number of 300 copies (Chen et al., 2005; MacGillavry et el., 2013). With that 
presumption, we would be able to make a rough calculation of the rate of synthesis, 
based on the starting intensity of pulse ligand being equal to 300 copies, thereby 
deducing the amount of pulse-labelled PSD-95 molecules remaining in each synapse 
after 24 hours, which in turn gives us an idea of the number of PSD-95 molecules that 
are represented by the chase ligand signal in these colocalising synapses (as the total 
number would still be 300). However, if we have to consider that many of these 
synapses may not be mature at DIV15, due to the high rate of synaptogenesis 
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between DIV14 and DIV21 (Lesuisse and Martin, 2002; Cohen et al., 2013), our core 
premise is not valid, thus preventing the calculation from having much validity at all. A 
further issue is that I am using a measurement of average puncta intensity, which 
provides an indication of PSD-95 concentration at a given synapse. However, it does 
not give an indication of total PSD-95 present at a synapse, as this would have 
required the measurement of integrated puncta intensity (i.e. aggregate intensity) to 
be used. Thus, I cannot work with the presumption that the maximal average puncta 
intensity is equal to 300 copies of PSD-95 in a synapse. For this reason, I will not 
attempt to calculate PSD-95 synthesis in this study, but rather evaluate relative 
synthesis rates by comparing the average chase puncta intensities. This will still give 
ample information about changes in synthesis, but not permit absolute synthesis rates 
to be calculated.  
 
In conclusion, I find that PSD-95 half-life in primary neurons between DIV15 and DIV16 
to be around 38 hours, which matches previously reported results (>36 hours, El-
Husseini et al., 2002; >24 hours, Todd et al., 2003). Nevertheless, one must take into 
consideration that this result is limited to this specific time window in the development 
of primary hippocampal neurons, and as this is still a period of great flux in terms of 
synaptic stability and synaptogenesis, the results may not be transposable onto 
neurons of other developmental ages. As such, this topic will be addressed again in 
chapter 4.  
 
3.5 Chapter conclusion 
 
This chapter has aimed to provide a detailed explanation of all of the experiments that 
act as the foundation of this project, and allowed me to proceed to ask the biologically 
intriguing questions presented in the subsequent chapter. I started off by probing the 
validity of the mouse model that is central to nearly every single experiment performed 
throughout the project, using biochemical, electrophysiological and microscopy-based 
techniques. I then went on to evaluate the functionality of using the HaloTag 
technology in a primary culture setting, and finally established a working method to 
analyse the turnover of PSD-95. These experiments, taken together, firmly establish 
that the KI mouse model is phenotypically normal, displaying no aberrant profile with 
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regards to fusion protein expression or localisation, or its electrophysiology. However, 
one point that must be noted is that no behavioural tests were performed. While 
unlikely given the other results, it cannot be ruled out that the mouse line used in this 
project may display some abnormal behavioural phenotype. A deeper analysis of this 
aspect may thus be warranted in future experiments. Furthermore, additional 
replicates of the biochemical analysis may be required in order to definitively confirm 
that PSD-95-HaloTag expression levels are not significantly different from PSD-95 
levels in WT mice.  
 
A further aspect that was noted was that while a reduction in the number of puncta 
labelled with the pulse ligand over a 24-hour time period does give some indication of 
a loss of ‘old’ PSD-95 proteins that are degraded and replaced by new, chase-labelled 
PSD-95 proteins, synaptic pruning is a viable alternative explanation for this, 
particularly at this early developmental stage. Future studies may wish to employ live 
cell imaging techniques in order to resolve such questions. Live imaging would allow 
for the observation of pruning of individual dendritic spines, as well as the visualisation 
of the degradation of PSD-95 molecules represented by a gradual dimming of pulse 
ligand signal at individual synaptic puncta. Such experiments were not within the 
scope of this project, but would provide valuable insights for future studies.  
 
The results presented in this chapter confirm that the HaloTag technology provides a 
fantastic tool for the study of PSD-95 turnover at the postsynaptic densities of live 
primary neurons. I then went on to use this HaloTag technology to work out the half-
life of PSD-95 between DIV15 and DIV16, which was found to be about 38 hours. The 
fact that this result matches those previously reported in the literature adds further 
confidence in the validity of the results. Overall, the result presented in chapter 3 
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4.1 Chapter overview 
 
The experiments that will be presented in this chapter are based upon the methods 
that I firmly established in chapter 3. All of the experiments utilise the HaloTag 
technology and our KI mouse line, and the majority of these experiments use the 
pulse-chase method in neuronal primary cultures established in chapter 3.4. This 
chapter will have two focal points: First, I will analyse PSD-95 turnover at single 
synapses rather than in bulk as I have done in chapter 3.4. Second, I will analyse 
PSD-95 turnover following the treatment of neurons with a chemical reagent.  
 
After I had successfully managed to establish a working protocol for performing pulse-
chase experiments, and had been able to use this protocol to observe and quantify 
PSD-95 turnover, I decided to apply various chemical modulators to the neuronal 
primary cultures and quantify their effect upon PSD-95 turnover. This decision was 
driven by my desire to a) observe the effect of known modulators of PSD-95 turnover 
using my method, and b) ask biologically pertinent questions in a cell culture system 
using the tools at my disposal. In order to do this, I designed a study that allowed me 
to gather a huge quantity of data simultaneously within a relatively small number of 
experiments. I will give a detailed description of this study in chapter 4.2.  
 
I decided to break up the data gathered during this study into two main parts- chapter 
4.3 will focus on the untreated control group and analyse normal PSD-95 turnover at 
a single-synapse level. I will also attempt to classify synapses into different types 
according to the data gathered in this section. In chapter 4.4 I will evaluate the effects 
that a range of modulatory chemical reagents known or thought to affect neuronal 
activity and/or PSD-95 regulation in CNS neurons has on PSD-95 turnover, both at 
the bulk and single-synapse level.  
 
In chapter 4.5 I will investigate PSD-95 turnover in mature neurons at a later 
developmental stage, DIV29+ (rather than DIV15+ for the other studies).  Finally, I will 




4.2 Overview of large-scale study 
 
In order to gather as many data sets as possible and concurrently maximising the 
comparability of these data sets by minimising the variation, I set up a total of eight 
identical experimental rounds. Each round of experiments was made up of a single 
set of hippocampal neuronal primary cultures, prepared from a single litter of PSD-
95HaloTag/HaloTag (homozygous) embryos taken at day E17.5. The hippocampi from all 
of the embryos in the litter were pooled together and, once in a single-cell suspension, 
plated out on 24-well glass coverslips according to the standard protocol (see chapter 
2.3.3). These primary cultures were grown until they had reached developmental 
stage DIV14, at which point the pulse ligand (R110Direct, 50nM) was added for 16 
hours. After pulse ligand incubation was complete on DIV15, coverslips were split up 
into groups according to their treatment. Each experiment contained 10 groups:  
 
1. Control group 1h: This group was only treated with the chase (TMR, 500nM) 
ligand for 1 hour before being fixed at DIV15. No other treatment was 
administered.  
 
2. Control group 24 hours: This group was treated with the chase ligand for 24 
hours before being fixed at DIV16. No other treatment was administered.  
 
3. Tetrodotoxin: This group was treated with tetrodotoxin at 1µM alongside the 
chase ligand for 24 hours before being fixed at DIV16.  
 
4. Bicuculline: This group was treated with bicuculline at 40µM alongside the 
chase ligand for 24 hours before being fixed at DIV16.  
 
5. Lactacystin: This group was treated with lactacystin at 1µM alongside the chase 
ligand for 24 hours before being fixed at DIV16.  
 
6. MG132: This group was treated with MG132 at 10µM alongside the chase 
ligand for 24 hours before being fixed at DIV16.  
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7. Anisomycin: This group was treated with anisomycin at 1µM alongside the 
chase ligand for 24 hours before being fixed at DIV16.  
 
8. Cycloheximide: This group was treated with cycloheximide at 3µM alongside 
the chase ligand for 24 hours before being fixed at DIV16.  
 
9. BDNF: This group was treated with BDNF at 3.7nM alongside the chase ligand 
for 24 hours before being fixed at DIV16.  
 
10. Ketamine: This group was treated with ketamine at 10nM alongside the chase 
ligand for 24 hours before being fixed at DIV16.  
 
Each group contained two coverslips per experimental round. The pulse-chase 
protocol was the standard protocol I had established in chapter 3.4, that is outlined in 
chapter 2.5.6. After cells had been fixed, the coverslips were individually mounted on 
glass slides in preparation for imaging. At this stage the experiment was blinded, such 
that I did not know which slide was part of which experimental group. This was done 
by asking another member of our lab to assign each slide a number, and record the 
treatment group that this number correlated with. Unblinding only occurred in the final 
stage of the experiment, once all of the data had been acquired and analysed (i.e. 
once all of the quantitative data such as average puncta intensity, number and 
colocalisation had been gathered). The slides were then imaged using the LSM510 
confocal microscope (63x magnification, zoom3.1) at previously established standard 
settings (see chapter 2.4.1).  
 
For each slide, six images were taken with attempts made to keep image locations as 
similar between slides as possible (along dendrites, excluding cell bodies). The Imaris 
software was then used to detect synaptic puncta as detailed in chapter 2.4.2. A 
colocalisation analysis was performed and as before, puncta were detected using a 
seed point estimation diameter of 300nm, with puncta considered colocalised if within 
300nm of each other (centre to centre). When using the puncta colocalisation tool, the 
Imaris software automatically sorts the entire population of puncta in each channel 
according to whether they do or do not colocalise with puncta in the other channel.  
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After puncta had been detected and colocalisation analysis performed for each image, 
the mean was calculated for each parameter (e.g. mean puncta intensity per image, 
mean puncta number per image). It was only at this stage that unblinding took place. 
After the identity of each coverslip in each experimental round had been revealed, the 
results of coverslips in the same treatment groups were merged (that is to say that the 
average value was calculated across all 12 data points, 6 data points from each 
coverslip). This means that for every experimental set, the results from 12 images 
were averaged together (6 images per coverslip and 2 coverslips per experimental 
group). Finally, after all eight rounds of experiments had been completed, the final 
mean value for each parameter was calculated across the eight sets of experiments. 
In this way, each set of experiments was values as an N of 1, having been derived 
from a genetically distinct embryonic litter.  
 
This experimental design allows me to compare the results from these experiments 
with a high degree of confidence that differences are due to treatment, particularly as 
all data sets were collected from the exact same cultures derived from the same pool 
of embryos, meaning genetic variability and differences in culture conditions could be 
discounted. Furthermore, while the nominal N is eight, the results are the end-product 
of analysing tens of thousands of synaptic puncta for each treatment group. Indeed, 
each treatment group is made up of 96 images (8 experiments, 2 coverslips per 
experiment, 6 images per coverslip). If we estimate about 500 synaptic puncta per 
image (given that according to figure 3.19.c about 600 puncta were labelled with the 
pulse ligand at the start of the experiment), we arrive at 48,000 synaptic puncta being 
analysed for each treatment group.  
 
Nevertheless, some sources of variability remain. For one, the fact remains that 
neurons were grown on different coverslips in separate wells, and it can frequently be 
observed that neurons on one coverslip grow differently to neurons on another 
coverslip. Thus, neuronal cell density and the extent of dendritic outgrowth can differe 
from well to well. This can have an impact on the data, for example if this affects the 
number of synapses per image. Likewise, there can be significant differences in 
neuronal growth between separate cultures. Another point to consider is that while 
cultures were derived from the embryonic hippocampus, cells within the hippocampus 
can be diverse, and thus some coverslips or imaged regions may contain a 
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preponderance of cells of one type over another. Furthermore, hippocampal 
dissections are technically challenging, and thus some amount of surrounding cortical 
tissue is inevitable included. This, again, can vary in its extent from culture to culture, 
potentially introducing a source of variability. While large sample sizes and pooling 
helps to mitigate these variabilities to some extent, a power calculation could have 
been a useful tool in order to work out the statistically required sample sizes to limit 
the impact.  
 
In the following section, chapter 4.3, I will only focus on the control groups in this study, 
and analyse PSD-95 turnover at a single-synapse level across these eight 
experiments. Thereafter, in chapter 4.4, I will turn my attention to the different 
treatment groups and evaluate the effect of these chemical reagents on PSD-95 





4.3 Analysing PSD-95 turnover in bulk and at a single-synapse 
level over 24 hours in untreated controls 
 
4.3.1 Introducing the concept of single-synapse analysis of PSD-95 
turnover 
 
The concept of protein turnover can be understood in different ways, and protein 
turnover can be studied using a variety of techniques. Some studies have used time-
lapse confocal microscopy to observe the appearance and disappearance of individual 
GFP-tagged PSD-95 puncta in transfected neuronal cell cultures (Marrs et al., 2001; 
Okabe et al., 1999; Okabe et al., 2001), but this does not give an indication of PSD-
95 degradation and synthesis and only allows for the study of synapse dynamics. 
Other studies have used photoactivatable GFP tagged to PSD-95 to visualise the 
degradation of PSD-95 at individual synapses over time (Sturgill et al., 2009). 
However, this technique does not allow for the observation of PSD-95 synthesis, only 
degradation. Fluorescence recovery after photobleaching (FRAP) is another 
technique that has been applied to the study of PSD-95 turnover at single-synapses 
(Zheng et al., 2010). This technique allows for an estimation of the size of the stable 
pool of the POI thereby giving an indication of the dynamism of a protein at synaptic 
locations, but it does not permit for synthesis or degradation to be evaluated.  
 
Furthermore, the vast majority of these studies are performed using transfected 
neuronal cultures, meaning that PSD-95 is being overexpressed, which can lead to 
enhanced basal synaptic transmission and spine size (El-Husseini et al., 2000; Stein 
et al., 2003; Choe and Ehrlich, 2006), as well as decreased dendritic branching 
(Charych et al., 2006). In addition, fusion protein expression is not under the control 
of the endogenous promoter, and fluorescent proteins require a certain amount of time 
(four hours in the case of GFP) to become fluorescent by oxidation (Okabe et al., 
1999). All of these factors can potentially have an effect on the experimental outcome.  
 
Those studies that wish to specifically study protein synthesis and degradation tend to 
use metabolic labelling techniques such as SILAC (Stable Isotope Labelling with 
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Amino acids in Cell culture). This method has been used to work out the half-lives of 
synaptic proteins, including PSD-95 (Cohen et al., 2013; El-Husseini et al., 2002). 
However, while this technique is undoubtedly well-suited for establishing the half-life 
of a protein, it can only be used to study proteins in bulk, never at individual synapses.  
 
Finally, there is a newer set of techniques involving non-canonical amino acid tagging 
that can be used to study protein turnover. FUNCAT (Fluorescent non-canonical 
amino acid tagging) involves the tagging of proteins with non-canonical amino acids 
followed by their detection using fluorescent labelling in situ, and can be used to 
visualise protein turnover at single-synapses in live primary neuronal cultures (Dieck 
et al., 2015). Quantitative non-canonical amino acid tagging (QuaNCAT) combines 
biorthogonal non-canonical amino acid tagging (BONCAT) with SILAC, allowing for 
the study of bulk protein turnover using mass spectrometry (Alvarez-Castelao et al., 
2015). Taken together, these techniques are able to cover most aspects of protein 
turnover, yet none of them allows for the simultaneous study of protein turnover at the 
bulk and single-synapse level. Furthermore, FUNCAT, while able to visualise the 
turnover of a POI at single synapses, is unable to differentially label older and newer 
subpopulations of the same protein, and can thus not give an insight into the 
abundance ratio of these two groups at individual synapses.   
 
The pulse-chase technique I established in chapter 3.4 using the HaloTag technology 
and the PSD-95HaloTag KI mouse line combines many of the strengths of the 
aforementioned approaches to studying PSD-95 turnover, and even allows for the 
simultaneous analysis of PSD-95 turnover in bulk and at single synapses. This 
versatility is one of the greatest strengths of the HaloTag technology. In chapter 3.4 I 
outlined how the pulse-chase application of different fluorescent HaloTag ligands can 
be used to measure the turnover of a tagged POI (PSD-95) in bulk. By measuring the 
fluorescence intensity of pulse or chase ligands at individual synaptic puncta, 
calculating the mean puncta intensity per image taken, and ultimately calculating the 
mean puncta intensity over a number of images that make up a time point, the average 
puncta intensity is calculated across a huge number of synaptic puncta. This gives a 
very reliable estimate of the amount of ‘old’ or ‘new’ PSD-95 present at PSDs in a 
culture at a certain time point. However, because we detect puncta intensity for each 
synapse separately, we are also able to use this method to analyse PSD-95 turnover 
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at individual synapses, and identity different synaptic types according to their PSD-95 
turnover profile.   
 
The first and simplest manner of analysing single-synapse data is to subdivide the 
bulk data according to whether the puncta labelled by one ligand colocalise with the 
puncta labelled by the other ligand. This results in the formation of three synaptic 
subgroups: synapses containing both pulse- and chase-labelled PSD-95, and 
synapses containing only pulse- or only chase-labelled PSD-95. This analysis can be 
performed in varying situations, such as after 24 hours of chase ligand incubation and 
after 48 hours of chase incubation. Shifts in the abundance as well as the mean 
intensity of puncta in these groups can then be analysed and interpreted.  
 
The fact that each synaptic punctum is a separate data point also allows for an 
analysis of the frequency of puncta intensities, i.e. how puncta are distributed across 
the range of fluorescence intensities. Such frequency distribution histograms may be 
skewed in different ways, which can indicate variations in population dynamics.   
 
Finally, because each synaptic punctum can be analysed for both its pulse and chase 
ligand intensity separately, it is possible to work out the ratio of pulse:chase ligand 
intensity for each synapse. These ratios can then be analysed further, such as by 
comparing changes in the average ratios at different time points, or by examining the 
frequency distributions of these ratios. One important point to bear in mind when 
comparing the relative intensities of pulse and chase ligands, however, is that pulse 
and chase ligands carry different fluorophores with different fluorescent properties, as 
well as having been acquired with different microscope parameters and detected with 
different detection parameters in the Imaris software. Thus fluorescence intensity 
ratios cannot give any information about the absolute abundance of one ligand relative 
to the other (for example, a 1:1 intensity ratio does not mean that pulse and chase 
ligands are equally abundant in a given synapse). Instead, it is the differences in the 
pulse:chase intensity ratios that are of significance- a decrease in the average 
pulse:chase ratio means that the chase ligand has become relatively more abundant 
than the pulse ligand. For example, if a synapse were to go from a pulse:chase ratio 
of 2:1 to a ratio of 1:1, then we can presume that relative to the pulse ligand, there is 
now twice as much chase ligand present.  
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Nevertheless, because only a single HaloTag ligand binds to a single HaloTag protein 
(fused to PSD-95), the fluorescence intensity of a synaptic punctum is directly 
proportional to the number of PSD-95 molecules present in that synapse. This means 
that if the average puncta intensity across all synapses doubles over the course of 24 
hours, we can presume that the average amount of PSD-95 labelled by that ligand 
has also doubled.  
 
In the following sections of chapter 4.2 I will expand the bulk analysis of PSD-95 
turnover performed in chapter 3.4 to the analysis at a single-synapse level. This will 
not only give interesting insights into the turnover of PSD-95, but also provide a 
reference point for the future analysis of data sets coming from primary neurons 























4.3.2 Analysing PSD-95 turnover over 24 hours 
 
In this section I will present the parts of the data from the large-scale study outlined in 
chapter 4.2 that pertain to the untreated control groups (1 hour of chase incubation 
and 24 hours of chase incubation). The details of the experiment design have been 
outlined in chapter 4.2, but briefly hippocampal primary cultures were derived from 
eight different litters of PSD-95HaloTag/HaloTag (homozygous) embryos. These cultures 
were grown until DIV14, at which point the pulse ligand (R110Direct, 50nM) was added 
for 16 hours. Following pulse ligand incubation, the majority of the media containing 
the pulse ligand was removed and replaced with media containing an excess of chase 
ligand (TMR, 500nM) at DIV15. Incubation with the chase ligand occurred for 1 hour 
and 24 hours, depending on the control group. Thereafter cells were fixed in 4% PFA, 
mounted on glass slides, imaged on an LSM510 confocal microscope and analysed 
using the Imaris software.  
 
4.3.2.1 Bulk analysis 
 
Briefly looking back at the single 48-hour pulse-chase experiment presented in chapter 
3.4.4 and figure 3.19, we see that the mean fluorescence intensity and number of 
synaptic puncta labelled by the pulse (R110) ligand diminished rapidly (intensity 
decreases statistically significantly from 67.11 ± 2.76 Arbitrary Units (AU) to 43.53 ± 
1.9 AU over the first 24 hours (Welch’s t-test: p=9.99x10-7). Concomitantly, the mean 
fluorescence intensity and number of synaptic puncta labelled by the chase (TMR) 
ligand went up over the first 24 hours, and then remained constant over the following 
24 hours (from no signal at all at the 1-hour time point to 30.50 ± 1.59 AU). The results 
from the new, large data set are very similar to these.  
 
Figure 4.1.a shows that the mean intensity of puncta labelled by the pulse (R110) 
ligand is 65.97 ± 1.69 AU at the 1-hour time point. After 24 hours of chase-labelling, 
the mean pulse ligand puncta intensity has decreased markedly down to 41.44 ± 0.85 
AU (statistically significant, Welch’s t-test p=9.51x10-8). Over the same 24-hour time 
period, the average puncta intensity of the chase (TMR) ligand shoots up to  
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a.        b.  
  
c.        d.  
  
Figure 4.1. Measuring mean PSD-95 puncta intensity and number per image in bulk.  
Neuronal primary cultures from pooled homozygous PSD-95HaloTag/HaloTag mouse hippocampi 
taken at embronal stage E17.5 were grown on glass coverslips until DIV14. At DIV14 they were 
labelled with the R110Direct HaloTag ligand (50nM, 16h), and on DIV15, the TMR ligand was 
added to the cultures at 500nM and the concentration of the R110 ligand reduced to 12.5nM. 
Cells were fixed in 4% PFA after either 1 hour or 24 hours of incubation. Coverslips were 
imaged on the LSM510, and puncta detected using the Imaris software. Average puncta 
fluorescence intensity per image as well as average puncta number per image were then 
calculated. This was performed across 8 different cultures (N=8), with the graphs here 
presenting the mean values across these eight cultures. a. Graph of the average R110 pulse 
ligand puncta intensity. Note the significant reduction in puncta intensity as pulse-labelled 
‘old’ PSD-95 proteins are degraded over time (Welch’s t-test, p=9.51x10-8). b. Graph of the 
average TMR chase ligand puncta intensity. Note the lack of signal after 1 hour of incubation 













































































































c. Graph of the average R110 pulse ligand puncta number. The significant decrease in puncta 
number mirrors the decrease in fluorescence intensity seen in (a.) (Welch’s t-test, p=0.0020). 
d. Graph of the average TMR chase ligand puncta number. As in (b.), no puncta are detected 
at the 1 hour incubation time point due to saturation by the pulse ligand.  
 
29.63 ± 1.42 AU (figure 4.1.b). When comparing these numbers to those of the single 
experiment from chapter 3.4.4, as mentioned above, it is striking how similar they are.  
 
When looking at puncta number, we see a similar pattern. From the earlier experiment 
we see in figure 3.19.c, pulse ligand puncta number decreases from a peak of 598.67 
± 69.1 puncta down to 329.55 ± 49.3 puncta over 24 hours (significant, p=0.005). 
Chase ligand puncta number goes up from no puncta detected at all to 386.09 ± 39.84 
puncta over the same time period. In the new data set (figure 4.1.c-d), the number of 
synaptic puncta labelled by the pulse ligand goes down significantly from 419.35 ± 
50.05 to 189.15 ± 26.64 (Welch’s t-test, p=0.002). The number of puncta labelled by 
the chase ligand goes up from no puncta detected to 192.66 ± 32.83 over 24 hours. 
While the results from the larger data set (figure 4.1) are lower than those observed in 
the single data set (figure 3.19), they clearly follow the same pattern.  
 
To complete this bulk analysis of PSD-95 turnover in untreated controls, I repeated 
the protein half-life calculation. With the single data set, the half-life of PSD-95 was 
found to be 38.43 hours (chapter 3.4.5). With the new numbers, this half-life is slightly 
decreased, to 35.78 hours. While this is a slight downwards revision, it is nonetheless 
very similar and consistent with the literature (‘approximately 36 hours’, El-Husseini et 
al., 2002).  
 
4.3.2.2 Single-synapse analysis A: Colocalised vs Non-Colocalised 
 
Following the bulk analysis, we move to the results of the single-synapse analysis by 
looking at differences in average puncta intensity between puncta of one ligand that 
colocalise with puncta of the other ligand, and those that do not colocalise. Figure 
4.2.a. shows that after 24 hours of chase ligand incubation, pulse-labelled puncta that 
are colocalised with chase-labelled puncta have a greater average intensity than those 
that are not colocalised. At this time point, colocalised pulse-labelled puncta had an 
average intensity of 45.13 ± 0.93 AU while non-colocalised puncta had an average  
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c.        d.  
  
Figure 4.2. Colocalised and non-colocalised puncta differ in their average puncta intensity 
and number.  
Average puncta fluorescence intensity (APFI) and number per image were calculated for pulse 
and chase ligand labelled synaptic puncta that are colocalised with puncta of the other ligand, 
and those that are not. a. Graph comparing pulse ligand (R110Direct) APFI of colocalised with 
non-colocalised puncta (difference is significant: Welch’s t-test, p=9.01x10-7). b. Graph 
comparing chase ligand (TMR) APFI of colocalised with non-colocalised puncta (difference is 
significant: Welch’s t-test, p=0.00016). c. Graph comparing average pulse ligand (R110Direct) 
puncta number per image of colocalised with non-colocalised puncta (difference is not 
significant: Welch’s t-test, p=0.18). d. Graph comparing average chase ligand (TMR) puncta 
number per image of colocalised with non-colocalised puncta (difference is not significant: 


















































































































intensity of 34.79 ± 0.80 AU. This difference is highly statistically significant (Welch’s 
t-test, p=9.01x10-7).  
 
Figure 4.2.b. shows the results of the same analysis for the chase ligand at the same 
24-hour time point. Just like with the pulse ligand, average chase ligand puncta 
intensity is greater in those puncta that are colocalised (34.88 ± 1.91 AU) with the 
pulse ligand than those that are not (22.54 ± 1.00 AU). Again, the difference is 
statistically significant (Welch’s t-test, p=0.00016).  
 
When looking at puncta number, the exact same picture emerges: Colocalised puncta 
are more numerous than non-colocalised puncta (figure 4.2.c). For the pulse ligand, 
there are on average 115.92 ± 17.98 colocalised puncta per image and 76.81 ± 21.29 
non-colocalised puncta per image (not significant, Welch’s t-test, p=0.18). For the 
chase ligand (figure 4.2.d), there are on average 114.00 ± 17.58 colocalised puncta 
per image and 78.65 ± 16.67 non-colocalised puncta per image (not significant, 
Welch’s t-test, p=0.17). In neither case is the difference statistically significant, 
however, which can be explained by the high degree of variance when it comes to 
puncta number per image.  
 
Next, I wanted to find out what percentage of synapses in the whole synaptic 
population expressed either both ligands (colocalised) or only one of the ligands but 
not the other. Figure 4.3. shows the results visualised as a pie chart. From this graph 
we can see that 28% of synapses contain only pulse ligands (i.e. ‘old’ PSD-95), 29% 
contain only chase ligands (‘new’ PSD-95) and in 43% of synapses pulse and chase 
ligands are colocalised.  
 
Taken together all of these results allow some very interesting insights into the whole 
synaptic population in hippocampal primary neurons at DIV15. Firstly, we can clearly 
observe that there are three distinct synaptic populations- those containing only ‘old’ 
PSD-95, those containing only ‘new’ PSD-95, and those containing a mixture of the 
two. The other interesting observation is that there is a clear link between puncta 
colocalisation and synapse fluorescence intensity (which directly correlates with PSD-
95 expression). For both ligands, pulse and chase, colocalised synapses display a 
greater fluorescence intensity. Since these synapses were likely present over the 
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course of the entire 24-hour pulse-chase experiment (and longer, due to the 16-hour 
pulse ligand incubation period), as they contain ‘old’ PSD-95 proteins, a possible 
explanation is that these are large, well-established and mature stable synapses that 
steadily turn over PSD-95. On the other hand, synapses containing only chase ligand 
(‘new’ PSD-95) may be young synapses that have only appeared over the final 24 
hours and were not present during pulse labelling. This may explain why they tend to 
express less PSD-95- they may simply still be immature. Synapses containing only 
the pulse ligand (‘old’ PSD-95) may on the other hand express less PSD-95 for other 
reasons- perhaps they are in the process of being pruned, or else they may have been 
silenced. I will discuss the implications of these observations further in chapter 4.3.3, 
but for now, we can clearly observe differences in PSD-95 expression over what 




Figure 4.3. Proportional representation of synaptic population by HaloTag ligand-labelling.  
Synaptic puncta were categorised according to whether they colocalised with puncta labelled 
by the other ligand or not. This pie chart depicts the proportional representation of the three 














4.3.2.3 Single-synapse analysis B- Frequency histograms 
 
Another interesting analytical perspective that is possible when analysing single-
synapses is to look at frequency histograms. As my data consists primarily of values 
for individual puncta, it is easy to plot such frequency histograms for entire populations 
of synaptic puncta. These graphs can then give valuable information about a 
population by their shape and skewness, allowing for reasonable deductions about 
the dynamic state of the population.  
 
Figure 4.4 shows a frequency distribution histogram of pulse ligand puncta at the 1-
hour time point, as well as a cumulative distribution function plot. Since there are no 
chase ligand puncta detectable at this stage, the data at this time point represents the 
entire population of synaptic puncta. Mean intensity is 65.97 ± 1.69 AU (as revealed 
in the bulk analysis above), with median intensity being 54.94 AU and the mode being 
42 AU (3.79% of puncta). Observing the shape of the histogram (Figure 4.4.a), we can 
immediately see that the histogram is asymmetric- there is a distinct positive 
skewness, i.e. low-intensity synaptic puncta are more common than high-intensity 
puncta. Indeed, 61% of puncta have an intensity that is lower than the mean intensity. 
We can also observe that the range of puncta intensities is quite large- puncta range 
in intensity from 18 to more than 220 arbitrary units. One possible explanation for this 
distribution is that at this developmental stage (DIV16), there are many immature 
synapses that are still growing in size and hence number of PSD-95 molecules 
expressed, and therefore the majority of synapses are small and low in PSD-95 count. 
If this is the case, we can expect the peak of the histogram (and therefore average 
puncta intensity) to shift upwards in older, mature neuronal cultures. An alternative 
explanation is that the overall synaptic population is simply very diverse in size and 
degree of PSD-95 expression, and that this population histogram accurately reflects 
the distribution of PSD-95 that is expressed by each synapse. If this is the case, we 
must deduce that the synaptic population, while heterogeneous, tends to have a 
preponderance of smaller synaptic puncta expressing relatively less PSD-95 and only 








Figure 4.4. Frequency distribution histogram and cumulative distribution function of 
synaptic puncta labelled with the pulse ligand at DIV15.  
a. The frequency distribution histogram depicts the full range of average puncta fluorescence 
intensities of pulse ligand puncta after 16 hours of incubation with the pulse ligand 
(R110Direct, 50nM), and 1 hour of incubation with the chase ligand (TMR, 500nM). The 
histograms reveals a positive skew and heterogenous synaptic population in terms of PSD-95 
expression levels. Mean intensity is 65.97 ± 1.69 arbitrary units (AU), with median intensity 
being 54.94 AU and the mode being 42 AU (3.79% of puncta). b. The cumulative distribution 
function shows the actual distribution of the data alongside the theoretical distribution if it 
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Looking at figure 4.4.b, we can see that the cumulative distribution function reveals 
that the actual data points are, for the most part, quite similar to the hypothetical points 
if the data points followed a perfectly normal distribution. This indicates that while the 
data does have a slight skew towards lower-intensity puncta, overall the data is 
nevertheless normally distributed.   
 
Next, we look at puncta intensity frequency distribution histograms for the 24-hour time 
point. Figure 4.5 shows four histograms representing the three distinct groups of 
synapses that make up the synaptic population at this point- pulse ligand puncta 
colocalised, pulse ligand puncta non-colocalised, chase ligand puncta colocalised and 
chase ligand puncta non-colocalised. Pulse ligand puncta that are colocalised with 
chase ligand puncta (figure 4.5.a) unsurprisingly display a very similar distribution 
curve to chase ligand puncta that are colocalised with pulse ligand puncta (figure 
4.5.c). Both graphs are slightly positively skewed, and taper out very gradually towards 
the higher puncta intensity. Both populations appear to be very heterogenous, with 
mildly sloping curves and relatively low peaks (pulse mode: 34 AU, 3.47%; chase 
mode: 19 AU, 3.96%). While this similarity may not be surprising given that both 
graphs represent the same population of synapses, viewed from the perspective of 
the two different ligands, it does nevertheless mean that over the course of the 24-
hour experiment PSD-95 expression levels in these synapses appear to remain 
constant. Thus, we can postulate that in these colocalising synapses, PSD-95 that is 
degraded is being replaced by newly synthesised PSD-95 at the same rate, keeping 
the overall PSD-95 expression level constant over this subpopulation of synapses.  
 
However, the picture we see in the other two synaptic populations is very different. 
Looking at figure 4.5.b, we see that the population of pulse ligand puncta that are not 
colocalised with chase ligand puncta appears to be much less diverse. The slopes are 
much steeper than in figure 4.5.a, and the mode has a much higher frequency value 
(mode 24 AU at 5.59%). The graph representing the population of chase ligand puncta 
that are not colocalised (figure 4.5.d) is similar but even more extreme. The shape of 
the graph displays a very pronounced peak at a low puncta intensity (bimodal, mode 
is 14 and 15 AU, at 8.53%), and very steep slopes with few outliers. The vast majority 
of the puncta frequencies are grouped around the modal values, i.e. a great proportion 
of these puncta are of low intensity compared to colocalising puncta (figure 4.5.c).  
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a.        b.  
  































































































































Average puncta fluorescence intensity (APFI)





Figure 4.5. Frequency distribution histograms of colocalised and non-colocalised pulse and 
chase ligand labelled synaptic populations.  
After 24 hours of chase-ligand labelling, synaptic populations labelled by both pulse and chase 
ligand were categorised according to whether they colocalised with puncta of the other 
ligand. A frequency distribution histogram for APFI was then plotted from each of these four 
populations. a. Graph represents pulse ligand puncta that are colocalised with chase ligand 
puncta. b. Graph represents pulse ligand puncta that are not colocalised with chase ligand 
puncta. c. Graph represents chase ligand puncta that are colocalised with pulse ligand puncta. 
d. Graph represents chase ligand puncta that are not colocalised with pulse ligand puncta. e. 
Cumulative distribution function of colocalised and non-colocalised Pulse-ligand labelled 
puncta at the 24-hour time point. The two populations are significantly different from each 
other (Kolmogorov-Smirnov test, two-tailed, p<0.0001).  
 
Next, the frequency distributions of pulse ligand puncta in figures 4.5.a and 4.5.b were 
compared using a cumulative distribution function (figure 4.5.e). This distribution 
indicates that low-intensity puncta are indeed more frequent in non-colocalising 
synapses than in colocalising synapses, which are more likely to display a greater 
intensity. This was probed using a two-tailed Kolmogorov-Smirnov test for difference, 
and the result conclusively indicated that the two populations are indeed distinct 
(p<0.0001).  
 
While the two graphs of non-colocalising puncta populations (4.5.b and 4.5.d) are 
similar in some ways, they also display differences: 4.5.d has a much higher frequency 
peak, and much steeper slopes, while 4.5.b is more evenly spread. It is likely that 
these two graphs capture two separate populations of puncta undergoing different 
transformations. Figure 4.5.b represents a population of synapses containing solely 
‘old’ PSD-95, and these synapses appear to be undergoing either pruning or 
stagnation as PSD-95 proteins that are being degraded are not being replaced with 
newly synthesised proteins. Indeed, a study by Cane et al. (2014) has shown that 
dendritic spines significantly reduce their PSD-95 content well before the actual 
pruning event. In this case, it could be expected that in preparation for pruning such 
synapses would cease to incorporate new PSD-95.  These synapses could also be 
undergoing a transition into becoming ‘silent’ synapses, characterised by their lack of 
AMPA receptor expression and most likely lacking PSD-95 (Huang et al., 2015; 
Béı ̈que et al., 2006), and are therefore reducing their protein content and slowing 
down protein turnover.  
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Figure 4.5.d, on the other hand, most likely represents ongoing synaptogenesis, as 
these synapses do not contain ‘old’ PSD-95 and are low in intensity. It is thus likely 
that these synapses have formed over the past 24 hours, and are in the process of 
enlarging their pool of PSD-95 (and other) proteins in the PSD. This would interestingly 
imply that newly formed synapses gradually build up PSD-95 levels as they mature, 
rather than importing the complete and final amount of PSD-95 allocated to that 
specific synapse by some predetermined mechanism. And alternative explanation is 
that these synapses have a much quicker turnover rate, and have simply broken down 
their entire contingent of ‘old’ PSD-95 and replaced it with ‘new’ PSD-95 over these 
24 hours. In that case, one could argue that synapses could be split into two groups- 
those that have a slower rate of turnover of PSD-95 and also contain much more PSD-
95 in total, and perhaps smaller synapses containing much fewer PSD-95 molecules 
that are turned over rapidly. To resolve this question one would have to use live 
imaging of neuronal cultures and observe protein turnover as it happens. However, 
with my method I am unable to rule out either one of these explanations, and perhaps 
both are correct to some extent. Nevertheless, my inclination is to attribute these result 
to synaptogenesis and conclude that chase-ligand labelled puncta that do not 
colocalise with the pulse ligand are most likely synapses that have been newly formed 
and therefore contain less PSD-95 at this stage. Indeed, Butko et al. (2012) found that 
newly-synthesised PSD-95 tends to be found preferentially at immature synapses, 








4.3.2.4 Single-synapse analysis C- Ratios 
 
In this section of the single-puncta analysis, I will focus solely on those synapses that 
contain both old and new PSD-95 molecules, i.e. synapses in which pulse and chase 
ligands colocalise. In the previous sections I have looked at the puncta labelled by on 
or the other ligand separately, but now I will investigate the relationship between the 
two ligands within these synapses.  
 
Figure 4.6 is a frequency histogram of the ratio of pulse:chase ligand intensity. I 
obtained this data by working out the ratio of pulse to chase ligand intensity at 
individual synapses, and plotting the frequencies of these ratios. I find that the mean 
pulse:chase ligand ratio is 2.55 ± 0.051 (SEM), with a median ratio of 2.06. The mode 
is a ratio of 1.7, with 5.14%. The range of ratios is quite large, from 0.6 to more than 
10, indicating a diverse synaptic population. Note that very few synapses have a 
pulse:chase ratio below 1, but since these are different fluorophores this does not 
necessarily mean that most of these synapses contain more old than new PSD-95. 
This graph may indicate that there is a high degree of heterogeneity with regards to 
PSD-95 turnover, as some synapses retain varying amounts of old PSD-95 and/or 
obtain newly synthesised PSD-95 at varying rates. However, such conclusions need 
to be treated with caution, since we do not know what the starting amount of old PSD-
95 in these synapses was. While we can presume that these synapses were already 
present during the pulse incubation time period and are therefore at least ~30 hours 
old, they may at that point have been well-established and mature synapses with a full 
contingent of PSD-95 molecules in their PSD, or have been in the early stages of 
synaptogenesis and thus still have been recruiting additional PSD-95 molecules while 
establishing their PSDs. Indeed, this graph looks strikingly similar in its shape to the 
intensity frequency histogram of synapses at the 1-hour time point displayed in figure 
4.4. This might imply that the PSD-95 turnover rate is the same in all synapses, but it 
is the starting amount of pulse-labelled PSD-95 that varies and thus causes the vast 






Figure 4.6. Frequency distribution histogram for pulse to chase ligand APFI ratios at 
colocalised synapses.  
In the synaptic population in which pulse and chase ligand-labelled PSD-95-HaloTag 
molecules were colocalised, the ratio of pulse ligand fluorescence intensity to chase ligand 
fluorescence intensity was calculated for each individual synapse. This histogram represents 
the frequencies of all the pulse:chase ratios. Note that pulse and chase ligands carry different 
fluorophores, such that their intensities cannot be compared. This means that a 1:1 ratio of 
pulse to chase ligand (i.e. a ratio of 1) does not mean that the number of pulse-labelled PSD-
95-HaloTag molecules is equal to the number of chase-labelled PSD-95-HaloTag molecules in 
that synapse. However, a punctum with a ratio of 2 contains twice as many pulse-labelled 
molecules relative to chase labelled molecules than a punctum with a ratio of 1. Note also the 
diverse spread of ratios, ranging from a ratio of 0.4 to above a ratio of 10. Mean ratio: 2.55 ± 
0.051 (SEM), Median ratio: 2.06, Mode: 1.7 (5.14%).  
 
However, there are differences between the two graphs- the modal puncta intensity in 
figure 4.4 having a frequency of 3.79% while the modal ratio in figure 4.6 has a 
frequency of 5.14% (note that the number of x-axis values is equal in the two graphs). 
This means that there are fewer low-intensity puncta at the start of the experiment 
than there are puncta with a low pulse:chase ligand ratio after 24 hours. There also 
appears to be a greater spread in the average pulse ligand puncta intensity at the 1-
hour time point than spread of ratios. However, type 3 synapses do not contribute to 
the graph of ratios of type 2 synapses, while these synapses were present at the 1-
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we cannot make definitive statements about PSD-95 turnover rates from this data 
alone, but there does seem to be an indication that PSD-95 turnover differs between 
type 2 synapses. Over the entire synaptic population, however, we can definitively say 
that PSD-95 turnover does indeed differ. This is simply because out of the synaptic 
population that was present throughout the entire experiment (type 2 and type 3 
synapses), type 3 synapses clearly experience no new PSD-95 synthesis, while type 
2 synapses do.  
 
I next decided to correlate pulse with chase ligand puncta intensity. I used a sample 
of twelve images to create the scatter plot depicted in figure 4.7.a. While there does 
appear to be a slight positive correlation, the R2 value is quite low (0.16). To expand 
this analysis a further, I sorted puncta by pulse ligand intensity into percentiles, and 
then measured average chase ligand intensity in each of these percentiles. The results 
in figure 4.7.b show that there is a very strong positive correlation (R2=0.96) between 
pulse ligand intensity percentile and average chase ligand intensity. When doing the 
opposite (plotting average pulse ligand intensity over the range of chase ligand 
percentiles, figure 4.7.c), the same strong correlation is observed (R2=0.92). Overall, 
then, it appears that among synapses that contain both pulse and chase ligand-tagged 
PSD-95 molecules there is a very strong positive correlation between pulse and chase 
ligand intensity. In other words, the more of one ligand a synapse contains, the more 
of the other ligand it will contain as well.  
 
While this does not sound surprising at first, it is actually not at all intuitive. Take a 
synapse with a low level of pulse ligand fluorescence intensity for instance. We might 
assume that such a synapse is immature, perhaps, as it may have had a small amount 
of PSD-95 within it while being pulse labelled. In this case, we would expect this 
synapse to recruit a large amount of new PSD-95 over the 24 hours of chase 
incubation, in order to bring its PSD up to a ‘regular’ level of PSD-95. In that case, we 
would expect synapses will little pulse ligand to express more chase ligand. Yet it is 







b.        c.  
  
Figure 4.7 Correlation of pulse ligand intensity with chase ligand intensity at colocalised 
synaptic puncta.  
a. The APFI of the pulse ligand was plotted against the APFI of the chase ligand at individual 
synapses in which the two ligands colocalise. There is a weak positive correlation, R2=0.16. b. 
Colocalising synapses were sorted by their pulse ligand APFI (lowest to highest). For each ten 
percentile steps, average chase ligand APFI was calculated. There is a strong positive 
correlation, R2=0.96. c. Colocalising synapses were sorted by their chase ligand APFI (lowest 
to highest). For each ten percentile steps, average pulse ligand APFI was calculated. There is 
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Pulse ligand signal over chase ligand 
intensity percentiles
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The other scenario is the opposite, where a synapse expresses a high level of pulse 
ligand. In that case we might presume that this synapse was large and mature at the 
start of the experiment during pulse labelling, and thus a large proportion of that pulse-
labelled old PSD-95 is still left after 24 hours of chase labelling. However, if this 
synapse already had a full complement of PSD-95 in its PSD, and was at this stage 
merely turning PSD-95 over at a ‘normal’ pace, why does it also recruit a high level of 
new PSD-95?  
 
While the results do not give an answer to these riddles, we can try to explain these 
phenomena nonetheless. One possible explanation is that synapses vary vastly both 
in the size of their overall PSD-95 pool as well as their rate of PSD-95 turnover. Smaller 
synapses may thus express a smaller overall amount of PSD-95, and only turn over a 
small part of these proteins. Larger synapses may express a lot of PSD-95 and have 
high rates of turnover.  
 
Indeed, a study by Gray et al. (2006) has shown that PSD-95 stability at synapses is 
activity- and size-dependent, with more active and larger synapses recruiting more 
PSD-95 molecules and inactive synapses losing them. Thus, PSD-95 levels in a given 
synapse may determine synaptic strength and size (Ehrlich and Malinow, 2004). There 
appears to be a causal link between synaptic size and PSD-95 turnover rates- highly 
active synapses may require a large amount of molecular machinery and therefore 
have large, dense PSDs.  
 
Large synapses have also been shown to retain PSD-95 for longer time periods than 
smaller synapses (Gray et al., 2006), which would explain the greater amount of old 
PSD-95 in colocalised synapses. Among type 2 synapses, then, greater amounts of 
PSD-95 appear to correlate with greater rates of PSD-95 turnover, likely linked to 





Figure 4.8. Synapses are very heterogeneous in their expression level of old and new PSD-
95 molecules.  
An example image from a hippocampal primary culture on DIV16, taken after 16 hours of 
pulse ligand (R110Direct, 50nM) incubation followed by 24 hours of chase-ligand (TMR, 
500nM) incubation. The pulse ligand thus labels ‘old’ PSD-95 proteins and the chase ligand 
labels newly-synthesised PSD-95 proteins. The pulse ligand is marked in green and the chase 
ligand in magenta, with white indicating areas of overlap. Puncta can be categorised by the 
presence of one or both ligands. Note the high degree of variability in puncta labelling, 




Old PSD-95 only 
New PSD-95 only 
Both old and new PSD-95 
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4.3.3 Classifying synaptic types and summary 
 
From the single-synapse analysis performed in 4.3.2, it is evident that the synaptic 
population is very diverse. While this diversity itself pertains to multiple different 
synaptic properties, such as old to new PSD-95 expression ratios and PSD-95 
turnover, it is very difficult to pin down these properties and their driving factors. 
Nevertheless, I will attempt to categorise synapses at least rudimentarily according to 
some of these traits.  
 
Figure 4.8 is a showcased example of what many confocal images taken after 24 
hours of pulse-chase labelling look like. The first thing that jumps out is the sheer 
diversity of the synaptic puncta. These synaptic puncta vary greatly in terms of size, 
shape, fluorescence intensity and, last but not least, the degree to which they express 
both ‘old’ and/or ‘new’ PSD-95. Simply by qualitatively appraising this image we can 
see many examples of synapses that express only old PSD-95 (pulse label only, 
green), only new PSD-95 (chase label only, magenta), and synapses in which both 
old and new PSD-95 are found (colocalisation, white). The other aspect, which I 
discussed in the previous section (chapter 4.3.2.4), is that we can clearly see that 
colocalised synapses vary greatly in the extent to which they contain old or new PSD-
95, i.e. the ratio of the two labels. While categorising these colocalising synapses by 
their ratio of pulse to chase ligand content is complicated by the lack of prerequisite 
data such as starting intensity, we can certainly attempt to categorise synapses 
according to the aforementioned binary factors: the presence or absence of one or the 
other ligand.  
 
In the table in figure 4.9 I give an overview of the three types of synapses I have 
observed. Type 1 synapses are made up of puncta containing only new PSD-95, i.e. 
PSD-95 labelled by the chase (TMR) ligand. Type 2 synapses contain a mixture of 
both old and new PSD-95, meaning both ligands colocalise in these synapses. Finally, 
type 3 synapses contain solely old PSD-95, labelled by the pulse (R110) ligand. In my 
further analysis I will be referring to synapses according to their type when I discuss 
the presence or absence of ligands and the category they thus fall into.  
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According to my results, type 1 synapses synthesise less new PSD-95 over the 24-
hour time period between DIV15 and DIV16 than type 2 (colocalised) synapses, and 
there are overall fewer type 1 synapses than type 2 synapses. The population of type 
1 synapses also yields a frequency histogram that is heavily skewed towards a low 
puncta intensity (figure 4.5.d), making this the most homogenous of the synapse 
populations in terms of PSD-95 expression level. There are two possible explanations  
 
 
Figure 4.9. Synapses can be categorised according to the presence of one or both HaloTag 
ligands.  
This table gives an overview of the three proposed types of synapses. Type 1 synapses contain 
only newly-synthesised PSD-95 molecules that are labelled with the chase (TMR) ligand. These 
synapses are proposed to be immature and newly formed by synaptogenesis. Type 3 synapses 
contain only previously-present, ‘old’ PSD-95 molecules that are labelled with the pulse 
(R110) ligand. These synapses are proposed to be inactive or stagnant, and are therefore not 
incorporating any newly-synthesised PSD-95 molecules into their PSD. Type 2 synapses 
contain both pulse and chase ligand-labelled PSD-95 molecules. These synapses are proposed 
to be mature, active synapses that are continuously turning over PSD-95 molecules.  
 
for type 1 synapse: first, they come about when synaptogenesis results in new 
synapses forming, and these synapses exclusively contain newly synthesised PSD-
95. Second, these synapses could have been present before the chase incubation 
phase and therefore contained old, pulse-labelled PSD-95, but all of this PSD-95 was 
degraded or cycled out of the synapse and replaced with newly-synthesised PSD-95. 
Using my HaloTag methodology without live-cell imaging it is impossible to rule out 
either of these explanations (and indeed both explanations may be partially correct).  
However, that fact that type 1 synapses have lower levels of PSD-95 expression and 
are fairly homogenous in this respect does make the first explanation more likely- that 
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these are predominantly immature synapses in the process of recruiting new PSD-95 
and establishing their PSD. Furthermore, a study by Butko et al. (2012) has 
demonstrated that new PSD-95 molecules tend to be found in immature synapses, 
whereas older PSD-95 molecules are preferentially found at mature spines. It seems 
that the most likely explanation, then, is that type 1 synapses are predominantly made 
up of immature synapses that have recently been formed.  
 
Type 3 synapses are very similar to type 1 synapses in multiple ways, but do have 
their differences. Like type 1 synapses, type 3 synapses contain less PSD-95 than 
type 2 (colocalised) synapses overall and also less ‘old’ PSD-95 more specifically. 
This histogram is also skewed towards a lower puncta intensity, but to a less extreme 
degree than is the case in type 1 synapses (the slopes are less steep and the 
frequency peak is lower- see figure 4.5.b). There is really only a single explanation for 
the presence of type 3 synapses, and that is that these are synapses that were present 
during the pulse labelling phase, but that did not synthesise any new PSD-95 during 
the subsequent 24-hour chase incubation phase. The question, rather, is why did 
these synapses not synthesise any new PSD-95? The answer will be hard to pin down, 
but and again there are two possibilities. As mentioned above in chapter 4.3.2.3, the 
first possibility is that these synapses are in the process of being degraded (pruned), 
and hence their pool of PSD-95 is not being replenished but rather broken down (see 
Cane et al., 2014). The other explanation is that these synapses are not very active, 
and thus not recruiting new PSD-95 but rather losing PSD-95 molecules. It is possible 
that synapses in such a state might not only reduce the total amount of PSD-95 (and 
probably also other proteins) they express, but also lower the rate of turnover of the 
proteins that they do retain.  
 
It is of interest to note that between DIV15 and DIV16 type 1 and type 3 synapses are 
equally common, both groups making up just under 30% of the total synaptic 
population (figure 4.3). Interestingly, therefore, the majority of synapses contains only 
a single type of ligand and not both.   
 
Finally, the largest single group of synapses is made up of type 2 synapses- those 
containing both old and new PSD-95. Synapses in this group contain the greatest 
quantity of PSD-95 overall and also of each ligand separately. This means that these 
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are also the synapses with the greatest rate of PSD-95 synthesis. This group makes 
up 43% of the entire synaptic population, and the frequency histograms of these 
puncta indicate that this is a very heterogeneous collection of synapses with regards 
to PSD-95 expression levels. Both pulse and chase histograms of type 2 synapses 
look very similar, with a wide intensity spread and a very low frequency peak below 
4% (figure 4.5). It is likely that type 2 synapses are relatively stable synapses, not too 
immature nor in decline, as they have been present for more than 24 hours and have 
a regular turnover of PSD-95. However, as revealed in chapter 4.3.2, type 2 synapses 
can be further broken down according to their pulse:chase ligand intensity ratios. 
When this analysis is performed, it reveals a very diverse population of synapses 
indeed. Nevertheless, the general trend appears to be that the more of one ligand is 
present, the more of the other will be present as well. It thus appears that overall, the 
synapses with the greatest rate of turnover of PSD-95 (as far as can be determined) 
are also those synapses that contain the largest amount of total PSD-95. One 
explanation of this phenomena is that these synapses are the most active and have 
therefore established a strong synaptic connection, which in turn results in a high rate 
of PSD-95 turnover. As we know that NMDAR activity enhances the recruitment of 
components of the protein synthesis and degradation machinery to individual dendritic 
spines (Bingol and Schuman, 2006; Ostroff et al., 2002), it could be postulated that 
this may lead to an enhanced protein turnover at these synapses. Indeed, Hruska et 
al. (2015) found that synaptic activity enhances PSD-95 turnover. The fact that these 
synapses also contain the greatest amount of both old and new PSD-95 supports the 
assumption that these synapses are particularly strong and stable (see Cane et al., 
2014). Thus, type 2 synapses are likely to be experiencing the greatest amount of 
NMDAR activation, which may in turn lead to enhanced rates of PSD-95 turnover as 









4.4 Drug treatment groups 
 
4.4.1 Introduction to drug treatment groups 
 
In this section I will provide the data collected over the course of this study that pertains 
to PSD-95 turnover in primary neurons treated with a variety of chemical agents. Here, 
I will briefly explain the rationale behind the inclusion of each of the chemicals used.  
 
The first chemical modulators I wanted to include in this study were tetrodotoxin (TTX) 
and bicuculline (BCC), due to their opposing effects on neuronal activity and the 
conflicting reports in the literature regarding their effect on PSD-95 expression levels 
and turnover. Both of these drugs have frequently been used to modulate the activity 
of excitatory neurons, either by directly blocking it (TTX) or by indirectly enhancing it 
via a blockade of inhibitory GABA-ergic neurons (BCC). TTX is a highly potent 
antagonist of voltage-gated sodium channels in excitatory neurons (Bane et al., 2014). 
BCC acts as an antagonist of GABAA receptors, thereby blocking inhibitory GABAergic 
transmission and increasing the activity of excitatory neurons (Ehlers, 2003). While 
the mechanisms of action of these two drugs are well known, the effects of enhanced 
or blocked neuronal activity on PSD-95 expression at synapses and on PSD-95 
turnover are less clearly defined. A study by Ehlers (2003) concluded that enhanced 
activity results in an increase in PSD-95 levels at synapses, while blocking activity 
reduces PSD-95 levels at synapses. The study by Ehlers also concluded that PSD-95 
turnover at a whole-cell level was unaffected by either treatment. In contrast, a number 
of studies demonstrated the opposite effect, namely that activity blockade increases 
PSD-95 levels at synapses and that enhancing neuronal activity reduces synaptic 
PSD-95 (Kim et al., 2007; Noritake et al., 2009; El-Husseini et al., 2002; Colledge et 
al., 2003). In contrast to the studies by Ehlers (2003) and Kim et al. (2007), who found 
no change, Colledge et al. (2003) found that enhanced neuronal activity led to a loss 
of PSD-95 at a whole-cell level. Butko et al. (2012) instead found that enhanced 
neuronal activity by bicuculline treatment caused an increase in PSD-95 synthesis. 
Likewise, while the studies by Ehlers (2003) and Noritake et al. (2009) found PSD-95 
synthesis to be unaffected by TTX treatment, a study by Okabe et al. (1999) revealed 
reduced dynamic turnover of PSD-95 clusters. The overall picture that emerges of the 
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effect of activity modulation on PSD-95 expression at synapses and PSD-95 turnover, 
then, is not very clear and warrants further investigation.  
 
Brain-derived neurotrophic factor (BDNF) is a chemical agent linked to many different 
neuronal functions, ranging from neuronal survival and maturation to dendritic and 
axonal growth and synaptogenesis. Furthermore, it is also linked to neuronal activity, 
but rather than affecting neuronal activation it is released at glutamatergic synapses 
in response to activity, affecting AMPA receptor currents and NMDAR-dependent 
long-term potentiation (Yoshii and Constantine-Paton, 2007). TrkB is the receptor to 
which BDNF binds, and NMDAR activation can lead to BDNF-TrkB signalling that in 
turn recruits PSD-95 to synapses, neuron-wide, in a synthesis-independent manner 
(Yoshii and Constantine-Paton, 2007). Other studies, too, have shown that BDNF 
causes PSD-95 to be trafficked to synapses, markedly enhancing synaptic PSD-95 
level (Hu et al., 2011). Finally, a study by Butko et al. (2012) appeared to indicate that 
3-hour BDNF treatment of DIV14 cultured neurons enhanced PSD-95 synthesis. 
Together, these results made BDNF an interesting treatment candidate to evaluate 
the effect on synaptic PSD-95 turnover using my HaloTag method.  
 
Ketamine is a chemical agent that has only fairly recently risen to prominence in 
neuroscience, when it was discovered that, if administered at low concentrations, it is 
extremely quick and effective at treating patients with otherwise treatment-resistant 
major depressive disorder (MDD) (Zarate et al., 2006). Interestingly, it has been 
established that patients with MDD display reduced levels of PSD-95 protein in certain 
brain regions (Feyissa et al., 2009). Furthermore, a number of studies have shown 
that low-dose (but not high-dose) ketamine treatment of rodents causes synaptic PSD-
95 levels to rise (Li et al., 2010; Choi et al., 2015; Browne & Lucki, 2013). I was thus 
intrigued to determine whether I would be able to discover a similar effect on synaptic 
PSD-95 levels and turnover in primary cultures of hippocampal neurons.  
 
Having chosen the above chemicals for my study due to their roles in modulating 
synapses and PSD-95 levels at synapses, but with questionable effect on the turnover 
of PSD-95, I decided to include two classes of drugs that would surely affect the 
synthesis and degradation of PSD-95. These two drugs groups were protein synthesis 
inhibitors and protein degradation inhibitors. Even if these drugs were perhaps less 
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exciting from a biological perspective since their effect and mode of action are well 
known, I nonetheless felt compelled to include them since it would give me the 
opportunity to use my method to measure assured changes in PSD-95 synthesis and 
degradation. I decided to include two drugs from each of these two classes, as these 
drugs are frequently used and well established, and also to act as controls for each 
other and allow for comparisons between results. For the inhibitors of protein 
degradation I decided to use the drugs lactacystin and MG132, whereas I opted for 
anisomycin and cycloheximide as the protein synthesis blockers.  
 
Lactacystin and MG132 are both known to block protein degradation, with lactacystin 
being a highly potent and selective proteasome inhibitor, while MG132 is known to 
inhibit both the proteasome and calpains (Hakim et al., 2016). The ubiquitin-
proteasome system (UPS) has been widely shown to be the major route by which 
PSD-95 is degraded, and blocking the proteasome with lactacystin or MG132 prevents 
PSD-95 degradation (Tsai et al., 2012; Colledge et al., 2003). Interestingly, lactacystin 
injections into the hippocampus of live mice have been demonstrated to cause full 
retrograde amnesia (Lopez-Salon et al., 2001), implicating the UPS and protein 
degradation as playing a role in memory formation. While lactacystin and MG132 are 
commonly used in studies that wish to modulate synaptic protein turnover (e.g. Ehlers, 
2003), a recent study by Hakim et al. (2016) is of particular interest as it found that 
blocking the proteasome with lactacystin did not lead to an increase in synaptic PSD-
95 levels, but rather, caused a profound suppression of PSD-95 synthesis. My goal in 
this study was to separately apply both lactacystin and MG132, measure the effects 
of these agents on synaptic PSD-95 turnover and investigate the phenomenon 
observed by Hakim et al. (2016).  
 
The final set of chemicals used in my study consists of the protein synthesis inhibitors 
anisomycin and cycloheximide. Cycloheximide inhibits the elongation step during the 
translation of proteins (Ennis and Lubin, 1964), whereas anisomycin acts on peptidyl 
transferase and prevents the release of nascent peptides from polyribosomes 
(Grollman, 1967). Both substances have been very widely employed in the study of 
synaptic protein synthesis (Todd et al., 2003; Noritake et al., 2009; Yoshii and 
Constantine-Paton, 2007), and have profound effects on memory retention in 
mammals (Tai and Schuman, 2008). Anisomycin, particularly, has been widely used 
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to study memory loss, as injecting it into hippocampal brain regions can disrupt the 
expression of fear memories (Frankland et al., 2006). Interestingly, lactacystin co-
injection can rescue anisomycin-induced fear learning (Lee et al., 2008). I thus decided 
to utilise the protein synthesis inhibitors anisomycin and cycloheximide as mechanistic 
opposites to the proteasome inhibitors lactacystin and MG132, and measure the 
effects on PSD-95 turnover that these drugs would have.  
 
Overall, I selected the chemical modulators that I wished to use for this study based 
upon two criteria: first, whether their effect was likely to affect the turnover of PSD-95, 
allowing me to apply my method to a scenario in which turnover is altered compared 
to untreated controls; and second, whether their effect was likely to address a 
biologically interesting question. In the next section, I will reveal the results from these 
experiments and discuss their implications.  
 
4.4.2.1 TTX and BCC: bulk analysis 
 
The first set of results that I will evaluate for the TTX- and BCC-treated cultures is the 
bulk data, and thereafter I will move on to the single-synapse data. In this first section, 
I will take the entire population of pulse or chase ligand labelled synapses together, 
and compare their results to the untreated control group.  
 
Figure 4.10.a shows the average intensity of pulse-ligand (R110) puncta in 
hippocampal primary neurons at DIV16 after having been treated with TTX (1µM) for 
24 hours, compared with untreated controls. Figure 4.10.b depicts the same results 
for neurons treated with BCC (40µM). Average pulse ligand intensity at the 1-hour time 
point is 65.97 ± 1.69 AU, and this goes down over the 24-hour chase period to 41.44 
± 0.85 AU in untreated controls. In TTX treated neurons, the pulse ligand intensity 
decreases to 46.36 ± 1.76 AU over 24 hours, and in BCC treated neurons to 48.92 ± 
3.51 AU. While the difference in pulse ligand intensity at the 24-hour time point 
compare to untreated controls is statistically significant in the TTX-treated group 
(Welch’s t-test, p=0.034), the difference between BCC-treated neurons and controls 
is not significant (p=0.087).  
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Figure 4.10.c and figure 4.10.d represent the bulk chase ligand (TMR) intensity after 
24 hours of chase incubation. From figure 4.10.c we can see that TTX treatment 
causes average chase puncta intensity to be only very slightly and insignificantly 
(Welch’s t-test, p=0.46) higher (31.61 ± 2.18 AU) than in untreated controls (29.63 ± 
1.42 AU). In figure 4.10.d, we see that BCC similarly has no significant (p=0.099) effect 
on average chase ligand puncta intensity (32.41 ± 0.49 AU).  
 
When looking at synaptic puncta number, a very similar result is obtained. In the 
untreated control group, pulse ligand puncta number decreases over the 24-hour 
chase period from 419.35 ± 50.05 to 189.15 ± 26.64 puncta per image. In the TTX 
treatment group, pulse ligand puncta number decreases to 284.00 ± 65.53 puncta over 
24 hours (figure 4.11.a), and in the BCC treatment group it decreases to 243.85 ± 
33.09 puncta over 24 hours (figure 4.11.b). Neither result was significantly different to 
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c.       d.  
  
Figure 4.10. The effects of Tetrodotoxin and Bicuculline on PSD-95 puncta intensities.  
Hippocampal neuronal primary cultures from PSD-95HaloTag/HaloTag mice were grown on glass 
coverslips and on DIV14 they were labelled with the R110Direct HaloTag ligand (50nM, 16h). 
On DIV15 the TMR ligand was added to the cultures at 500nM for 1 hour and 24 hours, 
alongside either tetrodotoxin (TTX) at 1µM or bicuculline (BCC) at 40µM. Coverslips were 
imaged on the LSM510, and puncta detected using the Imaris software. Average puncta 
fluorescence intensity per image (APFI) was then calculated. This was performed across 8 
different cultures (N=8), with the graphs here presenting the mean values across these eight 
cultures. a. Graph of the average R110 pulse ligand puncta fluorescence intensity following 
TTX treatment. APFI is significantly higher after 24 hours in the TTX group than in untreated 
controls (Welch’s t-test, p=0.034). b. Graph of the average R110 pulse ligand puncta intensity 
following BCC treatment. APFI is not significantly higher after 24 hours in the BCC group than 
in untreated controls (Welch’s t-test, p=0.087). c. Graph of the average TMR chase ligand 





















































































































and untreated controls is not significant (Welch’s t-test, p=0.46). d. Graph of the average TMR 
chase ligand puncta fluorescence intensity following BCC treatment. The difference between 
the BCC group and untreated controls is not significant (Welch’s t-test, p=0.099).  
 
a.       b.  
  
c.       d.  
  
Figure 4.11. The effects of Tetrodotoxin and Bicuculline on PSD-95 puncta numbers.  
As in figure 4.10, hippocampal neuronal primary cultures from PSD-95HaloTag/HaloTag mice were 
grown for 14 days in vitro, and thereafter pulse-chase experiments performed using the 
R110Direct and TMR HaloTag ligands. Tetrodotoxin (TTX) at 1µM or bicuculline (BCC) at 40µM 
were added alongside the chase ligand for 1 or 24 hours. The graphs here present the mean 
values across eight cultures (N=8). a. Graph of the average R110 pulse ligand puncta number 
following TTX treatment. The number is not significantly higher after 24 hours in the TTX 
group than in untreated controls (Welch’s t-test, p=0.22). b. Graph of the average R110 pulse 
ligand puncta number following BCC treatment. The number is not significantly higher after 
























































































































average TMR chase ligand puncta number following TTX treatment. The difference between 
the TTX group and untreated controls is not significant (Welch’s t-test, p=0.32). d. Graph of 
the average TMR chase ligand puncta number following BCC treatment. The difference 
between the BCC group and untreated controls is not significant (Welch’s t-test, p=0.39).  
 
Similarly, chase ligand puncta number per image is only insignificantly different in both 
TTX- and BCC-treated groups when compared to untreated controls (Welch’s t-test, 
TTX: p=0.32, BCC: p=0.39). While untreated controls had on average 192.66 ± 32.83 
chase-ligand puncta per image, images from the TTX-treated group contained an 
average of 256.66 ± 51.32 puncta (figure 4.11.c) and images from the BCC-treated 
group contained an average of 242.85 ± 45.04 puncta (figure 4.11.d).  
 
It is therefore difficult to tell from the results whether TTX treatment has an effect on 
bulk PSD-95 turnover. The only result that was significantly different from untreated 
controls was the average synapse intensity of the pulse ligand after 24 hours of TTX 
treatment (figure 4.10.a), with all other results being insignificantly different from 
controls. While it is difficult to interpret this lone significant result, it is possible that this 
indicates that a blockade of synaptic signalling may reduce the degradation rate of 
synaptic PSD-95, which would indicate an overall increase in PSD-95 levels at 
synapses in the light of the result that synthesis rates remain unchanged. This result 
would match some of the aforementioned results in the literature that indicate that 
activity blockade causes an enrichment of PSD-95 at the synapse. It is possible, then, 
that in response to reduced neuronal firing the degradation of PSD-95 is lowered while 
synthesis is retained constant, thereby increasing synaptic PSD-95 levels and thus 
potentially increasing the clustering of signalling receptor complexes at the 
postsynaptic membrane. Future studies could explore this result further by 
investigating the surface expression levels of AMPA and NMDA receptor complexes 
following TTX application, for instance.  
 
On the other hand, bicuculline treatment did not have a measurable impact upon PSD-
95 expression levels at synapses, and synaptic puncta numbers were unaffected by 
both drugs.  
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4.4.2.2 TTX and BCC: single-synapse analysis 
 
As in chapter 4.3.2.2, I will first analyse the single-synapse results by splitting 
synapses up into colocalised and non-colocalised groups. However, having 
categorised synapses into three types in chapter 4.3.3, I will be using these categories 
during my analysis here. Type 1 synapses are made up of puncta containing only new 
(chase-labelled) PSD-95. Type 2 synapses contain a mixture of both old and new 
PSD-95. Type 3 synapses contain only old (pulse-labelled) PSD-95.   
 
Looking at figure 4.12.a we see that in type 2 synapses, the average puncta 
fluorescence intensity after 24 hours of chase-ligand incubation is 45.13 ± 0.93 AU in 
untreated controls, while it is 50.35 ± 2.41 AU in TTX-treated cultures. This difference 
is not statistically significant (Welch’s t-test, p=0.079). In type 3 synapses (figure 
4.12.b), the average puncta fluorescence intensity at the same time point is markedly 
lower, 34.79 ± 0.80 AU for controls and 38.64 ± 1.56 AU following TTX treatment. 
Again, the difference is not significant (p=0.055). Next, I compare the average puncta 
fluorescence intensity (APFI) of type 2 with type 3 synapses within the TTX-treated 
group only (figure 4.12.c). Type 2 synapses (50.35 ± 2.41 AU) have a significantly 
greater APFI than type 3 synapses (38.64 ± 1.56 AU) (p=0.0021). The results are, 
therefore, very similar to untreated controls. Neither type 2 nor type 3 synapses differ 
in their APFI from controls, and as in the control group (figure 4.2.a), type 2 synapses 
are significantly more fluorescent than type 3 synapses.  
 
We next look at the chase ligand, and evaluate the effect of TTX treatment on the 
chase ligand APFI in type 2 and type 1 synapses. In figure 4.12.d we see that the 
chase ligand APFI is essentially the same in the TTX-treated group as in the control 
group for type 2 synapses (35.17 ± 2.56 AU in the TTX group, 34.88 ± 1.91 AU in the 
control group) (Welch’s t-test, p=0.93). Similarly, the chase ligand APFI in type 1 
synapses treated with TTX does not differ from untreated controls (about 22 AU, figure 
4.12.e) (p=0.71). Finally, the APFI of type 2 (35.17 ± 2.56 AU) and type 1 (21.87 ± 
1.44 AU) synapses treated with TTX differs significantly (p=0.0013) (figure 4.12.f), like 
in the control group.  
  
 161 
a.       b.  
  
c.       d.  
  





























































































































































TTX Chase ligand- type 2 and type 1
Colocalised Non-Colocalised
 162
Figure 4.12. The effect of tetrodotoxin on PSD-95 average puncta intensity at synaptic types.  
Average puncta fluorescence intensity (APFI) per image was calculated for pulse and chase 
ligand labelled synaptic puncta in type 1, type 2 and type 3 synapses separately. Images were 
taken after 24 hours of pulse-chase treatment with 50nM R110Direct ligand (pulse) and 
500nM TMR ligand (chase) in hippocampal primary cultures from PSD-95HaloTag/HaloTag mice on 
DIV16. TTX (1µM) was applied for 24 hours together with the chase ligand between DIV15 
and DIV16. The graphs here present the mean values across eight cultures (N=8). a. Pulse 
ligand (R110Direct) APFI per image in synapses where pulse and chase ligands colocalise (type 
2). The difference between the TTX group and untreated controls is not statistically significant 
(Welch’s t-test, p=0.079). b. Pulse ligand (R110Direct) APFI per image in synapses where pulse 
and chase ligands do not colocalise (type 3). The difference between the TTX group and 
untreated controls is not statistically significant (Welch’s t-test, p=0.055). c. Comparison of 
pulse ligand APFI per image in type 2 synapses and type 3 synapses following TTX treatment. 
The difference between the two groups is statistically significant (Welch’s t-test, p=0.0021). 
d. Chase ligand (TMR) APFI per image in synapses where pulse and chase ligands colocalise 
(type 2). The difference between the TTX group and untreated controls is not statistically 
significant (Welch’s t-test, p=0.93). e. Chase ligand (TMR) APFI per image in synapses where 
pulse and chase ligands do not colocalise (type 1). The difference between the TTX group and 
untreated controls is not statistically significant (Welch’s t-test, p=0.71). f. Comparison of 
chase ligand APFI per image in type 2 synapses and type 1 synapses following TTX treatment. 
The difference between the two groups is statistically significant (Welch’s t-test, p=0.0013).  
 
Figure 4.13 now looks at the effect of BCC treatment on the APFI of type 2 and type 
3 synapses. Essentially, the results are the same as for the TTX-treated group, in that 
the results mirror untreated controls. In type 2 synapses, BCC treatment results in an 
APFI of 54.49 ± 3.76 AU (compared to 45.13 ± 0.93 AU in controls) (p=0.055). In type 
3 synapses, BCC treatment yields an APFI of 39.44 ± 3.27 AU (compared to 34.79 ± 
0.80 AU in controls) (p=0.22). Within the BCC-treated group, type 2 synapses are 
significantly more fluorescent than type 3 synapses (p=0.013) (figure 4.13.c).  
 
Within the BCC group, the results for the chase ligand are again very similar to those 
of the TTX group. Type 2 synapses do not differ significantly in their APFI (around 37 
AU, figure 4.13.d) from controls (p=0.17), and type 1 synapses are even closer to the 
control group in their APFI (about 22 AU, p=0.63, figure 4.13.e). As in controls, type 2 
(38.83 ± 1.94 AU) and type 1 (21.97 ± 0.53 AU) synapses are very significantly 
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Figure 4.13. The effect of bicuculline on PSD-95 average puncta intensity at synaptic types.  
Average puncta fluorescence intensity (APFI) per image was calculated for pulse and chase 
ligand labelled synaptic puncta in type 1, type 2 and type 3 synapses separately. Images were 
taken after 24 hours of pulse-chase treatment with 50nM R110Direct ligand (pulse) and 
500nM TMR ligand (chase) in hippocampal primary cultures from PSD-95HaloTag/HaloTag mice on 
DIV16. BCC (40µM) was applied for 24 hours together with the chase ligand between DIV15 
and DIV16. The graphs here present the mean values across eight cultures (N=8). a. Pulse 
ligand (R110Direct) APFI per image in synapses where pulse and chase ligands colocalise (type 
2). The difference between the BCC group and untreated controls is not statistically significant 
(Welch’s t-test, p=0.055). b. Pulse ligand (R110Direct) APFI per image in synapses where pulse 
and chase ligands do not colocalise (type 3). The difference between the BCC group and 
untreated controls is not statistically significant (Welch’s t-test, p=0.22). c. Comparison of 
pulse ligand APFI per image in type 2 synapses and type 3 synapses following BCC treatment. 
The difference between the two groups is statistically significant (Welch’s t-test, p=0.013). d. 
Chase ligand (TMR) APFI per image in synapses where pulse and chase ligands colocalise (type 
2). The difference between the BCC group and untreated controls is not statistically significant 
(Welch’s t-test, p=0.17). e. Chase ligand (TMR) APFI per image in synapses where pulse and 
chase ligands do not colocalise (type 1). The difference between the BCC group and untreated 
controls is not statistically significant (Welch’s t-test, p=0.63). f. Comparison of chase ligand 
APFI per image in type 2 synapses and type 1 synapses following BCC treatment. The 
difference between the two groups is statistically significant (Welch’s t-test, p=0.00020).  
 
Looking at puncta numbers, the results are essentially the same for both the TTX and 
BCC groups. Type 1, type 2 and type 3 synapses all have a very similar number of 
synaptic puncta per image as the untreated control group. No group of synapses, be 
they colocalised or not, differs in puncta number from untreated controls. Figure 4.14 
shows the synaptic puncta numbers for the both pulse and chase ligands in the TTX 
treated group, and figure 4.15 does the same for the BCC treated group. The only 
point of difference between the treatment groups and the control group was that in 
controls, there was no statistically significant difference between colocalised and non-
colocalised pulse and chase puncta (figure 4.2.c and figure 4.2.d). However, in the 
TTX treatment group, non-colocalised (type 1) chase ligand puncta were significantly 
lower in number than colocalised (type 2) chase ligand puncta (figure 4.14.f) (Welch’s 
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Figure 4.14. The effect of tetrodotoxin on PSD-95 average puncta number at synaptic types.  
Average puncta number per image was calculated for pulse and chase ligand labelled synaptic 
puncta in type 1, type 2 and type 3 synapses separately. Images were taken after 24 hours of 
pulse-chase treatment with 50nM R110Direct ligand (pulse) and 500nM TMR ligand (chase) 
in hippocampal primary cultures from PSD-95HaloTag/HaloTag mice on DIV16. TTX (1µM) was 
applied for 24 hours together with the chase ligand between DIV15 and DIV16. The graphs 
here present the mean values across eight cultures (N=8). a. Pulse ligand (R110Direct) average 
puncta number per image in synapses where pulse and chase ligands colocalise (type 2). The 
difference between the TTX group and untreated controls is not statistically significant 
(Welch’s t-test, p=0.13). b. Pulse ligand (R110Direct) average puncta number per image in 
synapses where pulse and chase ligands do not colocalise (type 3). The difference between 
the TTX group and untreated controls is not statistically significant (Welch’s t-test, p=0.64). c. 
Comparison of pulse ligand average puncta number per image in type 2 synapses and type 3 
synapses following TTX treatment. The difference between the two groups is not statistically 
significant (Welch’s t-test, p=0.089). d. Chase ligand (TMR) average puncta number per image 
in synapses where pulse and chase ligands colocalise (type 2). The difference between the 
TTX group and untreated controls is not statistically significant (Welch’s t-test, p=0.13). e. 
Chase ligand (TMR) average puncta number per image in synapses where pulse and chase 
ligands do not colocalise (type 1). The difference between the TTX group and untreated 
controls is not statistically significant (Welch’s t-test, p=0.77). f. Comparison of chase ligand 
average puncta number per image in type 2 synapses and type 1 synapses following TTX 




In the BCC group, I found the opposite to be the case, with type 3 (non-colocalised) 
pulse ligand puncta being significantly lower in number than type 2 (colocalised) pulse 
ligand puncta (figure 4.15.c) (p=0.038). This was not the case for the chase ligand 
(figure 4.15.f) (p=0.079). While these results do differ from the untreated control group 
(figure 4.2.c and 4.2.d), the same trend can be seen in these control group graphs, 
and it is likely that these results were simply caused by a higher degree of variation 
among the control group.  
 
Next, we look at the overall synaptic population as per its distribution into type 1 (only 
new, chase labelled PSD-95), type 2 (mixed population of old and new PSD-95) and 
type 3 (only old, pulse labelled PSD-95) synapses (figure 4.16). Figure 4.16.a shows 
the synaptic population of untreated controls, while figure 4.16.b shows the TTX-
treated synaptic population and 4.16.c shows the BCC-treated synaptic population. 
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Figure 4.15. The effect of bicuculline on PSD-95 average puncta number at synaptic types.  
Average puncta number per image was calculated for pulse and chase ligand labelled synaptic 
puncta in type 1, type 2 and type 3 synapses separately. Images were taken after 24 hours of 
pulse-chase treatment with 50nM R110Direct ligand (pulse) and 500nM TMR ligand (chase) 
in hippocampal primary cultures from PSD-95HaloTag/HaloTag mice on DIV16. BCC (40µM) was 
applied for 24 hours together with the chase ligand between DIV15 and DIV16. The graphs 
here present the mean values across eight cultures (N=8). a. Pulse ligand (R110Direct) average 
puncta number per image in synapses where pulse and chase ligands colocalise (type 2). The 
difference between the BCC group and untreated controls is not statistically significant 
(Welch’s t-test, p=0.21). b. Pulse ligand (R110Direct) average puncta number per image in 
synapses where pulse and chase ligands do not colocalise (type 3). The difference between 
the BCC group and untreated controls is not statistically significant (Welch’s t-test, p=0.68).  
c. Comparison of pulse ligand average puncta number per image in type 2 synapses and type 
3 synapses following BCC treatment. The difference between the two groups is statistically 
significant (Welch’s t-test, p=0.038). d. Chase ligand (TMR) average puncta number per image 
in synapses where pulse and chase ligands colocalise (type 2). The difference between the 
BCC group and untreated controls is not statistically significant (Welch’s t-test, p=0.21). e. 
Chase ligand (TMR) average puncta number per image in synapses where pulse and chase 
ligands do not colocalise (type 1). The difference between the BCC group and untreated 
controls is not statistically significant (Welch’s t-test, p=0.69). f. Comparison of chase ligand 
average puncta number per image in type 2 synapses and type 1 synapses following BCC 
treatment. The difference between the two groups is not statistically significant (Welch’s t-
test, p=0.079).  
 
 
We immediately observe that the three pie charts look very similar. In all three graphs, 
roughly 26% of synapses contain only one of the two ligands (i.e. are type 1 or type 3 
synapses), and thus about 48% of synapses contain both ligands (type 2 synapses). 
Only in the TTX-treated group is the percentage of type 1 synapses slightly lower 
(20%), even here the difference compared to the number of type 3 synapses (27%) is 
not significant (Welch’s t-test, p=0.53). It therefore appears that in all three groups, 
about half of the synaptic population consists of mixed old and new PSD-95 and a 
quarter of synapses contains either old or new PSD-95. Blocking or enhancing 
synaptic activity with TTX or BCC respectively appears to have no impact on this 
distribution of synaptic types. Similarly, in all three treatment groups colocalised type 
2 synapses express both more old and more new PSD-95 than the total amount of 











































Figure 4.16. Proportional representation of synaptic population by HaloTag ligand-labelling 
following activity modulation.  
Synaptic puncta were categorised according to whether they colocalised with puncta labelled 
by the other ligand or not. This pie chart depicts the proportional representation of the three 
types of synaptic puncta observed.  
Images were taken after 24 hours of pulse-chase treatment with 50nM R110Direct ligand 
(pulse) and 500nM TMR ligand (chase) in hippocampal primary cultures from PSD-
95HaloTag/HaloTag mice on DIV16. a. In untreated controls, 28% of puncta contain only the pulse 
(R110Direct) ligand (type 3), 43% of puncta contain both pulse and chase (TMR) ligands (type 
2), and 29% contain only the chase ligand (type 1). b. Following 24 hours of TTX treatment 
(1µM), 27% of puncta contain only the pulse (R110Direct) ligand (type 3), 53% of puncta 
contain both pulse and chase (TMR) ligands (type 2), and 20% contain only the chase ligand 
(type 1). c. Following 24 hours of BCC treatment (40µM), 26% of puncta contain only the pulse 
(R110Direct) ligand (type 3), 47% of puncta contain both pulse and chase (TMR) ligands (type 
2), and 27% contain only the chase ligand (type 1).  
 
 
Finally, I will look into the data pertaining to the ratio of pulse to chase ligand average 
puncta fluorescence intensity within type 2 (colocalised) synapses. As in figure 4.6 
when I looked into the ratios for the control group only, I graphed a frequency 
histogram to depict the frequencies of different pulse:chase ligand ratios in TTX and 
BCC treated groups. In figure 4.19 I compare these histograms, with figure 4.19.a 
representing the untreated control group, figure 4.19.b the TTX-treated group, and 
figure 4.19.c the BCC-treated group.   
When looking at the shapes of these three histograms, it is quite evident that there is 
no marked difference in these results. As I discussed in chapter 4.3.2.4, this large 
spread in ratios and great heterogeneity indicates a heterogenous synapse population 
with likely differing rates of PSD-95 turnover. In figure 4.19.d I compare the mean 
ratios of pulse to chase ligand APFI. For the control group, the mean ratio is 2.55 ± 
0.051 (SEM), with a median ratio of 2.06. The mode is a ratio of 1.8, with 8.76%. For 
the TTX-treated group, the mean ratio is 2.31 ± 0.039 (SEM), with a median ratio of 
2.05. The mode is a ratio of 1.6, with 8.83%. For the BCC-treated group, the mean 







a.       b.  
 
c.       d.  
  
Figure 4.17. Cumulative distribution functions of average puncta fluorescence intensity 
following TTX treatment.  
CDFs were constructed using the single-synapse data following TTX treatment, and compared 
with the untreated control group. Whether the difference was statistically significant or not 
was tested using the Kolmogorov-Smirnov test for difference. a. Comparison between R110 
ligand puncta in colocalised type 2 synapses of TTX-treated neurons with those in untreated 
controls. The difference is significant (Kolmogorov-Smirnov, p<0.0001). b. Comparison 
between R110 ligand puncta in non-colocalised type 3 synapses of TTX-treated neurons with 
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Comparison between TMR ligand puncta in colocalised type 2 synapses of TTX-treated 
neurons with those in untreated controls. The difference is significant (Kolmogorov-Smirnov, 
p=0.004). d. Comparison between TMR ligand puncta in non-colocalised type 1 synapses of 
TTX-treated neurons with those in untreated controls. The difference is significant 
(Kolmogorov-Smirnov, p<0.0001).  
 
 
a.       b.  
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Figure 4.18. Cumulative distribution functions of average puncta fluorescence intensity 
following BCC treatment.  
CDFs were constructed using the single-synapse data following BCC treatment, and compared 
with the untreated control group. Whether the difference was statistically significant or not 
was tested using the Kolmogorov-Smirnov test for difference. a. Comparison between R110 
ligand puncta in colocalised type 2 synapses of BCC-treated neurons with those in untreated 
controls. The difference is significant (Kolmogorov-Smirnov, p<0.0001). b. Comparison 
between R110 ligand puncta in non-colocalised type 3 synapses of BCC-treated neurons with 
those in untreated controls. The difference is significant (Kolmogorov-Smirnov, p=0.016). c. 
Comparison between TMR ligand puncta in colocalised type 2 synapses of BCC-treated 
neurons with those in untreated controls. The difference is significant (Kolmogorov-Smirnov, 
p=0.011). d. Comparison between TMR ligand puncta in non-colocalised type 1 synapses of 
BCC-treated neurons with those in untreated controls. The difference is significant 
(Kolmogorov-Smirnov, p=0.013).  
 
with 9.04%. It appears, therefore, that the differences in pulse to chase ligand APFI in 
these three treatment groups do not differ by much, with very similar frequency 
distribution histograms and similar mean, median and modal ratio values.  
 
Next, I sorted puncta by pulse ligand intensity into percentiles, and then measured 
chase ligand APFI in each of these percentiles the way I had also done it in figure 
4.7.b for the control group only. The results indicate that both TTX- and BCC-treated 
groups have very strong positive correlations between pulse and chase ligand APFI, 
similar to the control group. For the control group R2=0.96 (figure 4.20.a), while for the 
TTX group R2=0.92 (figure 4.20.b) and for the BCC group R2=0.81 (figure 4.20.c).  
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a.       b.  
  
c.       d.  
  
Figure 4.19. Graphs showing the ratio of pulse to chase ligands at individual type 2 synapses 
following activity modulation.  
In the synaptic population in which pulse and chase ligand-labelled PSD-95-HaloTag 
molecules were colocalised (type 2), the ratio of pulse ligand fluorescence intensity to chase 
ligand fluorescence intensity was calculated for each individual synapse. The frequency 
histograms represent the frequencies of all the pulse:chase ratios. a. Frequency distribution 
in untreated controls. Mean ratio: 2.55 ± 0.051 (SEM), Median ratio: 2.06, Mode: 1.8 (8.76%). 
b. Frequency distribution following 24 hours of TTX (1µM) treatment. Mean ratio: 2.31 ± 
0.039 (SEM), Median ratio: 2.05, Mode: 1.6 (8.83%). c. Frequency distribution following 24 
hours of BCC (40µM) treatment. Mean ratio: 2.84 ± 0.071 (SEM), Median ratio: 2.34, Mode: 
1.8 (9.04%). d. Comparison of mean pulse:chase ligand ratio in untreated controls with TTX 
and BCC treated cultures. Differences are statistically significant in the TTX group (Welch’s t-
test, p=0.00016) and the BCC group (Welch’s t-test, p=0.0011).  
 
 
Lastly, cumulative distribution functions (CDF’s) were calculated for each of the eight 
groups (Figure 4.17 and 4.18). Visually, the CDF curves of the treated groups look 
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that indicates a normal distribution. However, a statistical test for difference between 
the curves, the Kolmogorov-Smirnov test for difference, revealed that in each of the 
eight graphs the curves differ just significantly from the control group. This, then, 
implies that treatment with these drugs does appear to affect the distribution of puncta 
intensities to a statistically significant extent.  
 
4.4.2.3 TTX and BCC: Discussion 
 
This fairly expansive investigation into the effect of activity modulation on PSD-95 
turnover has resulted in some interesting insights. The main conclusion from this 
study, however, seems to be that over a 24-hour time window, blocking or enhancing 
excitatory neuronal activity has a negligible impact upon PSD-95 synthesis and 
degradation.  
 
Interestingly, the only statistically significant results following activity modulation was 
that TTX appears to have reduced the loss of PSD-95 at synapses. Previous studies 
have found PSD-95 to be elevated following TTX treatment (Kim et al., 2007; Noritake 
et al., 2009; El-Husseini et al., 2002), but only at synaptic locations. These same 
studies, as well as a study by Colledge et al. (2003) found that enhancing activity 
reduces synaptic PSD-95 levels. Indeed, these studies described that NMDAR activity 
specifically caused increased destabilisation and degradation of PSD-95 at synapses. 
It stands to reason, then, that blocking such activity will reduce the loss of synaptic 
PSD-95. Thus, my observation of reduced PSD-95 loss matches that of other studies. 
However, along the same vein one might expect BCC, which increases excitatory 
neuronal activity by reducing GABAergic inhibition, to enhance turnover of PSD-95, 
but this was not observed. Another study, by Butko et al. (2012), found BCC to 
increase new PSD-95 synthesis. Such an effect could also not be observed.  
 
Frequency histograms of pulse:chase ligand ratios at mixed-ligand (type 2) synapses 
have the same shape in treated and untreated groups, and mean ratios are very 
similar. The proportion of the total synaptic population that is made up of type 1, type 
2 and type 3 synapses is also nearly identical in all three groups.  
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Figure 4.20 Correlation of pulse ligand intensity with chase ligand intensity at colocalised 
synaptic puncta following activity modulation.  
Colocalising (type 2) synapses were sorted by their pulse ligand APFI (lowest to highest). For 
each ten percentile steps, average chase ligand APFI was calculated. a. In untreated controls, 
there is a strong positive correlation, R2=0.96. b. In the TTX-treated cultures, there is also a 
strong positive correlation, R2=0.92. c. In the BCC-treated cultures, the correlation is slightly 
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4.4.3.1 BDNF: bulk analysis 
 
The next set of data I will look at is the BDNF results set. Again, I will first cover the 
bulk data, and then move on to a single-puncta analysis.  
 
Figure 4.21.a shows the average intensity of pulse-ligand (R110) puncta in 
hippocampal primary neurons at DIV16 after having been treated with BDNF (3.7nM) 
for 24 hours, compared with untreated controls. Compared to controls, where APFI 
drops down to 41.44 ± 0.85 AU over 24 hours, APFI only drops down to 45.44 ± 1.30 
AU in BDNF-treated cultures.  
This difference, while fairly small, is statistically significant (Welch’s t-test, p=0.024).  
 
Similarly, we see that 24 hours of BDNF treatment results in a small but significant 
increase in chase ligand APFI (figure 4.21.b). Untreated controls display an APFI of 
29.63 ± 1.42 AU, while BDNF-treated cultures have a significantly higher APFI of 34.85 
± 1.55 AU (p=0.026).  
 
When looking at synapse number (figure 4.21.c-d), the results are similar to those of 
puncta intensity. For both the pulse and the chase ligand, puncta number is increased 
in BDNF-treated cultures compared with untreated controls, particularly for the chase 
ligand (control: mean 192.66 ± 32.83 synapses per image; BDNF: mean 296.87 ± 
42.15 synapses per image) (figure 4.21.d). However, due to the high variation these 
results are not statistically significant (pulse ligand: p=0.25; chase ligand: p=0.073).  
 
 
4.4.3.2 BDNF: single-synapse analysis 
 
While at a bulk level BDNF causes significantly more pulse-labelled, old PSD-95 to be 
found at synapses than in untreated controls, at the single-synapse level (figure 4.22) 
I find that in type 2 synapses (old and new PSD-95 colocalised) this increase is not 
significant (p=0.098, figure 4.22.a). However, in non-colocalised type 3 synapses the 
difference is indeed significant (p=0.036, figure 4.22.b), with BDNF-treated neurons 
displaying an APFI of 38.45 ± 1.32 AU compared to that of untreated controls at  
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a.       b.  
  
c.       d.  
  
Figure 4.21. The effect of BDNF on PSD-95 puncta intensities and numbers.  
Hippocampal neuronal primary cultures from PSD-95HaloTag/HaloTag mice were grown on glass 
coverslips and on DIV14 they were labelled with the R110Direct HaloTag ligand (50nM, 16h). 
On DIV15 the TMR ligand was added to the cultures at 500nM for 1 hour and 24 hours, 
alongside BDNF (3.7nM). Average puncta fluorescence intensity (APFI) and number per image 
were then calculated. This was performed across 8 different cultures (N=8), with the graphs 
here presenting the mean values across these eight cultures. a. Graph of the R110 pulse ligand 
APFI following BDNF treatment. APFI is significantly higher after 24 hours in the BDNF group 
than in untreated controls (Welch’s t-test, p=0.024). b. Graph of the average TMR chase ligand 
APFI following BDNF treatment. APFI is significantly higher in the BDNF group than in 
untreated controls (Welch’s t-test, p=0.026). c. Graph of the average pulse ligand puncta 
number following BDNF treatment. The difference between the BDNF group and untreated 
controls after 24 hours is not significant (Welch’s t-test, p=0.25). d. Graph of the average 
chase ligand puncta number following BDNF treatment. The difference between the BDNF 
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Figure 4.22. The effect of BDNF on PSD-95 average puncta intensity at synaptic types.  
Average puncta fluorescence intensity (APFI) per image was calculated for pulse and chase 
ligand labelled synaptic puncta in type 1, type 2 and type 3 synapses separately. Images were 
taken after 24 hours of pulse-chase treatment with 50nM R110Direct ligand (pulse) and 
500nM TMR ligand (chase) in hippocampal primary cultures from PSD-95HaloTag/HaloTag mice on 
DIV16. BDNF (3.7nM) was applied for 24 hours together with the chase ligand between DIV15 
and DIV16. The graphs here present the mean values across eight cultures (N=8). a. Pulse 
ligand (R110Direct) APFI per image in synapses where pulse and chase ligands colocalise (type 
2). The difference between the BDNF group and untreated controls is not statistically 
significant (Welch’s t-test, p=0.098). b. Pulse ligand APFI per image in synapses where pulse 
and chase ligands do not colocalise (type 3). The difference between the BDNF group and 
untreated controls is statistically significant (Welch’s t-test, p=0.036). c. Comparison of pulse 
ligand APFI per image in type 2 synapses and type 3 synapses following BDNF treatment. The 
difference between the two groups is statistically significant (Welch’s t-test, p=0.00031).  
d. Chase ligand (TMR) APFI per image in synapses where pulse and chase ligands colocalise 
(type 2). The difference between the BDNF group and untreated controls is statistically 
significant (Welch’s t-test, p=0.036). e. Chase ligand APFI per image in synapses where pulse 
and chase ligands do not colocalise (type 1). The difference between the BDNF group and 
untreated controls is not statistically significant (Welch’s t-test, p=0.073). f. Comparison of 
chase ligand APFI per image in type 2 synapses and type 1 synapses following BDNF 
treatment. The difference between the two groups is statistically significant (Welch’s t-test, 
p=0.00012).  
 
34.79 ± 0.80 AU. When looking at the chase ligand results (figure 4.22.d-f), we can 
observe the opposite effect: APFI is significantly greater than controls in type 2 
(colocalised) synapses (p=0.036, figure 4.22.d), but this is not the case in type 1 
synapses (p=0.073, figure 4.22.e).  
 
Looking at puncta numbers (figure 4.23), the results match up with the bulk number 
data in figure 4.21: None of the results are significantly different to the control group, 
yet the pattern still indicates that puncta numbers are increased by BDNF, particularly 
for the chase ligand (figure 4.23.d-e).  
 
Looking at the proportion of the total synaptic population that the three synaptic types 
make up, the pie chart in figure 4.24 reveals that the number of type 1 synapses (only 
new, chase-labelled PSD-95) has gone up relative to the other two types. Type 1 
synapses now make up a total of 35% of synapses (figure 4.24.b), compared to 29% 
in the control group (4.24.a), and this appears to be at the expense of type 3 synapses 
(down to 21% from 28% in controls). However, the difference between type 1 and type 
3 synapses is just barely not statistically significant (Welch’s t-test, p=0.060).  
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a.       b.  
  
c.       d.  
  






























































































































































Figure 4.23. The effect of BDNF on PSD-95 average puncta number at synaptic types.  
Average puncta number per image was calculated for pulse and chase ligand labelled synaptic 
puncta in type 1, type 2 and type 3 synapses separately. Images were taken after 24 hours of 
pulse-chase treatment with 50nM R110Direct ligand (pulse) and 500nM TMR ligand (chase) 
in hippocampal primary cultures from PSD-95HaloTag/HaloTag mice on DIV16. BDNF (3.7nM) was 
applied for 24 hours together with the chase ligand between DIV15 and DIV16. The graphs 
here present the mean values across eight cultures (N=8). a. Pulse ligand (R110Direct) average 
puncta number per image in synapses where pulse and chase ligands colocalise (type 2). The 
difference between the BDNF group and untreated controls is not statistically significant 
(Welch’s t-test, p=0.12). b. Pulse ligand average puncta number per image in synapses where 
pulse and chase ligands do not colocalise (type 3). The difference between the BDNF group 
and untreated controls is not statistically significant (Welch’s t-test, p=0.92). c. Comparison 
of pulse ligand average puncta number per image in type 2 synapses and type 3 synapses 
following BDNF treatment. The difference between the two groups is statistically significant 
(Welch’s t-test, p=0.012). d. Chase ligand (TMR) average puncta number per image in 
synapses where pulse and chase ligands colocalise (type 2). The difference between the BDNF 
group and untreated controls is not statistically significant (Welch’s t-test, p=0.11). e. Chase 
ligand average puncta number per image in synapses where pulse and chase ligands do not 
colocalise (type 1). The difference between the BDNF group and untreated controls is not 
statistically significant (Welch’s t-test, p=0.060). f. Comparison of chase ligand average puncta 
number per image in type 2 synapses and type 1 synapses following BDNF treatment. The 
difference between the two groups is not statistically significant (Welch’s t-test, p=0.33).  
 
Moving to the analysis of pulse to chase ligand ratios at single synapses, we can see 
that there is no clear difference in the frequency distribution histograms between 
controls and BDNF-treated cultures (figures 4.25.a-b). The shapes of the histograms 
are very similar, covering the same range of ratios with very similar peaks. In the BDNF 
group, the mean ratio is 2.39 ± 0.064 (SEM), with the median ratio being 1.99 and the 
mode being a ratio of 1.2, at 9.18%. (For the control group the values are: mean ratio: 
2.55 ± 0.051 (SEM); median ratio: 2.06; mode: 1.8 (8.76%)). It therefore does not 
appear as though BDNF affects pulse to chase ligand ratios at individual synapses.  
 
Next, figure 4.25.c shows the APFI for the chase ligand at the different percentiles of 
the pulse ligand intensity. While the trend is the same as for the control group (a 
positive correlation between puncta intensities), the R2 value is lower than the very 










Figure 4.24. Proportional representation of synaptic population by HaloTag ligand-labelling 
following BDNF treatment.  
Synaptic puncta were categorised according to whether they colocalised with puncta labelled 
by the other ligand or not. This pie chart depicts the proportional representation of the three 
types of synaptic puncta observed.  
Images were taken after 24 hours of pulse-chase treatment with 50nM R110Direct ligand 
(pulse) and 500nM TMR ligand (chase) in hippocampal primary cultures from PSD-
95HaloTag/HaloTag mice on DIV16. a. In untreated controls, 28% of puncta contain only the pulse 
(R110Direct) ligand (type 3), 43% of puncta contain both pulse and chase (TMR) ligands (type 
2), and 29% contain only the chase ligand (type 1). b. Following 24 hours of BDNF treatment 
(3.7nM), 21% of puncta contain only the pulse (R110Direct) ligand (type 3), 44% of puncta 
contain both pulse and chase (TMR) ligands (type 2), and 35% contain only the chase ligand 


























a.       b.  
  
c.       d.  
 
Figure 4.25. Cumulative distribution functions of average puncta fluorescence intensity 
following BDNF treatment.  
CDFs were constructed using the single-synapse data following BDNF treatment, and 
compared with the untreated control group. Whether the difference was statistically 
significant or not was tested using the Kolmogorov-Smirnov test for difference. a. Comparison 
between R110 ligand puncta in colocalised type 2 synapses of BDNF-treated neurons with 
those in untreated controls. The difference is significant (Kolmogorov-Smirnov, p<0.0001). b. 
Comparison between R110 ligand puncta in non-colocalised type 3 synapses of BDNF-treated 
neurons with those in untreated controls. The difference is not significant (Kolmogorov-
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of BDNF-treated neurons with those in untreated controls. The difference is not significant 
(Kolmogorov-Smirnov, p=0.313). d. Comparison between TMR ligand puncta in non-
colocalised type 1 synapses of BDNF-treated neurons with those in untreated controls. The 
difference is not significant (Kolmogorov-Smirnov, p=0.063).  
 
Lastly, cumulative distribution functions (CDF’s) were calculated for each of the four 
groups (Figure 4.25). As before, a visual inspection indicates that the CDF curves of 
the treated groups look highly similar to those of untreated controls, displaying a very 
similar S-shaped curve that indicates a normal distribution. In this group, only a single 
test indicated statistically significant difference: the comparison between treated and 
untreated puncta within colocalising pulse (R110) puncta, i.e. type 2 synapses 
(Kolmogorov-Smirnov, p<0.0001). The other three groups were not statistically 
different from untreated controls: type 3 synapses (p=0.061), type 2 synapses chase 
ligand (p=0.313) and type 1 synapses (p=0.063). This indicates that the two synaptic 
populations are identical in terms of their average puncta fluorescence intensity 
distributions, meaning that the probability of a punctum having a specific intensity is 












Figure 4.26. Graphs showing the ratio of pulse to chase ligands and correlation of pulse 
ligand intensity with chase ligand intensity at individual type 2 synapses following 
BDNF treatment.  
In the synaptic population in which pulse and chase ligand-labelled PSD-95-HaloTag 
molecules were colocalised (type 2), the ratio of pulse ligand fluorescence intensity to chase 
ligand fluorescence intensity was calculated for each individual synapse. The frequency 
histograms represent the frequencies of all the pulse:chase ratios. a. Frequency distribution 
in untreated controls. Mean ratio: 2.55 ± 0.051 (SEM), Median ratio: 2.06, Mode: 1.8 (8.76%). 
b. Frequency distribution following 24 hours of BDNF (3.7nM) treatment. Mean ratio: 2.39 ± 
0.064 (SEM), Median ratio: 1.99, Mode: 1.2 (9.18%). c. Type 2 synapses were sorted by their 
pulse ligand APFI (lowest to highest). For each ten percentile steps, average chase ligand APFI 
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4.4.3.3 BDNF: Discussion 
 
It seems from these results, then, that BDNF does have an effect on total PSD-95 at 
synapses. Both pulse and chase ligand APFI are significantly higher (albeit not by a 
lot) than in untreated controls. This necessarily implies that total PSD-95 numbers at 
synapses are increased, too. Taken at face value, these results imply that BDNF 
causes an increase in PSD-95 synthesis (chase ligand), but also causes more old 
PSD-95 (pulse ligand) to be found at synapses. While the increased amount of new 
PSD-95 can only be explained by enhanced synthesis, the increased amount of old 
PSD-95 has two explanations- a reduced degradation of old PSD-95, or the cycling of 
old PSD-95 into synapses from dendrites and adjacent synapses. While my method 
does not allow me to distinguish between these two explanations, it does support the 
studies by Hu et al (2011) and Yoshii and Constantine-Paton (2007) that found BDNF 
to cause the trafficking of PSD-95 to synapses. On the other hand, my results are 
based on the analysis of thousands of synapses averaged together, meaning that if a 
synapse recruits old PSD-95 at the expense of an adjacent synapse (see Gray et al., 
2006), then overall levels of old PSD-95 should not, on average, be higher. The 
indication, then, is that PSD-95 degradation is reduced following BDNF treatment.  
My finding that PSD-95 synthesis is enhanced stands in contrast to the study by Yoshii 
and Constantine-Paton, who did not observe this effect, but supports the findings of 
Butko et al. (2012). While I found the increase in synaptic chase puncta number to be 
statistically insignificantly (figure 4.19.d, p=0.073), the difference was nevertheless 
marked, and quite close to becoming statistically significant. Furthermore, figure 4.22 
shows that the proportion of type 1 synapses has increased as well. These results 
seem to support the positive role that BDNF plays in dendritic outgrowth and 
synaptogenesis, although a greater time window would perhaps have been required 
to make such large structural changes manifest themselves more noticeably. Out of 
all of my results, puncta numbers are the most variable, making these results the least 
likely to be statistically significant. A larger sample size would thus also have been 
useful.  
 
Looking at the single-synapse level, compared to controls I found an increase in old 
PSD-95 at type 3 synapses and an increase in new PSD-95 at type 2 synapses. One 
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possible explanation for this is that type 2 synapses, which are presumably steadily 
turning over PSD-95, synthesise or recruit more new PSD-95 in response to BDNF 
(i.e. their rate of PSD-95 turnover changes to allow an increase in new PSD-95 in 
these synapses). This is supported by findings by Butko et al. (2012). Type 3 
synapses, on the other hand, that only contain old PSD-95, respond to the BDNF 
stimulus by reducing their rate of PSD-95 degradation. This appears strange if 
assuming that type 3 synapses are undergoing pruning. However, as mentioned 
before they may also be in a state of low activity, tending towards becoming quiet 
synapses, and if that is the case they may not contain much protein synthesis 
machinery such as polyribosomes anymore. Instead, they may need to respond to the 
BDNF signal by reducing degradation, and thus enhancing their PSD-95 levels. 
Nevertheless, their responsiveness to BDNF does create a lot of uncertainty about the 
nature of type 3 synapses. Type 1 synapses, however, are probably newly formed 
synapses, and are therefore already recruiting new PSD-95 to rapidly establish their 
PSDs. In these synapses, BDNF does not cause an increased rate of PSD-95 
recruitment, as they are already at the limit of their synthesis and recruitment 
capabilities. While this is only one possible scenario to explain the results obtained in 

















4.4.4.1 Ketamine: bulk analysis 
 
Moving to the group treated with ketamine, I initially set up experiments with two doses 
of ketamine- one high, and the other low. Since previous studies (Zarate et al., 2006; 
Li et al., 2010; Choi et al., 2015) had shown that ketamine only exhibits its effect of 
treating major depressive disorder and enhancing PSD-95 levels at low doses, but not 
high doses, I decided to test both in order to observe this difference. For the first two 
cultures, I therefore exposed neurons to ketamine at both high (10µM) and low (10nM) 
doses. However, after 24 hours of incubation, neurons exposed to 10µM ketamine all 
died. While the mechanism of action of ketamine that causes the anti-depressive effect 
has not yet been fully established (Gould et al., 2017), it is thought to exert its effect 
through a variety of different routes. These include the disinhibition of pyramidal 
neurons by blocking NMDA receptors on inhibitory GABA-ergic interneurons, which 
induces a glutamate surge and AMPA receptor activation, thereby stimulating BDNF 
release and increased protein synthesis (Abdallah et al., 2016). This mechanism of 
action would explain the increased PSD-95 levels that have been reported previously, 
and the glutamate surge could explain the toxic effect on neurons at high 
concentrations over 24 hours of exposure. Since this neurotoxic effect prevented me 
from gaining any data from the high-dose treatment group, I decided to cease this 
treatment, and focus solely on low ketamine doses (10nM).  
 
The first noticeable result was that pulse ligand APFI was significantly higher after 24 
hours of chase incubation with ketamine than in untreated controls (figure 4.27.a). 
While in controls APFI went down to 41.44 ± 0.85 AU over 24 hours, the APFI only 
went down to 50.95 ± 2.20 AU in the ketamine-treated group. This difference was 
statistically very significant (Welch’s t-test, p=0.0091). Chase ligand APFI, on the other 
hand, was unaffected by ketamine treatment (figure 4.27.b, p=0.31). Likewise, 
synaptic puncta number appeared to be unchanged in ketamine-treated cultures 
compared to controls, for both pulse-ligand puncta (figure 4.27.c, p=0.46) and chase-
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Figure 4.27. The effect of ketamine on PSD-95 puncta intensities and numbers.  
Hippocampal neuronal primary cultures from PSD-95HaloTag/HaloTag mice were cultured until 
DIV14, when they were labelled with the R110Direct HaloTag ligand (50nM, 16h). On DIV15 
the TMR ligand was added to the cultures at 500nM for 1 hour and 24 hours, alongside 
ketamine (10nM). APFI and number per image were then calculated. This was performed 
across 8 different cultures (N=8), with the graphs here presenting the mean values across 
these eight cultures. a. Graph of the R110 pulse ligand APFI following ketamine treatment. 
APFI is significantly higher after 24 hours in the ketamine group than in untreated controls 
(Welch’s t-test, p=0.0091). b. Graph of the average TMR chase ligand APFI following ketamine 
treatment. APFI is not significantly higher in the ketamine group than in untreated controls 
(Welch’s t-test, p=0.31). c. Graph of the average pulse ligand puncta number following 
ketamine treatment. The difference between the ketamine group and untreated controls 
after 24 hours is not significant (Welch’s t-test, p=0.46). d. Graph of the average chase ligand 
puncta number following ketamine treatment. The difference between the ketamine group 

















































































































4.4.4.2 Ketamine: single-synapse analysis 
 
At a single-synapse level, I was only able to observe statistically significant differences 
compared to controls in the APFI of the pulse ligand for both type 2 and type 3 
synapses. In type 2 synapses (colocalised), pulse ligand APFI was significantly higher 
at 56.49 ± 2.80 AU than in controls, with 45.13 ± 0.93 AU (figure 4.28.a, p=0.013). In 
type 3 synapses (non-colocalised), the APFI was 41.94 ± 1.66 AU compared to 34.79 
± 0.80 AU for controls (figure 4.28.b, p=0.0084). For the chase ligand (figure 4.25.d-
f), no differences in APFI were observed in type 2 and type 1 synapses. Similarly, 
synaptic puncta numbers did not differ from controls for any synaptic type (figure 4.29).  
 
When looking at the overall synaptic population and proportion of synaptic types 
(figure 4.30), we see that there are in fact fewer type 1 (chase ligand only) synapses 
than synapses of other types. While this finding runs counter to the proposed 
mechanism of ketamine action, which postulates that ketamine enhances 
synaptogenesis (Abdallah et al., 2016), and average puncta number for type 1 
synapses following ketamine treatment is lower than in controls (figure 4.29.e), this 
difference is not statistically significant (p=0.31).  
 
At individual type 2 synapses, the ratios of pulse to chase ligands appears to be very 
similar to untreated controls (figure 4.32). The frequency histograms have a very 
similar shape and distribution, with the ketamine-treated group having an average ratio 
of 3.09 ± 0.050 (SEM), with the median ratio being 2.57 and the mode being a ratio of 
2, at 7.23%. (For the control group the values are: mean ratio: 2.55 ± 0.051 (SEM); 
median ratio: 2.06; mode: 1.8 (8.76%)). It therefore does not appear as though 
ketamine affects pulse to chase ligand ratios at individual synapses.  
 
Next, when puncta were sorted by pulse ligand intensity into percentiles (figure 4.32.c), 
and the correlating average chase ligand intensities for these puncta calculated, the 
graph showed a strong positive correlation (R2=0.79), although not as strong as for 
the control group (R2=0.96, figure 4.7.b). Nevertheless, it is clear that as with TTX, 
BCC and BDNF treated cultures, ketamine treatment does not affect the  
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Figure 4.28. The effect of ketamine on PSD-95 average puncta intensity at synaptic types.  
Average puncta fluorescence intensity (APFI) per image was calculated for pulse and chase 
ligand labelled synaptic puncta in type 1, type 2 and type 3 synapses separately. Images were 
taken after 24 hours of pulse-chase treatment with 50nM R110Direct ligand (pulse) and 
500nM TMR ligand (chase) in hippocampal primary cultures from PSD-95HaloTag/HaloTag mice on 
DIV16. Ketamine (10nM) was applied for 24 hours together with the chase ligand between 
DIV15 and DIV16. The graphs here present the mean values across eight cultures (N=8). a. 
Pulse ligand (R110Direct) APFI per image in synapses where pulse and chase ligands colocalise 
(type 2). The difference between the ketamine group and untreated controls is statistically 
significant (Welch’s t-test, p=0.013). b. Pulse ligand APFI per image in synapses where pulse 
and chase ligands do not colocalise (type 3). The difference between the ketamine group and 
untreated controls is statistically significant (Welch’s t-test, p=0.0084). c. Comparison of pulse 
ligand APFI per image in type 2 synapses and type 3 synapses following ketamine treatment. 
The difference between the two groups is statistically significant (Welch’s t-test, p=0.0035). 
d. Chase ligand (TMR) APFI per image in synapses where pulse and chase ligands colocalise 
(type 2). The difference between the ketamine group and untreated controls is not 
statistically significant (Welch’s t-test, p=0.65). e. Chase ligand APFI per image in synapses 
where pulse and chase ligands do not colocalise (type 1). The difference between the 
ketamine group and untreated controls is not statistically significant (Welch’s t-test, p=0.77). 
f. Comparison of chase ligand APFI per image in type 2 synapses and type 1 synapses following 
ketamine treatment. The difference between the two groups is highly statistically significant 
(Welch’s t-test, p=3.35x10-5).  
 
strong pattern that synapses with a stronger pulse ligand APFI also display a stronger 
chase ligand APFI.  
 
Lastly, CDF’s were calculated for each of the four groups (figure 4.31). Again, a view 
of the CDF curves of the treated groups indicates a shape similar to those of untreated 
controls. However, one can observe that in each of the four graphs the treated group’s 
curve is shifted slightly to the right relative to untreated controls. This indicates that 
the expected fluorescence intensity of a given punctum is slightly higher in the 
ketamine-treated group than the control group. In this treatment group, all of the 
synaptic types were found to be statistically significant different: In each case, the 
Kolmogorov-Smirnov test for difference indicated that the treated groups were 
different to controls by a high margin (p=0.0004 or lower). Overall, then, this data 
indicates qualitatively and quantitatively that ketamine may enhance PSD-95 




4.4.4.3 Ketamine: Discussion 
 
The main finding from this study regarding the effect of ketamine on PSD-95 is that 
the bulk APFI value for the pulse ligand is significantly higher following 24 hours of 
ketamine treatment than in controls (figure 4.27.a). This higher intensity could be 
detected at the level of type 2 and type 3 synapses. Chase ligand intensity, however, 
was unaffected. While this result does not allow me to definitively state that total PSD-
95 levels at synapses increased, since it only represents old, pulse-labelled PSD-95, 
this does appear to be the implication. It appears that this result is the effect of reduced 
PSD-95 degradation, but not increased synthesis. Interestingly, this occurs at both 
type 2 and type 3 synapses, unlike with BDNF, which only affects type 3 synapses. 
Contrary to BDNF treatment, however, ketamine does not enhance the synthesis of 
new PSD-95. Thus, ketamine may activate different cellular pathways and responses 
than BDNF, which is somewhat surprising given that ketamine has been proposed to 
cause BDNF release at synapses (Browne & Lucki, 2013). Nevertheless, ketamine’s 
complete effect on neurons is still not fully understood, and is thought to be complex, 
making it difficult to say why it appears to significantly reduce the degradation of PSD-
95 at synapses while not affecting its synthesis. Indeed, it is possible that ketamine 
exerts part of its effect through the stabilisation of PSD-95 at the PSD, thus effecting 
the increased glutamate transmission observed (Duman et al., 2012).  
As mentioned above, my results did not support the finding that ketamine causes 
increased synaptogenesis (Abdallah et al., 2016), with the number of observed type 1 
synapses slightly lower than in the control group, albeit not statistically significantly. 
The results do warrant a further investigation of the effect of ketamine on PSD-95 
turnover, however, and one next step would be to perform western blots of cultures 
treated with ketamine in conjunction with my pulse-chase method, in order discover 
whether ketamine enhances total PSD-95 levels. Also, using a single ligand as 
opposed to pulse-chase labelling, in the presence of ketamine, would give valuable 
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Figure 4.29. The effect of ketamine on PSD-95 average puncta number at synaptic types.  
Average puncta number per image was calculated for pulse and chase ligand labelled synaptic 
puncta in type 1, type 2 and type 3 synapses separately. Images were taken after 24 hours of 
pulse-chase treatment with 50nM R110Direct ligand (pulse) and 500nM TMR ligand (chase) 
in hippocampal primary cultures from PSD-95HaloTag/HaloTag mice on DIV16. Ketamine (10nM) 
was applied for 24 hours together with the chase ligand between DIV15 and DIV16. The 
graphs here present the mean values across eight cultures (N=8). a. Pulse ligand (R110Direct) 
average puncta number per image in synapses where pulse and chase ligands colocalise (type 
2). The difference between the ketamine group and untreated controls is not statistically 
significant (Welch’s t-test, p=0.36). b. Pulse ligand average puncta number per image in 
synapses where pulse and chase ligands do not colocalise (type 3). The difference between 
the ketamine group and untreated controls is not statistically significant (Welch’s t-test, 
p=0.92). c. Comparison of pulse ligand average puncta number per image in type 2 synapses 
and type 3 synapses following ketamine treatment. The difference between the two groups 
is not statistically significant (Welch’s t-test, p=0.13). d. Chase ligand (TMR) average puncta 
number per image in synapses where pulse and chase ligands colocalise (type 2). The 
difference between the ketamine group and untreated controls is not statistically significant 
(Welch’s t-test, p=0.36). e. Chase ligand average puncta number per image in synapses where 
pulse and chase ligands do not colocalise (type 1). The difference between the ketamine 
group and untreated controls is not statistically significant (Welch’s t-test, p=0.31). f. 
Comparison of chase ligand average puncta number per image in type 2 synapses and type 1 
synapses following ketamine treatment. The difference between the two groups is not 









Figure 4.30. Proportional representation of synaptic population by HaloTag ligand-labelling 
following ketamine treatment.  
Synaptic puncta were categorised according to whether they colocalised with puncta labelled 
by the other ligand or not. This pie chart depicts the proportional representation of the three 
types of synaptic puncta observed.  
Images were taken after 24 hours of pulse-chase treatment with 50nM R110Direct ligand 
(pulse) and 500nM TMR ligand (chase) in hippocampal primary cultures from PSD-
95HaloTag/HaloTag mice on DIV16. a. In untreated controls, 28% of puncta contain only the pulse 
(R110Direct) ligand (type 3), 43% of puncta contain both pulse and chase (TMR) ligands (type 
2), and 29% contain only the chase ligand (type 1). b. Following 24 hours of ketamine 
treatment (10nM), 27% of puncta contain only the pulse (R110Direct) ligand (type 3), 55% of 
puncta contain both pulse and chase (TMR) ligands (type 2), and 18% contain only the chase 
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Figure 4.31. Cumulative distribution functions of average puncta fluorescence intensity 
following ketamine treatment.  
CDFs were constructed using the single-synapse data following ketamine treatment, and 
compared with the untreated control group. Whether the difference was statistically 
significant or not was tested using the Kolmogorov-Smirnov test for difference. a. Comparison 
between R110 ligand puncta in colocalised type 2 synapses of ketamine-treated neurons with 
those in untreated controls. The difference is significant (Kolmogorov-Smirnov, p<0.0001). b. 
Comparison between R110 ligand puncta in non-colocalised type 3 synapses of ketamine-
treated neurons with those in untreated controls. The difference is significant (Kolmogorov-
Smirnov, p<0.0001). c. Comparison between TMR ligand puncta in colocalised type 2 synapses 
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(Kolmogorov-Smirnov, p=0.0004). d. Comparison between TMR ligand puncta in non-
colocalised type 1 synapses of ketamine-treated neurons with those in untreated controls. 
The difference is significant (Kolmogorov-Smirnov, p<0.0001).  




Figure 4.32. Graphs showing the ratio of pulse to chase ligands and correlation of pulse 
ligand intensity with chase ligand intensity at individual type 2 synapses following 
ketamine treatment.  
In the synaptic population in which pulse and chase ligand-labelled PSD-95-HaloTag 
molecules were colocalised (type 2), the ratio of pulse ligand fluorescence intensity to chase 
ligand fluorescence intensity was calculated for each individual synapse. The frequency 
histograms represent the frequencies of all the pulse:chase ratios.  
a. Frequency distribution in untreated controls. Mean ratio: 2.55 ± 0.051 (SEM), Median ratio: 
2.06, Mode: 1.8 (8.76%). b. Frequency distribution following 24 hours of ketamine (10nM) 
treatment. Mean ratio: 3.09 ± 0.050 (SEM), Median ratio: 2.57, Mode: 2 (7.23%). 
c. Type 2 synapses were sorted by their pulse ligand APFI (lowest to highest). For each ten 
percentile steps, average chase ligand APFI was calculated. Following ketamine treatment, 
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4.4.5.1 Proteasome inhibitors- Lactacystin and MG132: bulk analysis 
 
As mentioned before, Lactacystin and MG132 are both commonly used to block 
protein degradation by inhibiting the proteasome, the organelle known to be the main 
agent of PSD-95 degradation. From figure 4.33, we can immediately observe that both 
of these drugs have a strong, and similar, effect on PSD-95. Unlike in the study by 
Hakim et al. (2016), I do indeed find that lactacystin, as well as MG132, have what 
appears to be a severe effect upon PSD-95 degradation. There is a massive difference 
in the APFI of the pulse ligand after 24 hours of incubation with either of the 
proteasome inhibitors. In figure 4.33.a we see that pulse ligand APFI drops from 65.97 
± 1.69 AU at the 1-hour time point to 55.12 ± 2.33 AU after being incubated with 
lactacystin for 24 hours. In contrast, pulse ligand APFI in the untreated control group 
is reduced to 41.44 ± 0.85 AU at the same time point. The difference between these 
two values is highly statistically significant (Welch’s t-test, p=0.00068). Following 
MG132 treatment for 24 hours, we see a similar effect as pulse ligand APFI falls to 
56.10 ± 3.03 AU (p=0.0024) (figure 4.33.b).  
 
Intriguingly, and matching the results reported by Hakim et al. (2016), I was also able 
to observe a marked effect upon PSD-95 synthesis. Figures 4.33.c and 4.33.d show 
that lactacystin and MG132 treatment both lead to a reduced synthesis of PSD-95, 
since chase ligand APFI is significantly lower for both groups. Lactacystin treatment 
(figure 4.33.c) results in a chase ligand APFI of 22.32 ± 1.45 AU, compared to 29.63 
± 1.42 AU for untreated controls (Welch’s t-test, p=0.0033). In the MG132-treated 
group (figure 4.33.d), PSD-95 synthesis is affected even more strongly, with chase 
ligand APFI reduced to 16.88 ± 0.72 AU (p=1.01x10-5).  
 
Moving to the puncta number analysis, the results mirror those obtained for the puncta 
fluorescence intensity in figure 4.33. All of the results except for those pertaining to 
pulse ligand puncta number following lactacystin (figure 4.34.a) were significantly 
different from untreated controls. In the MG132-treated group, pulse ligand puncta 
number (mean 316.60 ± 43.36 puncta per image) was significantly higher than the 
mean 189.15 ± 26.64 puncta per image for controls (figure 4.34.b, p=0.031). In the 
lactacystin group, the mean puncta number per image was also higher than in controls  
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Figure 4.33. The effects of Lactacystin and MG132 on PSD-95 puncta intensities.  
Hippocampal neuronal primary cultures from PSD-95HaloTag/HaloTag mice were grown for 14 days 
in vitro, and thereafter pulse-chase experiments performed using the R110Direct and TMR 
HaloTag ligands. Lactacystin at 1µM or MG132 at 10µM were added alongside the chase 
ligand for 1 or 24 hours. The graphs here present the mean values across eight cultures (N=8). 
a. Graph of the average R110 pulse ligand puncta fluorescence intensity following lactacystin 
treatment. APFI is significantly higher after 24 hours in the lactacystin group than in untreated 
controls (Welch’s t-test, p=0.00068). b. Graph of the average R110 pulse ligand puncta 
intensity following MG132 treatment. APFI is significantly higher after 24 hours in the MG132 
group than in untreated controls (Welch’s t-test, p=0.0024). c. Graph of the average TMR 
chase ligand puncta fluorescence intensity following lactacystin treatment. The difference 
between the lactacystin group and untreated controls is significant (Welch’s t-test, p=0.0033). 
d. Graph of the average TMR chase ligand puncta fluorescence intensity following MG132 
treatment. The difference between the MG132 group and untreated controls is highly 
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Figure 4.34. The effects of Lactacystin and MG132 on PSD-95 puncta numbers.  
Hippocampal neuronal primary cultures from PSD-95HaloTag/HaloTag mice were grown for 14 days 
in vitro, and thereafter pulse-chase experiments performed using the R110Direct and TMR 
HaloTag ligands. Lactacystin at 1µM or MG132 at 10µM were added alongside the chase 
ligand for 1 or 24 hours. The graphs here present the mean values across eight cultures (N=8). 
a. Graph of the average R110 pulse ligand puncta number following lactacystin treatment. 
The number is not significantly higher after 24 hours in the lactacystin group than in untreated 
controls (Welch’s t-test, p=0.14). b. Graph of the average R110 pulse ligand puncta number 
following MG132 treatment. The number is significantly higher after 24 hours in the MG132 
group than in untreated controls (Welch’s t-test, p=0.031). c. Graph of the average TMR chase 
ligand puncta number following lactacystin treatment. The difference between the lactacystin 
group and untreated controls is significant (Welch’s t-test, p=0.025). d. Graph of the average 
TMR chase ligand puncta number following MG132 treatment. The difference between the 

















































































































with 273.72 ± 45.38 puncta, but the difference in this case wasn’t statistically 
significant (figure 4.34.a, p=0.14). Chase ligand puncta number was much lower 
compared to the 192.66 ± 32.83 puncta per image value for the control group in the 
lactacystin group (mean 94.53 ± 18.82 puncta per image, p=0.025, figure 4.34.c) and 
in the MG132 group as well (mean 38.78 ± 8.75 puncta per image, p=0.0019, figure 
4.34.d).  
 
Overall, then, I find bulk puncta number to be dramatically affected by both lactacystin 
and MG132 treatment. In terms of both average puncta fluorescence intensity (APFI) 
and average puncta number per image both drugs cause the pulse ligand numbers to 
remain higher than in the control group (implying a lower PSD-95 degradation rate), 
while chase ligand numbers are lower than in the control group (implying a lower PSD-
95 synthesis rate).   
 
4.4.5.2 Proteasome inhibitors- Lactacystin and MG132: single-synapse 
analysis 
 
Once the results are sorted by synaptic types, it is interesting to see that the great 
differences in the fluorescence intensity values between the control group and the 
drug-treated groups are primarily being driven by type 2 (colocalised) synapses. For 
both lactacystin (figure 4.35.a) and MG132 (figure 4.36.a) the pulse ligand intensity 
differs most significantly from controls in type 2 synapses (control: 45.13 ± 0.93 AU; 
lactacystin: 77.33 ± 2.92 AU, p=1.22x10-5; MG132: 103.49 ± 4.86 AU, p=1.33x10-5). 
At type 3 synapses (pulse-ligand only), the values are still statistically significantly 
different from controls, but less so (lactacystin: p=0.0017, figure 4.35.b; MG132: 
p=9.66x10-5, figure 4.36.b).  
 
The same is true of the chase ligand- colocalised type 2 synapses exhibit a much 
greater degree of difference from controls than type 1 synapses. In figure 4.35.d we 
see that in type 2 synapses chase ligand APFI following lactacystin treatment is 
significantly lower with 22.38 ± 1.44 AU than the control group’s value of 34.88 ± 1.91 
AU (p=0.00019). This holds true for the MG132-treated group, with a value of 16.57 ± 
0.73 AU (p=9.22x10-6, figure 4.36.d). At type 1 synapses, the differences are not  
 204
a.       b.  
  
c.       d.  
  






































































































































































Figure 4.35. The effect of lactacystin on PSD-95 average puncta intensity at synaptic types.  
Average puncta fluorescence intensity (APFI) per image was calculated for pulse and chase 
ligand labelled synaptic puncta in type 1, type 2 and type 3 synapses separately. Images were 
taken after 24 hours of pulse-chase treatment with 50nM R110Direct ligand (pulse) and 
500nM TMR ligand (chase) in hippocampal primary cultures from PSD-95HaloTag/HaloTag mice on 
DIV16. Lactacystin (1µM) was applied for 24 hours together with the chase ligand between 
DIV15 and DIV16. The graphs here present the mean values across eight cultures (N=8). a. 
Pulse ligand (R110Direct) APFI per image in synapses where pulse and chase ligands colocalise 
(type 2). The difference between the lactacystin group and untreated controls is statistically 
significant (Welch’s t-test, p=1.22x10-5). b. Pulse ligand APFI per image in synapses where 
pulse and chase ligands do not colocalise (type 3). The difference between the lactacystin 
group and untreated controls is statistically significant (Welch’s t-test, p=0.0017). c. 
Comparison of pulse ligand APFI per image in type 2 synapses and type 3 synapses following 
lactacystin treatment. The difference between the two groups is statistically significant 
(Welch’s t-test, p=2.76x10-6). d. Chase ligand (TMR) APFI per image in synapses where pulse 
and chase ligands colocalise (type 2). The difference between the lactacystin group and 
untreated controls is statistically significant (Welch’s t-test, p=0.00019). e. Chase ligand APFI 
per image in synapses where pulse and chase ligands do not colocalise (type 1). The difference 
between the lactacystin group and untreated controls is not statistically significant (Welch’s 
t-test, p=0.097). f. Comparison of chase ligand APFI per image in type 2 synapses and type 1 
synapses following lactacystin treatment. The difference between the two groups is not 
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Figure 4.36. The effect of MG132 on PSD-95 average puncta intensity at synaptic types.  
Average puncta fluorescence intensity (APFI) per image was calculated for pulse and chase 
ligand labelled synaptic puncta in type 1, type 2 and type 3 synapses separately. Images were 
taken after 24 hours of pulse-chase treatment with 50nM R110Direct ligand (pulse) and 
500nM TMR ligand (chase) in hippocampal primary cultures from PSD-95HaloTag/HaloTag mice on 
DIV16. MG132 (10µM) was applied for 24 hours together with the chase ligand between 
DIV15 and DIV16. The graphs here present the mean values across eight cultures (N=8). a. 
Pulse ligand (R110Direct) APFI per image in synapses where pulse and chase ligands colocalise 
(type 2). The difference between the MG132 group and untreated controls is statistically 
significant (Welch’s t-test, p=1.33x10-5). b. Pulse ligand APFI per image in synapses where 
pulse and chase ligands do not colocalise (type 3). The difference between the MG132 group 
and untreated controls is statistically significant (Welch’s t-test, 9.66x10-5). c. Comparison of 
pulse ligand APFI per image in type 2 synapses and type 3 synapses following MG132 
treatment. The difference between the two groups is statistically significant (Welch’s t-test, 
p=7.90x10-6). d. Chase ligand (TMR) APFI per image in synapses where pulse and chase ligands 
colocalise (type 2). The difference between the MG132 group and untreated controls is 
statistically significant (Welch’s t-test, p=9.22x10-6). e. Chase ligand APFI per image in 
synapses where pulse and chase ligands do not colocalise (type 1). The difference between 
the MG132 group and untreated controls is statistically significant (Welch’s t-test, p=0.0069). 
f. Comparison of chase ligand APFI per image in type 2 synapses and type 1 synapses following 
MG132 treatment. The difference between the two groups is not statistically significant 
(Welch’s t-test, p=0.81).  
 
statistically significant in the lactacystin group (p=0.10, figure 4.35.e). In the MG132 
group the differences are still very statistically significant (p=0.0069, figure 4.36.e), but 
much less so than in type 2 synapses.  
 
Interestingly, for both treatment groups the chase ligand is not different in its APFI 
when comparing type 2 with type 1 synapses (figure 4.35.f and figure 4.36.f), in 
contrast with the control group (figure 4.2.b). For the pulse ligand, the difference 
between type 2 and type 3 synapses is still very significant (lactacystin: figure 4.35.c, 
p=2.76x10-6; MG132: figure 4.36.c, p=7.90x10-6).  
 
Looking at puncta number, we see the results actually diverge from the puncta 
intensity results for the first time. In both the lactacystin and the MG132 groups, APFI 
in type 2 synapses is much higher than in controls (figure 4.35.a and figure 4.36.a), 
while average puncta number in type 2 synapses is lower than in controls (figure 
4.37.a and figure 4.38.a). While mean pulse ligand puncta number per image for the 
untreated control group is 115.92 ± 17.98, the value for the lactacystin group is 85.10 
± 15.90 (p=0.22) and the value for the MG132 group is 34.00 ± 8.15 (p=0.0021). At 
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type 3 synapses, the opposite is the case (figure 4.37.b and figure 4.38.b). 
Interestingly, the majority of pulse-labelled puncta are found to be type 3 synapses 
(figure 4.37.c and figure 4.38.c). The explanation for this is that many synapses that 
have not synthesised any new PSD-95 at all following drug treatment and therefore 
become type 3 synapses would have been type 2 synapses under control conditions.  
 
Looking at chase ligand puncta numbers, the main observation is that puncta numbers 
are strongly reduced compared to controls. This effect is particularly pronounced in 
non-colocalised type 1 synapses, with images from lactacystin-treated cultures having 
an average of 10.92 ± 3.70 synaptic puncta (figure 3.37.e) and from MG132-treated 
cultures 6.17 ± 1.49 puncta (figure 3.38.e). These values differ very significantly from 
the average 78.65 ± 16.67 puncta per image in controls (lactacystin: p=0.0045; 
MG132: p=0.0033). The reduction in type 2 synapses labelled by the chase ligand is 
much less pronounced, and thus there are significantly fewer type 1 synapses labelled 
by the chase ligand than type 2 synapses (lactacystin: figure 4.37.f, p=0.0031; MG132: 
figure 4.38.f, p=0.014).  
 
This skewed distribution of synaptic types becomes very clear when looking at the pie 
chart in figure 4.39. Here we can clearly see that the vast majority of synapses is made 
up of type 3, pulse-only synapses. Type 2 synapses are drastically reduced in number, 
and there are barely any type 1 synapses. Following lactacystin treatment (figure 
4.39.b), the numbers are type 3: 66%, type 2: 30% and type 1: 4%. Following MG132 
treatment (figure 4.39.c), the numbers are even more skewed- type 3: 88%, type 2: 
10% and type 1: 2%. Compare this to untreated controls (figure 4.39.a), and the shift 
becomes very evident. From these numbers, there is one conclusion we can come to: 
a large number of type 3 synapses would, in untreated control conditions, have been 
classified as type 2 synapses instead. However, following proteasome inhibition, they 
have not incorporated any newly-synthesised PSD-95 into their PSDs, thereby leading 
to their classification as type 3 synapses.  
 
We then turn to looking at the ratios between pulse and chase ligands at type 2 
synapses (Figure 4.42). From the shapes of the frequency histograms, we can see 
that a transformation of the synaptic population has taken place. Compared to the 
curves for lactacystin (figure 4.42.b) and MG132 (figure 4.42.c), the control group’s  
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Figure 4.37. The effect of lactacystin on PSD-95 average puncta number at synaptic types.  
Average puncta number per image was calculated for pulse and chase ligand labelled synaptic 
puncta in type 1, type 2 and type 3 synapses separately. Images were taken after 24 hours of 
pulse-chase treatment with 50nM R110Direct ligand (pulse) and 500nM TMR ligand (chase) 
in hippocampal primary cultures from PSD-95HaloTag/HaloTag mice on DIV16. Lactacystin (1µM) 
was applied for 24 hours together with the chase ligand between DIV15 and DIV16. The 
graphs here present the mean values across eight cultures (N=8).  
a. Pulse ligand average puncta number per image in synapses where pulse and chase ligands 
colocalise (type 2). The difference between the lactacystin group and untreated controls is 
not statistically significant (Welch’s t-test, p=0.22). b. Pulse ligand average puncta number per 
image in synapses where pulse and chase ligands do not colocalise (type 3). The difference 
between the lactacystin group and untreated controls is statistically significant (Welch’s t-
test, p=0.019). c. Comparison of pulse ligand average puncta number per image in type 2 
synapses and type 3 synapses following lactacystin treatment. The difference between the 
two groups is statistically significant (Welch’s t-test, p=0.023). d. Chase ligand (TMR) average 
puncta number per image in synapses where pulse and chase ligands colocalise (type 2). The 
difference between the lactacystin group and untreated controls is not statistically significant 
(Welch’s t-test, p=0.21). e. Chase ligand average puncta number per image in synapses where 
pulse and chase ligands do not colocalise (type 1). The difference between the lactacystin 
group and untreated controls is statistically significant (Welch’s t-test, p=0.0045). f. 
Comparison of chase ligand average puncta number per image in type 2 synapses and type 1 
synapses following lactacystin treatment. The difference between the two groups is 
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Figure 4.38. The effect of MG132 on PSD-95 average puncta number at synaptic types.  
Average puncta number per image was calculated for pulse and chase ligand labelled synaptic 
puncta in type 1, type 2 and type 3 synapses separately. Images were taken after 24 hours of 
pulse-chase treatment with 50nM R110Direct ligand (pulse) and 500nM TMR ligand (chase) 
in hippocampal primary cultures from PSD-95HaloTag/HaloTag mice on DIV16. MG132 (10µM) was 
applied for 24 hours together with the chase ligand between DIV15 and DIV16. The graphs 
here present the mean values across eight cultures (N=8). a. Pulse ligand average puncta 
number per image in synapses where pulse and chase ligands colocalise (type 2). The 
difference between the MG132 group and untreated controls is statistically significant 
(Welch’s t-test, p=0.0021). b. Pulse ligand average puncta number per image in synapses 
where pulse and chase ligands do not colocalise (type 3). The difference between the MG132 
group and untreated controls is statistically significant (Welch’s t-test, p=0.00097). c. 
Comparison of pulse ligand average puncta number per image in type 2 synapses and type 3 
synapses following MG132 treatment. The difference between the two groups is statistically 
significant (Welch’s t-test, p=0.00050). d. Chase ligand (TMR) average puncta number per 
image in synapses where pulse and chase ligands colocalise (type 2). The difference between 
the MG132 group and untreated controls is statistically significant (Welch’s t-test, p=0.0019). 
e. Chase ligand average puncta number per image in synapses where pulse and chase ligands 
do not colocalise (type 1). The difference between the MG132 group and untreated controls 
is statistically significant (Welch’s t-test, p=0.0033).  
f. Comparison of chase ligand average puncta number per image in type 2 synapses and type 
1 synapses following MG132 treatment. The difference between the two groups is statistically 
significant (Welch’s t-test, p=0.014).  
 
histogram (figure 4.42.a) is strongly positively skewed. The control group’s histogram 
has a fairly well-defined peak (mode 1.8 at 8.76%), and the slopes are relatively steep 
compared to the histograms in the drug-treated groups. The mean ratio for the control 
group is 2.55 ± 0.051 (SEM), with the median ratio being 2.06. For both treatment 
groups the histograms display much more gradually sloping curves, with no well-
defined peak. The ratios are also evidently much greater than in the control group. In 
the lactacystin group, the mean ratio is 7.19 ± 0.18 (SEM) (figure 4.42.d), with a 
median ratio of 6.03. The mode is a ratio of 6, with 3.78%. In the MG132 group, the 
mean ratio is 10.25 ± 0.21 (SEM) (figure 4.42.d), with a median ratio of 9.56. The mode 
is a ratio of 8.6, with 4.92%. Apart from the very wide spread of values, we can also 
observe that in the treatment groups the mode is less clearly defined, and much less 
pronounced (around 4% as opposed to around 8%). Next, figure 4.43 reveals that the 
correlation between pulse and chase ligand intensity in type 2 synapses remains 
unchanged following lactacystin or MG132 treatment. For both drugs we see that as 
pulse ligand intensity goes up by percentiles, chase ligand intensity goes up as well 







































Figure 4.39. Proportional representation of synaptic population by HaloTag ligand-labelling 
following proteasome inhibition.  
Synaptic puncta were categorised according to whether they colocalised with puncta labelled 
by the other ligand or not. This pie chart depicts the proportional representation of the three 
types of synaptic puncta observed.  
Images were taken after 24 hours of pulse-chase treatment with 50nM R110Direct ligand 
(pulse) and 500nM TMR ligand (chase) in hippocampal primary cultures from PSD-
95HaloTag/HaloTag mice on DIV16. a. In untreated controls, 28% of puncta contain only the pulse 
(R110Direct) ligand (type 3), 43% of puncta contain both pulse and chase (TMR) ligands (type 
2), and 29% contain only the chase ligand (type 1). b. Following 24 hours of lactacystin 
treatment (1µM), 66% of puncta contain only the pulse (R110Direct) ligand (type 3), 30% of 
puncta contain both pulse and chase (TMR) ligands (type 2), and 4% contain only the chase 
ligand (type 1). c. Following 24 hours of MG132 treatment (10µM), 88% of puncta contain 
only the pulse (R110Direct) ligand (type 3), 10% of puncta contain both pulse and chase (TMR) 
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c.       d.  
  
Figure 4.40. Cumulative distribution functions of average puncta fluorescence intensity 
following lactacystin treatment.  
CDFs were constructed using the single-synapse data following lactacystin treatment, and 
compared with the untreated control group. Whether the difference was statistically 
significant or not was tested using the Kolmogorov-Smirnov test for difference. a. Comparison 
between R110 ligand puncta in colocalised type 2 synapses of lactacystin-treated neurons 
with those in untreated controls. The difference is significant (Kolmogorov-Smirnov, 
p<0.0001). b. Comparison between R110 ligand puncta in non-colocalised type 3 synapses of 
lactacystin-treated neurons with those in untreated controls. The difference is significant 
(Kolmogorov-Smirnov, p<0.0001). c. Comparison between TMR ligand puncta in colocalised 
type 2 synapses of lactacystin-treated neurons with those in untreated controls. The 
difference is significant (Kolmogorov-Smirnov, p<0.0001). d. Comparison between TMR ligand 
puncta in non-colocalised type 1 synapses of lactacystin-treated neurons with those in 
untreated controls. The difference is not significant (Kolmogorov-Smirnov, p=0.137).  
 
Lastly, CDF’s were calculated for each of the eight groups (Figures 4.40 and 4.41). In 
these two treatment groups (lactacystin and MG132), the CDF curves of the treated 
groups have similar shapes to untreated controls, except for type 1 synapses. For both 
treatments, type 1 synapses are so low in frequency that the curves are in fact lines. 
It is of interest to note that the results reflect what previous graphs have also shown- 
that pulse ligand (R110) puncta following treatment are more likely than controls to 
have a higher APFI. This is evident by the shift of the curve to the right. Conversely, 
for chase ligand (TMR) puncta, drug treatment results in a lower expected APFI, as 
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The only curve found to not be significantly different from the untreated control group 
when tested using the Kolmogorov-Smirnov test for difference was that belonging to 
type 1 synapses when treated with lactacystin (p=0.137). All other groups were found 
to be significantly different from the control group. This difference is due to the high 
percentage of puncta overlap between the lactacystin-treated group and the untreated 
control group, which can be seen when viewing the two curves (figure 4.40.d).   
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Figure 4.41. Cumulative distribution functions of average puncta fluorescence intensity 
following MG132 treatment.  
CDFs were constructed using the single-synapse data following MG132 treatment, and 
compared with the untreated control group. Whether the difference was statistically 
significant or not was tested using the Kolmogorov-Smirnov test for difference. a. Comparison 
between R110 ligand puncta in colocalised type 2 synapses of MG132-treated neurons with 
those in untreated controls. The difference is significant (Kolmogorov-Smirnov, p<0.0001). b. 
Comparison between R110 ligand puncta in non-colocalised type 3 synapses of MG132-
treated neurons with those in untreated controls. The difference is significant (Kolmogorov-
Smirnov, p<0.0001). c. Comparison between TMR ligand puncta in colocalised type 2 synapses 
of MG132-treated neurons with those in untreated controls. The difference is significant 
(Kolmogorov-Smirnov, p<0.0001). d. Comparison between TMR ligand puncta in non-
colocalised type 1 synapses of MG132-treated neurons with those in untreated controls. The 
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Figure 4.42. Graphs showing the ratio of pulse to chase ligands at individual type 2 synapses 
following proteasome inhibition.  
In the synaptic population in which pulse and chase ligand-labelled PSD-95-HaloTag 
molecules were colocalised (type 2), the ratio of pulse ligand fluorescence intensity to chase 
ligand fluorescence intensity was calculated for each individual synapse. The frequency 
histograms represent the frequencies of all the pulse:chase ratios. a. Frequency distribution 
in untreated controls. Mean ratio: 2.55 ± 0.051 (SEM), Median ratio: 2.06, Mode: 1.8 (8.76%). 
b. Frequency distribution following 24 hours of lactacystin (1µM) treatment. Mean ratio: 7.19 
± 0.18 (SEM), Median ratio: 6.03, Mode: 6 (3.78%). c. Frequency distribution following 24 
hours of MG132 (10µM) treatment. Mean ratio: 10.25 ± 0.21 (SEM), Median ratio: 9.56, 
Mode: 8.6 (4.92%). d. Comparison of mean pulse:chase ligand ratio in untreated controls with 
lactacystin and MG132 treated cultures. Differences are statistically significant for both the 
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Figure 4.43 Correlation of pulse ligand intensity with chase ligand intensity at colocalised 
synaptic puncta following proteasome inhibition.  
Colocalising (type 2) synapses were sorted by their pulse ligand APFI (lowest to highest). For 
each ten percentile steps, average chase ligand APFI was calculated. a. In untreated controls, 
there is a strong positive correlation, R2=0.96. b. In the lactacystin-treated cultures, there is 
also a strong positive correlation, R2=0.86. c. In the MG132-treated cultures, the correlation 
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4.4.5.2 Proteasome inhibitors- Lactacystin and MG132: discussion 
 
The results presented in the previous sections strongly indicate that the proteasome 
inhibitors lactacystin and MG132 have a profound effect upon the expression and 
turnover of PSD-95 at the synapse. Nearly all characteristics that I am monitoring over 
this study, such as pulse and chase ligand puncta intensity and number, synaptic 
types, frequencies and ratios, appear to be affected by the treatment with these 
chemicals. Overall, the main findings in the treatment groups compared to untreated 
controls are:  
 
1. Overall (bulk) pulse ligand APFI remains significantly higher over 24 hours. This 
effect could also be observed at both type 2 and type 3 synapses.  
2. Overall (bulk) chase ligand APFI rises to a much lower level over these 24 
hours. This appears to be mediated chiefly through type 2 and much less so 
type 1 synapses.  
3. Type 1 and type 2 synapses contain equal amounts of new PSD-95, unlike 
untreated controls.  
4. There are significantly fewer type 1 synapses.  
5. There are significantly fewer type 2 synapses. 
6. There are significantly more type 3 synapses.  
7. Within type 2 synapses, the ratio of pulse:chase ligand APFI is skewed strongly 
towards the pulse ligand.    
 
Let us take a closer look at the study by Hakim et al. (2016). This study used 
multiplexed and pulsed SILAC, in addition to immunocytochemistry, in primary 
cultures of rat hippocampal neurons to measure synthesis and degradation rates of 
synaptic proteins following suppression of proteasomal activity by 10µM lactacystin, 
applied for 10 hours (immunocytochemistry) and 24 hours (SILAC). 
Immunocytochemically the study found no change in total synaptic PSD-95 levels at 
all after the 10 hours of incubation. Following the 24-hour incubation and analysis by 
SILAC, the study found no reduction in PSD-95 degradation, but were able to measure 
a significant reduction in PSD-95 synthesis.  
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In my study, which in fact used lactacystin at a ten-fold lower concentration (1µM), had 
I been able to measure total synaptic PSD-95 levels it is possible that I, too, would 
have seen no significant change. This is because pulse ligand intensity remained high, 
even though chase ligand intensity was significantly lower than in controls. The overall 
amount of PSD-95 present at synapses, then, may have remained unchanged.  
 
It became clear once the results were analysed that a measurement of total PSD-95 
levels would have proved highly useful and would have helped some of the questions 
that remain unanswered at this stage. There are various techniques that could have 
been employed in order to gain information on this. Firstly, western blotting could have 
been performed, allowing for a quantitative read-out of total PSD-95 levels in neuronal 
cultures. Secondly, single-ligand labelling using the HaloTag system could have been 
used, using one ligand to label treated and untreated cultures and comparing relative 
fluorescence intensities. This would have accomplished much the same as an 
antibody staining approach for PSD-95, which is a conventional method frequently 
used to measure total protein levels, including at synaptic locations.  
 
As mentioned in previous experiments, there are two possible explanations for the 
pulse ligand APFI remaining high: reduced degradation of PSD-95, or degraded PSD-
95 being replaced by extra-synaptic PSD-95, potentially cycled in from other 
synapses. However, I am looking at the entire population of synapses, such that PSD-
95 molecules moving between synapses should overall be accounted for. There is 
also other evidence that points in the direction of degradation being affected. Firstly, 
type 3 (pulse-only) synapses contain greater amounts of old PSD-95 than controls, 
which further implies a reduced degree of PSD-95 degradation. Indeed, there are 
significantly greater numbers of type 3 synapses. It is possible that blocking 
proteasomal activity inhibits the pruning of synapses, and there is some evidence 
supporting a role for the proteasome in synaptic pruning (DiAntonio et al., 2004; 
Riccomagno et al., 2015). Secondly, type 2 (mixed) synapses display pulse-to-chase 
ligand ratios that are heavily skewed towards the pulse ligand. This is the effect of 
reduced degradation of old PSD-95 (which remains much higher than in controls), but 
also because less new PSD-95 is recruited (chase ligand intensity is much lower than 
in controls). Indeed, these results imply that many type 2 synapses effectively turned 
into type 3 synapses by virtue of not incorporating new PSD-95. While some amount 
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of cycling of dendritic PSD-95 into synapses may occur, it is very likely that old PSD-
95 levels at synapses remain high due to reduced degradation brought on by the 
proteasome blockade of lactacystin or MG132.  
 
The other interesting finding is that there is reduced synthesis of PSD-95, matching 
the finding by Hakim et al. (2016). While this result cannot be interpreted in any other 
way, there is a second aspect to it that is more intriguing. Not only is PSD-95 synthesis 
reduced at existing type 2 and type 3 synapses, but there are also fewer type 1 
synapses. As discussed in chapter 4.3.3, type 1 synapses are most likely newly 
formed, immature synapses that are recruiting new PSD-95 in order to establish their 
PSDs. Reduced numbers of these type 1 synapses, then, may imply that 
synaptogenesis is reduced in these cultures. As Hakim et al. (2016) propose, blocking 
proteasomal activity may have deep-reaching consequences for the cell as a whole, 
and trigger such reactions as the unfolded protein response (UPR) and integrated 
stress response. These responses are further implicated in causing synaptic loss in 
various disease states, and thus the first stage of this in immature primary neurons 
may be an immediate and significant reduction in synaptogenesis. Alternatively, 
synaptogenesis may still be going on unhindered, but new synapses may simply not 
be incorporating PSD-95. However, since PSD-95 is known to be critical for the 
structural maturation of synaptic spines (El-Husseini et al., 2000), healthy 
synaptogenesis may become impossible, or this could lead to the handicapping of the 
synaptic maturation process. Indeed, the lack of PSD-95 may cause more silent 
synapses to be formed, if synaptogenesis is indeed still ongoing at the usual rate, 
since this appears to be the effect of knocking down or knocking out PSD-95 in mouse 
models (Huang et al., 2015; Béı q̈ue et al., 2006). What is also intriguing about type 1 
synapses is that while their numbers have gone down significantly, their rate of 
incorporation of new PSD-95 has not been affected to the same extent. Following 
lactacystin treatment, type 1 synapses still contained the same amount of new PSD-
95 as untreated controls, while MG132 only had a slight (albeit significant) effect. What 
this implies is that while there are fewer new synapses being formed, those that are 
formed still recruit new PSD-95 at similar, only slightly reduced, rates. This gives 
further credence to the concept that immature synapses, newly formed, are recruiting 
PSD-95 in order to fill their PSD to a predetermined quota and thus allow them to 
stabilise. Even if PSD-95 synthesis is dramatically depressed across the neuron, then, 
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these new synapses still continue to synthesise and/or recruit specifically new PSD-
95 at a nearly unaffected rate. This is reminiscent of the all-or-nothing incorporation of 
AMPARs. In this phenomenon, the loss of PSD-95 increases the number of silent 
synapses containing no AMPARs at all, while those synapses that retain an AMPAR 
presence do so at a normal level: they still contain the full complement of receptors 
(Elias et al., 2006; Ehrlich et al., 2007). The result of this effect is that unlike in 
untreated cultures, which display significantly more new PSD-95 in type 2 synapses 
than type 1 synapses, cultures treated with proteasome inhibitors have equal amounts 
of new PSD-95 in type 2 and type 1 synapses.  
 
Finally, another interesting observation is that there is a drastic effect by these 
chemicals on the frequency histogram of pulse:chase ratios in type 2 synapses. This 
is particularly evident when this histogram is compared to the frequency histogram of 
pulse ligand intensities at the 1-hour time point (figure 4.4). Although not definitive, 
this result seems to imply that blocking proteasomal activity affects different synapses 
to differing extents, as otherwise one might expect a histogram that is similar in shape 
to that of the control group after 24 hours (figure 4.42.a), and merely shifted towards 
a greater ratio value. However, the actual result displays not only a shift, but also a 
wholesale alteration of the histogram’s shape.  
 
I do want to reiterate at this point that I used lactacystin at a 10-fold lower concentration 
(1µM) than the standard 10µM used throughout the literature (Hakim et al., 2016; 
Colledge et al., 2003; Ehlers, 2003). This most likely explains the slightly lower effect 
of lactacystin treatment than MG132 treatment. Nevertheless, it drives home the 
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Figure 4.44. The effects of Anisomycin and Cycloheximide on PSD-95 puncta intensities.  
Hippocampal neuronal primary cultures from PSD-95HaloTag/HaloTag mice were grown for 14 days 
in vitro, and thereafter pulse-chase experiments performed using the R110Direct and TMR 
HaloTag ligands. Anisomycin at 1µM or cycloheximide at 3µM were added alongside the chase 
ligand for 1 or 24 hours. The graphs here present the mean values across eight cultures (N=8). 
a. Graph of the average R110 pulse ligand puncta fluorescence intensity following anisomycin 
treatment. APFI is significantly higher after 24 hours in the anisomycin group than in 
untreated controls (Welch’s t-test, p=0.00019). b. Graph of the R110 pulse ligand APFI 
following cycloheximide treatment. APFI is significantly higher after 24 hours in the 
cycloheximide group than in untreated controls (Welch’s t-test, p=3.39x10-5). c. Graph of the 
average TMR chase ligand puncta fluorescence intensity following anisomycin treatment. The 
difference between the anisomycin group and untreated controls is highly significant (Welch’s 
t-test, p=2.41x10-5). d. Graph of the TMR chase ligand APFI following cycloheximide 
treatment. The difference between the cycloheximide group and untreated controls is highly 
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Figure 4.45. The effects of Anisomycin and Cycloheximide on PSD-95 puncta numbers.  
Hippocampal neuronal primary cultures from PSD-95HaloTag/HaloTag mice were grown for 14 days 
in vitro, and thereafter pulse-chase experiments performed using the R110Direct and TMR 
HaloTag ligands. Anisomycin at 1µM or cycloheximide at 3µM were added alongside the chase 
ligand for 1 or 24 hours. The graphs here present the mean values across eight cultures (N=8). 
a. Graph of the average R110 pulse ligand puncta number following anisomycin treatment. 
The number is significantly higher after 24 hours in the anisomycin group than in untreated 
controls (Welch’s t-test, p=0.037). b. Graph of the average R110 pulse ligand puncta number 
following cycloheximide treatment. The number is significantly higher after 24 hours in the 
cycloheximide group than in untreated controls (Welch’s t-test, p=0.0051). c. Graph of the 
average TMR chase ligand puncta number following anisomycin treatment. The difference 
between the anisomycin group and untreated controls is significant (Welch’s t-test, 
p=0.0016). d. Graph of the average TMR chase ligand puncta number following cycloheximide 
treatment. The difference between the cycloheximide group and untreated controls is 

















































































































4.4.6.1 Protein synthesis inhibitors- Anisomycin and Cycloheximide: bulk 
analysis 
 
The final set of chemicals I used in my study were the protein synthesis inhibitors 
anisomycin and cycloheximide. Both are widely used, and have been shown to affect 
memory retention in live mammals. I decided to use these drugs for a similar reason 
as the proteasome inhibitors: I reasoned that blocking protein synthesis would surely 
have a noticeable effect on PSD-95 turnover, and thus provide interesting insights 
while also allowing me to test my HaloTag pulse-chase method in a state of cellular 
perturbation.   
 
One thing to note at this point is that I decided to use anisomycin at a concentration of 
1µM and cycloheximide at 3µM because I discovered that higher concentrations of 
these two drugs (anisomycin: 10µM; cycloheximide: 72µM) for 24 hours cause drastic 
cell death in primary cultures. My initial thought was to use these drugs to completely  
block all protein synthesis and thus prevent any chase ligand signal from being 
detectable, however, after my first pilot experiments I had to settle on reducing protein 
synthesis with lower doses of these two chemicals.  
 
When first looking at the results of the bulk analysis of average puncta fluorescence 
intensity (APFI) for both anisomycin and cycloheximide treated cultures (figure 4.44), 
the first observation is that the graphs look strikingly similar to those of the proteasome 
inhibitor-treated cultures in the previous section (figure 4.33). The APFI of the pulse 
ligand after 24 hours is much higher than in untreated controls (anisomycin: figure 
4.44.a, 61.2 ± 2.39 AU, p=0.00019; cycloheximide: figure 4.44.b, 60.16 ± 1.85 AU, 
p=3.39x10-5; untreated control: 65.97 ± 1.69 AU). Likewise, the APFI of the chase 
ligand after 24 hours is much lower than in untreated controls (anisomycin: figure 
4.44.c, 17.28 ± 0.48 AU, p=2.41x10-5; cycloheximide: figure 4.44.d, 17.05 ± 0.46 AU, 
p=2.22x10-5; untreated control: 29.63 ± 1.42 AU). Somewhat surprisingly, then, these 
two protein synthesis inhibitors appear to not only block the synthesis of new PSD-95, 
but also reduce PSD-95 degradation.  
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The results for bulk puncta numbers (figure 4.45) are, likewise, very similar to those 
obtained from the proteasome inhibitors (figure 4.34). Average pulse ligand puncta 
number per image is higher than in controls for both drugs, while chase ligand puncta 
number is much lower than in controls (figure 4.45, p<0.05).  
 
4.4.6.2 Protein synthesis inhibitors- Anisomycin and Cycloheximide: 
single-synapse analysis 
 
At the next stage of analysis, the similarities to the results obtained from the 
proteasome-inhibitor treatment continue. In figures 4.46 and 4.47 we see that the 
discrepancy between the control group and treatment group is greater in type 2 
synapses than in type 3 synapses in terms of APFI of the pulse ligand. For both 
synaptic types, pulse ligand intensity is a lot higher than in controls. This is the case 
for both anisomycin (figure 4.46.a-b) and cycloheximide (figure 4.47.a-b) treatment. 
The difference between control and treatment fluorescence intensity is highly 
significant in each case (p<5x10-5). For the chase ligand, the results are again 
incredibly similar to those obtained following proteasome inhibition. Figures 4.46 and 
4.47 show that type 2 synapses contain much less new PSD-95 (chase ligand APFI is 
far below controls), while in type 1 synapses the APFI is significantly lower than in 
controls (p<0.05), but much less so. Following anisomycin treatment, for instance, type 
2 synapses exhibit an APFI of 17.10 ± 0.45 AU compared to 34.88 ± 1.91 AU for 
controls (p=2.14x10-5; figure 4.46.d), while type 1 synapses have an APFI of 18.95 ± 
1.26 AU compared to 22.54 ± 1.00 AU for controls (p=0.049, figure 4.46.e). The results 
are nearly identical following cycloheximide treatment (figure 4.47.d-e). Again, type 1 
and type 2 synapses are no different in their chase ligand APFI (figures 4.46.f and 
figure 4.47.f), unlike in controls (figure 4.2.b).  
 
Puncta numbers are again very similar to those under the influence of proteasome 
inhibitors- very many type 3 (pulse ligand-only) synapses are found (figures 4.48.b 
and 4.49.b), with only very few type 2 synapses and barely any type 1 synapses 
(chase-ligand only). These results are made particularly clear by the pie chart in figure 
4.50, as we can see that about 90% of synapses in anisomycin and cycloheximide 
treated groups contain only pulse ligands (old PSD-95), 9% contain both ligands and   
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Figure 4.46. The effect of anisomycin on PSD-95 average puncta intensity at synaptic types.  
Average puncta fluorescence intensity (APFI) per image was calculated for pulse and chase 
ligand labelled synaptic puncta in type 1, type 2 and type 3 synapses separately. Images were 
taken after 24 hours of pulse-chase treatment with 50nM R110Direct ligand (pulse) and 
500nM TMR ligand (chase) in hippocampal primary cultures from PSD-95HaloTag/HaloTag mice on 
DIV16. Anisomycin (1µM) was applied for 24 hours together with the chase ligand between 
DIV15 and DIV16. The graphs here present the mean values across eight cultures (N=8). a. 
Pulse ligand (R110Direct) APFI per image in synapses where pulse and chase ligands colocalise 
(type 2). The difference between the anisomycin group and untreated controls is statistically 
significant (Welch’s t-test, p=4.31x10-7). b. Pulse ligand APFI per image in synapses where 
pulse and chase ligands do not colocalise (type 3). The difference between the anisomycin 
group and untreated controls is statistically significant (Welch’s t-test, 1.76x10-5). c. 
Comparison of pulse ligand APFI per image in type 2 synapses and type 3 synapses following 
anisomycin treatment. The difference between the two groups is statistically significant 
(Welch’s t-test, p=7.15x10-8). d. Chase ligand (TMR) APFI per image in synapses where pulse 
and chase ligands colocalise (type 2). The difference between the anisomycin group and 
untreated controls is statistically significant (Welch’s t-test, p=2.14x10-5). e. Chase ligand APFI 
per image in synapses where pulse and chase ligands do not colocalise (type 1). The difference 
between the anisomycin group and untreated controls is statistically significant (Welch’s t-
test, p=0.049). f. Comparison of chase ligand APFI per image in type 2 synapses and type 1 
synapses following anisomycin treatment. The difference between the two groups is not 
statistically significant (Welch’s t-test, p=0.21).  
 
1% contain only the chase ligand. The conclusions are the same as those arrived at 
for the proteasome inhibitors: both of these classes of drugs massively reduce PSD-
95 synthesis, while appearing to (most likely but not certainly) diminish PSD-95 
degradation. This appears to have the effect of reducing synaptogenesis (fewer type 
1 synapses), and moving synapses that would otherwise have become type 2 
synapses through continuous PSD-95 turnover to become type 3 synapses by not 
incorporating newly synthesised PSD-95.  
 
The graphs depicting the pulse:chase ratio at type 2 synapses appear alike in 
anisomycin and cycloheximide treatment groups (figure 4.53). In both graphs, the 
shape differs greatly from the control group, and is shifted massively towards higher 
ratios. For the anisomycin treatment group, the mean ratio is 12.99 ± 0.32 (SEM) 
(figure 4.53.d), with a median ratio of 13.00 and a mode of 13.2 with 4.12%. For the 
cycloheximide treatment group, the mean ratio is 14.12 ± 0.34 (SEM) (figure 4.53.d), 
with a median ratio of 13.89. The cycloheximide frequency histogram (figure 4.53.c) is 
trimodal, with modes of 11.2, 13.8 and 15.5, all at 3.61%. These graphs have no clear  
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Figure 4.47. The effect of cycloheximid on PSD-95 average puncta intensity at synaptic types 
Average puncta fluorescence intensity (APFI) per image was calculated for pulse and chase 
ligand labelled synaptic puncta in type 1, type 2 and type 3 synapses separately. Images were 
taken after 24 hours of pulse-chase treatment with 50nM R110Direct ligand (pulse) and 
500nM TMR ligand (chase) in hippocampal primary cultures from PSD-95HaloTag/HaloTag mice on 
DIV16. Cycloheximide (3µM) was applied for 24 hours together with the chase ligand between 
DIV15 and DIV16. The graphs here present the mean values across eight cultures (N=8). a. 
Pulse ligand (R110Direct) APFI per image in synapses where pulse and chase ligands colocalise 
(type 2). The difference between the cycloheximide group and untreated controls is 
statistically significant (Welch’s t-test, p=5.82x10-6). b. Pulse ligand APFI per image in synapses 
where pulse and chase ligands do not colocalise (type 3). The difference between the 
cycloheximide group and untreated controls is statistically significant (Welch’s t-test, 7.00x10-
6). c. Comparison of pulse ligand APFI per image in type 2 synapses and type 3 synapses 
following cycloheximide treatment. The difference between the two groups is statistically 
significant (Welch’s t-test, p=4.37x10-6). d. Chase ligand (TMR) APFI per image in synapses 
where pulse and chase ligands colocalise (type 2). The difference between the cycloheximide 
group and untreated controls is statistically significant (Welch’s t-test, p=2.04x10-5). e. Chase 
ligand APFI per image in synapses where pulse and chase ligands do not colocalise (type 1). 
The difference between the cycloheximide group and untreated controls is statistically 
significant (Welch’s t-test, p=0.0019). f. Comparison of chase ligand APFI per image in type 2 
synapses and type 1 synapses following cycloheximide treatment. The difference between 
the two groups is not statistically significant (Welch’s t-test, p=0.31).  
 
peak, and experience a wide range of ratios, ranging from 1.2 to more than 27. Note 
that these protein synthesis inhibitors do appear to have an even more pronounced 
effect than the proteasome inhibitors, as the ratio range has shifted from about 1.8 – 
20 (proteasome inhibitors) to about 1.6 – 27 (synthesis inhibitors).  
 
Next, type 2 synapses still exhibit a positive correlation between pulse and chase 
ligand average puncta intensity (figure 4.54) (anisomycin: R2=0.50; cycloheximide: 
R2=0.62). However, the correlations are less pronounced than in the untreated control 
group (R2=0.96).  
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Figure 4.48. The effect of anisomycin on PSD-95 average puncta number at synaptic types.  
Average puncta number per image was calculated for pulse and chase ligand labelled synaptic 
puncta in type 1, type 2 and type 3 synapses separately. Images were taken after 24 hours of 
pulse-chase treatment with 50nM R110Direct ligand (pulse) and 500nM TMR ligand (chase) 
in hippocampal primary cultures from PSD-95HaloTag/HaloTag mice on DIV16. Anisomycin (1µM) 
was applied for 24 hours together with the chase ligand between DIV15 and DIV16. The 
graphs here present the mean values across eight cultures (N=8).  
a. Pulse ligand average puncta number per image in synapses where pulse and chase ligands 
colocalise (type 2). The difference between the anisomycin group and untreated controls is 
statistically significant (Welch’s t-test, p=0.0015). b. Pulse ligand average puncta number per 
image in synapses where pulse and chase ligands do not colocalise (type 3). The difference 
between the anisomycin group and untreated controls is statistically significant (Welch’s t-
test, p=0.0029). c. Comparison of pulse ligand average puncta number per image in type 2 
synapses and type 3 synapses following anisomycin treatment. The difference between the 
two groups is statistically significant (Welch’s t-test, p=0.0018). d. Chase ligand (TMR) average 
puncta number per image in synapses where pulse and chase ligands colocalise (type 2). The 
difference between the anisomycin group and untreated controls is statistically significant 
(Welch’s t-test, p=0.0014). e. Chase ligand average puncta number per image in synapses 
where pulse and chase ligands do not colocalise (type 1). The difference between the 
anisomycin group and untreated controls is statistically significant (Welch’s t-test, p=0.0030). 
f. Comparison of chase ligand average puncta number per image in type 2 synapses and type 
1 synapses following anisomycin treatment. The difference between the two groups is 
statistically significant (Welch’s t-test, p=0.00036).  
 
Finally, CDF’s were calculated for each of the eight groups (Figures 4.51 and 4.52). 
The resulting curves look similar to those for the previous set of drugs, lactacystin and 
MG132. In these two treatment groups (anisomycin and cycloheximide), type 1 
synapses are very low in frequency, such that the curves look very different to the 
control group. As before, the curves of type 2 and type 3 synapses are shifted- to the 
right for the pulse ligand and the left for the chase ligand. This indicates a greater 
probability of pulse ligand puncta having a higher APFI and reduced probability of 
chase ligand puncta having a high APFI, relative to controls. It is also noteworthy that 
the curves in figure 4.51.a and 4.52.a are steeper for the controls and shallower for 
the treated group. This indicates that the vast majority of the control group puncta are 
of a lower intensity, with very few having a high intensity, but in the case of the drug 
treatment groups the puncta intensities are much more spread, with a substantial 
percentage of puncta found at high intensities. For example, from figure 4.51.a, 90% 
of control puncta have an APFI below 68 AU, while 90% of anisomycin-treated puncta 
have an APFI below 172 AU.  
 234
The only curve found to not be significantly different from the untreated control group 
when tested using the Kolmogorov-Smirnov test for difference was that belonging to 
type 1 synapses when treated with cycloheximide (p=0.606). All other groups were 
found to be significantly different from the control group. This difference is due to the 
high degree of puncta overlap between the treated group and the control group, which 
is also visually discernible.  
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Figure 4.49. The effect of cycloheximide on PSD-95 average puncta number at synaptic 
types.  
Average puncta number per image was calculated for pulse and chase ligand labelled synaptic 
puncta in type 1, type 2 and type 3 synapses separately. Images were taken after 24 hours of 
pulse-chase treatment with 50nM R110Direct ligand (pulse) and 500nM TMR ligand (chase) 
in hippocampal primary cultures from PSD-95HaloTag/HaloTag mice on DIV16. Cycloheximide 
(3µM) was applied for 24 hours together with the chase ligand between DIV15 and DIV16. 
The graphs here present the mean values across eight cultures (N=8). a. Pulse ligand average 
puncta number per image in synapses where pulse and chase ligands colocalise (type 2). The 
difference between the cycloheximide group and untreated controls is statistically significant 
(Welch’s t-test, p=0.0032). b. Pulse ligand average puncta number per image in synapses 
where pulse and chase ligands do not colocalise (type 3). The difference between the 
cycloheximide group and untreated controls is statistically significant (Welch’s t-test, 
p=0.00030). c. Comparison of pulse ligand average puncta number per image in type 2 
synapses and type 3 synapses following cycloheximide treatment. The difference between 
the two groups is statistically significant (Welch’s t-test, p=0.00043). d. Chase ligand (TMR) 
average puncta number per image in synapses where pulse and chase ligands colocalise (type 
2). The difference between the cycloheximide group and untreated controls is statistically 
significant (Welch’s t-test, p=0.0031). e. Chase ligand average puncta number per image in 
synapses where pulse and chase ligands do not colocalise (type 1). The difference between 
the cycloheximide group and untreated controls is statistically significant (Welch’s t-test, 
p=0.0029). f. Comparison of chase ligand average puncta number per image in type 2 
synapses and type 1 synapses following cycloheximide treatment. The difference between 








































Figure 4.50. Proportional representation of synaptic population by HaloTag ligand-labelling 
following the inhibition of protein synthesis.  
Synaptic puncta were categorised according to whether they colocalised with puncta labelled 
by the other ligand or not. This pie chart depicts the proportional representation of the three 
types of synaptic puncta observed. Images were taken after 24 hours of pulse-chase 
treatment with 50nM R110Direct ligand (pulse) and 500nM TMR ligand (chase) in 
hippocampal primary cultures from PSD-95HaloTag/HaloTag mice on DIV16. a. In untreated 
controls, 28% of puncta contain only the pulse (R110Direct) ligand (type 3), 43% of puncta 
contain both pulse and chase (TMR) ligands (type 2), and 29% contain only the chase ligand 
(type 1). b. Following 24 hours of anisomycin treatment (1µM), 91% of puncta contain only 
the pulse (R110Direct) ligand (type 3), 8% of puncta contain both pulse and chase (TMR) 
ligands (type 2), and 1% contain only the chase ligand (type 1). c. Following 24 hours of 
cycloheximide treatment (3µM), 89% of puncta contain only the pulse (R110Direct) ligand 
(type 3), 10% of puncta contain both pulse and chase (TMR) ligands (type 2), and 1% contain 
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c.       d.  
  
Figure 4.51. Cumulative distribution functions of average puncta fluorescence intensity 
following anisomycin treatment.  
CDFs were constructed using the single-synapse data following anisomycin treatment, and 
compared with the untreated control group. Whether the difference was statistically 
significant or not was tested using the Kolmogorov-Smirnov test for difference. a. Comparison 
between R110 ligand puncta in colocalised type 2 synapses of anisomycin-treated neurons 
with those in untreated controls. The difference is significant (Kolmogorov-Smirnov, 
p<0.0001). b. Comparison between R110 ligand puncta in non-colocalised type 3 synapses of 
anisomycin-treated neurons with those in untreated controls. The difference is significant 
(Kolmogorov-Smirnov, p<0.0001). c. Comparison between TMR ligand puncta in colocalised 
type 2 synapses of anisomycin-treated neurons with those in untreated controls. The 
difference is significant (Kolmogorov-Smirnov, p<0.0001). d. Comparison between TMR ligand 
puncta in non-colocalised type 1 synapses of anisomycin-treated neurons with those in 
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Figure 4.52. Cumulative distribution functions of average puncta fluorescence intensity 
following cycloheximide treatment.  
CDFs were constructed using the single-synapse data following cycloheximide treatment, and 
compared with the untreated control group. Whether the difference was statistically 
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between R110 ligand puncta in colocalised type 2 synapses of cycloheximide-treated neurons 
with those in untreated controls. The difference is significant (Kolmogorov-Smirnov, 
p<0.0001). b. Comparison between R110 ligand puncta in non-colocalised type 3 synapses of 
cycloheximide-treated neurons with those in untreated controls. The difference is significant 
(Kolmogorov-Smirnov, p<0.0001). c. Comparison between TMR ligand puncta in colocalised 
type 2 synapses of cycloheximide-treated neurons with those in untreated controls. The 
difference is significant (Kolmogorov-Smirnov, p<0.0001). d. Comparison between TMR ligand 
puncta in non-colocalised type 1 synapses of cycloheximide-treated neurons with those in 
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Figure 4.53. Graphs showing the ratio of pulse to chase ligands at individual type 2 synapses 
following protein synthesis inhibition.  
In the synaptic population in which pulse and chase ligand-labelled PSD-95-HaloTag 
molecules were colocalised (type 2), the ratio of pulse ligand fluorescence intensity to chase 
ligand fluorescence intensity was calculated for each individual synapse. The frequency 
histograms represent the frequencies of all the pulse:chase ratios. a. Frequency distribution 
in untreated controls. Mean ratio: 2.55 ± 0.051 (SEM), Median ratio: 2.06, Mode: 1.8 (8.76%). 
b. Frequency distribution following 24 hours of anisomycin (1µM) treatment. Mean ratio: 
12.99 ± 0.32 (SEM), Median ratio: 13.00, Mode: 13.2 (4.12%). c. Frequency distribution 
following 24 hours of cycloheximide (3µM) treatment. Mean ratio: 14.12 ± 0.34 (SEM), 
Median ratio: 13.89, Modes: 11.2, 13.8, 15.4 (all 3.61%). Note that the graph s trimodal. d. 
Comparison of mean pulse:chase ligand ratio in untreated controls with anisomycin and 
cycloheximide treated cultures. Differences are statistically significant in for both the 
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a.       b.  
  
c.      
 
Figure 4.54 Correlation of pulse ligand intensity with chase ligand intensity at colocalised 
synaptic puncta following protein synthesis inhibition.  
Colocalising (type 2) synapses were sorted by their pulse ligand APFI (lowest to highest). For 
each ten percentile steps, average chase ligand APFI was calculated. a. In untreated controls, 
there is a strong positive correlation, R2=0.96. b. In the lactacystin-treated cultures, there is a 
weak positive correlation, R2=0.50. c. In the MG132-treated cultures, the correlation is also 
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4.4.6.3 Protein synthesis inhibitors- Anisomycin and Cycloheximide: 
discussion 
 
I will limit my discussion of the effects of anisomycin and cycloheximide on PSD-95 
turnover in this section, as the results in this section, chapter 4.4.6, are incredibly 
similar to those obtained using the proteasome inhibitors in chapter 4.4.5. Instead, I 
will focus on trying to explain the phenomena observed in these subchapters based 
upon the evidence and the literature as well as I can in the next subchapter, 4.4.7.  
 
Nevertheless, I will summarise my findings here in order to provide an overview of the 
results obtained. As with proteasome inhibitors, the main observations are:  
 
1. Overall (bulk) pulse ligand APFI remains significantly higher over 24 hours. This 
effect could also be observed at both type 2 and type 3 synapses.  
2. Overall (bulk) chase ligand APFI rises to a much lower level over these 24 
hours. This appears to be mediated chiefly through type 2 and much less so 
type 1 synapses.  
3. Type 1 and type 2 synapses contain equal amounts of new PSD-95, unlike 
untreated controls.  
4. There are significantly fewer type 1 synapses.  
5. There are significantly fewer type 2 synapses. 
6. There are significantly more type 3 synapses.  
7. Within type 2 synapses, the ratio of pulse:chase ligand APFI is skewed strongly 
towards the pulse ligand.    
 
As with proteasome inhibitors, this class of drugs appears to have two effects on PSD-
95: Firstly, more old PSD-95 is retained at synapses. This is most likely due to 
decreased PSD-95 degradation, although replenishment from freely diffusing dendritic 
PSD-95 cannot be ruled out completely. Secondly, less newly-synthesised PSD-95 is 
incorporated into synapses, the obvious explanation being that less PSD-95 is being 
synthesised in the cell. We can therefore conclude that these drugs have two effects: 
one is linked directly to the action of the drug; in this case the inhibition of protein 
synthesis preventing new PSD-95 from being formed. The other is a knock-on effect, 
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here reducing the loss of old PSD-95. All of the other observations, such as changes 
in the balance between synaptic types and in the ratio of pulse to chase ligands in 
mixed-ligand synapses are merely by-products of these two effects. In order to 
underline the significance of the effect of these two classes of drugs on the ratios of 
pulse to chase ligands at type 2 synapses, I have directly compared all of the drug-
treatment groups with each other in terms of these ratios. Figure 4.55 shows just how 
strongly PSD-95 ratios are affected compared to the other treatment groups.  
 
The fact that two groups of drugs with opposing mechanisms of actions have such 
similar outcomes in terms of their effect on both PSD-95 synthesis and degradation is 
something that is very much worth noting, and something that warrants further 
investigation. It implies that both of these drugs have far reaching consequences in 
their use, as they appear to affect not only the target mechanism, but other neuronal 
mechanism as well. Given that both these classes of drugs are very widely used, and 
their apparent secondary effects are not widely reported (particularly those pertaining 
to the protein synthesis inhibitors), it may become necessary to take the knock-on 
effects reported here into account when designing any future experiments involving 
these chemicals.  
 
















Figure 4.55. The ratio of pulse:chase ligands in type 2 synapses is perturbed most strongly 
following treatment with proteasome inhibitors and protein synthesis inhibitors.  
The mean pulse to chase ligand ratio at individual colocalised type 2 synapses was calculated 
for cultures treated with one of a list of drugs (detailed below). Note that ratios were 
calculated for each synapse, and the mean ratio across all synapses calculated. All of these 
treatment groups differed in their mean ratio statistically significantly from untreated 
controls (Welch’s t-test): tetrodotoxin (1µM, p=0.00016), bicuculline (40µM, p=0.0011), BDNF 
(3.7nM, p=0.047), ketamine (10nM, p=7.11x10-14), lactacystin (1µM, p=9.10x10-103), MG132 
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4.4.7 Correction for multiple testing 
 
Throughout this study, statistical significance of the difference between two sets of 
data was evaluated using Welch’s T-test, as outlined in the methods section in chapter 
2. While this does provide an accurate indication, it must be noted that the samples 
from which the results in this drugs-treatment chapter were derived were part of the 
same batch of cells, with the same control group used for each treatment group. This 
means that while all of the treatment groups were not compared with each other, but 
only with the control group, a correction for multiple testing should be considered. In 
this instance, the Bonferroni correction for multiple testing was used. The Bonferroni 
correction divides the required value of P to attain statistical significance (usually 
P=0.05) by the number of times the null hypothesis is tested within a sample. In this 
case, we had one control group and 8 treatment groups. Each treatment group was 
compared once with the control group, making it a total of 8 times that the null 
hypothesis was tested. Thus, the P value that was tested against was 0.05/8 = 
0.00625. Therefore, if P<0.00625 the difference was deemed statistically significant.  
 
When testing all of the results in this chapter with the Bonferroni correction, i.e. when 
using P=0.00625 as the bar for significance, the following five results are affected:  
 
• Ketamine treatment, bulk analysis, pulse ligand (P=0.0091).  
 
• Ketamine treatment, single-synapse analysis, pulse ligand colocalised 
(P=0.0125).  
 
• Ketamine treatment, single-synapse analysis, pulse ligand non-colocalised 
(P=0.0084).  
 
• BDNF treatment, bulk analysis, pulse ligand (P=0.0241).  
 
• BDNF treatment, bulk analysis, chase ligand (P=0.0263).  
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In all five of the above cases, the difference between the treatment group and the 
untreated control group is only statistically significant at a level of P<0.05 but not at 
the level of P<0.00625.  
 
This indicates that in these instances, the chance that the difference between the two 
groups occurred by chance is greater than 5%, due to multiple testing. It is interesting 
to see that all five of the above instances are allocated to two treatment groups: 
ketamine treatment and BDNF treatment. Furthermore, in the case of ketamine 
treatment the bulk analysis of the pulse ligand is in fact made up of the combined 
results of the single-synapse analysis of the pulse ligand that is colocalised and the 
one that is not colocalised. It thus makes sense that if the single-synapse analysis is 
affected by the Bonferroni correction, the associated bulk analysis would too. Similarly, 
the single synapses analysis for both colocalised and non-colocalised puncta in the 
BDNF group (pulse and chase) is not statistically significant, making it unsurprising 
that the associated bulk analysis results are affected by the Bonferroni correction.  
 
This correction for multiple testing does call into question some of the conclusions 
derived earlier in the chapter and may indicate that both ketamine and BDNF treatment 
have no significant impact on synaptic PSD-95 turnover. Nevertheless, since 
treatment groups were not actually compared with each other, but rather each 
separate treatment group with the same control group, in effect making them separate 
experiments, there is a reduced need for a correction for multiple testing. However, it 
is worth bearing these results in mind when interpreting the results from the two 




4.4.8 Subchapter discussion 
 
Overall, the results from this study that analysed the effects of various chemical agents 
upon PSD-95 turnover at synapses were very varied, in some cases yielding startling 
results. Treatment of hippocampal neurons with the activity modulators tetrodotoxin or 
bicuculline for 24 hours was found to only result in a single significant outcome: 
blocking neuronal firing with TTX causes an enhanced retention of old PSD-95 at 
synapses. This does not correlate with some literature that has found TTX to reduce 
synaptic PSD-95 levels (Colledge et al., 2003; Noritake et al., 2009; Kim et al., 2007; 
El-Husseini et al., 2002). However, it does match other literature that indicates that 
higher rates of synaptic activity, particularly NMDAR activation, cause an enhanced 
loss of PSD-95 at synapses by degradation (Colledge et al., 2003) or trafficking out of 
the spine (Sturgill et al., 2009). If neuronal activity is reduced by TTX, then, PSD-95 
may be stabilised at PSDs instead. On the flip side, Ehlers (2003) and Butko et al. 
(2012) found that enhancing excitatory neuronal activity by reducing GABAergic 
inhibition with BCC increased synaptic PSD-95 levels, which Butko and colleagues 
found to be down to enhanced synthesis, while Ehlers did not. My lack of significant 
results following BCC treatment, then, are not unexpected given that there is no clear 
consensus in the field on the effect of enhanced neuronal activity by BCC on PSD-95 
turnover.  
 
BDNF has long been recognised as causing enhanced PSD-95 levels at synapses 
(Hu et al., (2011); Yoshii and Constantine-Paton (2007)), making my result 
unsurprising but matching with previous literature. I find that both old and new PSD-
95 molecules are enriched at synapses following BDNF treatment for 24 hours, 
implying that PSD-95 synthesis is enhanced and old PSD-95 either experiences 
reduced degradation, or enhanced recruitment to synapses. Increased PSD-95 
synthesis has also been observed by Butko et al. (2012), and together these results 
mean that overall synaptic PSD-95 levels are increased by BDNF treatment.  
 
The effect of low-dose ketamine treatment on PSD-95 has so far not been studied 
extensively, but some studies have suggested that it causes enhanced PSD-95 levels 
at synapses in live rodents (Li et al., 2010; Choi et al., 2015; Browne & Lucki, 2013). 
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While I was unable to observe any enhanced synaptogenesis, as has been reported 
by Abdallah et al. (2016), I did measure increased levels of old PSD-95 at synapses. 
This results was found both at type 2 and type 3 synapses. As with BDNF treatment, 
this implies that ketamine may enhance the localisation of PSD-95 at synapses. It may 
further signify that PSD-95 is stabilised at synapses rather than degraded, for instance 
by increasing palmitoylation and thereby preventing its cycling out of the PSD. Since 
ketamine is linked to an enhanced BDNF-release at synapses (Browne & Lucki, 2013), 
it is not unexpected for the two drugs to have a similar effects. Nevertheless, 
ketamine’s effect is restricted to old PSD-95 molecules being enriched at synapses, 
while BDNF also increases new PSD-95 synthesis. Moreover, ketamine’s effect on old 
PSD-95 retention compared to controls is markedly more significant (p=0.0091) than 
that of BDNF (p=0.024). Interestingly, patients with major depressive disorder are 
reported as displaying lower levels of NR2A and NR2B subunits of NMDARs (Feyissa 
et al., 2009), as well as PSD-95, which is required for the formation of 1.5MDa NMDAR 
supercomplexes (Frank et al., 2016). Furthermore, major depression appears to result 
in the internalisation of the GluA1 subunit of AMPARs, and ketamine rapidly increases 
glutamate transmission (Duman et al., 2012). Thus, it is conceivable that ketamine 
exerts its influence to some extent by causing PSD-95 to be enriched at synapses and 
therefore also enhancing glutamate receptor clustering at the PSD. What is particularly 
interesting about these results is that while previous studies have used western blots 
to measure total PSD-95 levels, and were able to observe moderate increases thereof, 
this is the first study to look at PSD-95 expression at the level of synapses of cultured 
hippocampal neurons, and specifically to look at new and old PSD-95 molecules 
separately. This result is certainly of great interest, and worth pursuing further.  
 
The proteasome inhibitors lactacystin and MG132 certainly delivered one of the most 
fascinating sets of results in this study. The literature is somewhat divided on the 
effects of these drugs, in that Hakim et al. (2016) reported no effect at all on PSD-95 
degradation but a strong synthesis blockade following lactacystin treatment. Other 
studies (Tsai et al., 2012; Colledge et al., 2003) have related a reduced level of PSD-
95 degradation by lactacystin and MG132. My study appears to support both of these 
findings: following 24 hours of either lactacystin or MG132 treatment, I find PSD-95 
degradation to be reduced and as well as PSD-95 synthesis to be down-regulated. 
The second set of results that was perhaps even more unexpected came from the 
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protein synthesis inhibitors. Along the same vein as the proteasome inhibitors, the 
protein synthesis blockers anisomycin and cycloheximide not only prevent new PSD-
95 from being synthesised, as one would expect and has been demonstrated in the 
literature (Ennis and Lubin, 1964; Grollman, 1967), but also reduce PSD-95 
degradation. Hakim et al. (2016) propose that the explanation for the reduced 
synthesis following lactacystin application is that blocking the proteasome prevents 
the degradation of misfolded proteins, leading to their accumulation, and thereby 
triggering various stress responses such as the unfolded protein response (UPR). In 
their paper, they explain the fact that they were not able to observe a reduced 
degradation of PSD-95 by postulating that other degradation pathways become active 
when the proteasome is blocked. However, this partially contradicts their theory that 
the cells activate various stress responses (as other proteins would then most likely 
also be degraded by similar alternative pathways), and furthermore, my study was 
able to clearly measure a reduction in PSD-95 degradation since old PSD-95 was 
retained at synapses to a significant extent. I would like to, therefore, propose a 
different explanation for these results and the results obtained using the protein 
synthesis inhibitors anisomycin and cycloheximide.  
 
My proposition would be a mechanisms of proteostasis, wherein synapses attempt to 
keep the levels of certain proteins such as PSD-95 within a certain concentration 
range. In order to attain this goal, the rates of synthesis and degradation of these 
proteins are aligned with these needs. Thus, if there is a surplus of PSD-95 because 
the proteasome has been inhibited and PSD-95 degradation slowed down, PSD-95 
synthesis is also reduced. If a drug blocks protein synthesis and there is a shortage in 
PSD-95, the response causes a reduction in PSD-95 degradation, to prevent 
depletion. We know that both protein synthesis and degradation are strongly regulated 
in neurons, with a coordinated crosstalk between the two systems ensuring that a 
balance is maintained (Alvarez-Castelao and Schuman, 2015). Indeed, this balance 
of protein synthesis and degradation is required for long term memories to form 
(Fonseca et al., 2006). Furthermore, individual proteins can display different half-lives 
in different cellular compartments (Boisvert et al., 2012), implying that turnover of 
individual proteins can be tightly regulated depending on cellular needs and regional 
differences. It seems logical, then, that a neuron would be able to down- or up-regulate 
both the synthesis and degradation rate of a protein such as PSD-95. This mechanism 
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would not necessarily mean that synthesis and degradation are controlled at a single-
synapse level, since it has been well-established that PSD-95 molecules move 
between synapses (Marrs et al., 2001; Sturgill et al., 2009; Zheng et al., 2010; Okabe 
et al., 2001), and synapses can rapidly and directly recruit PSD-95 without relying on 
new synthesis (Gray et al., 2006). Thus, individual synapses may enhance their PSD-
95 levels by trafficking in dendritic PSD-95. However, various post-translational 
modifications of PSD-95 have been described as enhancing its stability at the PSD, 
such as palmitoylation (Fukata et al., 2013) and phosphorylation (Nelson et al., 2013). 
It is thus certainly conceivable that individual synapses are able to control the level of 
PSD-95 palmitoylation and phosphorylation in order to stabilise it at the synapse, or 
conversely to destabilise it if required. My proposed model, then, involves a dynamic 
interplay of tightly controlled PSD-95 synthesis, degradation and cycling in and out of 
the synapse, depending on each synapse’s need. This is mediated through various 
protein-protein interactions, and post-translational modifications, as well as local 
synthesis and degradation at dendritic spines. This model describes a form of 
proteostasis, whereby individual synapses can keep their concentrations of PSD-95 
within a certain range.  
Under normal conditions, synapses may increase or decrease their need for PSD-95 
depending upon the synapse’s level of activity and state of potentiation. A synapse 
undergoing high levels of activity and LTP may recruit new PSD-95 to bolster the PSD-
95 levels in its PSD and meet enhanced structural needs. Indeed, Butko et al. (2012) 
showed that synapses experiencing enhanced activity preferentially incorporate 
newly-synthesised PSD-95. A synapse undergoing long periods of inactivity or LTD 
may destabilise PSD-95 in its PSD and thus cycle some of its PSD-95 out and back 
into the dendrite, to become available for neighbouring synapses, or enhance 
degradation. The majority of the time, this system would most likely be in equilibrium, 
with a further slow background rate of PSD-95 turnover as older proteins are degraded 
and need to be replaced by newly synthesised ones. However, a whole-system 
perturbation such as the application of a protein synthesis inhibitor or proteasome 
blocker may cause a drastic unbalancing. Suddenly, the cell is confronted by a 
widespread shortage or surplus of PSD-95, and needs to meet the changed demands. 
The cell conceivably responds by altering its synthesis or degradation rates, 
depending on the situation. It may be this mechanism that explains the dual effects of 
the synthesis inhibitors and proteasome inhibitors. This model has also already been 
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put forward in the review by Hanus and Schuman (2015) to explain the rapid and more 
long-term changes in synaptic protein turnover that have been observed in various 
studies, and may satisfactorily explain some of the observed phenomena in this study. 
Furthermore, this model has important implications for any studies planning on using 
either of these groups of drugs. The underlying message is clear: altering protein 
synthesis or degradation has strong effects on the proteostatic equilibrium that binds 
these two processes together, and the resulting crosstalk needs to be considered 
when designing experiments.  
 
4.5 Developmental study 
 
4.5.1 PSD-95 turnover in cultures aged DIV28+ 
 
The vast bulk of the work throughout my project was performed on primary cultures 
aged between DIV14 and DIV16. This is a relatively immature stage in neuronal 
development, during which a high level of synaptogenesis is still ongoing (Lesuisse 
and Martin, 2002; Cohen et al., 2013). I therefore wished to compare my results to 
older cultures as well, at a stage when neurons have developmentally matured. For 
this reason, I decided to perform the same analysis as I have done so far, on both bulk 
and single-synapse data, in cultures aged between DIV28 and DIV30. I set up three 
separate hippocampal primary cultures, derived from three different litters of PSD-
95HaloTag/HaloTag (homozygous) embryos aged E17.5 as in previous studies, and allowed 
the neurons to develop normally for 28 days (N=3). On DIV28, I applied the pulse 
ligand (R110Direct, 50nM) as per the standard protocol (see chapter 2.5.6) for 16 
hours. On DIV29, when pulse ligand incubation was complete, most of the neurobasal 
(NB) media was replaced with preconditioned NB media containing the chase ligand 
(TMR), and incubated with this chase ligand (final concentration 500nM). For the 1-
hour time point, chase incubation was kept to 1 hour, after which cells were fixed in 
4% PFA. For all other cells, chase-incubation lasted for 24 hours, and thereafter cells 
were fixed, mounted, imaged and analysed as usual.  
In figure 4.48 I show some example images taken from cultures aged DIV29+. Figure 
4.56.a shows pulse-labelled puncta after the 16-hour pulse incubation and subsequent  
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a.       b.  
  
c.       d.  
  
Figure 4.56. Pulse-chase labelling of mature neuronal primary cultures at DIV29+.  
Example images of pulse-chase labelling in hippocampal primary cultures prepared from PSD-
95HaloTag/HaloTag mice. Cultures were grown on glass coverslips until DIV28, when pulse ligand 
was added for 16 hours (R110Direct, 50nM). On DIV29, chase ligand (TMR, 500nM) was added 
for 1 and 24 hours. After incubation, cells were fixed in 4% PFA, imaged using the LSM510, 
and puncta analysed using the Imaris software. a. Image showing the pulse ligand 
(R110Direct) channel after 1 hour of chase (TMR) incubation. b. Image showing the chase 
ligand (TMR) channel after 1 hour of chase incubation. Note the lack of signal, as HaloTag 
binding sites are saturated by the pulse ligand, preventing chase ligand binding. c. Image 
showing the pulse ligand channel after 24 hours of chase incubation. d. Image showing the 
chase ligand channel after 24 hours of chase incubation. Note the presence of TMR-labelled 
puncta, as new PSD-95-HaloTag proteins have been synthesised over the 24 hours, and these 





1-hour chase incubation (DIV29). As in previous experiments in immature neurons, 
the pulse ligand signal is very strong. In contrast, no chase ligand signal is visible at 
this time point at all (figure 4.56.b). 24 hours later (DIV30), pulse ligand puncta are still 
very clearly visible (figure 4.56.c). However, chase ligand puncta have now begun to 
appear as well (figure 4.56.d).  
 
In figure 4.57 I compare the bulk APFI of cultures at DIV29-30 with the results for 
cultures aged between DIV15-16. From the graph in figure 4.57.a we can first observe 
that the APFI for the pulse ligand at the 1-hour time point is slightly higher at DIV29 
(72.45 ± 3.32 AU) than at DIV15 (65.97 ± 1.69 AU), but this difference is not statistically 
significant (Welch’s t-test, p=0.15). After 24 hours, however, we can observe a marked 
difference between neurons aged DIV16 and DIV30. Pulse ligand APFI at DIV30 is 
significantly higher at this time point (60.90 ± 4.13 AU) than at DIV16 (41.44 ± 0.85 
AU). Here, the difference is statistically significant (p=0.016). What is also interesting 
to note is that for the older (DIV29+) neurons, the difference in APFI of the pulse ligand 
is not much different between DIV29 (1-hour time point) and DIV30 (24-hour time 
point). While APFI has gone down, the difference is not statistically significant 
(p=0.074).  
 
Next, in figure 4.57.b we can see chase ligand APFI at the 24-hour time point. While 
the intensity is slightly higher at DIV30 (34.88 ± 2.48 AU) than at DIV16 (29.63 ± 1.42 
AU), this difference is not statistically significant (p=0.12).  
 
Looking at puncta numbers, we can first see that there are a lot more synaptic puncta 
at the 1-hour time point in older cultures than younger ones (figure 4.57.c, 601.77 ± 
76.85 puncta per image at DIV29 compared to 406.16 ± 76.57 puncta per image at 
DIV15). However, due to the great variability this difference is not statistically 
significant (Welch’s t-test, p=0.097). At the 24-hour time point, we can see that the 
pulse ligand puncta number has not gone down by much in older cultures (down to an 
average of 536.77 ± 37.34 puncta per image, p>0.05, figure 4.57.c), while it has gone 
down significantly for young cultures (down to an average of 189.15 ± 26.64 puncta 
per image, figure 4.57.c). The difference between these values is statistically highly 
significant (p=0.00024). The number of chase-ligand labelled puncta at the 24-hour 
time point (figure 4.57.d) is also significantly higher at DIV30 than DIV16 (p=0.0078).  
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Figure 4.57. PSD-95 puncta intensities and numbers in cultures at DIV15+ and DIV29+.  
Hippocampal neuronal primary cultures from PSD-95HaloTag/HaloTag mice were grown on glass 
coverslips for 14 days and 28 days. At DIV14 and DIV28, cultures were incubated with the 
pulse ligand (R110Direct, 50nM) for 16 hours. Thereafter, cultures were incubated with the 
chase ligand (TMR, 500nM) for 1 hour and 24 hours. Average puncta fluorescence intensity 
(APFI) and number per image were then calculated. This was performed across eight different 
cultures (N=8) for the control group and three different cultures at DIV29+ (N=3). The graphs 
here present the mean values across these cultures. a. Graph of the R110 pulse ligand APFI. 
At the 1-hour time point, the difference between cultures aged DIV15 and DIV29 is not 






















































































































cultures aged DIV15 and DIV29 is statistically significant (p=0.016). The difference within the 
DIV15+ group between the 1-hour and the 24-hour time points is significant (p=9.51x10-8). 
However, the difference within the DIV29+ group between the 1-hour and the 24-hour time 
points is not significant (p=0.074). b. Graph of the average TMR chase ligand APFI after 24 
hours of chase incubation. APFI is not significantly different between cultures aged DIV16 and 
DIV30 (Welch’s t-test, p=0.12). c. Graph of the average R110 pulse ligand puncta number. In 
the DIV15+ group, pulse ligand puncta number goes down significantly over the 24 hours 
(Welch’s t-test, p=0.002). In the DIV29+ group this difference between puncta number at the 
1-hour time point and the 24-hour time point is not significant (p=0.49). However, pulse 
ligand puncta number at the 24-hour time point differs significantly between cultures in the 
DIV15+ group and the DIV29+ group (p=0.00024). The two groups do not differ significantly 
at the 1-hour time point (p=0.097). d. Graph of the average TMR chase ligand puncta number 
after 24 hours of chase incubation. Puncta number is significantly different between cultures 
aged DIV16 and DIV30 (Welch’s t-test, p=0.0078).  
 
Looking at synaptic types, the overall picture that emerges is that the changes that the 
different synaptic types undergo between DIV29 and DIV30 in terms of the overall 
trend are very similar to those between DIV15 and DIV16. However, the absolute 
values do in some instances differ significantly between older and younger cultures. 
Furthermore, while the results of the younger synapses are based upon a sample size 
of N=8, the older cultures only have an N=3 sample size. This has the effect of making 
differences in values less statistically significant. For instance, there is a difference in 
pulse ligand APFI between type 2 (colocalised) and type 3 (non-colocalised) synapses 
for cultures at DIV30 (figure 4.58.c) and DIV16 (figure 4.2.b). However, this difference 
is not significant at DIV30 (p=0.21) while it is significant at DIV16 (p=9.01x10-7).  
 
Regarding average puncta fluorescence intensity (APFI), cultures at DIV30 have a 
higher value for both pulse and chase ligands at type 1, type 2 and type 3 synapses 
(i.e. in all cases; see figure 4.58). However, the difference between cultures aged 
DIV30 and DIV16 is not statistically significant in any of these cases (p>0.05).  
 
Puncta number results need to be treated with caution, as there are significantly more 
synaptic puncta per image overall at DIV30 than DIV16. Thus, results with a greater 
absolute number of synaptic puncta at DIV30 than DIV16 in individual types of 
synapses give no valuable information. However, there is one interesting point to be 
made: at DIV16, the difference in chase-labelled puncta number is not significant 
between type 2 (colocalised) and type 1 (non-colocalised) synapses (figure 4.2.d, 
p=0.17). However, at DIV30 there are significantly fewer type 1 synapses than type 2  
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Figure 4.58. The effect of age on PSD-95 average puncta intensity at different synaptic types 
in primary cultures.  
Average puncta fluorescence intensity (APFI) per image was calculated for pulse and chase 
ligand labelled synaptic puncta in type 1, type 2 and type 3 synapses separately. Images were 
taken after 24 hours of pulse-chase treatment with 50nM R110Direct ligand (pulse) and 
500nM TMR ligand (chase) in hippocampal primary cultures from PSD-95HaloTag/HaloTag mice. 
Experiments were started (pulse incubation) either at DIV14 or DIV28. This was performed 
across eight different cultures (N=8) for the control group and three different cultures at 
DIV29+ (N=3). The graphs here present the mean values across these cultures. a. Pulse ligand 
(R110Direct) APFI per image in synapses where pulse and chase ligands colocalise (type 2). 
The difference between cultures aged DIV16 and DIV30 is not statistically significant (Welch’s 
t-test, p=0.12). b. Pulse ligand APFI per image in synapses where pulse and chase ligands do 
not colocalise (type 3). The difference between cultures aged DIV16 and DIV30 is not 
statistically significant (Welch’s t-test, p=0.078).  
c. Comparison of pulse ligand APFI per image in type 2 synapses and type 3 synapses in 
cultures aged DIV30. The difference between the two groups is not statistically significant 
(Welch’s t-test, p=0.21). d. Chase ligand (TMR) APFI per image in synapses where pulse and 
chase ligands colocalise (type 2). The difference between cultures aged DIV16 and DIV30 is 
not statistically significant (Welch’s t-test, p=0.32). e. Chase ligand APFI per image in synapses 
where pulse and chase ligands do not colocalise (type 1). The difference between cultures 
aged DIV16 and DIV30 is not statistically significant (Welch’s t-test, p=0.094).  
f. Comparison of chase ligand APFI per image in type 2 synapses and type 3 synapses in 
cultures aged DIV30. The difference between the two groups is not statistically significant 
(Welch’s t-test, p=0.15).  
 
synapses, even though the sample size is smaller (figure 4.59.f, p=0.027). This 
indicates that fewer new synapses are being formed between DIV29 and DIV30 than 
between DIV15 and DIV16; a result consistent with a reduced level of synaptogenesis 
in older neurons. This result is further supported by figure 4.60.b, where we can see 
that at DIV30 only 16% of synapses are chase-only type 1 synapses, while 48% are 
colocalised type 2 synapses and 36% are pulse-only type 3 synapses. At DIV16 (figure 
4.60.a), in contrast, we see that the percentage of type 1 synapses is nearly double 
that of DIV30, at 29%. The conclusion from these results, therefore, must be that 
synaptogenesis is reduced in older cultures compared to younger ones.  
 
Figure 4.61 shows the frequency distribution histograms over the range of average 
puncta fluorescence intensities for pulse-ligand puncta at the 1-hour time point. We 
can see from the shapes of the two graphs that cultures at DIV15 (figure 4.61.a) and 
DIV29 (figure 4.61.b) have very similar distributions. Both show a positive skew, with 
similarly steep curves. At DIV29 the peak is slightly higher (48 AU) than at DIV15  
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Figure 4.59. The effect of age on PSD-95 average puncta number at different synaptic types 
in primary cultures.  
Average puncta number per image was calculated for pulse and chase ligand labelled synaptic 
puncta in type 1, type 2 and type 3 synapses separately. Images were taken after 24 hours of 
pulse-chase treatment with 50nM R110Direct ligand (pulse) and 500nM TMR ligand (chase) 
in hippocampal primary cultures from PSD-95HaloTag/HaloTag mice. Experiments were started 
(pulse incubation) either at DIV14 or DIV28. This was performed across eight different 
cultures (N=8) for the control group and three different cultures at DIV29+ (N=3). The graphs 
here present the mean values across these cultures. a. Pulse ligand (R110Direct) average 
puncta number per image in synapses where pulse and chase ligands colocalise (type 2). The 
difference between cultures aged DIV16 and DIV30 is statistically significant (Welch’s t-test, 
p=0.016). b. Pulse ligand average puncta number per image in synapses where pulse and 
chase ligands do not colocalise (type 3). The difference between cultures aged DIV16 and 
DIV30 is not statistically significant (Welch’s t-test, p=0.14). c. Comparison of pulse ligand 
average puncta number per image in type 2 synapses and type 3 synapses in cultures aged 
DIV30. The difference between the two groups is not statistically significant (Welch’s t-test, 
p=0.36). d. Chase ligand (TMR) average puncta number per image in synapses where pulse 
and chase ligands colocalise (type 2). The difference between cultures aged DIV16 and DIV30 
is statistically significant (Welch’s t-test, p=0.016). e. Chase ligand average puncta number per 
image in synapses where pulse and chase ligands do not colocalise (type 1). The difference 
between cultures aged DIV16 and DIV30 is not statistically significant (Welch’s t-test, p=0.62). 
f. Comparison of chase ligand average puncta number per image in type 2 synapses and type 
3 synapses in cultures aged DIV30. The difference between the two groups is statistically 
significant (Welch’s t-test, p=0.027).  
 
(42 AU), which is probably due in part to the reduced amount of synaptogenesis and 
thus presence of fewer small, immature synapses.  
 
The final aspect of the results section for this study looks at the ratios between pulse 
and chase ligands at type 2 synapses, after 24 hours. From figure 4.62.b we can see 
that type 2 synapses at DIV30 are slightly more heterogeneous than at DIV16 (figure 
4.62.a), as the graph’s slopes are even more shallow, with a gentler peak that is also 
lower (5.15% compared to 8.76%). The mean ratio (3.42 ± 0.028) is higher, as is the 
median ratio (2.89), than at DIV16 (mean: 2.55 ± 0.051; median: 2.06) (figure 4.62.c). 
Colocalised type 2 synapses, then, contain a greater proportion of old PSD-95 at 
DIV30 than at DIV16. The explanation for this is most likely that type 2 synapses at 
DIV16 are still less mature, and therefore recruiting more newly-synthesised PSD-95, 
than at DIV30.  
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Finally, I find that the positive correlation between pulse and chase ligand intensity, 
when type 2 synapses grouped by pulse ligand APFI percentile, remains strongly 





Figure 4.60. Proportional representation of synaptic population by HaloTag ligand-labelling 
at different developmental stages.  
Synaptic puncta were categorised according to whether they colocalised with puncta labelled 
by the other ligand or not. This pie chart depicts the proportional representation of the three 
types of synaptic puncta observed.  
Images were taken after 24 hours of pulse-chase treatment with 50nM R110Direct ligand 
(pulse) and 500nM TMR ligand (chase) in hippocampal primary cultures from PSD-
95HaloTag/HaloTag mice. Cultures were ages DIV16 or DIV30 at the time of data collection.  
a. At DIV16, 28% of puncta contain only the pulse (R110Direct) ligand (type 3), 43% of puncta 
contain both pulse and chase (TMR) ligands (type 2), and 29% contain only the chase ligand 
(type 1). b. At DIV30, 36% of puncta contain only the pulse (R110Direct) ligand (type 3), 48% 
of puncta contain both pulse and chase (TMR) ligands (type 2), and 16% contain only the chase 























a.       b.  
  
Figure 4.61. Frequency distribution histograms of synaptic puncta labelled with the pulse 
ligand at different developmental stages.  
The histograms depict the full range of average puncta fluorescence intensities of pulse ligand 
puncta after 16 hours of incubation with the pulse ligand (R110Direct, 50nM), and 1 hour of 
incubation with the chase ligand (TMR, 500nM). a. At DIV15, the histograms reveals a positive 
skew and heterogenous synaptic population in terms of PSD-95 expression levels. Mean 
intensity is 65.97 ± 1.69 arbitrary units (AU), with median intensity being 54.94 AU and the 
mode being 42 AU (3.79% of puncta). b. At DIV29, the histograms also shows a positive skew 
and heterogenous synaptic PSD-95 population. Mean intensity is 72.45 ± 3.32 AU, with 
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a.       b.  
  
c.       d.  
  
Figure 4.62. Graphs showing the ratio of pulse to chase ligands at individual type 2 synapses 
at different developmental stages.  
In the synaptic population in which pulse and chase ligand-labelled PSD-95-HaloTag 
molecules were colocalised (type 2), the ratio of pulse ligand fluorescence intensity to chase 
ligand fluorescence intensity was calculated for each individual synapse. The frequency 
histograms represent the frequencies of all the pulse:chase ratios. a. Frequency distribution 
at DIV16. Mean ratio: 2.55 ± 0.051 (SEM), Median ratio: 2.06, Mode: 1.8 (8.76%). b. Frequency 
distribution at DIV30. Mean ratio: 3.42 ± 0.028 (SEM), Median ratio: 2.89, Mode: 2.6 (5.15%). 
c. Comparison of mean pulse:chase ligand ratio in cultures aged DIV16 and DIV30. The 
difference is statistically significant (Welch’s t-test, p=9.24x10-48). d. Colocalising (type 2) 
synapses were sorted by their pulse ligand APFI (lowest to highest). For each ten percentile 
steps, average chase ligand APFI was calculated. At DIV30, there is a strong positivie 
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4.5.2 Discussion of developmental study 
 
There are a few major findings from this study that stand out particularly. The main 
observations are:  
 
1. The loss of pulse ligand signal over 24 hours appears to be much smaller 
between DIV29 and DIV30 compared to that between DIV15 and DIV16. This 
effect is so pronounced that there is in fact no significant difference in the 
DIV29+ group between pulse ligand APFI at the 1-hour and 24-hour time points 
(figure 4.57.a).  
 
2. There is a significantly reduced number of type 1 synapses at DIV30 compared 
to DIV16. We can observe this in two different figures: Firstly, figure 4.59.f 
shows us that there are significantly fewer type 1 synapses than type 2 
synapses at DIV30, while at DIV16 this difference is not significant (figure 
4.2.d). Secondly, figure 4.60 illustrates nicely that the proportion of synapses 
that belong to type 1 has shrunk dramatically at DIV30 compared to DIV16.  
 
3. The other finding is that apart from the two points mentioned above, most other 
results are remarkably similar in the two experimental groups. While some 
absolute numbers do differ between the two groups, particularly regarding 
puncta numbers, these results must be seen in the context of the larger total 
number of synapses at DIV30 than DIV16. However, the frequency histograms 
are, for instance, remarkably similar between the two groups.  
 
Working upwards, point number 3 indicates that while neuronal primary cultures may 
overall be more mature at around 4 weeks after plating down than around 2 weeks 
after plating, the general characteristics of these synaptic populations are 
nevertheless similar. Synapses are clearly very heterogenous in terms of their average 
puncta fluorescence intensity at both developmental stages, indicating that even 
among mature synapses, there appears to be a wide range in terms of PSD-95 
expression. Most type 2 synapses at DIV16 are also very similar to type 2 synapses 
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at DIV30, for instance in terms of their ratio of pulse to chase ligand intensity. The 
main difference in these synapses appears to be the rate of PSD-95 turnover.  
 
Point number 2 is an unsurprising and expected observation. Since it is known that 
synaptogenesis takes place mainly throughout the first 3 weeks after primary neurons 
are plated down, and slows down thereafter (Lesuisse and Martin, 2002; Cohen et al., 
2013), it is to be expected that there would be a lower number of type 1 synapses that 
contain purely newly-synthesised PSD-95 at DIV30 than DIV16. This simply reflects 
reduced synaptogenesis in mature cultures. What is more surprising is that there are 
more type 3 synapses, i.e. synapses that contain solely old but no new PSD-95 at all. 
In chapter 4.3.3 it was postulated that these synapses may not be incorporating new 
PSD-95 as they are perhaps in the process of being pruned away, or that they are in 
the process of turning into ‘silent’ or ‘quiet’ synapses with a very slow rate of PSD-95 
turnover. There is no biological explanation as to why there should be greater rates of 
synaptic pruning in 4-week old cultures than 2-week old cultures, particularly since 
synaptogenesis is reduced. It is also possible that these synapses are replacing 
degraded PSD-95 from dendritic PSD-95, diffusing between spines. However, a more 
likely explanation is that these synapses simply turn over PSD-95 at a very slow rate, 
if at all, and perhaps newly-synthesised PSD-95 in these synapses is so small in 
number that is falls below the detection parameters set on the Imaris software. It is, 
ultimately, another piece of evidence for there being a great discrepancy in PSD-95 
turnover rates between individual synapses, with some synapses experiencing high 
and others low rates of PSD-95 turnover. Likely, this is simply linked to lower levels of 
activity in these synapses (Hruska et al., 2015). Nevertheless, this observation further 
enhances the mystery surrounding type 3 synapses, and their rate of PSD-95. Clearly, 
this type of synapse will require further investigation.  
 
The final point of observation is the most interesting and perhaps surprising one. The 
fact that pulse ligand intensity does not significantly go down over 24 hours strongly 
indicates that the PSD-95 degradation rate slows down at this developmental stage. 
Indeed, this may be linked to the increase in type 3 synapse numbers. When 
calculating PSD-95 half-life using these new values, a half-life of 95.79 hours is 
obtained. This is of course vastly greater than the 35.78 hours obtained at DIV16. 
While the ~36-hour result for PSD-95 half-life at DIV16 matches that found in the 
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literature (>36 hours, El-Husseini et al., 2002; >24 hours, Todd et al., 2003), all of 
these results also used younger primary cultures, between DIV14 and DIV21. 
However, a study by Cohen at al. (2013) found a PSD-95 half-life value of 88 hours, 
significantly closer to my result of ~96 hours at mature cultures. In that study, the 
method used was SILAC, but with a greatly enhanced labelling period (7 days). 
However, a study conducted in live, 9-week old mice using stable isotope labelling of 
mammals (SILAM) yielded a half-life of 367 hours (Price et al., 2010). While this 
primarily implies a difference between protein turnover in cultures and live animals, it 
may also be that the developmental stage has a significant impact on the result. 
Indeed, a study by Mammen et al. (1997) has shown that the half-life of another 
synaptic protein, GluR1, differs significantly between neuronal cultures at DIV11 and 
younger cultures at DIV4. My results for the culture at DIV30 are restricted to three 
biological replicates, however, limiting the scope of interpretation of these results. 
Nevertheless, there appears to be a clear indication that PSD-95 experiences 
developmental shifts in its rate of turnover.  
 
4.6 Chapter conclusion 
 
In chapter 3, I introduced the PSD-95HaloTag KI mouse line and presented the data to 
establish this mouse as a viable tool for the study of SPD-95 turnover. I then set about 
presenting a pulse-chase method with which I am able to measure the turnover of 
PSD-95 in hippocampal primary cultures, and performed a basic experiment, allowing 
me to work out PSD-95 half-life. In this chapter, I have taken these basic tools and 
used them to deepen my understanding of PSD-95 turnover from a bulk to a single-
synapse level. In doing so I was able to categorise synapses into three different types, 
according to their PSD-95 expression profile. By splitting synapses up based on 
whether they express only old, only new or both old and new PSD-95, I could analyse 
these subgroups separately. Furthermore, I was able to calculate and plot frequency 
histograms of ratios of pulse to chase ligands within individual synapses that 
expressed both, as well as plotting frequency histograms of average puncta 
fluorescence intensities in different synaptic types.  
 
 268
From this data I was able to conclude that type 2 synapses, containing both old and 
new PSD-95, are most likely mature and stable synapses that continuously turn over 
PSD-95, experience high rates of activity, and therefore contain not only the greatest 
amount of PSD-95 overall, but also more old and more new PSD-95 than type 1 and 
type 3 synapses. This finding was consistent throughout all of my experiments, in 
untreated cultures, cultures treated with various chemical agents, and also in older 
cultures around DIV30.  
 
Type 1 synapses are almost certainly immature synapses that have recently formed 
via synaptogenesis and are in the process of establishing PSDs and incorporating 
essential proteins such as PSD-95. The fact that they only contain new PSD-95 makes 
sense in this context of immaturity (Butko et al., 2012). Their intensity frequency 
histogram fits this explanation, as it is skewed towards lower average fluorescence 
intensities, and perhaps most indicative is the finding that these synapses are reduced 
in frequency in mature cultures around DIV30, a time known to experience lower rates 
of synaptogenesis than younger cultures. To probe into this further, it would perhaps 
be interesting to stain for presynaptic vesicle markers, and correlate these markers 
with synaptic types. Butko et al. (2012) found that immature synapses containing 
newly synthesised PSD-95 were opposed to presynaptic active zones with very few 
neurotransmitter vesicles. This, then, may be a further avenue of approach to clarify 
the identity of type 1 synapses with greater certainty.  
 
Type 3 synapses are older synapses that exclusively contain old PSD-95 (pulse-
labelled), but no new PSD-95. This type of synapses is the most difficult to interpret. 
They contain less old PSD-95 than do type 2 synapses, and their lack of new PSD-95 
implies that PSD-95 turnover in these synapses may be drastically reduced compared 
to other synapses. A study by Ehrlich et al. (2007) postulates that PSD-95 is necessary 
for structural changes in synapses to be able to take place following LTP and LTD. 
They show that transient changes in PSD-95 at synapses causes a bidirectional 
modification of synaptic transmission and spine morphology. If changes in synaptic 
strength cause changes in PSD-95, it seems intuitive that a lack of change in PSD-95 
levels may be an indicator of no change in strength occurring at such synapses. 
Furthermore, a weakening of a given synapse may lead to the loss of PSD-95, without 
any concomitant gain to replace lost molecules. Such synapses, then, would contain 
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a reduced amount of old PSD-95, but no new PSD-95. This is precisely what we seen 
in type 3 synapses: lower levels of old PSD-95 than in type 2 synapses, with no new 
PSD-95 present. We also see an increase in the number of such type 3 synapses in 
older cultures (DIV30), when we might expect synaptic strength to be undergoing less 
flux than at an earlier developmental stage, and indeed the number of synapses being 
strengthened (type 2 synapses, to some extent) may be closer to the number that are 
simultaneously being weakened than in immature neurons, where net synaptic change 
may tend towards a strengthening. Thus, it seems that type 3 synapses are synapses 
undergoing a weakening of synaptic transmission or no change at all. Indeed, they 
may be transitioning towards a ‘silent’ state, in which a synapse expresses no AMPA 
receptors and most likely no PSD-95 (Huang et al., 2015; Béı ̈que et al., 2006). 
However, since silent synapses have been associated with an immature synaptic 
state, this is less likely than the explanation of a simple reduction in synaptic strength.  
 
The study involving the application of various drugs to the primary cultures during the 
24-hour chase period yielded a variety of interesting results. The direct neuronal 
activity modulators TTX and BCC did not appear to affect PSD-95 turnover markedly, 
although TTX did enhance the retention of old PSD-95 at synapses. BDNF treatment 
raised overall synaptic PSD-95 levels, affecting both synthesis and degradation rates. 
Ketamine treatment appeared to retain more old PSD-95 at synapses, which is 
indicative of enhanced PSD-95 cycling into synapses from dendrites or reduced PSD-
95 degradation.  
 
The proteasome inhibitors lactacystin and MG132, along with the protein synthesis 
inhibitors anisomycin and cycloheximide, had the strongest impact upon PSD-95 
turnover. Both classes of drugs affected PSD-95 synthesis and degradation to a 
similar degree, surprisingly, leading me to put forward a theoretical proteostatic 
mechanism. This mechanism postulates that protein synthesis and degradation are 
tightly interconnected and balanced mechanisms, at least for certain crucial synaptic 
proteins such as PSD-95. Synapses aim to retain PSD-95 levels within certain 
concentration ranges, and if PSD-95 levels are skewed in any way, for instance by a 
drug, the neuron responds by modulating PSD-95 synthesis or degradation in order to 
match synaptic demand in a homeostatic response.  
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Finally, it appears that PSD-95 turnover in older cultures differs significantly from 
turnover rates at an earlier developmental stage. In my study I find PSD-95 half-life 
significantly increased at DIV30 compared to DIV16, and I am also able to observe a 
significant reduction in synaptogenesis in older cultures.  
 
Overall, then, the pulse-chase protocol using the HaloTag system in a PSD-95HaloTag 
KI mouse line appears well-suited for the study of the turnover of PSD-95 at synapses. 
The method displays clear strengths compared to other methods used to evaluate 
protein turnover, such as SILAC or FRAP. It is very versatile, allowing for bulk analysis 
as well as single-synapse analysis and the differential labelling of ‘old’ and ‘new’ 
subpopulations of the same protein. This last point, particularly, lets it stand out as a 
technique, as not only can these two subpopulations of the same protein be analysed 
separately, but also in a complementary fashion when looking at ratios of both types 
within single synapses. Some of the weaknesses of the study, such as being unable 
to definitively separate protein degradation from diffusion out of individual synapses, 
and being unable to measure total PSD-95 levels, can be solved by modifying the 
experimental approach. Using a single-ligand labelling protocol to supplement the 
pulse-chase labelling would allow for the monitoring of changes of total PSD-95 levels 
at synapses. Performing western blots on some of the cultures would have given 
further evidence of total PSD-95 changes in cells or synapses (using synaptosome 
preparations). Indeed, the fact that HaloTag ligands can bind to HaloTag fusion 
proteins within cell lysate, withstand boiling in SDS, and are highly quantitative without 
requiring an antibody staining makes this another interesting method of analysing 
changes in PSD-95 levels. Finally, a live-cell imaging approach would allow for the 
visualisation of PSD-95 dynamics, including mobility, synthesis and degradation, in 






Chapter 5: Conclusion 
 
 
5.1 Summary of findings 
5.1.1 PSD-95-HaloTag knock-in mice are phenotypically normal 
5.1.2 HaloTag ligands used in a pulse-chase paradigm to investigate PSD-95 
turnover 
5.1.3 Categorising synapses according to PSD-95 turnover profiles 
5.1.4 The effects of activity modulation on PSD-95 turnover 
5.1.5 The effects of BDNF treatment on PSD-95 turnover 
5.1.6 The effects of ketamine treatment on PSD-95 turnover 
5.1.7 The effects of proteasome inhibition on PSD-95 turnover 
5.1.8 The effects of protein synthesis inhibition on PSD-95 turnover 
5.1.9 PSD-95 turnover at different developmental ages 
5.2 Methodological considerations 
5.3 Critiques and improvements 


















5.1 Summary of findings 
 
5.1.1 PSD-95-HaloTag knock-in mice are phenotypically normal 
 
The results in chapter 3.2.1 indicate by SDS PAGE that PSD-95 levels in PSD-95-
HaloTag mice are not significantly different from WT mice. It is also demonstrated that 
PSD-95-HaloTag fusion proteins localise to 1.5MDa supercomplexes, just like WT 
mice (chapter 3.2.2). Chapter 3.2.3 demonstrates that PSD-95-HaloTag mice are 
electrophysiologically normal. Brain slices prepared from het PSD-95-HaloTag mice 
also show that PSD-95 expression levels display a normal patterning when stained 
with HaloTag ligands (chapter 3.3.2). Primary cultures from PSD-95-HaloTag mice 
display a clear punctate staining at dendritic synapses when immunocytochemically 
stained for PSD-95 (chapters 3.3.3-5). Overall, it can be concluded that PSD-95-
HaloTag KI mice are phenotypically normal as they express normal levels of PSD-95 
and display a normal localisation of PSD-95 in the brain, to synapses and into 
postsynaptic supercomplexes.  
 
5.1.2 HaloTag ligands used in a pulse-chase paradigm to investigate 
PSD-95 turnover 
 
First, in chapter 3.3, it is demonstrated that the HaloTag technology can be used to 
visualise PSD-95-HaloTag fusion proteins in a primary culture setting. This is done by 
establishing that fluorescent HaloTag ligand puncta in primary cultures colocalise with 
anti-PSD-95 antibody staining, are opposed by presynaptic markers, and are located 
along dendrites stained for MAP2, as well as being absent in WT mice. Next, it was 
found that the TMR and R110Direct HaloTag ligands used in my experiments are 
fluorescently stable over 24 hours in cells kept in cell culture incubators for 24 hours, 
and proven that labelling cells with one ligand saturates all HaloTag binding sites, 
preventing the binding of a second ligand. A pulse-chase method by which it is 
possible to separately label previously-present (‘old’) and newly synthesized PSD-95 
with two different fluorescent ligands was then established, allowing for the separate 
analysis and monitoring of subpopulations of the same target protein. Thus, it is found 
that over 48 hours, between DIV15 and DIV17, old PSD-95 is steadily degraded and 
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new PSD-95 is synthesized and incorporated into synapses. PSD-95 half-life is 
calculated to be approximately 36 hours, in line with some previous literature (El-
Husseini et al., 2002).  
 
5.1.3 Categorising synapses according to PSD-95 turnover profiles 
 
In chapter 4.3, PSD-95 turnover at single synapses is analysed. Synapses are 
castegorised into three types: type 1 synapses contain only newly synthesised PSD-
95, type 2 synapses contain both new and old PSD-95, and type 3 synapses contain 
only old PSD-95. This means that synapses have different rates of PSD-95 turnover, 
which is evident when looking at the synaptic population that was present throughout 
the entire experiment (type 2 and type 3 synapses): type 3 synapses clearly 
experience no new PSD-95 synthesis, while type 2 synapses do.  
It is found that at DIV16, the majority of synapses are type 2 synapses. It is further 
found that on average, type 2 synapses contain both more old and more new PSD-95 
than either type 1 or type 2 synapses. Finally, it is found that type 2 synapses are very 
heterogeneous, both in terms of their total PSD-95 expression level and in terms of 
their ratio of old to new PSD-95 expression.  
 
5.1.4 The effects of activity modulation on PSD-95 turnover 
 
PSD-95 turnover in the presence of either tetrodotoxin (TTX) or bicuculline (BCC) is 
analysed. The results indicate that slightly but significantly more old PSD-95 is 
retained at synapses than in untreated controls following 24 hours of TTX treatment, 
while synthesis remains unchanged, indicating a slight increase in synaptic PSD-95. 
However, none of the other results differed significantly from untreated controls.  
 
5.1.5 The effects of BDNF treatment on PSD-95 turnover 
 
Following 24 hours of BDNF treatment, it is found that slightly but significantly more 
old PSD-95 is retained at synapses than in untreated controls. It is also found that 
there is a significant increase in new PSD-95 at synapses following BDNF treatment. 
Together, this indicates that total PSD-95 levels at synapses go up. When analysing 
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synaptic types, it is found that type 3 synapses retain significantly more old PSD-95 
than controls, yet colocalised type 2 synapses do not. Further, BDNF treatment causes 
significantly more new PSD-95 to be found at type 2 synapses, but type 1 synapses 
do not contain more new PSD-95 than untreated controls.  
 
5.1.6 The effects of ketamine treatment on PSD-95 turnover 
 
Following 24 hours of ketamine treatment, it is found that similar to TTX and BDNF 
treatment, significantly more old PSD-95 is retained at synapses. This difference is 
significant both at type 2 and type 3 synapses. New PSD-95 levels at synapses are 
unaffected, as are puncta numbers.  
 
5.1.6 The effects of proteasome inhibition on PSD-95 turnover 
 
The proteasome inhibitors lactacystin and MG132 were separately added to primary 
cultures for 24 hours. It was found that both drugs have profound effects on PSD-95 
turnover at all levels. Both drugs significantly reduced the degradation of PSD-95, and 
both drugs significantly reduced the synthesis of PSD-95. It was found that both type 
3 and type 2 synapses have reduced PSD-95 degradation. Type 2 synapses were 
found to have much less new PSD-95 than untreated controls. Type 1 synapses, 
however, had the same amount of new PSD-95 as controls following lactacystin 
treatment, and only slightly (albeit significantly) less new PSD-95 than controls 
following MG132 treatment.  
Like in untreated controls, type 2 synapses retain more old PSD-95 than type 3 
synapses.  
Type 1 and type 2 synapses contain equal amounts  of new PSD-95, unlike untreated 
controls, which display significantly more new PSD-95 in type 2 synapses than type 1 
synapses.  
Both drugs have the effect of vastly reducing the amount of type 1 synapses present, 
while significantly reducing type 2 synapse numbers and greatly increasing the 
number of type 3 synapses.  
As can be expected from these results, type 2 synapses display a marked increase in 




5.1.7 The effects of protein synthesis inhibition on PSD-95 turnover 
 
The protein synthesis inhibitors anisomycin and cycloheximide were added to primary 
cultures for 24 hours. The results were very similar to those collected following 
treatment with proteasome inhibitors. Both drugs significantly reduced the degradation 
of PSD-95, and both drugs significantly reduced the synthesis of PSD-95. Both type 3 
and type 2 synapses were found to have reduced PSD-95 degradation. Type 2 
synapses were again found to have much less new PSD-95 than untreated controls. 
Type 1 synapses had only slightly (but significantly) less new PSD-95 than controls 
following anisomycin and cycloheximide treatment.  
Like in untreated controls, type 2 synapses retain a lot more old PSD-95 than type 3 
synapses.  
Unlike in controls, type 1 and type 2 synapses contain the same amount of new PSD-
95.  
As with proteasome inhibitors, I find that protein synthesis inhibitors have the effect of 
massively reducing the amount of type 1 synapses present, while significantly 
reducing type 2 synapse numbers and greatly increasing the number of type 3 
synapses.  
Again, type 2 synapses displayed a marked increase in the ratio of old:new PSD-95 
in colocalising type 2 synapses.  
 
5.1.8 PSD-95 turnover at different developmental ages 
 
PSD-95 turnover rates were compared between cultures aged DIV15-DIV16 and 
DIV29-DIV30. It was found that the average amount of PSD-95 per synapse at the 
start of the experiment was the same in both groups. However, at DIV29-30 synapses 
displayed a significantly lower rate of PSD-95 degradation, while still incorporating 
new PSD-95 to the same extent as synapses at DIV15-16. At the single-synapse level, 
none of the results differed significantly, which was most likely due to the smaller 
sample size of cultures at DIV29-30. However, the observed trend was that PSD-95 
 276
degradation at DIV29-30 was reduced both in type 3 and type 2 synapses to an equal 
extent.  
As a proportion of the whole synaptic population, cultures aged DIV30 were found to 
contain more type 3 synapses and fewer type 1 synapses than at DIV16, while the 
proportion of type 2 synapses remained roughly equal. Indeed, there were significantly 
fewer type 1 synapses than type 2 synapses at DIV30 in absolute numbers as well. 
This indicates reduced synaptogenesis at older cultures.  
Within type 2 synapses, the ratio of pulse:chase ligands was significantly higher at 




5.2 Methodological considerations 
 
In this project, I set out with two goals in mind: first, to establish a working method 
using the HaloTag technology that would allow me to monitor the turnover of PSD-95; 
and second, to use this method to evaluate how PSD-95 turnover is affected by 
various changes. In working towards these goals, I obtained many results that 
provided me with intriguing insights into synapse biology. In this section, I will discuss 
the methodological considerations that need to be taken into account when using this 
method, and the consequences this has for my results. I will not, at this stage, discuss 
the biological implications of my findings further, as I have already done so within the 
relevant subchapter discussions in chapter 4.  
 
Firstly, a brief recap of the pulse-chase labelling method and the subsequent 
quantification will be provided. The method is based around the principle that the 
HaloTag pulse ligand (R110Direct) will label all existing PSD-95-HaloTag fusion 
proteins present in the neurons at the start of the experiment. This is important as it 
means that one has captured the entire population of PSD-95 proteins that are present 
at this time, allowing for their monitoring from this point onwards. It is also critical to 
this method because proteins tagged with the pulse ligand cannot be tagged with the 
chase (TMR) ligand, ensuring that there is a clearly defined boundary between two 
subpopulations of PSD-95: those present at the start of the experiment, and those 
synthesised thereafter. Nevertheless, pulse-labelled PSD-95 proteins are very diverse 
in terms of their age, and some of them will be nearing the end of their metabolic 
lifespan while others will only recently have been synthesised. This also sets the 
method apart from metabolic labelling experiments using SILAC, for instance, 
because in such experiments proteins are tagged as they are being synthesised, 
which means that the duration of the labelling period is a critical determinant of the 
size of the tagged protein population. This has both advantages and disadvantages: 
while the HaloTag method can be certain to have labelled the entire PSD-95 
population present at the start of the experiment, this population is much more diverse, 
while when using SILAC one knows that all labelled proteins were synthesised during 
the labelling period and not before. However, if one wants to capture a large enough 
sample size, then long labelling times are needed for SILAC, which in fact creates the 
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same outcome- one doesn’t know at what point in the labelling process proteins were 
synthesised. Ultimately, then, it appears to be advantageous that the HaloTag pulse-
chase labelling technique captures the entire population of target proteins present at 
the start of the experiment. PSD-95 proteins synthesised after the chase ligand has 
been added, on the other hand, are a lot more homogenous: they have all been 
synthesised within the chase period (usually 24-hours). One of the strengths of the 
method, then, is the clear and distinct labelling of ‘old’ and ‘new’ target proteins.  
 
One of the major advantages of this method over other methods is the fact that 
proteins can be studied at individual synapses, something that SILAC for example is 
unable to do. This has allowed for the measuring of PSD-95 turnover at synapses, 
rather than at a cell-wide level. However, it comes with a caveat that was addressed 
throughout the previous discussions of results in the various subsections. This is the 
fact that, as mentioned in chapter 1, PSD-95 is a dynamic and mobile protein known 
to be cycled into and out of synapses without this necessarily being due to synthesis 
and degradation. Indeed, this is mainly the ‘turnover’ rate that FRAP experiments 
measure, rather than the metabolic turnover rate of synthesis and degradation. This 
means that when looking at a single synapse, a reduction in pulse-labelled PSD-95 
can mean that old proteins were degraded- or cycled out of the synapse. This means 
that looking at ratios of old to new PSD-95 within synapses are perhaps not very 
informative, since they are the combined result of turnover and mobility. Nevertheless, 
when mean values are calculated across a very large number of synapses, the results 
are a reliable indicator of PSD-95 degradation and synthesis. This is because 
molecules may move from one synapse to another, but they will be included in the 
overall calculation no matter which synapse they are at. Therefore, ‘bulk’ turnover 
rates are reliable indicators of overall PSD-95 synthesis and degradation. How, then, 
are these results set apart from other bulk techniques, such as SILAC? Besides the 
fact that only synaptic, but not cytoplasmic, PSD-95 is included, my method allows for 
single synapses to be categorised into three different types. This is certainly a novel 
insight into the turnover of PSD-95 at synapses. These categories also restrict, to 
some extent, the mobility of PSD-95 between synapses of different categories. While 
PSD-95 molecules may indeed be moving regularly between synapses within type 2 
(colocalised) synapses, type 3 synapses contain solely old PSD-95, and furthermore, 
contain less old PSD-95 than type 2 synapses do, on average. While it is hard to pin 
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down the degradation rate of PSD-95 at such synapses (they could be 
degrading/cycling out PSD-95 faster than type 2 synapses, thus containing less old 
PSD-95; or they may have started off with less PSD-95 to begin with), we can conclude 
that they experience no influx of new PSD-95. We can therefore infer that these are 
synapses in a state of decline or stagnation, and can be expected to be experiencing 
little synaptic activity, which is correlated with PSD-95 turnover (Hruska et al., 2015). 
Indeed, Cane et al.’s (2014) finding that synapses tend to lose PSD-95 a significant 
time period before being pruned indicates that this may be the best explanation for the 
state of type 3 synapses.  
Along the same vein, type 2 synapses contain both old and new PSD-95, indicating 
that PSD-95 turnover and mobility are ongoing in these synapses. As mentioned in 
chapter 4, these synapses appear to be very diverse in terms of their total PSD-95 
content. While Butko et al. (2012) found that new PSD-95 molecules tend to localise 
to newly formed synapse, my analysis indicates that type 2 synapses contain more 
newly-synthesised PSD-95 than do type 1 synapses. This indicates that these are 
stable spines (as Cane et al. (2014) show that greater levels of PSD-95 in a synapse 
correlate with stability) and that they are also quite active, as they are experiencing 
ongoing PSD-95 turnover (Hruska et al., 2015). This makes sense given that this is 
the most numerous (43%) of the three types of synapses. Interestingly, Butko et al. 
(2012) also found that stimulated synapses preferentially recruit newly-synthesized 
PSD-95, rather than recruiting old PSD-95 from a common dendritic pool that gets 
replenished by synthesis. This does indicate that the presence of new PSD-95 at 
synapses is a marker of synaptic activity. Furthermore, Bingol and Schuman (2006) 
found that synaptic activity enriches synapses in proteasomes, linked to PSD-95 
degradation. Colledge et al. (2003) also found that NMDAR activity induces PSD-95 
ubiquitination and subsequent degradation at synapses. Taken together, the evidence 
points to the turnover of PSD-95 that was measured at synapses being a 
measurement of PSD-95 synthesis and degradation more so than protein mobility.  
Finally, type 1 synapses contain only new PSD-95 and are clearly newly formed 
synapses, in line with Butko et al.’s (2012) finding. Since Cane et al. (2014) found that 
dendritic spines that failed to recruit PSD-95 were unstable and rapidly pruned away 
again, it seems likely that these type 1 synapses are stable, and in the process of 
recruiting PSD-95 to a newly forming PSD. Interestingly, the fact that new PSD-95 
levels, and thus also total PSD-95 levels, are on average lower in type 1 synapses 
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than in type 2 synapses indicates that PSD-95 is recruited to new synapses after 
synaptogenesis in a gradual fashion. This is opposed to the possibility that PSDs might 
establish a full complement of PSD-95 in an all-or-nothing approach.  
Clearly, then, this sort of analysis of subpopulations of synapses is a unique feature 
of this HaloTag method. It allows for a novel approach to analysing proteins and their 
dynamics, and allows synaptic heterogeneity to be probed in a unique fashion.  
 
One further methodological consideration to be mentioned is that the results pertaining 
to puncta numbers are very variable, and only in extreme cases statistically significant. 
When imaging coverslips, areas containing large amounts of dendritic branches were 
selected and it was aimed to minimise the presence of cell bodies. Nevertheless, 
images varied greatly in the density of dendritic branches and hence of synaptic 
puncta. Thus, while puncta number results tend to mirror puncta intensity results and 
also often differ from controls in many cases, the results are frequently not significant 
due to the high variance within the results. As can be seen in the various graphs, error 
bars denoting the standard error of the mean tend to be very large for graphs 






5.3 Critiques and improvements 
 
In this section, I will outline areas of my project that I believe could have been done 
differently or could have had additional elements that would have strengthened the 
results and the conclusions drawn from them.  
 
The first point to be brought up here is one that was addressed repeatedly while 
discussing the results. One element that many previous studies have analysed and 
emphasised is the changes in total PSD-95 levels following various chemical 
treatments, such as activity modulation. With my technique, old and new PSD-95 
proteins are labelled with two different ligands, which provides new information about 
these two subpopulations. However, it also loses the ability to discern whether total 
PSD-95 levels in cells or synapses have changed. It is still possible to infer that total 
PSD-95 at synapses has gone up, on average, if both more pulse ligand is being 
retained and more chase ligand is being incorporated, such as following BDNF 
treatment. Nevertheless, a more direct measure would be ideal, and would yield useful 
additional information. For instance, it would be very useful to find out if treatment with 
proteasome inhibitors or protein synthesis inhibitors affects total PSD-95 levels, or if 
neurons are indeed able to retain PSD-95 levels within a certain range by regulating 
synthesis or degradation according to the proteostatic model. This analysis would be 
useful at a whole-cell level, as well as at a synaptic level.  
In other studies, total PSD-95 levels have been analysed by western blotting at a 
whole-cell levels, and by immunohistochemistry at a synaptic level. However, in this 
area, too, the HaloTag technology provides key advantages over some of these 
approaches.  
 
Firstly, in order to get a whole-cell measurement of PSD-95 levels, one could have 
cultured additional wells of primary neurons, and after drug treatment, harvested these 
for biochemical analysis rather than imaging. At that point, a synaptosome preparation 
could have been performed to enrich for synaptic proteins, or else whole-cell lysate 
could have been analysed. As analysis methods, the first obvious choice would be to 
perform SDS PAGE and western blotting analysis, using antibodies against PSD-95 
or the HaloTag protein. Using an antibody against the HaloTag would have the 
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advantage of circumventing potential false positive labelling that can arise when using 
an antibody against PSD-95, as MAGUK proteins are structurally quite similar, and 
some of the commercially available antibodies are known not to distinguish between 
some of these proteins due to epitope similarities. However, another approach would 
be to label PSD-95-HaloTag fusion proteins with a HaloTag ligand directly, as 
demonstrated in chapter 3.3.1. This would be highly specific and quantitative, and 
avoid common pitfalls of western blotting: western blots often display non-specific 
binding and antibody cross-reactivity, all of which would be avoided by a direct 
labelling with HaloTag ligands. The results would also be more quantitative, as a single 
ligand binds to a single protein, whereas this is not the case for antibodies. The results 
could then be analysed similarly to a western blot by using a denaturing gel followed 
by a quantification of the intensity of the bands corresponding to PSD-95-HaloTag.  
To probe this more directly at a synaptic level, the single-ligand labelling presented in 
chapter 3.3.6 would be ideal. This works very much like a normal immunocytochemical 
antibody staining. By labelling synapses with a single ligand only, one tags all PSD-
95 proteins present; yet, again, this technique is a lot more quantitative than antibody 
staining. This is because antibody staining can vary in its effectiveness and 
occasionally display variance between samples. When using a saturating 
concentration of a HaloTag ligand, on the other hand, one can be certain that one has 
tagged the entire population of PSD-95. In this way, changes in synaptic PSD-95 
levels can easily be visualised and quantified, and compared to untreated controls. 
Nevertheless, conventional immunocytochemistry could also have been used, and 
both of these methods would have allowed to me gather data on the overall 
fluorescence intensity corresponding to total PSD-95 levels in different cultures. These 
various methods, then, would allow for the quantification of total PSD-95 expression 
at cells or synapses, and would be useful adjuncts to the experiments performed by 
me.  
 
Another set of experiments that could have been performed in order to strengthen the 
validity of the results is to perform a toxicity assay for the various drugs that were used 
to treat the primary cultures. Such an assay would have involved treating the neurons 
with the chemical compounds in the same manner and at the identical concentration 
as during the experiments, but to evaluate their effect on neuronal viability thereafter. 
There are various assays that can be used to analyse whether neurons are undergoing 
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apoptosis and necrosis. One assay, for instance, gives an indication of cell membrane 
integrity by monitoring lactate dehydrogenase release (Cummings et al., 2004). The 
reason why this may be important is that some of the effects observed after drug 
treatment could conceivably be explained by a breakdown of cellular mechanisms 
during apoptosis or necrosis. For example, proteasome inhibitors and protein 
synthesis inhibitors appear to cause a marked reduction in both PSD-95 synthesis and 
degradation. However, if the neuron is undergoing cell death, it is possible that PSD-
95 turnover is disrupted by this, rather than a direct effect of the drug. Dying cells may, 
thus, cease to synthesise and degrade proteins. It would, therefore, be useful to 
perform such an assay in order to remove this possibility as an alternative explanation 
for the results. However, it is worth noting that it is unlikely that cell death is an 
explanation for the results obtained during this study. Firstly, the health of neuronal 
cultures was closely monitored after the 24-hour treatment period by a visual 
inspection using a light microscope. Experience in working with primary cultures 
allowed for the visual identification of the markers of cell death in these cultures, and 
this led to the exclusion of ketamine treatment at a high concentration from the 
experimental groups due to the induction of cell death brought on by this treatment 
(see chapter 4.4.4.1). Secondly, concentrations used in this project matched those 
used widely in the literature, and indeed were occasionally below these levels (see 
lactacystin treatment, chapter 4.4.5.3). Nevertheless, an assay would have been ideal 
in order to definitively reject such alternative explanations.  
 
Another additional point of analysis to be made that would likely have been useful and 
interesting is the method of synaptic puncta analysis. The Imaris software was used 
to identify synaptic puncta and calculate their average puncta fluorescence intensity. 
This provides a good indication of the concentration of PSD-95 molecules present at 
the synapse, since each PSD-95 molecule is tagged with a single fluorescent ligand 
molecule in a highly quantitative way. Average fluorescence intensity, thus, reveals a 
lot about the concentration of PSD-95 at a given synapse. However, this measurement 
does not give an indication of the total amount of PSD-95 in the synapse, since a large 
and a small PSD may contain the same concentration of PSD-95 but different total 
amounts.   
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Thus, integrated puncta intensity quantified by the Imaris software is a second 
measurement that would have been very informative when used in addition to average 
intensity/concentration. This measurement is the results of the sum of fluorescence 
units within a detected punctum structure, and would provide a measurement of the 
total amount of PSD-95 present in each synapse. While it would not make a good 
standalone measurement without taking into account PSD-95 concentration as well, it 
would certainly be an excellent adjunct to my current method of quantifying PSD-95 in 
synapses. It would, however, necessitate taking into account puncta area as well. It is 
conceivable, for instance, that newly formed synapses containing only new PSD-95 
(i.e. type 1 synapses) might have a smaller area than mature synapses. Indeed, 
puncta area is another measurement that could be of interest. It might be intriguing to 
analyse whether any of the chemical modulations have an effect on PSD-95 puncta 
area, as it is conceivable that some may affect spine morphology and perhaps lead to 
changes in the size of spines and PSDs.  
Thus, adding the measurements of integrated puncta intensity and puncta area to the 
results would have added further interesting perspectives to the analysis of PSD-95’s 




5.4 Future directions 
 
Apart from including the improvements mentioned in the above section, chapter 5.3, 
in future studies, there are various other experiments that could be performed. Many 
of the following suggestions are experiments that are fascinating in their own right, 
rather than contributing additional value to the experiments that were performed.  
 
The first set of experiment that would be a logical ‘next step’ is to probe further into 
the synaptic heterogeneity observed, and attempt to understand what determines 
synaptic types. While it can be stated with some confidence that type 1 synapses are 
immature synapses recently formed through synaptogenesis, the identity of type 3 
synapses, containing only old but no new PSD-95, is a lot less clear. Interpretations 
were put forward as to their identity, but further investigation is surely warranted. An 
analysis of other synaptic markers could be a first step in this analysis. This could be 
used to ascertain that type 1 synapses are indeed immature (for instance by labelling 
presynaptic neurotransmitter vesicles, which should be present in much smaller 
numbers at the presynaptic boutons of immature synapses (Butko et al., 2012)).  
 
To probe whether type 3 synapses are in a silent state, it might be interesting to stain 
for AMPAR subunits, and observe whether type 3 synapses have lower levels of 
AMPAR expression. Furthermore, presynaptically silent synapses have also been 
described, and these can be identified by their lack of FM 1-43 dye uptake following 
stimulation (Yao et al., 2006). While technically challenging, it might be possible to 
probe for such characteristics. Other postsynaptic markers could of course also be 
tested for: the activity-induced protein Arc/Arg3.1 (Arc) is a good indicator of synaptic 
activity, for instance. It might, therefore, be of interest to stain cultures for Arc, and 
correlate the expression of this protein with synaptic types. While this could be used 
to discover whether type 3 synapses indeed do not experience much activity and are 
therefore stagnant in their rate of PSD-95 turnover, it could also be interesting to probe 
type 2 synapses further. Thus, one might be able to correlate increased Arc expression 
with different ratios of old to new PSD-95 at individual synapses. This is particularly 
interesting because our lab actually has a further knock-in mouse line, expressing Arc 
fused to the ‘Venus’ yellow fluorescent protein (YFP). By crossing this mouse line with 
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the PSD-95-HaloTag mice, it would be very simple to observe both these proteins and 
correlate synaptic activity with PSD-95 turnover and different synaptic types.  
 
Another set of experiments that would be of great interest is live imaging. This would 
allow for the visualisation of PSD-95 dynamics, for instance by using two-photon 
microscopy similar to the study by Gray et al. (2006), but in cultures, and thereby 
visualising the movement of fluorescently labelled PSD-95 proteins between dendritic 
spines. Combining this method with the HaloTag pulse-chase labelling technique 
could provide interesting insights, as it could reveal differential mobility between old 
and new PSD-95. This could also reveal differences in PSD-95 dynamics at synapses 
of different types. It would most likely be necessary to remove unbound ligands from 
the medium as far as possible, but this should not be a massive hurdle. Clearly, this 
is a particularly interesting avenue to proceed along in future studies. Thus, one could 
combine such a live imaging approach with drug treatments such as activity 
modulation. This would allow for an observation of the effects of activity blockade or 
enhancement on PSD-95 dynamics at individual synapses in a direct and very short-
term fashion, including synthesis and degradation rates at dendritic spines.  
 
Further, spatial interactions between PSD-95 and other proteins, as well as PSD-95’s 
cellular spatial distribution, could be looked at using the HaloTag technology. 
Combining Pulse-Chase labelling protocols as utilised during this project with labels 
and tags that allow for the identification of individual neurons could allow for an 
interesting analysis of PSD-95 dynamic in individual neurons, and thereby allow for 
the contrasting of PSD-95 turnover results between single neurons and even different 
dendrites of the same neuron. For example, sparse transfections using a fluorescent 
protein tagged to a cytoplasmic protein could allow only some few neurons to express 
fluorescent proteins along their dendrites, as well as dye filling of single neurons. By 
studying PSD-95 turnover within synapses that are associated with a labelled neuron 
and contrasting the results with another single labelled neuron on the same coverslip 
could allow for interesting insights into differences in PSD-95 turnover between cells. 
In this way, it would perhaps be possible to create categories of neurons that display 
certain PSD-95 turnover profiles rather than just categories of synapses, as was done 
in this project. Indeed, one could even go a step further and combine such an 
approach with the activation of specific individual neurons using techniques such as 
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calcium uncaging and channel rhodopsins to gain a better understanding of the effect 
of activity on PSD-95 turnover at single synapses. Such an approach would be a lot 
more precise than the ‘bulk’ targeting of whole cultures using drugs like TTX or BCC. 
As such, the results they could yield would be a lot more discerning in many ways.  
 
As mentioned in the introduction, the HaloTag technology can also be used to purify 
proteins and their binding partners (chapter 1.3.3.). Combined with a pulse-chase 
labelling protocol, this could be used to isolate solely PSD-95 that has been newly 
synthesised. To this end, one could begin an experiment in very similar fashion to my 
experiments, with minor changes and a biochemical affinity capture protocol at the 
end. For example, a fluorescent ligand A could be used to label pre-existing old PSD-
95. Instead of using a second fluorescent ligand as the chase ligand, however, one 
could use the commercially available biotin ligand instead (a ligand with a biotin 
functional group attached). If newly synthesised proteins are now labelled with the 
biotin ligand, then these proteins can selectively be affinity-purified by using 
streptavidin or avidin beads. Thus, after the 24-hour chase labelling protocol (perhaps 
in the presence of a chemical modulator), the cultured neurons could be harvested, 
lysed and snap frozen. Streptavidin beads can then be used to capture PSD-95-
HaloTag fusion proteins that are labelled with the biotin chase ligand B, while not 
capturing old proteins tagged with the fluorescent pulse ligand A. In this way, one 
could purify multiprotein supercomplexes that are, perhaps, assembled only by newly 
synthesised PSD-95 in response to activity. Once isolated, these complexes can then 
be biochemically analysed and compared to the complexes captured without a 
chemical stimulus, or all known PSD-95 complexes. Indeed, this protocol could also 
be used to capture complexes containing only old PSD-95. In that case, one would 
use the biotin ligand as the pulse ligand, and chase with a fluorescent ligand. In that 
case, the affinity purification step would isolate only complexes containing old PSD-
95 but not those containing new PSD-95 (although complexes containing both old and 
new PSD-95 would also be captured). There are surely myriads of interesting 
questions and manipulations one could include in such an experimental set-up, and 
this highlights very well just how versatile the HaloTag technology is.  
 
A further highly interesting direction one could take is to utilise the homemade HaloTag 
ligands that cause the acute degradation of a tagged protein. As described in the 
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introduction (chapter 1.3.4) these ligands are hydrophobic and cause a tagged protein 
to be marked for degradation. This ligand was developed in the lab of Craig Crews, 
and I was in fact able to obtain a sample of these ligands. I only tested them a few 
times, but was able to qualitatively observe a marked reduction in PSD-95 antibody 
staining in primary cultures after applying this ligand (called PROTAC). While the 
application protocol requires refinement, it is easily possible to imagine a number of 
ways this ligand could be used to probe PSD-95’s function further. If one could 
degrade old PSD-95 using this ligand as the pulse ligand, for example, then remove 
most of this ligand and add a second chase ligand that is fluorescent in order to 
outcompete the remaining PROTAC ligands (exactly like in my pulse-chase protocol), 
one would be able to visualise newly synthesised PSD-95 following complete removal 
of old PSD-95. It would be interesting to see if the cell responds by massively 
increasing PSD-95 synthesis in such a scenario, and if some synapses will be able to 
preferentially recruit this PSD-95 over other synapses. The effects on other proteins 
could also be explored, such as on AMPA and NMDA receptors, and how this effects 
the number of synaptic puncta present (perhaps synapses are lost). Equally so, new 
PSD-95 synthesis could effectively be prevented while retaining old PSD-95 by pulse 
labelling it with a fluorescent ligand first, and then following this up with the PROTAC 
ligand. Unlike protein synthesis inhibitors such as anisomycin, this would not affect 
other proteins, solely PSD-95. It would thus be absolutely fascinating to monitor 
whether this has the same effect as using these drugs in blocking not only PSD-95 
synthesis but also degradation. If so, this experiment would provide a vital next step 
in support of the proteostatic model of synapses keeping PSD-95 levels within a 
specific range by controlling its synthesis and degradation (see chapter 4.4.7). 
Numerous other applications for this PROTAC ligand could surely be found.  
 
Finally, the greatest step forward and utmost achievement would be to manage to 
label PSD-95-HaloTag fusion proteins in live mice. Indeed, this is something I tried on 
a few occasions, but was unable to accomplish. Multiple previous studies have used 
the HaloTag labelling system in live mice, however, the target proteins were always 
located within tumours xenografted into the flanks of mice, and HaloTag ligands were 
delivered by intraperitoneal injections. This means that ligands were injected in close 
proximity to the tumours, and did not have to pass additional hurdles such as the 
blood-brain barrier (BBB). Since the HaloTag ligands are tiny and cell membrane 
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permeating, they should be able to cross the BBB, and personal communications with 
Promega have revealed that there is a large pharmaceutical company that is currently 
working on creating an assay using the HaloTag technology to determine whether 
drugs cross the BBB or not. The difficulty in labelling fusion proteins in the brain, then, 
is most likely linked to dosage and clearance. Ligands need to be administered at a 
concentration high enough to allow them to penetrate into the brain at a concentration 
that is high enough to label a significant amount of proteins. Since the ligands will 
invariably diffuse throughout the entire animal, and thus be dilute throughout the 
volume of its body, they must be administered at a very high concentration indeed. My 
first experiment involved administration by intraperitoneal injection, and following 
experiments were performed with tail-vein injections. However, in no instance could a 
significant synaptic puncta staining be observed in slices taken from injected mice. It 
is possible that ligand quantity was insufficient and/or clearance was rapid. Incubation 
time was 24 hours, but future studies will have to attempt to establish a clearance rate. 
This could, for instance, be done by taking blood samples from injected mice at set 
intervals after injection, isolate the plasma, and analyse the fluorescence intensity of 
the ligands within. Other studies have also applied the ligand by tail-vein injection 
(Hong et al., 2011), and established that clearance of the ligands occurred rapidly 
through the hepatobiliary or renal pathway. Neklesa et al. (2011) also monitored ligand 
clearance, and found serum levels to drop by 75% over 24 hours. Ultimately, a more 
direct but more invasive approach might be the injection of the ligand directly into the 
brain. This would reduce the issues of dilution and clearance to a great extent. If the 
labelling of PSD-95 in the brains of live mice is indeed accomplished, this would prove 
to be a breakthrough, but create a whole host of new questions. If one wanted to probe 
the temporal aspects of PSD-95 in a similar fashion as this project has done, one 
would need to ascertain that proteins are saturated with one ligand before applying a 
second ligand. This second ligand could, however, be applied post-mortem to brain 
slices. If one were to be able to solve the host of technical issues (how quickly is the 
unbound pulse ligand cleared, to prevent it from continuing to label newly synthesised 
PSD-95?), one could ask truly profound questions. Learning and memory exercises 
could be applied to mice, and PSD-95 synthesised in response to such stimulation 
localised at a whole-brain as well as single-synapse level. At that point, the HaloTag 
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